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Abstract 
This research centres on the experiences of people with Parkinson's disease (PD) 
and how they perceive two autonomic non-motor symptoms, bowel and bladder 
dysfunction, both highly associated with PD. Many studies have addressed urinary and 
faecal incontinence among general populations; however, few have focused on 
populations of people with PD. Further, no evidence of the personal burden that is 
associated with the presence of these autonomic dysfunctions has been reported.  
The position of this thesis is that the burden experienced by people with PD who 
also suffer from bowel and bladder dysfunction significantly affects their ability to fully 
participate in a social life and that the current clinical management used to treat either of 
these two symptoms fails to alleviate their burdensomeness. Using a novel mix of 
qualitative and quantitative research methods it was possible to identify the type, 
presence and legitimacy of the symptoms experienced by participants; how they 
searched for and used available clinical resources; and whether their search for 
additional personal resources alleviated or cause additional burdens and disruptions to 
their life quality. 
The study comprised 67 people with PD who were experiencing a bowel or 
bladder dysfunction or a combination of both. They completed a series of quantitative 
surveys and answered semi-structured interview questions focused on the symptoms 
and their current management. Quantitative data were subjected to a range of 
descriptive and inferential statistical analyses and, to bring participants' perceptions to 
the forefront, qualitative data were converted into participant-generated quantitative 
burden scales that were used to statistically compare and contrast all other quantitative 
data sets, in gauging the severity and importance of the participants’ experiences. This 
process ensured the participants’ voices remained central though out the study.  
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This study is the first to reveal that (a) participant descriptions of their bowel 
and bladder dysfunctions are directly linked to their PD neuropathophysiology rather 
than to other influences commonly associated with older people; (b) the physical 
burdens these people recounted were significantly in excess of what would be 
considered common in non-PD populations suffering from bowel and bladder 
dysfunction; (c) the ability of these people to source information and assistance was 
significantly impaired by their own preconceived attitudes toward bowel and bladder 
dysfunction and their construction of what constitutes a legitimate health concern; (d) 
their bladder and bowel dysfunctions were psychologically burdensome and the 
presence of these symptoms created high levels of anxiety and emotional distress when 
compared to any of their other identified PD non-motor symptoms; (e) for these people 
common management practices widely used in clinical practice to treat chronic 
constipation provided scant symptom relief; (f) these people found the self-imposed 
social restrictions made in response to the unpredictability of their bowel and bladder 
dysfunction, affected their ability to participate fully in social activities and therefore 
negatively affected their quality of life.  
The major strength of the study is its focus on the individual’s experience of PD, 
rather than on the more commonly investigated experience of informal and formal 
carers or healthcare providers. Burden highlighted in this way brings balance to the 
understanding of PD in terms of how it affects individuals and the challenges involved 
in managing this little known phenomena. 
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Chapter 1: Introduction 
1.1 Background/statement of the problem 
The purpose of this study is to gain a deeper understanding of two commonly 
reported, yet poorly investigated non-motor symptoms (NMS); the first affects the 
normal function of the bowel and the second affects the bladder of people with 
Parkinson’s disease (PD). PD is a slowly progressive neurodegenerative disorder with a 
highly individualised clinical picture that affects between 1% and 2% of the 3.08 
million Australians over the age of 60, although it should be noted that 20% of those 
diagnosed with PD are younger than 60 years (Deloitte Access Economics, 2011). This 
means people with PD often live and age in their communities for many years, 
experiencing a slow unpredictable deterioration of their abilities which diminishes their 
independence. Many of the individual clinical symptoms, especially those affecting the 
motor function of the person with PD, are well explored and documented. However, 
little is known about two of the most commonly occurring autonomic symptoms in PD, 
bowel and bladder dysfunction, beyond that of their basic pathophysiological 
occurrence and prevalence. These autonomic symptoms have been highlighted in recent 
studies as common and burdensome (Chaudhuri & Odin, 2010; Gallagher, Lees, & 
Schrag, 2010; Li, Zhang, Chen, Zhang, Pei, Hu, & Wang, 2010; O'Sullivan, Williams, 
Gallagher, Massey, Silveira-Moriyama, & Lees, 2008), yet to date no study has focused 
on how these symptoms burden the individual and whether they contribute to decisions 
by people with PD about their living arrangements or choosing care and treatment in 
terms of the financial, emotional or social effects these choices generate. 
The prevalence of PD has been estimated in European (Lees, 2010) and 
American studies (Wright, Willis, Evanoff, Lian, Criswell & Racette, 2010) to affect 
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between one to four people per 1000 population. Parkinson’s Australia, the national 
peak body representing Australians with PD, estimates Australia lies midway between 
these American and European estimates (Access Economics, 2007). Australian 
prevalence estimates of 362 people over the age of 50 years per 100,000 were 
established by Mehta, Kifley, Wang, Rochtchina, Mitchell, & Sue, (2007) in their study 
of people aged 50 years and over known to be taking PD medications. PD 
predominantly affects people over 60 years of age and is slightly more prevalent in 
males than in females (Australian Bureau of Statistics [ABS], 2010; Mehta et al., 2007; 
Soh, McGinley, Watts, Iansek & Morris, 2012; Schapira, 2008). There is little evidence 
that it affects any specific racial group at higher rates than others (Chan et al., 2005; 
Factor, Feustel, Friedman, Comella, Goetz, C. Kurlan,  … Pfeiffer, 2003; Jones, 
Marcantonio & Rabinowitz, 2003; Miller & Daniels, 2000; Noble, 2000; Pradilla, 
Vesga & Leon-Sarmiento, 2003; Sloan, Sales, Liu, Fishman, Nichol, Suzuki, & Sharp, 
2003). Community healthcare providers are generally of the view that PD is a 
commonly occurring neurodegenerative disorder affecting community dwelling older 
people. 
The cause of PD is a slow deterioration and eventual death of neurons within the 
substantia nigra, found in the midbrain of the cerebellum. No definitive aetiological 
factors have been identified as the trigger for this neuro-degeneration (Gómez-Esteban, 
Zarranz, Lezcano, Tijero, B., Luna, Velasco,  … Garamendi, 2007; Peto, Jenkinson & 
Fitzpatrick, 1998). However, current understanding is that PD is multifactorial 
(Schapira, 2008). The diagnosis of PD is made on the clinical presentation of four 
cardinal motor symptoms together with a positive response to the drug Levodopa. These 
cardinal motor symptoms are involuntary resting tremors; stiffness of the muscles or 
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rigidity; a slowness of, or an inability to initiate, movement, known as bradykinesia; and 
finally, postural instability caused by disturbances in the person’s gait and balance, 
often with an accompanying flexion of the upper body (Calne, 1995; Hawkes, Del 
Tredici & Braak, 2010; Krishnan, Sarma, Sarma & Kishore, 2011; Marjama-Lyons & 
Koller, 2001; Pahwa & Lyons, 2010; Rahman, Griffin, Quinn, Jahanshahi, Rahman, 
Griffin, … Jahanshahi, 2008; Siderowf, 2001; Uitti, 1998; Vaughan & Hardie, 2002). 
Most commonly, a definitive medical diagnosis of PD is made when these motor 
dysfunctions become apparent in the mid-stages of the disease (Gómez-Esteban et al., 
2007; Tolosa, Gaig, Santamaria & Compta, 2009; Zhao, Wee, Chan, Seah, Au, Lau,   … 
Tan, 2010). Discussions among researchers of the appropriateness of using these 
symptoms as a definitive diagnostic tool, revolves around the frequency of diagnostic 
errors found at post-mortem and the likelihood that these errors may have prevented 
proper clinical management (Abbott, Naismith & Lewis, 2011; Abdo, van de 
Warrenburg, Burn, Quinn & Bloem, 2010; Newman, Breen, Patterson, Hadley, Grosset, 
& Grosset, 2009; Vilariño-Güell, Ross, Wider, Jasinska-Myga, Cobb, Soto-Ortolaza, … 
Melrose, 2010), especially in presentations of other Parkinson-like disorders such 
progressive supranuclear palsy (PSP) (Williams & Lees, 2009). The prevalence of 
misdiagnoses is believed to be diminishing with the advent and use of genetic testing, 
neuro-imaging and transcranial ultrasound, all of which allow accurate and earlier 
detection of neuron destruction (Rahman et al., 2008).  
There is some disputation regarding the benefit and usefulness of this type of 
early detection in non-specialised generic clinical settings as the costs of diagnostic 
investigations are high and any consumer benefits from early diagnosis are 
questionable, especially if disease prevention is not yet possible (Berg, 2008) and 
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disease management is not dependent on or affected by early intervention (Li et al., 
2010). In more recent studies, autonomic bowel disfunction, specifically constipation, 
has been identified as being a reliable early diagnostic indicator and its use in diagnosis 
may offer a lower cost option to accurate early detection (Rayner & Horowitz, 2013; 
Ross, Abbott, Petrovitch, Tanner, & White, 2012).  
Abbott et al (2011) concured with these findings and drew them closer to the 
issues that drive the current study by stating that Australian family medical practitioners 
(GP) display significant knowledge gaps around all aspects of PD. Importantly, if GPs 
find difficulties in diagnosing and providing management options for patients with PD 
focused on the four cardinal motor symptoms, then it is likely that the more obscure 
NMS would pose more difficulty for GPs to identify as being specifically related to PD. 
1.2 Limitations of previous research 
Cardinal motor symptoms continue to dominate the field of PD research while 
the more subtle symptoms, such as slow gut motility, depression, anxiety, mental 
confusion, sleep disturbances, constipation and urinary incontinence (UI), remain in the 
background in terms of clinical recognition and treatment, despite being acknowledged 
as being significantly disabling. More recently, some of these NMS symptoms have 
been recognised as prodromal to the onset of cardinal motor signs. In the case of 
constipation, there is growing acceptance by clinicians that this symptom can actually 
be predictive of PD (Campbell, Marbella & Layde, 2000; Hillen & Sage, 1996; Li et al., 
2010; Palmer, 2009; Sakakibara, Uchiyama, Yamanishi, Shirai & Hattori, 2008; 
Weintraub, Moberg, Duda, Katz & Stern, 2004). Still, beyond prevalence and 
physiology, little evidence exists about the extent to which autonomic bowel and 
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bladder NMS burden the person with PD and how they manage to live their lives in 
ways that compensate for their condition. 
1.3 Need for the study 
PD is one of the most recognisable and more common neurological chronic 
illnesses within the over 60’s Australian community. The current generation of older 
adults is far less likely than previous generations to adopt a passive role in the 
management of their disease and it is expected that they will demand a consumer-
orientated approach to healthcare services (Flynn, Smith, & Freese, 2006; Redfern & 
Ross, 2006). Adults with PD actively seek and share information with others about their 
disease through a variety of mediums including the internet and via the plethora of 
disease-specific community organisations and support groups, such as Parkinson’s 
Australia (2008). These community health services begin with GPs who are under 
pressure to provide cost effective clinical services that meet the needs and expectations 
of this literate, discerning and independent older population (Abbott, Naismith, & 
Lewis, 2011; Nicholson, Jackson, Marley, & Wells, 2012). However, the information 
available to the person with an autonomic bowel and bladder dysfunction is limited, and 
in many instances GPs do not provide clear guidelines for evidenced-based management 
(Coggrave, Wiesel, & Norton, 2009). GPs have been reported to attribute these non-
motor symptoms to normal ageing processes rather than to these people’s 
neuropathology and provide bowel and bladder management strategies that do not 
incorporate neurologically focused strategies (Bennett & Gaines, 2010; Depp & Jeste, 
2009; Stewart, Chipperfield, Perry & Weiner, 2012). Consequently, the strategies 
suggested are not in line with the health consumer’s needs, nor are they compatible with 
the person with PD’s social context, adding to their feelings of being a burden to 
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themselves and others (Cousineau, McDowell, Hotz & Herbert, 2003; McPherson, 
Wilson & Murray, 2007). Published research indicates that the more a person believes 
they are burdensome to others, the more inclined they are to make health and lifestyle 
choices they believe will lessen the perception that they are a burden on others, but 
which may not be in their own best interest (Edwards & Ruettiger, 2002; Gallagher, 
Lees, & Schrag, 2010; Li et al., 2010; McPherson, Wilson & Murray, 2007; McPherson, 
Wilson, Lobchuk, Brajtman et al., 2007; McPherson, Wilson, Murray et al., 2007; 
Simmons, 2007).  
The available bowel and bladder research mostly originates from an ageing or 
gendered perspective rather than from a neurological focal point and, as such, 
concentrates on containing incontinence rather than treating dysfunctions (Chiarelli, 
Bower, Wilson, Attia & Sibbritt, 2005; Kepenekci, Keskinkilic, Akinsu, Cakir, Elhan, 
Erkek, & Kuzu, 2011; Macmillan, Merrie, Marshall & Parry, 2004; Slieker-ten Hove, 
Pool-Goudzwaard, Eijkemans, Steegers-Theunissen, Burger, & Vierhout, 2010; 
Teunissen, van den Bosch, van den Hoogen & Lagro-Janssen, 2004; Whitehead, 
Borrud, Goode, Meikle, Mueller, Tuteja,  …Ye, 2009). Additionally, incontinence 
prevalence studies have reported that many people choose not to report their bowel and 
bladder symptoms to their doctors. This phenomenon was identified by an Australian 
continence research group who attributed symptom non-disclosure to the person with 
incontinence (Pearson, Tucker, Bolt, Kelly, Eastwood, Finucane, & Paterson, 2002) as: 
 not seeing their incontinence as a problem 
 not having an expectation beyond their current self-care 
 hiding the existence of incontinence due to embarrassment 
 hoping the incontinence would self-resolve 
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 not having the words or the opportunity to explain to others, in particular 
their doctors. 
People with PD are known to present with higher rates of bowel and bladder 
dysfunction than non-affected older people, yet knowledge of how these progressive 
neurological disease symptoms are differentiated and managed in general medical 
practice settings is scant (Coggrave, Wiesel, Norton & Brazzelli, 2006; Kishi, Ogawa, 
Sakakibara, Tateno, Uchiyama, Yamamoto, & Yamanishi, 2011; Reimann, Schmidt, 
Herting, Prieur, Junghanns, Schweitzer,  … Ziemssen, 2010; Sakakibara et al., 2008; 
Tapia, Khalaf, Berenson, Globe, Chancellor, & Carr, 2013). The importance of the 
current study is that it specifies neurological issues related to PD, rather than taking the 
more common position that normal processes of ageing are the cause of symptoms. This 
research addresses an existing gap between what is known about these PD symptoms 
and the effectiveness of interventions offered to and utilized by people with PD who 
experience autonomic bowel and bladder dysfunction. 
1.4 Aims and purpose of the study 
This study explores the effects of two poorly researched PD-specific symptoms, 
bowel and bladder dysfunction. While these autonomic dysfunctions have been reported 
to affect people with PD, the nature and extent of that influence has not been explored 
in any meaningful way (Bannister, 2000; Coggrave et al., 2006; Winney, 1998).  
The study has three specific aims that strive to address these gaps in knowledge 
about autonomic bowel and bladder NMS. The first is to explore what specific bowel 
and bladder symptoms burden the daily lives of persons with PD, as they describe them. 
The results of this exploration are reported in Chapter Five of this thesis. The second 
aim is to investigate the ways these NMS affect people’s quality of life (QoL). The 
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results of this exploration are reported in Chapter Six. Finally, the study aims to 
investigate if principles of symptom non-disclosure as described by Pearson, Tucker, 
Bolt et al. (2002) are applicable to this group of people. The results of this exploration 
are reported in Chapter Seven. 
These aims are embedded in three research questions addressed in this study: 
1. What are the bio-psycho-social burdens of bowel and/or bladder dysfunction 
for a person with PD? 
2. What specific QoL factors, as measured by the PD questionnaire (PDQ)-39, 
are affected by bowel and bladder dysfunction? 
3. What are the therapeutic experiences of the health consumer with PD, 
specifically regarding their reports of bowel and bladder dysfunction? 
The implications of this research lie in informing future bowel and bladder 
treatment design, moving attention from an acute care focus where the person with PD 
is seen as a recipient of care, towards a more inclusive chronic healthcare focus that 
regards people with PD as significant contributors to the management of their own 
disease. The findings of this study will also contribute clarity and depth to 
understanding of these two PD related NMS as well as informing other people with 
analogous neurological diseases, such as multiple sclerosis, where the burden of bowel 
and bladder dysfunction is of equal concern. 
1.5 Design of study/methodology 
This study has used a mixed method design to enable a more comprehensive 
understanding of this little explored topic, to generate a picture of the types of bowel 
and bladder dysfunction most commonly reported and to show how these dysfunctions 
challenge the individual. The study participants completed a series of quantitative 
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surveys; The Hoehn & Yahr, a PD specific disease staging tool; the Schwab & England, 
a PD specific tool that identified each participants’ ability to perform activities of daily 
living; the PDQ-39, a QoL survey; the Non-Motor Symptom Scale (NMSS), a survey 
that identifies a range of PD specific non-motor symptoms in terms of their severity and 
frequency; and a grouping of four numerical psychometric scales that cover areas of 
disability, QoL, health perception and treatment satisfaction. These data were bolstered 
by the qualitative data collected in the form of reflective notes used to assist researcher 
recall and contextualisation of participant statements made in response to open-ended 
questions about their bowel and bladder symptoms. These qualitative and quantitative 
data were reviewed as a whole, giving a depth and interpretive value to both collections.  
The uniqueness of this study lies in its approach to analysis of both qualitative 
and quantitative data. Personal qualitative statements made by participants were 
categorised into symptom presentation groups before being allocated numerical 
psychometric ratings by the participants and then combined with reflective notes into a 
series of quantitative data sets. The participants’ personal qualitative statements were 
also explored and categorised into common themes to add a rich understanding of the 
emotional significance to the participants of these numerical transformations. All of the 
resulting quantitative data sets, comprised of the standard surveys and the participant 
generated ratings scales, were then statistically compared and contrasted to give a multi-
dimensional picture from which a connotative meaning of this condition could be 
extrapolated. This complex process of data collection, data transformation and analysis 
is explained in more depth in Chapter Four. 
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1.6 Outline of the thesis 
The eight chapters that comprise thesis are as follows: This chapter provides a 
brief overview of the study, highlighting gaps in the research literature and providing 
the rationale and justification for undertaking the study. Chapter Two provides a 
contextual critique of the bio-psycho-social aspects of Parkinson’s disease and bowel 
and bladder dysfunction in populations of older Australians without and with PD. This 
review provides insights on how taking an age-centred approach to healthcare delivery 
has influenced bowel and bladder management for this group of people. Chapter Three 
explores the literature in terms of viewing PD from a disability-centred theoretical 
approach as opposed to more traditional age-centred theoretical models and conceptual 
frameworks that currently influence the health management of many chronic diseases. 
Chapter Four outlines the ethical and research processes used in the study, the choice of 
research methods and the specific characteristics of this type of convergent research.  
Chapters Five to Seven present the study’s research findings with each of these 
three chapters addressing one of the three research questions, allowing the information 
to be organised in a logical structure. Chapter Five addresses Research Question 1: 
What are the bio-psycho-social burdens of bowel and/or bladder dysfunction as 
experienced by a person with PD? This chapter presents each participants’ demographic 
and disability profiles and includes participant interpretations of their current health and 
level of disability. Chapter Six addresses Research Question 2: What specific QoL 
factors, as measured by the PDQ-39, are affected by bowel and or bladder dysfunction? 
The final results chapter is Chapter Seven, which addresses Research Question 3: What 
are the therapeutic experiences of the health consumer with PD, specifically regarding 
their reports of bowel and bladder dysfunction? 
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Chapter Eight provides a summary discussion of the results presented in the 
preceding three chapters. This chapter draws together participants’ experiences, values 
and priorities as they relate to the presence of these two autonomic symptoms in the 
form of key findings. Following the presentation of these key findings, a series of future 
research possibilities and clinical opportunities are recommended. These 
recommendations are used to promote ways that could improve the lifestyle of people 
with PD. Specifically, in terms of reducing the burden the participants’ state, they 
experience living with a bowel and bladder dysfunction. A considered account of the 
study’s limitations is also provided in this concluding chapter alongside a reflective 
discussion of the study’s significance. The findings of this study will be used to 
generate suitable clinical approaches, which can be employed by clinicians who wish to 
manage bowel and bladder dysfunction among people with PD. 
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Chapter 2: Contextualising the burdens experienced by older people and those 
with Parkinson’s disease 
This chapter provides a scientific and technical context for understanding the 
pathophysiological cause of PD symptoms and the burdens experienced by people with 
a bowel or bladder dysfunction or incontinence. This is achieved by exploring the 
construct of non-neurological bowel or bladder dysfunction in older people before 
investigating bowel or bladder dysfunction as a co-morbidity in those with a 
neurological dysfunction commonly associated with older age. Sub-sections are used to 
organise this review of literature, the first addresses normal age-related bowel or 
bladder functional changes. The second focuses on bowel or bladder changes 
specifically related to the person, regardless of their age with PD. The third and final 
section highlights similarities and differences between expected age-related bowel or 
bladder changes and those specific to the neurological pathology associated with PD. 
The importance of distinguishing between these constructs has a bearing on the 
successful management of bowel or a bladder dysfunction and incontinence. 
2.1 Normal age-related bowel or bladder functional decline 
2.1.1 Defining normal ageing. 
When referring to inanimate objects like furniture or vehicles, age as a 
numerical measurement is an easily understood concept. The same cannot be said when 
compiling a meaningful picture or profile of a person. In the human genus, a slow 
process of organ and cellular degradation occurs naturally throughout the lifespan and 
both onset and effects are experienced differently by each person (Carey, 2003). 
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Ageing, in general, places the person at a much higher risk of disablement and disease. 
However, normal age-related change in physiology should not itself be defined as a 
disease (Tosato, Zamboni, Ferrini & Cesari, 2007). 
Before Rowe and Kahn’s seminal article in 1987, ageing definitions primarily 
focused on the negative degenerative aspects of ageing. They struggled to incorporate 
the concept of normal organ and cellular degeneration within a construct of success. 
Rowe and Kahn (1987) were among the first to present the older person as ageing 
successfully if they were able to function at a high level across three defined attributes: 
physical, mental and social wellbeing. 
Recently, definitions have moved beyond these objectively measured attributes 
to include subjective personal insights generated from the older person about their lived 
experience, giving rise to definitions of success that include optimistic and effective 
styles of living, together with the person’s continued ability to participate in their social 
and community environs (Depp & Jeste, 2009; Jeste, Depp & Vahia, 2010; Phelan, 
Anderson, Lacroix & Larson, 2004). It is this perspective that guides the current study 
in its choices of research method and data analysis. 
2.1.2 Contextual use of age in health services. 
Age is an important construct that is often used to define and identify the 
interests, values and similarities of groups of people. Australian healthcare utilises age 
to prioritise funding allocations and efficiencies related to service delivery for the 
benefit of the largest number of persons without raising concerns of favouritism, 
stereotyping or discrimination (McKie, Shrimpton, Hurworth, Bell, & Richardson, 
2008). 
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Statistical collections of information about population lifespan have enabled us 
to estimate an average potential length of life in years. The ABS has estimated the life 
span for those aged 50 today is for Australian women, 84 years and for men, 79 years 
(ABS, 2010 ). This shows a rise in life expectancy over the previous two decades of six 
years for women and four years for men, making the Australian population one of the 
highest ranked in terms of life expectancy in the world (ABS, 2010; 2011). However, 
associated with this life expectancy is the likelihood of these people experiencing some 
of a range of conditions that fall outside the normal physiological changes of ageing. 
In 2006(a), the AIHW estimated 80% of Australians over 65 years of age 
experienced in excess of four chronic health concerns. The ABS (2010) also reported 
that this group was hospitalised at a much higher rate due to these chronic illnesses than 
any other age-delimited group. The array of these conditions or co-morbidities can 
burden the older person with a high degree of disability and poorer health outcomes 
(Marengoni, Von Strauss, Rizzuto, Winblad & Fratiglioni, 2009; Valderas, Starfield, 
Sibbald, Salisbury & Roland, 2009). 
Chen, Covinsky, Cenzer, Adler and Williams (2012), Alma, Van der Mei, 
Groothoff and Suurmeijer (2012) and Sells, Sledge, Wieland, Walden, Flanagan, Miller, 
& Davidson (2009) have described the negative effect of these co-morbid conditions as 
extending beyond their physical manifestation to affect the older person’s ability to 
maintain a sense of psychological and social wellbeing; ageing them beyond their actual 
years and, according to Marengoni et al. (2009), contributing to their overall mortality. 
2.1.3 Chronic disease states in the ageing population. 
A widespread expectation within Australian society is that a longer lifespan be 
accompanied by one's ability to live out these additional years in relative comfort and 
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good health. The unpredictable nature of biological ageing has, according to Ahan, 
Saderberg and Lundman (2003), Dentzer and Metz (2009), Lynn and Adamson (2003), 
Lunney, Lynn, Foley, Lipson and Guralnik (2003) and Waite, Broe, Creasey, Greyson, 
Cullen, O’Toole, & Edelbrock (1997), affected this generation of older people, causing 
them to confront their expectations of what 'ageing well' means. The current generation 
of older people are unlike previous generations in that they are mostly well educated, 
have higher expectations of healthcare services and are not shy about making healthcare 
demands (Giordano, 1988; White, 2012). These demands place pressures on health 
service providers and planners alike, to meet the expectations of this well-informed, 
consumer-rights driven group, despite healthcare services being restricted by increasing 
healthcare costs and access to finite resources. The tension between appropriate 
healthcare provision and cost allocation in chronic healthcare services has become a 
universally shared concern, with many developed economies now looking at better 
ways to manage their finite capital resources while servicing increasing demands for 
quantity and quality in healthcare. 
In 2003, the RAND corporation, a United States (US)-based think tank, 
published the white paper ‘Living Well at the End of Life: Adapting Healthcare to 
Serious Chronic Illness in Old Age’ (Lynn & Adamson, 2003). The report outlined the 
need for the government to recognise and make provision within an already tight fiscal 
healthcare budget, for an asymmetric population shift towards an ageing society. The 
shift was predicted to incur higher utilisation of healthcare and affect the US’s ability to 
provide good healthcare services to the estimated 87 million older Americans by the 
year 2050 (Federal Interagency Forum on Aging-Related Statistics, 2010; Nay & 
Garratt, 2009; Redfern & Ross, 2006). Similar profiles have been reported by other 
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comparable countries, Australia included, raising concerns amongst healthcare planners 
as to how they will effectively meet the needs of a population that uses health services 
at a higher rate and over a longer period of time than the much smaller population of 
younger people paying tax (ABS, 2009a; AIHW, 2006a; Castles & Uhr, 2007; Curtin & 
Lubkin, 1995; Ironside, Scheckel, Wessels, Bailey, Powers, & Seeley, 2003; OECD, 
2011). 
Schoen, Osborn, How, Doty and Peugh (2009) pointed to the ineffective 
approach used to manage chronic disease states in a similar way to that of an acute 
episode of disease or injury. This approach oversimplifies chronic diseases as an 
extended form of an acute illness that directs medical interventions along calculated 
timelines for treatment and cure, many of which may neither be obtainable nor 
achievable. Where a false expectation of cure is promoted, the danger of frustration 
increases for the treating doctors and the person with a chronic illness. This does little to 
assist the person to adapt to any lifestyle disruptions caused by their chronic disease, 
and also fails to generate research interest within the medical fraternity who are widely 
reported as perceiving chronic health problems in the elderly to be frustratingly 
unresponsive as well as less profitable to treat (Carter, Walker & Furler, 2002; Higashi, 
Tillack, Steinman, Harper & Johnston, 2012; McWilliam, 2009; Murrow & Oglesby, 
1996). Incontinence is a chronic healthcare problem frequently viewed in this manner, 
and Wagg, Potter, Peel, Irwin, Lowe, & Pearson (2007) and Potter, Peel, Mian, Lowe, 
Irwin, Pearson, & Wagg (2007) claimed that the poor management of incontinence 
among older people is endemic. 
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2.1.4 Chronic incontinence among older populations. 
To be continent a person must have an “ability to store urine in the bladder or 
faeces in the bowel and to excrete voluntarily where and when it is socially appropriate” 
(Getliffe & Dolman, 2007, p. 3). UI or faecal incontinence (FI) are not normal signs of 
ageing, nor are they chronic diseases—they are the symptoms of underlying structural 
or pathological change (AIHW, 2013; Kraus, Bavendam, Brake & Griebling, 2010; 
Landefeld, Bowers, Feld, Hartmann, Hoffman, Ingber, … Trock, 2008; Wagg, Cardozo, 
Chapple, Diaz, de Ridder, Espuna-Pons, … Kirby, 2008). Chronic UI and FI develop 
slowly over a prolonged period that differs from an acute presentation of incontinence 
such as is experienced during a urinary tract infection. Chronic UI and FI are known to 
be prevalent in older populations, in groups of women and among people with physical 
disabilities or those living in institutionalised settings (AIHW, 2012a, 2012b; Chiarelli, 
2010; Department of Health and Ageing, 2011; Dooley et al., 2008; Kepenekci et al., 
2011; Sims, Browning, Lundgren-Lindquist & Kendig, 2011; Slieker-ten Hove et al., 
2010; Tozun, Ayranci & Unsal, 2009; Whitehead et al., 2009). 
Chronic incontinence is often overlooked by clinicians and sufferers alike, 
especially if their attitudes towards the management and treatment of incontinence are 
prejudiced. For instance, they may believe that nothing can be done to reverse the 
incontinence; or that incontinence is an inevitable part of growing older; or a normal 
consequence of pregnancy and birth (Chen et al., 2012; Newman, 1999, 2002; Sims et 
al., 2011; Slieker-ten Hove et al., 2010).   
Other factors identified as persuasive in people not raising the issue of bladder 
or bowel dysfunction with their doctor have been explored by Horrocks, Somerset, 
Stoddart, and Peters (2004) in their study of barriers that prevent older people from 
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seeking treatment. They found that urinary dysfunction was regarded by the sufferer as 
shameful and embarrassing. These feelings are significant factors that impair self-
confidence and limit any mention of urinary dysfunction with their doctors. A later 
study by Welch, Taubenberger and Tennstedt (2011) also identified that people with 
urinary dysfunction were inclined to overcome their embarrassment of urinary 
dysfunction and speak about it to their doctor only when the embarrassment of the 
symptom was outweighed by a need to seek treatment. They also noted that participants 
reported they had raised the issue of urinary dysfunction in passing during an unrelated 
clinical consultation, but not primary issue. The findings of these and other studies, 
exploring why people choose not to report urinary dysfunctions to their doctors, all 
concluded that it is essential that a person with urinary dysfunction feels comfortable 
speaking with their doctor and some assurance that their expression of concern will be 
taken seriously. Most importantly, the urinary symptom itself needs to be more 
pronounced and disturbing than any other physical symptom before the person will 
initiate a discussion about these symptoms with their doctors ( Elenskaia, Haidvogel, 
Heidinger, Doerfler, Umek, & Hanzal, 2011; Pearson et al., 2002; Stenzelius, 
Mattiasson, Hallberg, & Westergren, 2004). There have been no similar studies 
conducted on bowel dysfunction, however authors writing on the prevalence of this 
symptom proposed that bowel dysfunction could be even more stigmatised than bladder 
dysfunction (Santos & Santos, 2011; Slieker-ten Hove et al., 2010; Whitehead et al., 
2009). These factors, together with clinician inattention, or negative attitude and 
prejudices, are reported by sufferers to be a major factor inhibiting them from reporting 
such problems or asking for assistance (Schoen et al., 2009; St. John, Wallis, Griffiths 
& McKenzie, 2010). As a consequence, chronic FI and UI are significant community 
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issues that remain under-reported, poorly managed and misunderstood (Abrams, 
Manson & Kirby, 2012; Alma et al., 2012; CFA, 2010; Chen et al., 2012; Teunissen, De 
Jonge, Van Weel & Lagro-Janssen, 2004). 
 
2.1.5 Definition of incontinence and dysfunction. 
Of the many definitions used to describe incontinence all incorporate the 
concept of an unrestrained or involuntary loss from either the bowel, FI, or bladder, UI. 
Some definitions incorporate aspects of urinary or faecal frequency, while others focus 
on the negative social or hygienic consequences of this involuntary loss (Abrams, 
Cardozo, Khoury & Wein, 2005; AIHW, 2006b, 2012a; Getliffe & Dolman, 2007; 
Hannestad, Rortveit, Sandvik & Hunskaar, 2000; Sims et al., 2011). While this plethora 
of definitional and interpretive positions is academically interesting, such definitional 
diversity has the potential to undermine confidence in the reliability and usefulness of 
UI or FI estimates of population prevalence (AIHW, 2012a, 2013; Doughty, 2006; 
Getliffe & Dolman, 2007; Landefeld et al., 2008). In recognition of this problem the 
International Continence Society (ICS) produced a lexicon of common incontinence-
related urological and urologynecological terms to ensure consensus and understanding 
of various aspects of bladder and bowel dysfunction. The ICS believed that by so doing 
they would ensure more consistent and accurate estimates of UI and FI prevalence 
(Abrams, Andersson, Birder, Brubaker, Cardozo, Chapple, Cottenden, Davila, de 
Ridder, Dmochowski, Drake, Dubeau, Fry, Hanno, Smith, 2010; Abrams, Artibani, 
Cardozo, Dmochowski, van Kerrebroeck, & Sand, 2006; Abrams, Cardozo, Fall, 
Griffiths, Rosier, Ulmsten, van Kerrebroeck, Victor, Wein, 2002). 
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Of particular interest to this current study is the differentiation between 
incontinence and dysfunction. This interest stems from the researcher’s own clinical 
experience of an outpatient continence clinic where people attending did not classify 
themselves as being incontinent, even though they had difficulties maintaining a 
continent state. 
Dysfunctions affecting the lower urinary tract (LUTD) are categorised by the 
ICS into storage, voiding and post-micturition dysfunctions (Abrams et al., 2012). 
Dysfunctions of urinary storage are the most commonly reported clinical symptoms 
such as diurnal and nocturnal frequency, urge or nocturia; all of which may occur with 
or without an accompanying UI. Urinary bladder emptying or voiding problems 
primarily affect men, especially in the presence of a prostatic size change which may 
involve a benign or malignant growth, resulting in urethral obstruction. This produces 
clinical symptoms such as hesitancy in micturition and retarded urine flow. Symptoms 
of post-micturition dysfunctions are those that leave a person with the feeling of not 
fully emptying their bladder or experiencing a ‘terminal dribble’ which is a small 
amount of urine leakage following what they person thinks is complete bladder 
emptying. Such symptoms are predominantly found in prostatic disease (Higa, Lopes & 
D’Ancona, 2013; Maserejian, Kupelian, McVary, Doshi, Link, & McKinlay, 2011). 
Dysfunctions of the lower bowel have not been able to be classified in a similar 
way because of the complexity of bowel neuroregulation (Awad, 2011; Vallès, Vidal, 
Clavé & Mearin, 2006). However, Landefeld et al. (2008) identified four cardinal 
physiological factors from which bowel function could be categorised: “rectal sensation; 
rectal storage; rectal emptying and behavioural or habitual bowel movements” (p. 449). 
Among older people the ability to maintain normalcy across all these functions is 
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compromised by factors that include: behavioural or habitual bowel habits; the use of 
pharmacological treatment prescribed in response to other medical conditions; changes 
in physical activity; diet and fluid intake; and slowing of gastric motility (Bhutto & 
Morley, 2008; Rayner & Horowitz, 2013). 
The ICS interpretation of ‘dysfunction’ provides a neutral description of any 
symptom that may be slower or faster than normal, or that does not meet the extreme 
symptoms of incontinence (Abrams et al., 2006). Therefore unless specified, the use of 
‘incontinence’ in this study should be regarded as different from the term ‘dysfunction’. 
In this thesis, only those terms and definitions set out by the ICS’s Scientific Committee 
on Terminology are used (Abrams, Andersson, Brubaker, Cardozo, Cottenden, Denis & 
Donovan, 2005; Abrams et al., 2010; Abrams et al., 2002; Lamontagne, Poncet, Careau, 
Sirois & Boucher, 2013). 
2.1.6 Prevalence of incontinence in the older population groups. 
The 2009 the ABS survey of UI and FI (2009a, 2009b) and the subsequent 
AIHW report on Disability, Ageing and Carers (2012a, 2013) identified 3 million 
Australians who experienced some degree of UI, 66% of whom were female. Globally, 
there is a strong correlation between gender, age and UI, with people over 60 years 
noted to have higher rates of UI than younger populations. Buckley and Lapitan (2010) 
reported prevalence rates for young-old females (60 to 79 years of age) at 30% to 61% 
and for the oldest-old (those over 80+ years of age) at 37% to 63%. For men, UI rates 
were lower than that for women, affecting 3% to 23% of men in the 60 to 79 age group 
and 8% to 22% of men aged 80+ years. In contrast to UI, FI rates between older men 
and women were reported by Whitehead et al. (2009) as being the same. They found 
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that FI occurred in less than 9% of the older (60+ years) population sampled and, unlike 
UI, they found no evidence to suggest a corresponding rise as people aged.  
Whitehead et al. (2009) also found a strong statistical correlation between the 
presence of FI and UI. The occurrence of both UI and FI is known as double 
incontinence (DI). Apart from drawing attention to the existence of this correlation, 
Whitehead et al. (2009) did not further address this finding however, Shamliyan, 
Wyman, Bliss, Kane and Wilt (2007) found a correlation between constipation, 
excessive straining of stools and DI. More recently, Akbarali, Grider, Gulick, 
Kuemmerle, Murthy, Qiao, … Yu (2012) attributed the presence of DI in ageing 
individuals to hyper-stimulation of the ageing afferent (sensory) pathways that send 
triggering messages to the anatomically aligned bowel and bladder, causing them to 
become jointly agitated. 
Comparable descriptions to the UI and FI definitions of weakness have been 
reported as occurring in epidemiological studies of incontinence. Research undertaken 
by Abrams et al. (2012), Abrams et al. (2010), Whitehead et al. (2009), Landefeld et al. 
(2008) Hawthorne (2006) and Thomas, Nay, Moore, Fonda, Hawthorne, Marosszeky, & 
Sansoni (2006) identified three common limiting factors that remain to be addressed in 
any substantive way. The first factor relates to the homogeneity and small sample sizes 
studied. The second is the use of specific procedures or diagnoses to select subjects, 
leaving little opportunity for comparisons with other research by not sharing the same 
diagnoses or providing the same procedures (Schmidt, Dogan, Langenbach & Zirngibl, 
2009). The final factor stems from the diverse and inconsistent use of definitions and 
modifications of research instrumentation (AIHW, 2013). 
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In FI, modifications were made to data collection tools, such as the Wexner 
Faecal Continence Grading Scale (Jorge, Marcio & Wexner, 1993), to either include or 
exclude uncontrolled flatus as a form of FI, allowing more participants to be classed as 
having FI when flatus is included (Sansoni, Marosszeky, Sansoni & Hawthorne, 2006; 
Santos & Santos, 2011). In UI, the multitude of diurnal, nocturnal frequency and 
nocturia definitions have resulted in ambiguous data. This problem was highlighted in a 
study on nocturia by Yoshimura (2012) and a systematic review on this same topic by 
Weiss, Wein, van Kerrebroeck, Dmochowski, Fitzgerald, Tikkinen, & Abrams (2011), 
both noting poor differentiation between nocturnal frequency and true nocturia, 
resulting in skewed results. 
Hawthorne (2006) and Chiarelli, et al., (2005) reported that the degree of 
difficulty caused by researchers choosing and then modifying instruments made it 
difficult for others to interpret or replicate previously completed research. The practice 
also contributes to the dearth of meta-analysis as researchers are unable to combine 
various small data sets (AIHW, 2013; Brickman, Coates & Janoff-Bulman, 1978; 
Coggrave, Wiesel & Norton, 2009; Getliffe & Dolman, 2007; Landefeld et al., 2008). 
Hawthorne (2006) concluded that “all of the measures [prevalence studies], to some 
degree, provided misleading estimates” (p. 69). 
Despite these important methodological problems, there is consensus that UI 
affects more women than men; that people over the age of 60 years are more heavily 
burdened by UI than younger people; that UI is more commonly reported than FI by a 
ratio of 1:5; and that men and women with FI are equally represented (AIHW, 2013; 
Brickman et al., 1978). 
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2.2 Bowel or bladder decline specifically related to the person with PD 
2.2.1 Pathogenesis of PD 
PD is a common neurodegenerative disease that is widely recognised as second 
only to Alzheimer’s dementia (Schapira, 2008) in frequency of diagnosis. PD is not 
found exclusively in older people and affects individuals in early to middle adulthood as 
well (McCall, 2003; Mellick,  2013; Špica, Pekmezović, Svetel, & Kostić, 2013).  Little 
is known about aetiology of PD development and there is little consensus in terms of 
causational theories for PD (Schapira, 2008). Over the past two decades, two areas of 
disease pathogenicity have emerged as likely explanations; first, that PD stems from a 
genetic basis and, second, that PD’s genesis is linked to environmental factors such as 
infections and toxins that create a neuro-inflammatory response (Corti, Lesage & Brice, 
2011; Hernán, Takkouche, Caamaño-Isorna & Gestal-Otero, 2002; Hernán, Chen, 
Schwarzschild & Ascherio, 2003; Morley & Hurtig, 2010); however, neither has been 
confirmed as the primary cause of bowel and bladder decline. 
2.2.1.1 Genetics 
It remains unclear how genetics may play a part in the development of PD and 
the symptoms of bowel and bladder decline, even though more than 27 genes have been 
identified as contributing to PD pathogenesis. One type of early onset PD that affects 
less than 10% of people with the disease has been directly linked to a specific autosomal 
recessive gene mutation (Corti et al., 2011). The more common clinical presentation of 
PD has a sporadic occurrence in older people and is believed to be to be more 
influenced by polymorphic gene mutation(s). It is thought that these genome profiles, 
singly or in combination, contribute to PD development by predisposing the person to a 
neuro-inflammatory reaction when in contact with unspecified environmental toxins 
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that are instrumental in dopamine cell death (Corti et al., 2011; Kumar, Lohmann & 
Klein, 2012; Schapira, 2008; Schulz, 2008). Kumar et al. (2012), Corti et al. (2011) and 
Morley and Hurtig (2010) asserted that knowledge of these high risk genes and their 
contribution to the complex pathogenesis of PD would lead to neuro-protective 
treatments and the development of more efficacious pharmacological agents as a 
response to bowel and bladder symptoms associated with PD. 
2.2.1.2 Environmental factors: neuro-inflammatory response 
Decline in bowel and bladder function may be explained by the aetiological 
theory that post viral or neuro-inflammatory responses contribute to the genesis of PD 
(Braak & Del Tredici, 2008; Kristensson, 2006; Mosley, Benner, Kadiu, Thomas, 
Boska, Hasan, … Gendelman, 2006; Ng, Lee, Cheung, Nicholls, Peiris, & Ip, 2010; 
Olanow & Tatton, 1999). According to Braak and Del Tredici (2008), an immune 
response is triggered by an unknown virus or toxin, causing a slow progressive 
deterioration of the entire nervous system, resulting in the death of nigral dopaminergic 
neurons and the laying down of Lewy bodies in their place (Kidd, 2000; Koller & 
Rueda, 1998; Lees, 2007; Powers et al., 2003; Weintraub, Comella & Horn, 2008). 
Research in this area also explored neuro-protective attributes of toxins such as caffeine 
and nicotine. Both are thought to inhibit the uptake of the neurotoxic agents or prevent 
inflammatory responses to the toxin that causes PD (Liu, Guo, Park, Huang, Sinha, 
Freedman … Chen, 2012; Noyce, Bestwick, Silveira-Moriyama, Hawkes, Giovannoni, 
Lees, & Schrag 2012; Palacios, Gao, McCullough, Schwarzschild, Shah, Gapstur, & 
Ascherio, 2012). 
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2.2.1.3 Lewy body presence in PD 
Braak and Del Tredici’s (2012) work on the LBP is recognised as the key in 
understanding the pathogenesis of PD. The foundation of their model is based around 
the progressive presence of LBP across the central nervous (CNS) and peripheral 
nervous (PNS) systems. These scientists have traced the presence and pathways of LBP 
up through the enteric nervous system (ENS) and the autonomic nervous system (ANS). 
The ANS is of particular interest to this current study, as it comprises both the 
sympathetic (SNS) and parasympathetic (PsNS) systems, which control voluntary and 
involuntary innervation to the bowel and the bladder. 
A diagnosis of PD is thought Braak and Del Tredici (2012) to be confirmed by 
the presence of Lewy body pathology (LBP), together with dopamine-producing cell 
loss within the substantia nigra. LBP is the result of an α-synucleina mutation and an 
incomplete clearance of protein synthesis within the cell, which ultimately prohibits 
normal cell functioning.  
The findings have given rise to a six-staged theory of LBP progression, the 
Braak Staging Model (Braak & Del Tredici, 2008) which tracks the pathogenesis of 
disease and cellular changes that cause symptoms to occur from the ENS up to and 
including the CNS. This model is unlike the Hoehn and Yahr (H&Y) (1967) motor 
symptom staging, which is based on post-diagnostic clinically evidenced symptom 
presentation. When comparing these models along a disease timeline, it is evident that 
PD is a slowly developing insidious chronic disease that produces a range of 
neurologically generated prodromal and cardinal motor symptoms that are hard to 
separate from ordinary non-neurological symptoms such as the bowel and bladder 
dysfunctions that are commonly found in ageing populations. 
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With an understanding of the pathogenesis of PD and symptom expression, 
especially symptoms affecting bowel and bladder function, the progressive nature of PD 
is able to be further examined using clinical assessment scales and pathological stage 
mapping. 
2.2.2 Clinical and pathological mapping of PD  
PD is highly individualistic in its presentation, yet the disease seems to progress 
through a series of logical and predictable phases, although there is variation in the 
overall time involved. Forsaa, Larsen, Wentzel-Larsen and Alves (2010) estimated 
mortality following PD diagnosis as ranging from two to 36 years.  
Hawkes, Del Tredici and Braak (2010) connected PD’s heterogeneous clinical 
picture with the irregularities in LBP and cell destruction to the subsequent neurological 
effect on internal organ function. For clinicians, the most commonly used PD trajectory 
model is the H&Y scale, a clinical staging system first developed in the early 1960s 
(Hoehn & Yahr, 1967). It focuses on clinically observable changes to motor function 
and then classifies them into five levels of disease severity. The person with PD may 
present with all or just a few of the cardinal motor symptoms used to diagnose PD 
which are: tremor, muscle rigidity, bradykinesia and postural instability. However, the 
disease does not always follow a chronological progression from one stage to the next. 
Reports in this research review indicate that people commonly accelerate through or 
completely skip these identified disease stages (Hawkes et al., 2010; Poewe & 
Mahlknecht, 2009; Zhao et al., 2010). 
The H&Y staging tool (represented in Table 2.1) was used in the current study 
to provide an interpretive guide that assisted the researcher in understanding the 
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collected data (Lees, 2010; Post, van der Eijk, Munneke, & Bloem, 2008; Zhao et al., 
2010) and grouping or categorising the data. 
Table 2.1 
H&Y Disease Severity Staging (1967) 
Stage 
one: 
diagnosis 
A mild unilateral disease. 
The initial presentation 
of cardinal motor 
symptoms. 
Mild symptoms of tremor, muscle 
rigidity, bradykinesia and minor postural 
instability. 
Stage 
two: 
A mild to moderate 
bilateral disease without 
any impairment to 
balance.  
The combination of previous symptoms 
plus problems with swallowing, voice 
changes, volume and intonation and lack 
of facial expression. 
Stage 
three: 
A moderate bilateral 
disease with postural 
instability. 
A marked deterioration of all stage two 
symptoms. In addition to problems with 
balance and postural stability. The person 
now requires some assistance with daily 
living. 
Stage 
four: 
A moderate to severe 
bilateral disease with 
some ability to walk or 
stand with assistance. 
A noticeable deterioration in all previous 
mentioned symptoms. The person now 
has significant problems with balance and 
is now no longer able to mobilise 
independently. 
Stage 
five: 
A severe disease where 
the person is wheelchair 
bound or bedridden. 
Significant deterioration in all symptoms. 
Now the person is confined by their motor 
symptoms to a bed or chair.  
 
To demonstrate the pathological and clinical relationship between the Braak 
staging model and the H&Y disease severity staging (see Figure 2.1), Hawkes et al. 
(2010) formulated a chronology of disease progression across a 40-year timeline from 
prodromal to post-clinical status. Twenty years was chosen for each period as it covers 
timeline variations known to occur in PD symptom expression (Hassan, Wu, Schmidt, 
Malaty, Dai, Miyasaki, & Okun, 2012; Hely, Morris, Traficante, Reid, O’Sullivan, & 
Williamson, 1999; Ross, et al., 2012; Zhao et al., 2010). During the prodromal stage, 
Braak and Del Tredici (2008) identified early LBP presence along the ENS where PD 
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non-specific symptoms such as bowel and bladder dysfunction are detected as a result 
of death of 80% of dopamine cells causing the cardinal motor symptoms most 
commonly associated with PD and inevitably, the death of the individual (Hoehn & 
Yahr, 1967). 
 
 
Figure 2.1. PD timeline.  Abbreviations: CA2=second section of the Ammon’s horn; CN X=motor 
component of cranial nerve X; RF=reticular formation; CN=central subnucleus of the amygdala; Meynert’s 
N=basal nucleus of Meynert; PPN=pedunculopontine tegmental nucleus; TEC=transentorhinal cortex. H (Hawkes 
et al, 2010, p. 80). 
The Baarak and Del Tredici model has relevance for the current study in 
particular during the first three stages where LBP is seen as affecting the ANS and 
progressive degeneration of bowel and bladder function (Hawkes et al., 2010), causing 
difficulty in emptying one's bowel as well as slowing faecal waste movement 
throughout the gastrointestinal tract (GIT), resulting in constipation. The bladder is also 
affected by neurological changes that cause detrusor hypersensitivity and sphincter 
 30 
 
dyssynergia (Braak & Del Tredici, 2008; Lim, Fox & Lang, 2009; Sakakibara et al., 
2008; Sakakibara, Tateno, Kishi, Tsuyuzaki, Uchiyama, & Yamamoto, 2012). 
Chaudhuri and Odin (2010) also noted pain and generalised bodily discomforts as 
further evidence of ANS neural pathway damage. On this basis, early yet clinically 
insignificant symptoms of pain, constipation and urinary detrusor hypersensitivity and 
dyssynergia, could be regarded as potential early predictors of PD and contribute to 
early diagnosis (Abbott, Petrovitch, White, Masaki, Tanner, Curb, Grandinetti, 
Blanchette, Popper, Ross, 2001; Awad, 2011; Del Tredici & Braak, 2012; Krishnan et 
al., 2011; Ross et al., 2012). 
2.2.3 Diagnosis, morbidity and mortality of PD 
A medical diagnosis of PD is most often made in the mid-stages of the disease 
when motor dysfunctions become apparent. High rates of misdiagnosis between other 
Parkinson-like disorders such as Progressive Supranuclear Palsy (PSP) have been 
reported by Lees (2012), Corti et al. (2011), Pahwa and Lyons (2010), Williams and 
Lees (2009), Weintraub et al. (2008) and Rao, Hofmann, & Shakil, (2006). These 
revelations are usually found during post-mortems and, because it is too late to have any 
effect on the management of the disorder, they are noted as unremarkable (Lees, 2012). 
Misdiagnosis of PD is believed to be diminishing with the use of genetic testing, neuro-
imaging and transcranial ultrasound, all of which enable accurate and earlier detection 
of neuron destruction, especially in more complex clinical presentations (Morley & 
Hurtig, 2010). Issues of cost and benefit are important considerations in the early 
diagnosis of PD, especially if disease prevention is not available and efficacious clinical 
management does not respond to early intervention (Marek, Jennings, Tamagnan, & 
Seibyl, 2008; Pahwa & Lyons, 2010). 
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2.2.4 Motor symptoms and NMS in PD 
The causes of the four cardinal motor symptoms of tremor, muscle rigidity, 
bradykinesia and postural instability tend to dominate research enquiry into PD rather 
than the diagnosis and management of the disabling symptoms of NMS—such as 
depression, anxiety, mental confusion, sleep disturbances, alterations in taste and smell, 
constipation and urinary dysfunction which are often overlooked by primary care 
physicians and medical specialists (O’Sullivan et al., 2008; Gallagher, Lees & Schrag, 
2010; Li et al., 2010; Mehndiratta, Garg & Pandey, 2011; Hassan et al., 2012; Noyce et 
al., 2012; Martinez-Martin et al., 2013).  
In 2006, Chaudhuri, Martinez Martin, Schapira, Stocchi, Sethi, Odin,… 
MacPhee recommended that the most commonly reported NMS should be formally 
identified. The resulting instrument, the NMS severity scale (NMSS) grouped these 
NMS into nine sub-groups according to their effect on the person’s  gastrointestinal 
tract; urinary system; cardiovascular system; sleep and fatigue; mood and cognition; 
perceptual problems and hallucinations; attention and memory; sexual functioning; as 
well as those symptoms not able to be clearly differentiated into systems or groupings 
such as pain, sensory deficits, weight gain and diaphoresis (Chaudhuri, et al., 2006). 
Since then, the research focus related to NMS has been more on validating the 
tool (Chaudhuri, Martinez-Martin, Brown et al., 2007; Martinez-Martin et al., 2013; 
Martinez-Martin et al., 2009), rather than on investigating the influence of NMS on the 
life quality of those with PD (Hinnell, Hurt, Landau, Brown & Samuel, 2012; Soh, 
Morris & McGinley, 2011). A systematic review of QoL within the PD literature by 
Soh et al. (2011) suggested that motor symptoms should not be considered solely 
responsible for poorer QoL, even though that research did not formally clarify the 
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relationship between poor QoL and other NMS. They attributed this lack of research 
interest in NMS symptoms to the fact that they are harder to manage, a factor of 
particular interest to this current study, especially the area of autonomic symptoms.  
Attempts to bridge the gap between specific non-motor aspects of PD and QoL 
were made by Shearer, Green, Counsell and Zajicek (2012), Hinnell et al. (2012), Soh et 
al. (2011) and Gallagher et al. (2010). Dysautonomias affecting the bowel and bladder 
were found to be statistically associated with poorer QoL, yet they were undervalued 
and poorly understood beyond that of their pathophysiology (Sakakibara et al., 2008; 
Sakakibara et al., 2012). This knowledge gap between knowing that bowel and bladder 
dysautonomias exist in this group of people and what effect they exert on a person’s life 
is of interest for the current study. 
2.2.5 Bowel and bladder dysautonomia in PD 
In PD, two of the most commonly reported NMS are constipation and lower 
urinary tract symptoms (LUTS) (Gallagher et al., 2010; Lim & Lang, 2010; Mehndiratta 
et al., 2011; Vaughan, 2012). People with PD commonly report problems with urinary 
storage: 60% report nocturia; 54% urinary urgency and 36% report urinary frequency; 
only 26% describe themselves as having UI (Kishi et al., 2011). Smaller numbers of 
people with PD (44%) describe their LUTS as a dysfunction of voiding, and men (70%) 
were more highly represented in this symptom group than women (28%) (Sakakibara et 
al., 2012). 
An understanding of the cause of these symptoms generates insights on the 
challenges faced by people with PD experiencing these symptoms. Essentially, PD 
causes LBP disruptions along the ENS and the ANS neurological pathways, which 
communicate incoming messages and outgoing instructions to the bowel and the 
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bladder (Blumenfeld, 2002; Sakakibara et al., 2008; Sakakibara et al., 2012). The ANS 
incorporates the sympathetic (SNS) and parasympathetic (PsNS) nervous systems. With 
regard to the bowel the SNS is responsible for maintaining anal sphincter closure, while 
the PsNS initiate’s a relaxation of this same sphincter, allowing the person to defecate. 
The effective neural coordination of both these systems balances the needs and 
requirements of the individual so that they remain socially continent (Blumenfeld, 2002; 
Politis et al., 2008; Weaver et al., 2009). 
Neurological control of the GIT is additionally controlled by the ENS 
(Lebouvier et al., 2009). The ENS coordinates the peristaltic muscle contractions that 
mix and move gastric contents, and regulates mucosal secretions and absorptive 
functions of the GIT. In PD faecal movement along the GIT is compromised due to the 
LBP on the neural pathways which create dyssynergy between the GIT’s ability to relax 
and contract, resulting in faecal expulsion difficulties (Cadeddu et al., 2005; Fowler, 
Sakakibara, Frohman, Brady & Stewart, 2007; Sakakibara et al., 2008).  
Bladder control is also affected by the LBP, because it alters the dopamine-basal 
ganglia pathways that induce the detrusor muscle to become hyper-contractile and 
disinhibited, causing urinary urgency and frequency which is most often reported by 
people with PD (Braak & Del Tredici, 2008; Lim et al., 2009; Sakakibara et al., 2008; 
Sakakibara et al., 2012). 
Constipation is reported to affect between 70% and 100% of people with PD, as 
compared to 0% to 30% in aged-matched populations without this disease (Gao, Chen, 
Schwarzschild & Ascherio, 2011; Kaye, Gage, Kimber, Storey & Trend, 2006; Rayner 
& Horowitz, 2013; Sakakibara et al., 2008). High levels of LUTS, between 30% to 
70%, also affect people with PD (Iacovelli et al., 2010; Sakakibara et al., 2012; 
 34 
 
Sammour et al., 2009; Vaughan, 2012). However, unlike bowel dysfunction, age-
matched prevalence estimates were difficult to locate in the literature, probably because 
of the difficulty in differentiating between people with PD who reported LUTS 
conditions, and age-matched non-diseased populations with UI. It is possible that the 
combination of expected high prevalence of LUTS in older populations makes it 
difficult to determine whether PD or age is the lead aetiological factor (Sammour et al., 
2009).  
Findings by Iacovelli et al. (2010) that age-matched healthy subjects 
demonstrate lower incidence of LUTS symptoms compared to their participants with 
PD, are consistent with those of Kishi et al. (2011), Winge, Skau, Stimpel, Nielsen and 
Werdelin (2006) and Sakakibara et al. (2001), Iacovelli and colleagues (2010) who 
compared their research samples against non-disabled cohorts from other studies. These 
general community prevalence studies presented LUTS or UI rates in women older than 
65 years as being between 30% and 60% and, in men, 3% to 23% (Buckley & Lapitan, 
2010); a result that is considerably lower than that found in PD populations.  
Reimann et al.’s (2010) study of the autonomic NMS incidence between PD and 
Parkinsonism syndromes also found similar rates of autonomic NMS occurring between 
those with PD and with PSP and importantly, the healthy neurologically intact control 
group were found to have frequency rates significantly different from those with PD. 
For those reporting constipation, a frequency of 11.1% was found in the control group 
as compared to 47% of the PD group. For urinary urgency, a frequency of 3.7% was 
reported in the control group as compared to those with PD, who reported urge at 
33.3%. UI was also reported as occurring with greater frequency in the PD group 
(33.3%) as compared to the control group (11.1%). 
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In the current study, the lack of research inquiry into symptoms and the findings 
outlined above are used as a basis for the argument that the presence of bowel and 
bladder dysfunction in this group of older adults is caused by LBP damage to their 
neurological pathways, rather than by age or gender-related characteristics.  
2.3 Bowel and bladder dysfunctions: distinguishing between ageing and PD 
presentations 
International reports indicate that common NMSs remain clinically under-
recognised and therefore under-treated in both PD specialised settings and in general 
medical clinical practices (Hu et al., 2011; Mehndiratta et al., 2011; Reimann et al., 
2010; Tolosa et al., 2009; van der Marck et al., 2009; Vaughan, 2012); nor has this topic 
received attention in Australian research. Reasons given for low rates of clinical 
detection include: restrictive clinical consultation times; the reluctance by the person 
with PD to raise NMS concerns with their doctor; and the difficulties encountered by 
both the neurologist’s and the GP’s ability to distinguish between age-related versus 
autonomic bowel and bladder dysfunctions (Hawkes, 2008; Hu et al., 2011). 
Difficulties in distinguishing between age and PD-related functional and 
physiological bowel and bladder dysfunction relate to aspects of diagnostic blurring and 
prejudicial attitudes held by clinicians (Bennett & Gaines, 2010; Higashi et al., 2012; 
Linden & Kurtz, 2010), as well as those held by persons with PD (Elenskaia et al., 
2011; Hatano, Kubo, Shimo, Nishioka & Hattori, 2009; Pearson, Tucker, Bolt et al., 
2002; Stewart et al., 2012). Doctors have been reported as not recognising or 
acknowledging the existence of PD in the management of their patients’ autonomic 
complaints (Hatano et al., 2009). This is consistent with people with PD complaining 
that their reports of NMS were either ignored or dismissed and that the much-needed 
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information they require to manage these NMS was not given. When Hatano et al. 
(2009) interviewed people with PD together with their carers, asking them about the 
care they received from their GP and PD neurologist, a range of unmet needs emerged, 
and inefficiencies in managing their autonomic dysfunctions were noted. Hatano’s study 
concluded that improved communication between doctors and their patients would 
enable them to focus on the neurological cause of the NMS rather than on the person’s 
age.  
As mentioned above, UI or FI are not part of normal ageing and while the 
prevalence of incontinence is higher in the older person, it is multi-factorial (AIHW, 
2012a; Jeste et al., 2010; Kraus et al., 2010; Liang et al., 2010). Discriminating between 
symptoms arising from normal age changes and pathological changes can be 
confounded by many other factors that feature among the older population. Factors such 
as the presence of multiple chronic conditions increase the likelihood for the older 
person to experience incontinence (Dmochowski & Gomelsky, 2011; Higa et al., 2013). 
The use of pharmaceutical agents used to manage these co-morbid states increases the 
likelihood of incontinence (Dmochowski & Gomelsky, 2011; Rayner & Horowitz, 
2013), and older people who are more socially isolated or functionally disabled by their 
chronic states are more likely to suffer incontinence (Chen et al., 2012; Hatfield, Hirsch 
& Lyness, 2013; Liang et al., 2010). 
Gerontological researchers such as Vaughan (2012) regard ageing and physical 
frailty as coexisting concepts and view bowel and bladder dysfunctions as linked, 
regardless of the pathophysiology involved. The problem with such an approach is the 
limitations it can place on clinician perceptions of what may be occurring for people 
with PD or other disease and encourage less than optimal effort in achieving a working 
 37 
 
and accurate diagnosis that can lead to effective interventions and greater understanding 
of the challenges faced by those with such symptoms. 
2.4 Conclusion 
The paucity of clinically validated treatments for UI, urinary dysfunctions and 
constipation leaves people with PD at risk of having clinical treatments chosen without 
due regard to the symptom biological origin. The inattention to these autonomic 
symptoms biological aetiology by treating doctors, has contributed little to the efficient 
elimination of these burdensome symptoms, nor does it provide a sound rationale to the 
person with PD as to why these symptoms are present. The limited acknowledgment of 
these biologically based personal burdens reflects a major gap in current PD knowledge 
and in not acknowledging these biological issues the person with PD is less able to 
sustain a positive attitude and to remain socially connected and resilient. In response, 
the current study has decided to locate PD within a disability construct as it enables a 
focus on how people live and manage these autonomic bowel and bladder NMS without 
negating their diseases’ biological origins. In understanding the biological, 
psychological and social mechanisms and challenges faced by this group of people, the 
possibility emerges for more insightful and effective clinical interventions.  
Clearly, PD is an unsettling and relentless disease that incorporates bowel and 
bladder NMS. It is poorly researched in terms of the burden facing those who have PD 
as well as those who care for and service them. Personal wellbeing requires competent 
clinical management, as well as advice and support related to living with an intrusive 
and unsettling chronic disease. These issues have been identified as stemming from 
gaps in research, which influence the clinical interventions offered to people with PD 
and as such are the focus of investigation in this study.   
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Chapter 3: Theoretical constructs underpinning quality of life and burden 
This chapter locates PD within a disability construct building on the biological 
concepts of age and disease discussed in the previous chapter; a conceptualization found 
to be wanting in terms of clarifying the needs of people with PD so that they are able to 
adequately manage their neurologically induced bowel and bladder dysfunction. By 
positioning these disease generated symptoms within a disability framework, the 
burdensome issues as experienced by the sufferer can be re-examined and re-
conceptualized. The research reviewed in this chapter explores current understanding of 
personal burden and disability; and identifies knowledge gaps in preparation for 
exploration of the following research aims to: 
 identify the origin and resulting burdensomeness of PD dysfunctions;  
 explore the ways these dysfunctions disrupt the subjective experience of a 
good life; and 
 describe how the individual incorporates and manages PD related 
dysfunctions in their life regardless of their age.   
By embedding these aims within disability, rather than a biological construct of 
age and disease, quality of life and burden impact are more effectively examined. 
 
3.1 Quality of life (QoL) and health related quality of life (HRQoL) 
The International Classification of Impairments, Disabilities and Handicaps 
(ICIDH) adopted by the World Health Organisation (WHO) in 1980 recognised the 
importance of environmental factors resulting in a disability becoming a handicap. Not 
unsurprisingly, dissatisfaction with this linear model led to several revisions 
culminating in the adoption of the International Classification of Functioning, Disability 
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and Health (ICF) in 2001 (WHO, 1980, 2001) The ICF is an innovative framework that 
builds upon the narrow medical or biological focus of chronic disease and disability to 
incorporate a broader bio-psycho-social approach. In so doing, a wider range of 
professionals working with people who have a disability have been engaged in 
considering the impact of causal factors on the person’s ability to participate in life. The 
ICF framework is used in this research to express a comprehensive bio-psycho-social 
approach to quality of life in the context of a person having a disability.  The ICF model 
is well regarded within the disability services research community and remains at the 
forefront in the exploration of issues related to burden, disability and community 
participation. 
The International Classification of Diseases (ICD-10) (WHO, 2008) a medical 
disease taxonomy currently under its eleventh revision, and the International 
Classification of Functioning, Disability and Health (ICF) (WHO, 2001) are  both a part 
of the WHO Family of International Classifications, and are used together in this study 
to provide a multiple layered coverage of the topic (see Figure 3.1). 
 
Figure 3.1 ICF framework (WHO, 2001; Bambra, Fox & Scott-Samuel, 2005). 
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The ICD categorises a ‘disability illness’ or ‘disease’ according to its aetiology. 
This taxonomy forms the first component of the ICF ‘health condition’, which in this 
study is PD. Factors, intrinsic and extrinsic to the PwD, are derived from the ‘health 
condition’ term and work in dynamic interaction with each other, creating influences 
that either inhibit or promote social inclusion, participation and the performance of daily 
activities.  For instance, continence is a body function that, if working well, does not 
interfere with people’s ADL or interrupt their social participation (see Figure 3.1). 
However, when PD disrupts the neurological function needed for appropriate bladder 
management, the person perceives a need for changes to be made in their activities and 
participation in a range of activities and areas of life engagement. Biological 
dysfunctions can also influence or be influenced by personal factors (intrinsic) and 
environmental factors (extrinsic) (see Figure 3.1), which complicate one's ability to 
participate and perform daily activities while compensating for the hurdles arising from 
their condition. These environmental and personal factors, or barriers, stem from 
financial, architectural and attitudinal influences and can contribute to or inhibit the 
person's connectedness with others, as well affecting their ability to adequately perform 
daily activities. The usefulness of the ICF is that it demonstrates a link between the 
ability of a PwD to function in their community and the individual facilitative or 
inhibitive contextual factors such as body dysfunction, cultural and attitudinal 
variations. These in turn enable researchers to identify and individualise the origin of 
the ‘burden’ incurred by the PwD (Nilsson, Westergren, Gunilla & Hagell, 2010).  
Being connected in positive ways with others is important in decreasing a 
person’s feelings that they are a burden. Poor social connectedness is reported to 
contribute to poor Quality of Life (QoL) experiences, which ultimately decrease an 
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individual’s ability to make effective changes and adaptations in response to their 
illness trajectory (Alma et al., 2012; Cote, Sprinzeles, Elliott & Kutscher, 2000; Gage, 
Hendricks, Zhang & Kazis, 2003; Garber & Friedman, 2003; Levasseur, Desrosiers & 
Noreau, 2004). Feelings of self-worth and optimism are also inextricably linked to the 
contribution a person believes they bring to a relationship with others. Alternatively, 
feelings of being a burden to those nearby, with no means of social reciprocity, have 
been linked to lower levels of life satisfaction (Olsen & Dahl, 2007; Verbrugge & Chan, 
2007). 
The linking of QoL to social participation and one's ability to adapt to life 
changes is not new. QoL researchers including Parmenter (1996), Montbriand (2004), 
Burton-Smith, McVilly, Yazbeck, Parmenter and Tsutsui (2009), Gallagher et al. (2010) 
and Alma et al. (2012) have all stressed the importance of a balanced life that includes 
aspects of both valued work and social activities for PwD. 
It has been claimed that the presence of a bowel or bladder symptom in people 
with PD does not elicit negative QoL responses (AIHW, 2012; Clarke & Bennett, 
2012). It is when these symptoms compromise the person’s usual, independent and safe 
access to a toilet, or when the symptom attracts unwanted attention, or when the person 
requires assistance to perform this self-care activity, that changes in QoL are reported 
(AIHW, 2012; Bichard & Knight, 2010; Clarke & Bennett, 2012; Khan, Pallant, Shea & 
Whishaw, 2009; Rahman et al., 2008; Slieker-ten Hove et al., 2010; Stenzelius, 
Mattiasson, Hallberg & Westergren, 2004; Vaughan et al., 2011).  
FI and UI are viewed in a negative way by modern society, as are attitudes held 
by the individual who is suffering from incontinence (Cochran, 2000; Elenskaia et al., 
2011; Keegan, 2012). Elenskaia et al. (2011) found that 60% of their study population 
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reported an extreme and debilitating embarrassment and shame in response to their UI. 
These negative feelings about incontinence are reported in the literature as affecting 
self-worth and creating an environment in which optimism is hard to maintain 
(Esbensen, Thomé & Thomsen, 2012; Fässberg et al., 2012; Haynes & Watt, 2008; 
Sells et al., 2009). Such feelings impede the older person’s ability to initiate or 
participate in social activities as they once did and they become less resilient in response 
to changes in their disease profile. It is at this point that a person’s QoL is reported to 
decrease with a concomitant increase of feelings of being a burden on others (Esbensen 
et al., 2012; Gallagher et al., 2010; Haynes & Watt, 2008; King, Willoughby, Specht & 
Brown, 2006; Sells et al., 2009). 
The WHO defined QoL as an “individual’s perception of their position in life in 
the context of the culture and value systems in which they live and in relation to their 
goals, expectations, standards and concerns” (WHOQOL Group, 1998, p. 1). QoL and 
Health Related Quality of Life (HRQoL) are terms used interchangeably in the health 
literature. QoL is a multi-dimensional construct, which incorporates daily physical 
mental and social functioning (de Boer, Spruijt, Sprangers & de Haes, 1998; Fleming, 
Cook, Nelson & Lai, 2005). HRQoL, is a more specific QoL measure that looks at 
changes in an individual’s lifestyle perceptions as they relate to their health or to a 
specific disease (Bowling, 1995; Forsaa et al., 2008; Walsh & Bennett, 2001). HRQoL 
tools have been primarily used by researchers to review and support the effectiveness of 
a health program or a medical intervention within specific disease groupings. These 
tools have become important indicators providing the evidentiary justification needed in 
tight fiscal environments, where resource allocation is hotly contested (Gage et al., 
2003). 
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Very little has been reported about the effect bowel and bladder symptoms have 
on QoL for people with PD (Gallagher et al., 2010; Hinnell et al., 2012; Jellinger, 
2009), in comparison with the multitude of reports on the NMS pathophysiology 
(Sakakibara et al., 2012), clinical presentation, differential diagnosis and treatment 
options available (Vaughan, 2012; Zesiewicz et al., 2010). This is despite the fact that 
these symptoms are recognised as affecting the majority of people with PD and are 
reported as significant contributors to disturbances in QoL (Gallagher et al., 2010; 
Hinnell et al., 2012).  
3.2 Measuring HRQoL in chronic illness: PD and bowel and bladder dysfunction 
The medical fraternity have taken a great interest in HRQoL measures, viewing 
them as ideal tools for evaluating therapeutic interventions, unlike sociologists who 
emphasise the subjective experiences of the individual. There is a multitude of 
specifically tailored HRQoL measures used primarily to assess health outcomes and 
program goals, although very few were developed or stemmed from the person’s 
perspective of what they saw as important (Bowling, 1995; Montbriand, 2004; 
Parmenter, 1994). The following is a list of HRQoL tools specifically developed for 
people with PD (Pablo Martinez-Martin et al., 2011):  
1. Belastungsfragebogen Parkinson Kurzversion (BELA-P-k) by Ellgring et al. 
(1993) 
2. PDQ-39 by Peto et al. (1998) 
3. PDQ Short Form (PDQ-8) by Jenkinson, Fitzpatrick, Peto, Greenhall and 
Hyman (1997b) 
4. Parkinson’s Impact Scale (PIMS) by Caln, Schulzer, Mak et al. (1996) 
5. PDQoL Questionnaire by de Boer, Wijker, Speelman and de Haes (1996) 
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6. PDQoL Scale (PDQUALIF) by Welsh, McDermott, Holloway et al. (1997) 
7. Parkinson’s Problem Schedule (PPS) by Brod, Mendelsohn and Roberts 
(1998) 
8. Scales for Outcomes in PD– Psychosocial (SCOPA-PS) by Marinus, Visser, 
Martinez-Martin, van Hilten and Stiggelbout (2003). 
Ahan, Saderberg and Lundman (2003) Curtin and Lubkin (1995), Glueckauf and 
Ketterson (2004), Ironside et al. (2003) and Martire, Lustig, Schulz, Miller and 
Helgeson (2004) have agreed that a chronic illness has negative effects on an older 
person’s QoL. However, for many years QoL researchers such as Montbriand (2004), 
Bowling (1995) and Parmenter (1994) have warned that grouping subjects solely 
according to their disease states will only result in a skewed view of HRQoL and 
chronic illness, and endorse the negative perception held by many health professionals 
that all older people have a poor QoL (Hyde, Wiggins, Higgs & Blane, 2003; 
Montbriand, 2004). Similar views can be seen in UI and FI HRQoL studies, where 
subjects are narrowly selected according to their gender and their age (Heidrich & 
Wells, 2004). As a result, healthcare providers may come to the erroneous belief that all 
older females are incontinent and have a low QoL potential. 
A review was undertaken of 200 PD-specific HRQoL studies published between 
the year 2000 and 2013 to explore their intent. It revealed that HRQoL tools were used 
in PD in three distinct ways: 
1. To validate the effectiveness of clinical interventions or programs (Ellis et 
al., 2005; Slowinski et al., 2007). 
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2. To measure QoL disturbance, specific to a particular motor or NMS such as 
facial animation (Huang, 2009; Tickle-Degnen & Lyons, 2004) or restless 
leg syndrome (Gomez-Esteban et al., 2007), and  
3. To validate or test pre-existing tools or develop new PD-specific HRQoL 
tools (Franchignoni et al., 2008; Johan Marinus, Visser, Martínez-Martín, 
van Hilten & Stiggelbout, 2003; Marinus, Visser & Stiggelbout, 2004; 
Martinez-Martin, Serrano-Dueñas, Forjaz & Serrano, 2007). 
Only 19% of the reviewed research focused on the person living with the 
disease. The remaining 81% evaluated the efficacy of health practitioners’ interventions, 
while others focused on reviewing, trialing or validating specified HRQoL tool(s). 
Table 3.1 summarises these findings in terms of the three outlined areas of HRQoL 
research focus.  
Table 3.1 
Review of 200 PD-specific HRQoL studies published between 2000 and 2013 
 Group 1: 
A HRQoL tool used 
to validate the 
effectiveness of 
clinical interventions 
or programs. 
Group 2: 
A HRQoL tool used to 
measure QoL 
disturbance, specific 
to a particular motor 
system or NMS. 
Group 3: 
A HRQoL study 
used to validation or 
test pre-existing or 
develop new PD-
specific HRQoL 
tools. 
Total 
N(%) 52 (26%) 38 (19%) 110 (55%) 
These findings support the view that current HRQoL research does not primarily 
focus on the person with the chronic illness or disease, and that the multidimensionality 
of HRQoL research in the context of the WHO’s definition is addressed only in the 
simplest of ways. This is a research deficit which, according to Montbriand (2004) and 
Parmenter (1994), reduces the living human entity to a collection of diseased parts. It is 
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suggested that HRQoL research needs to be more focused on the person who interacts 
with their environment in a dynamic way according to their interpretations, experiences 
and expectations. In this way, influences thought to affect HRQoL, such as social 
isolation, perceptions of being a burden on others and the economic effects of living 
with a chronic illness, can be explored (Engstrom & Nordeson, 1995; Hagell & Nilsson, 
2009; Schrag, Jahanshahi & Quinn, 2000). 
People living with a chronic illness like PD and symptoms such as incontinence 
are less likely to participate in social activities outside their home, promoting social 
isolation and decreasing their perception of having a good life (Cardol et al., 2002; 
Gallagher et al., 2010). Whetten-Goldstein, Cutson, Zhu and Schenkman (2000) 
identified financial worries as a significant factor known to contribute to social 
isolation. The expense of buying disposable continence products could prompt a person 
with a chronic illness to choose between participating in a social activity and purchasing 
equipment that allows them to remain clean and dry. Cousineau, McDowell, Hotz and 
Herbert (2003) further expanded this point in their finding that in addition to direct 
financial factors, non-monetary worries such as fear, anxiety or the lack of social 
assistance and support also isolated people.  
Haynes and Watt (2001), McPherson et al. (2007), McPherson, Wilson, 
Lobchuk and Brajtman (2007) and McPherson et al. (2007) described how people with 
chronic illnesses feel inhibited to ask for assistance and prioritise needs like showering, 
eating or dressing over non-essential social activities so as not to be a burden on others. 
The decision by people to prioritise care requests provides an insight into the 
complexities of using an informal care-giver who is also a spouse, and into how those 
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requiring care and those providing this assistance still require some reciprocal exchange 
so that feelings of dependence and burden are minimised (Cousineau et al., 2003; 
Martinez-Martin, Forjaz et al., 2007; McPherson et al., 2007; McPherson, Wilson, 
Lobchuk & Brajtman, 2007).  
Reports by Murray et al. (2005) and Murray and Sheikh (2008) indicated that 
people made end-of-life choices according to the level of burden they believed 
themselves to be causing. These researchers provided stories of individuals who were 
not considering an active suicide, but did consider other more socially acceptable means 
of not prolonging their lives, such as not accepting further medical intervention for an 
acute infection or not taking opportunities that could extend their lives. The issues 
surrounding reciprocity are significant and, while under-represented in the health 
literature, the importance of understanding what poor HRQoL scores could mean for the 
person with a chronic illness and the relationship between HRQoL and burden should 
not be disregarded. 
3.3 Burden 
People often discuss issues surrounding the effect their disease has on them and 
how each new symptom or issue, such as constipation or over active bladder (OAB) 
syndrome, places burden on them, affecting their physical, financial or emotional selves 
(Fuller, Welch, Backer & Rawl, 2005). These burdens have a negative effect on 
personal relationships and on the sufferer’s ability to cope and adapt to the ongoing 
degenerative changes encountered in disease states such as PD (Backer, 2000). Backer 
(2000) and Charlton and Barrow (2002) cited cases of people with PD who reported 
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feelings of overwhelming suffering that brought them to the view that life was 
intolerable. 
3.3.1 Defining burden 
Burden is used across diverse contexts spanning fields such as health, religion, 
law, politics and economics, giving rise to many opportunities for interpretations to be 
made. These fields share a central tenet that burden enumerates (objective) or rates 
(subjective) a predefined physical load that someone has to carry. To identify how 
‘burden’ is used in the PD health literature, a broad review was undertaken to provide a 
deeper understanding of the use of the term and its effect in disability and healthcare. 
The word ‘burden’ is used across many sub-specialities and sub-contexts in 
health services and varies widely in its conceptualisation and usage. The subjective 
account of ‘burden’ is used to express personal feelings and beliefs. The second use of 
‘burden’ is more objective, using numerical scores; an approach used in many disease or 
disability prevalence studies. Rarely has any study used both subjective and objective 
aspects of ‘burden’ together. The utility of this conceptual separation allows health 
economists to differentiate quantitative data from the subjective appreciation of health 
issues. However, there is a danger that the more subjective or personal aspects of 
‘burden’ can be overwhelmed or lost amid prevalence scores generated in healthcare 
and disability research using scientific positivistic methods. Quantitative representations 
of ‘burden’ have been in ascendancy for several decades. Allowing for the objective 
economic concept of disease or disablement to be measured in regard to its effect on a 
society. However, this objective measurement has little regard to the ‘burden’ 
experienced by those with a disabling chronic illness. 
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3.3.2 Objective accounts of burden 
Quantitative estimates of ‘burden’ are needed by governments and planners of 
services for social community and special needs groups addressing the needs of the 
majority (Evans & Etienne, 2010; OECD, 2011; Garin et al., 2010; WHO, 2008). A 
review of the literature on ‘burden’ revealed three dominant themes (see Table 3.2): 
1. The first defined a public face of burden; these articles used numbers of 
diseases or disabilities encountered in specified global or local communities 
found in the Survey of Disability, Ageing and Carers (SDAC) conducted by 
the ABS.  
2. The second addressed objective burden in terms of numerical indices to 
calculate life expectancy for those living with a disability. These are 
commonly known as disability-adjusted life years (DALYs) (Murray et al., 
2013; Polinder, Haagsma, Stein & Havelaar, 2012).  
3. The final theme incorporated studies that focused on the financial cost and 
societal implications of supporting people with a disease or disability within 
their social groups, in particular the cost of care and support (Jiang & 
Hesser, 2012). Each of these themes placed a numerical value on ‘burden’ as 
a basis for the allocation of resources and social planning of health and 
social care services. 
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Table 3.2 
Review of the public face of burden: studies published between 2010 and 2013 
Totals Group 1: Numbers of 
diseases or disabilities 
encountered in 
specified communities 
Group 2: Indices of 
life expectancy for 
those living with a 
disability 
Group 3: Societal 
Financial costs to 
support people with a 
disease or disability 
within their social group 
Total 
N=3407 
(100%) 
 
2278 (66.8%) 
 
229 (6.7%) 
 
900 (26.4%) 
 
PD-specific 
Total 
N=242 
(100%) 
206 (85.1%) 8 (3.3%) 28 (11.5%) 
 
The use of ‘burden’ to determine societal worth is evident within health 
economics literature. The utilitarian philosophy that underlies health economics 
evaluates the value of contributions people make against the value of the resources they 
use (Rhodes, Battin & Silvers, 2012). As a result, those with chronic health problems 
are encouraged to accept more responsibility (Porter, 2010), to be more resilient and 
self-reliant (Clarke & Bennett, 2012) and to show gratitude for the services provided to 
them (Olsen & Dahl, 2007; Verbrugge & Chan, 2007). 
The WHO and the World Bank use an economic rationalist approach to produce 
and fund epidemiological data needed for estimating current and future global 
healthcare needs. Personal illness, disability and disease experiences are configured into 
internationally comparable statistics used to predict and make recommendations for 
distribution of health resources (Garin et al., 2010; OECD, 2011). On this basis, the 
WHO and the World Bank are able to present comparable measures and projections, 
used to plan for the global distribution of scarce health resources to emerging 
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economies. Numerical ‘burdens’ of disease ratings are also used to disseminate 
information to developed economies using similar measures so that they may gauge 
their own healthcare resource needs and plan against future trend projections (Graycar, 
1983; Hillermann, 2008; Malhotra, 2008; OECD, 2011; Olsen & Dahl, 2007; Pusey, 
2003; Rhodes et al., 2012). 
3.3.3 Subjective accounts of burden (Personal Burden) 
In contrast to objective ‘burden’ described above, the subjective dimension of 
burden centres on the physical, emotional or economic needs of individuals with an 
illness, disease or disability, their family and their informal care networks. Literature on 
the topic of ‘burden’ as a subjective phenomenon was found to have three themes.  
1. Burden as told by the individual with the chronic disease, in this case PD.  
2. Burden as experienced by others caring for the person with PD, primarily the 
spouse or daughters of the person with PD.  
3. The public, society-based burden focused on large groups diagnosed with the 
disease.  
The assumption that the literature would focus on subjective issues and would 
explore the more personal aspects of burden in as much detail and with an equal 
distribution across all the themes proved to be incorrect. In a similar way to literature 
around objective ‘burden’, subjective burden research also tended to discount the 
experiences of individuals with the disease. Preference was given to the voices of 
others, such as families and caregivers, exploring their emotional or economic hardships 
and disruptions. The person living with the chronic disease was often regarded as 
simply providing context for the ‘burden’ of those nearby (Davis, Gilliss, Deshefy-
Longhi, Chestnutt & Molloy, 2011; Martinez-Martin, Rodriguez-Blazquez & Forjaz, 
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2012; McLaughlin et al., 2011; Razali, Ahmad, Rahman, Midin & Sidi, 2011; Shin, 
Lee, Youn, Kim & Cho, 2012). 
3.3.4 Depiction of burden in published research 
The current ambiguity related to the depiction of burden by researchers is 
summarised in Figure 3.2, this figure illustrates the ways burden is interpreted and used 
in scholarly literature to date. The person with PD is depicted as a one-way contributor 
and as a causal factor within the larger scheme, not as a multi-dimensional participant 
acknowledged as being burdened by the disease. Researchers such as Martinez-Martin 
et al. (2012), Martinez-Martin et al. (2008), Shin et al. (2012) and Razali et al. (2011) 
have linked PD with the individual by describing their symptoms, physiological 
dysfunction or their effect on others, rather than as a person burdened or limited by their 
symptoms. This one-way representation is denoted by a broken line in Figure 3.2.  
Indicative of Personal Burden Indicative of Public Burden  
Disease      Epidemiological 
data 
 
     
Economic 
effect of 
the 
disability 
or disease  
  
 
Effect on 
self 
 Effect on 
family or 
carers 
   Effect on 
society: 
Prioritisation 
of services 
Figure 3.2  
Depiction of burden in published research 
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A computer search using ‘burden’ as a key term in the Medline and Cumulative 
Index to Nursing and Allied Health Literature (CINAHL) health and medical databases 
for 2005 to 2013 revealed that 98% of Medline and 95% CINAHL articles that mention 
the issue of burden did not address burden as it is encountered by the sufferer. Most 
recounted a macro or society-based view to support the socio-political effect of each 
symptom, disability or disorder and the potential burden on the global, geographical or 
culturally defined community. 
The search for researcher uses of burden used the word ‘burden’ as the primary 
or starting key search term and then new keywords generated from the literature were 
introduced one at a time to create a broad search lattice. Search limitations applied to all 
searches were that articles be based on human research, published within 2005 to 2013 
and published in English. The initial ‘burden’ score of articles was, in Medline, 46,258, 
and in CINAHL, 11,938. The unequal ratio was expected, as CINAHL, a database 
primarily generated for nurses and allied health professions, is more inclined to generate 
less large-scale positivist research than is found in the medical database Medline.  
Key words generated from within the literature were: psychological factors, 
coping, stress, disability and psychological adaptation. These keywords were used 
singly and then in combination with ‘burden’ to refine the search. Finally, the key term 
of PD was used to sort the most relevant articles, which were then retrieved. Twenty-
two duplicate articles were recognised and removed from the searches, leaving 39 
articles relevant to PD. The process and findings are summarised in Table 3.3. 
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Table 3.3 
Medline and CINAHL literature pubilished on burden between 2005 to 2013  
Medline Burden *Psychological factors *Coping *Stress *Disability *Psychological adaptation Total 
Sub-total 46258 1800 7051 28013 131909 24964 193737 
Combined burden and * 
 
27 183 818 1953 699 3680 
Per cent of total burden 
 
1.5 2.59 2.92 1.48 2.8 1.89 
PD and burden and * 
 
0 1 8 0 6 15 
Total percent of combined burden and * (% of total burden) 0.40% (0.007%) 
6 Duplicates removed 
Leaving 9 
CINAHL Burden *Psychological factors *Coping *Stress *Disability *Psychological adaptation Total 
Sub-total 11938 669 11997 42990 21070 7831 84557 
Combined burden and * 
 
17 672 2838 737 233 4497 
Per cent of total burden 
 
2.54 5.6 6.6 3.49 2.97 5.31 
PD and burden and * 
 
0 6 30 8 2 46 
Total percent of combined burden and * (% of total burden) 1.02% (0.054%) 
16 Duplicates removed 
Leaving 30 
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Each of the final articles was categorised according to research focus and 
previously established themes. These were—Group 1: The individual with PD’s 
experience of burden (N=5, 12.8%), Group 2: The burden experienced by the family as 
informal carers (N=25, 64.1%) and Group 3: The burden experienced by society (N=9, 
23%). A full listing of this reviewed literature is provided in Appendix A. Only 5 
articles included a discussion about the burden PD places on the individual, with the 
other 87% referring to the effect the disease has on others, either caring for the sufferer 
or accounting for the monetary or non-monetary costs encountered by the family or 
wider society. This finding is not unique to PD; other chronic illnesses, such as 
Alzheimer’s and strokes, are also noted to be similarly addressed, especially if the 
sufferer is an older adult (Ahan et al., 2003; Cousineau et al., 2003; Haynes & Watt, 
2008; McPherson, Wilson, Lobchuk & Brajtman, 2007). 
The information gathered from these searches began to frame the argument that 
the word ‘burden’ has been captured by health economists and researchers to objectify 
those with chronic illness as causes of burden on others. McGuire et al. (2002) called 
for the use of burden to be more consistent, stating that one of the major issues with the 
concept of burden is its inconsistent usage. They stated that, in the main, the lack of an 
agreed definition beyond that of simply “a negative impact of illness” (McGuire et al. 
2002, 179) has prohibited researchers seeing burden beyond the effect on others. The 
everyday use of the term ‘burden’ in conversation or in the context of discussions 
between health consumers and their health practitioners embeds the burdensomeness of 
the disease for them (Davis et al., 2011; Fässberg et al., 2012; McPherson, Wilson, 
Lobchuk & Brajtman, 2007; McPherson, Wilson & Murray, 2007; Verbrugge & Chan, 
2007). 
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3.4 Adaptation 
Little is known about how non-disabled older adults maintain a positive QoL. A 
study by Hildon, Smith, Netuveli and Blane (2008) found that well older adults are 
more resilient to adverse or small changes if they are able to find ways to balance the 
disruptiveness of these adverse events with resources that offer a modicum of structure 
and stability. Clarke and Bennett (2012) extended discussions of structure and stability, 
aligning them with a person’s continued ability to perform acts of self-care, endowing 
them with a sense of control over their lives. Schalock and Alonso (2013) also asserted 
that control, dignity and self-determination for people with disabilities are primary 
social determinants most highly associated with reports of positive QoL. These findings 
are consistent with other research showing that people who believe they are well 
endowed in these attributes are more inclined to feel good about themselves and report 
higher life satisfaction. Conversely, those people who are no longer able to perform 
basic ADLs, such as being able to wash, dress or toilet themselves, report much lower 
levels of life satisfaction (Alma et al., 2012; Clarke & Bennett, 2012; Cummins, 2005; 
Hildon et al., 2008; King et al., 2012; Levasseur et al., 2004; Schalock, 2004). 
As people age, a commonly reported concern is that they do not wish to become 
a burden on others. Hildon et al. (2008), in a study of elders, reported only a minor 
association existing between chronic illness and feelings of being a burden. According 
to the ABS (2009) and the AIHW (2006), most older people have more than one 
chronic health condition, yet these chronic conditions do not overly restrict every 
elderly person. Hildon and colleagues (2008) found the support structures, routines and 
relationships embedded in people’s lives enabled or disabled their participation in 
resiliently adapting to these stressful life challenges. This was interpreted to mean that 
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older people do not report small, yet manageable deficiencies and declines, reserving 
their complaints for when these deficiencies become too complex and overwhelm their 
adaptive strategies. 
The person with PD needs to find a dynamic balance between social 
participation and the burden encountered so that they are able to remain in contact with 
their community and society at large. It is only when these peoples’ resources, support 
structures, relationships and routines are not available or are not sufficient to counter the 
burden encountered that they experience deterioration in life satisfaction levels. In the 
current study, it is suggested that the taboo surrounding socially disruptive bowel and 
bladder symptoms interferes with a person’s ability to seek out new and effective 
recourses needed to maintain this equilibrium and as such results in high degree of 
burden. 
3.5 Conclusion 
By reviewing the biological, sociological and psychological attributes of QoL, 
burden and adaptation, the contextual frameworks that have influenced the researcher’s 
assumptions have been clarified. This chapter began by exploring the QoL constructs 
used to determine what a ‘good satisfying life’ means and how clinicians and others 
have reinterpreted QoL constructs, focusing not on the individual’s perceptions of their 
QoL, but into measurable indicators of medical interventions provided. The use of these 
measurable indicators has reframed many QoL studies giving them a different focus 
from that of the original 1998 WHOQoL group’s outline of what constitutes a primary 
attribute of QoL.  
There was no evidence of published QoL research that analysed the disturbance 
caused by assisting people with toileting from the perspective of the person with PD. 
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The dearth of QoL studies, especially with reference to the symptom of constipation or 
UI or urge and frequency, indicates that as this topic is not regarded as clinically 
important and therefore not given high research priority.  Alternately, toileting issues 
are difficult to raise and discuss in clinical settings for the client and the physician who 
are often unaware of the symptoms' impact on the person’s QoL and may disregard 
defecation and urination issues as unimportant. Such attitudes have reduced the 
likelihood of these symptoms being included in measures of PD burden and in QoL 
research. The focus of research has continued to be on the family, specifically the 
spouse and daughters of the person with PD, and not on the person with PD associated 
bowel and bladder symptoms. At no point through the review of published research 
were bowel and bladder symptoms given any independent status or prominence in 
burden or QoL studies.  The lack of definitional consensus was found to be a critical 
factor contributing to the person with PD being undermined or depicted as insignificant 
in most research outputs.  
There is a pressing need to obtain critical insights, previously unknown, about 
living with a disability that has socially embarrassing symptoms. For instance, the 
person with PD needs to be asked to share their story, not the caregivers’ and not the 
health service providers’ experiences. This study proposes to examine the factors that 
may reduce the person with Parkinson’s disease capacity to make adaptive changes in 
their life, not because they cannot make these changes, but rather because they do not 
want to disturb ‘others’ who are deemed more worthy of concern by the health and 
general community than the person with PD.  
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3.5.1 Research aims and questions 
The research aims and questions have been constructed to facilitate this research 
and to further develop an understanding about burdensome symptoms experienced by 
adults with the neurodegenerative disease of PD.  
The overall objective of this research is to explore the impact of these two 
under-researched NMS commonly encountered in PD, has on the sufferer. While these 
autonomic dysfunctions have been reported to affect many people with PD, they remain 
inadequately investigated from the perspective of the person with PD in a meaningful 
way (Bannister, 2000; Coggrave et al., 2006; Winney, 1998).  
The study has three specific aims to address gaps in knowledge about autonomic 
bowel and bladder NMS. The first is to explore the extent of burden experienced by 
those with specific bowel and bladder symptoms arising from PD. The second is to 
investigate ways in which these NMS affect people’s quality of life (QoL). Finally, the 
study will investigate how people locate, obtain and manage treatment strategies. 
These aims are embedded within the following research questions: 
1. What are the bio-psycho-social burdens of bowel and/or bladder dysfunction 
for a person with PD? 
2. What specific QoL factors, as measured by the PDQ-39, are affected by 
bowel and bladder dysfunction? 
3. What are the therapeutic experiences of the health consumer with PD, 
specifically regarding their reports of bowel and bladder dysfunction? 
 
  
 60 
 
Chapter 4: Research processes 
The focus of this chapter centres on the research methods and procedures used to 
address the three research questions discussed in Chapter 3: 
4. What are the bio-psycho-social burdens of bowel and/or bladder dysfunction 
for a person with PD? 
5. What specific QoL factors, as measured by the PDQ-39, are affected by 
bowel and bladder dysfunction? 
6. What are the therapeutic experiences of the health consumer with PD, 
specifically regarding their reports of bowel and bladder dysfunction? 
4.1 Research design 
The mixing of research data collection and analysis methods was first described by 
Denzin in 1970 (cf Denzin, 2009) as methodological triangulation, based on the 
“unobtrusive method” proposed by Webb, Campbell, Schwartz, and Sechrest, who 
suggested, “Once a proposition has been confirmed by two or more independent 
measurement processes, the uncertainty of its interpretation is greatly reduced. The most 
persuasive evidence comes through a triangulation of measurement processes” (2000:p.3). 
Triangulation offers compelling ways in which researchers can validate social and 
behavioural data and add richness to focused, numerically based questionnaires. The 
triangulation of mixed data methods is also recognised as a rigorous way to generate 
and validate the personal effect of a disease beyond mere epidemiological accounts of 
disease (McVilly, Stancliffe, Parmenter & Burton‐Smith, 2008; Plewis & Mason, 2005). 
This position is also supported by Brannen (2005), Flick (1992), Hoskins and Mariano 
(2004), Johnstone (2004) and Niglas (2004), who agreed that the mixing of subjective 
and objective data creates opportunities for increased richness and clarity of 
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understanding that is difficult to achieve when using objective accounts alone to explore 
social phenomena.  
Mathison (1988) postulated that mixed method research is far better placed to 
appreciate the importance of differences within and between research approaches and 
data. She warned, however, that results generated can provide inconsistent and 
incongruent outputs, raising more questions than answers. Mathison’s concerns will be 
addressed in this current research in the following ways. First, bowel and bladder 
dysfunctions are known to be significantly associated with this disease and only those 
burdened by a bowel or bladder symptom will be included and interviewed. Second, the 
development and exploration of questions, missed or only addressed in brevity by 
existing tools, will be used to generate both subjective burden scores and rich spoken 
interview data, which will be fully integrated into the research findings. Finally, the 
researcher, an expert continence clinician, can draw on her experience to provide 
contextual validation. Applying these guidelines to this current research provides 
protection from a potential interpretive maze that Mathison saw as generating 
incongruent and mixed messages. 
Mixed method typology as described by Denzin (2009) is able to accommodate 
a diverse range of research needs. Denzin specifically categorised the application of 
mixed method triangulation across four sub-groups. The first, data specific 
triangulation, refers to multiple sampling across time, person or situation. Second, is the 
use of multiple investigators, third is analysis involving interpreting data from multiple 
theoretical standpoints and fourth is more than one approach being used to collect and 
analyse data. This research is more aligned with Denzin’s fourth approach to mixed 
method design. 
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In terms of research design, combinations of mixed method research are 
unlimited, provided that any collective use of quantitative or qualitative procedures is 
acknowledged as moving into the realm of mixed method research (Boddy et al., 2007; 
Dusek et al., 2010; Pretzer-Aboff, Galik & Resnick, 2011). This study will incorporate 
quantitative survey design alongside a qualitative semi-structured interview based on an 
inductive principle, which generates theoretical understanding. 
4.2 Qualitative Theory - Semi-structured interviews using inductive content 
analysis  
In addition to the quantitative surveys used a series of semi-structured interviews 
were conducted to learn about how the participants interpret their experiences of the 
phenomenon under consideration and to gain insight into the participant ‘s interpretation 
of their day-to-day reality living with Parkinson Disease. This participant generated data 
is analyzed using inductive content analysis.  
Content analysis is a subject-sensitive method (Krippendorff 1980) offering 
significant flexibility in terms of mixing research designs (Harwood & Garry 2003). 
Content analysis also offers more than a one-dimensional view of the data, providing 
the research with more than a series of unsophisticated descriptions of the spoken word. 
It is used to generate thoughtful meanings and to ascertain critical elements the words 
spoken (Vaismoradi, Turunen, & Bondas, 2013).  According to Elo & Kyngäs (2008) 
and Vaismoradi et al. (2013) inductive content analysis is the most appropriate 
analyitical approach for a study exploring a previously little known phenomenon. 
Approaching the participant’s semi-structured qualitative interview question responses 
in this manner enables this research to generate theoretical opinions through the 
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development of data driven categories. These categories will then be used to advance an 
interpretative insight and understanding of the contextual influence bowel and bladder 
dysfunction had on each participant’s lives, so that their health beliefs, attitudes and 
expectations can be better understood. 
A secondary qualitative data collection is also generated in the form of reflective 
notes during the interview. Reflective notes are a well-accepted method used in 
qualitative data collections, where the researcher journals what they see and what they 
understand at that time of interview and then later, uses these notes to reflect on the 
conversations and experiences had with participants (Bowling et al., 2007).  These 
reflections were used in this instance to diagnostically categorise and understand how 
the participants were influenced in their choices and use of health services. This 
information provides insights as a basis for challenging how current services are 
delivered and how they may be altered to meet the needs of a group of people who have 
PD and bowel and bladder dysfunction. 
The use of a mixed method design (interpretive content analysis and statistical 
analysis) to study PD and the presence of bowel and bladder dysfunction enabled 
participants with PD to convey their experiences to the researcher in a way that 
promoted deep understanding of how bowel and bladder symptoms affect their life. 
Through this approach the researcher also acknowledges participants’ contributions by 
ensuring the research findings are accessible and in a form that participants can relate to 
and use. McVilly et al. (2008) proffered this as a significantly important consideration 
for people with a disability, who often believe themselves to be unheard and their 
complaints trivialised. 
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As demonstrated in Figure 4.1, this current research used a concurrent analysis 
of qualitative and quantitative data sets (Leech & Onwuegbuzie, 2007). Further, this 
type of triangulated research design provided an innovative way of converging the data 
by calculating a numerical value representing each participant's voice and thereby 
enabling this transformed content to be included in quantitative data analysis. By 
approaching the analysis in such a way participants’ voices remained the central focus 
of this study rather than an add-on to any central quantitative calculations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Research design flowchart 
Semi-Structured interview (N = 67) 
Open-ended Interview  
Questions 
Reflective Notes. Quantitative Data Collections 
 
 
Enrolment  
Assessed for eligibility 
(N = 73) Not suitable on presentation  
(n = 6) 
   
Selected and Interviewed (N = 67) 
Descriptive Analysis  
 
Convergence and Analysis of Quantitative & Qualitative Data: 
 
Transformation of Qualitative Data  
 
 
Qualitative Content Analysis 
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The research was designed to enable the generation of a picture, which typifies 
bowel and bladder dysfunction most commonly reported by this target group, and 
enabled exploration of how these dysfunctions challenge individuals with PD. The 
participants, adults diagnosed with PD, were invited to complete a series of specific PD 
surveys on QoL, disease staging and disability impact scales and questionnaires. These 
tools, commonly used in clinical neurological and general health settings, are frequently 
referred to in the literature and have been extensively tested for validity and reliability. 
The tests selected for use in this study are discussed in more depth as each instrument is 
introduced later within this chapter. 
 PDQ-39 (Jenkinson, Fitzpatrick, Peto, Greenhall & Hyman, 1997; 
Jenkinson, Fitzpatrick & Petro, 1998) (see Appendix B). 
 NMSS (Chaudhuri, Martinez-Martin, Brown et al., 2007) (see Appendix C). 
 H&Y (Hoehn & Yahr, 1967) (see Appendix D). 
 Schwab and England (S&E) ADL (Gillingham & Donaldson, 1969) (see 
Appendix E). 
 Numerical Rating Scales  
With the exception of the PDQ-39, which will be self-administered and 
submitted prior to the interview, all other survey tools were completed at the time of the 
interview. The researcher read each question or statement to the participant, who was 
asked to give his or her answers accordingly. 
In addition to the completion of these surveys, interviews were conducted using 
a formal schedule of questions about the participants’ bowel and bladder symptoms (see 
Appendix F). The interview schedule combined both psychometric numerical rating 
scales (NRS) and open-ended questions. The open ended questions asked participants 
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about their day-to-day living and how their bowel and bladder non-motor symptoms 
directly affect their life, whilst the NRS provided participants with an opportunity to 
numerically rate these experiences. 
The five psychometric NRS scales used were: 
The Subjective Severity Score (S3) group which consist of four simple 4 and 5 point 
numerical rating scales (NRS). In this research, these NRS are employed to elicit a 
numerical ranking of the participant’s disease severity, the participant’s wellbeing and 
the participants’ satisfaction with the continence service they received. The S3 response 
scales were grammatically altered to correspond with the specific question asked. 
a. S3-Health 
b. S3-Disability 
c. S3-Qol 
d. S3- Satisfaction 
The fith NRS scale, the Symptom Burden Score (SBS) was used to elicit a numerical 
ranking of the participant’s bowel and or bladder symptom severity and its impact or 
burden. These rankings were additionally used to organise the participant s’ spoken 
words into degree of burden categories.  
The contemporaneous reflective notes made by the researcher assisted in the 
construction of a contextual framework of meaning that was then used to diagnostically 
categorise continence problem expressed by each participant. These reflective notes 
provided useful memory prompts and points of reference, together with the participant 
data, to generate a deeper and more inclusive interpretation of each participant’s 
experiences. Though the construction of these reflective notes researcher bias was able 
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to be identified early and mediated allowing for a more confident convergence of all 
participant generated evidence. 
4.3 Research procedures 
4.3.1 Ethical considerations 
Following ethics approval from the Human Research and Ethics Committee 
(HREC) University of Sydney (see Appendix H), the New South Wales (NSW) 
Association for PD and the Brain and Mind Research Institute (B&MI) were 
approached and asked to disseminate information to their members. Potential 
participants received information about the research via an article placed in the PD 
newsletter and on the Association for PD website, or via a letter inviting them to 
participate (see Appendix G), which was included in a regular mail-out from the PD 
clinic held at the B&MI. Additional information was sent by PD NSW to local 
organisers of PD support groups, asking them to inform their members of the research. 
All announcements and invitations included the researcher’s contact phone number and 
invited people interested in finding out more about the research to contact the researcher 
to arrange receipt of a research pack (see Appendix G). The research pack was sent to 
everyone who made an enquiry about joining the research project. The research pack 
included a covering letter and other documents informing them: 
 the purpose of the research, 
 a description of the nature of the study, the type of questions that would be 
asked and the potential benefits and risks that may be encountered when 
choosing to participate, 
 how to respond if there was a problem or if they had any concerns regarding 
the research, and 
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 that the research involved one telephone interview. 
Consent forms and a meeting schedule were also included so that people 
interested in becoming a participant in this research could sign and return their 
completed consent forms, as well as indicate their preferred contact details and the best 
time, morning, afternoon or evening, for the researcher to telephone. 
The confidentiality of participants and their details was maintained throughout 
the project by ensuring that no identifying information appeared on any of the 
completed questionnaires, interview schedules or notes made by the researcher. The 
participants were all assigned a coded number, which was used on all documentation in 
preference to names. The researcher was the only person with the complete listings of 
names and corresponding code numbers. These lists and all identifiable documents were 
stored separately in a locked filing cupboard inside the researcher’s single occupant 
office that was also locked. The papers are stored in a secure research archival room 
where they will remain following the completion of this project. The archived 
questionnaires and consents will be destroyed according to the HREC protocol after 
seven years. 
To reduce any risks each participant was informed that their involvement or 
non-involvement would not affect the delivery of any of their health services. The 
Continence Foundation helpline number was also available to be provided to any 
participant should it become apparent that their bowel or bladder dysfunction was 
causing undue distress, or if they stated they needed further information or if during the 
course of the interview an unexpected emotional effect was observed. If any participant 
was thought by the researcher to need acute medical attention for a urinary or bowel 
dysfunction such as an infection, there was an option for them to be referred to their 
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local GP for diagnosis and treatment. The name and number of the researcher, her 
faculty advisors and the University of Sydney HREC’s contact details were provided to 
all participants via the Participant Information Letter and participants were encouraged 
to make contact if they needed assistance or if an unexpected problem occurred. 
4.3.2 Sample size 
Sample size estimations in mixed method research are not well documented and, 
according to Collins, Onwuegbuzie and Jiao Qun (2007) and Onwuegbuzie and Leech 
(2007), are more often influenced by the dominant research model used; that is, larger 
sized samples in quantitative dominant research and smaller sample sizes in qualitative 
dominant research. With power of analyses calculations not available for mixed method 
research, recommendations have been made by expert researchers such as Creswell 
(2002) (cited in Onwuegbuzie & Leech, 2007) and Morse (1994) (cited in Onwuegbuzie 
& Leech, 2007), who advised the use of an arbitrary 30 to 50 interviews for studies 
classified as purely ethnographic. In deference to these expert recommendations and as 
this research uses a mixed concurrent equal status approach, expressed as a QUANT ⇆ 
QUAL research typology (Boddy et al., 2007) a slightly larger yet manageable sample of 
between 60 and 70 participants was chosen to ensure trustworthy data that will enable a 
full exploration of the topics in question, although this information will not be regarded 
as generalisable beyond the sample population (Collins et al., 2007; Francis et al., 
2010).  
4.3.3 Sample 
Data were obtained from a purposive sample of between 60 and 70 people, all of 
whom experienced a dysfunction with either or both their bowel or their bladder. Table 
4.1 itemises the inclusion and exclusion criteria used to select or reject research 
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participants. In particular, people were excluded from this research if unable to self-
report, or had no bowel or bladder dysfunction and did not have a medical diagnosis of 
PD. Those meeting the inclusion criteria were invited to take part in a 45-minute 
telephone interview.  
Table 4.1 
Inclusion Criteria: Attributes and disagnosis 
Inclusion criteria 
 
The person being recruited had been diagnosed as having idiopathic PD. 
The participant be experiencing some dysfunction with either their bowel 
or bladder. 
The person be able to converse via a telephone in English. 
No male to female ratio was imposed as the main inclusion criteria was 
bowel or bladder dysfunction not gender. 
Exclusion criteria 
 
Persons unable to participate in a telephone interview. 
People without access to a telephone. 
People with Parkinson’s symptoms not yet diagnosed by a medical 
practitioner. 
People not experiencing any bowel or bladder dysfunction. 
4.4 Quantitative ⇆ Qualitative data collection procedures  
4.4.1 Semi-structured interview questions  
During a 45 minute telephone interview, participants were invited to tell their 
story of bowel or bladder dysfunction. The researcher made extensive notes during the 
interview, which were read back to each participant in the form of quotations—‘you 
said’—and summaries—‘what you have told me is’—before moving on to the next 
question. This gave each participant an opportunity to validate or add information that 
may have been missed by the researcher. The conversations were not audio-taped, but 
instead conducted in accord with the principles of a clinical consultation, where the 
practitioner listens and makes contemporaneous notes. The interviews took, on average, 
45 minutes each. 
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4.4.2 Instrumentation - Semi-structured interview questions. 
The current study used a concurrent methodologically structured survey tool 
containing six questions, scored quantitatively, and six questions that were qualitatively 
themed (see Table 4.2). This is a novel approach in the exploration of bowel and 
bladder dysfunction, as it enabled the participants’ to rank their words of defence and 
explanation, into a unidimentional numerical rating score (NRS). The use of these NRS 
allows the study to generate a truly personalised quantitative numerical appreciation of 
each participant’s unique experience. The NRS group are used throughout this study to 
augment the other instruments’ data collections that specify numerical accounts. 
Moreover, the NRS group assisted in the categorisation of qualitative statements which 
were also used to explore their diagnostic origin and: 
 the treatments and products the participants use to manage their bowel and 
bladder concerns, and 
 the degree of satisfaction they obtained from the use of these treatments and 
products. 
Psychometric rating scales are widely used to reliably measure individual’s 
subjective experiences in healthcare environments and in health related research. They 
are extensively used to lineally evaluate, pain, depression, anxiety, global improvement 
and satisfaction. The SBS was adapted from the commonly used pain rating scale 
delveloped by McCaffery & Beebe (1993). The scoring was in accord with McCaffery 
& Beebe’s original scaling. Validation of this amended tool was beyond the scope of 
this project but is recommended for future research. However in terms of content and 
face validity it is consistant with specialists in the field of PD and the participants were 
able to comprehend and respond to the question asked.  
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The two most commonly used scale types are the Visual Analogue Scale (VAS), 
where a person is presented with a linear visual aid on which they indicate their score 
and the Numerical Rating Scale (NRS), where a person is prompted to verbally indicate 
the level of symptom severity according to an increasing numerical value. The VAS and 
the NRS have been extensively evaluated for validity and sensitivity and are both 
preferred by clinicians, patients and researchers to measure the subjective severity of a 
physiological or psychological disturbance (Hjermstad etal. 2011, Ferreira-Valente, 
Pais-Ribeiro & Jenson. 2011). As this research involved remotely conversing with 
participants, the NRS was chosen as it enabled participants to rate their Health Status, 
Disability, QoL, Burden and Satisfaction verbally at the time of interview. 
The rationale for constructing the semi-structured interviews stemmed from the 
non-availability of any other suitable tool. All other investigative bowel or bladder 
instruments specifically address the issue of incontinence, and while some people with 
PD have incontinence, many others do not. By focusing only on incontinence 
opportunities to see if other aspects, such as participants’ attitudes or burdens, evident 
alongside bowel or bladder symptoms, were limited.  The overall strength of the data 
collection was improved by having a tool that would capture concurrent quantitative 
and qualitative data. The validity and usefulness of the semi-structured interview tool 
was ensured by a group of six independent continence nurse consultants who reviewed 
it in terms of its appropriateness prior to the study.   
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Table 4.2 
Survey Questions 
Data type Specific questions asked  
Demographic 
 
DOB 
How long ago were you diagnosed with PD? 
Quantitative 
questions 
How would you describe the severity of your Parkinson’s symptoms?        
S3-Disability: 1=very mild; 2=mild; 3=moderately; 4=severely affected 
What PD motor symptoms do you have? How do you rate these symptoms in terms of burden?   
SBS: 1=no burden - 10=extreme burden 
What bowel/bladder symptoms do you have? How do you rate these symptoms in terms of burden?   
SBS: 1=no burden - 10=extreme burden 
How would you describe your overall health at present?  
S3-Health: 1=good; 2=fair; 3=poor; 4=very poor 
How much do you think your bowel/bladder problem affects your life? 
S3-QoL: 1=not at all; 2=a little; 3=moderately; 4=a lot 
Have you spoken to anyone to ask for help/assistance for these bowel/bladder problem, who were 
they? Were you satisfied with their help/assistance? 
1: Yes/No. ... Specify.  
2: S3-Satisfaction: 1=very unsatisfied; 2=unsatisfied; 3=neutral; 4=satisfied; 5=very 
unsatisfied. 
Qualitative 
questions 
How would you describe your bowel/bladder difficulties? 
Have you spoken to anyone to ask for help/assistance for this problem? 
What treatments/products have you tried to solve your difficulties, were they successful? 
NB: A detailed analyisis of these survey questions is presented in chapter’s 5, 6 & 7. 
Two conventional diagnostic criteria were used to classify and clarify the 
symptoms reported by each participant in order to ensure the completeness of the 
qualitative data capture and to assist in theme construction.  The first was, the Rome III 
criteria for bowel dysfunction, specifically constipation and diarrhoea (Chatoor & 
Emmnauel, 2009). The second was, the International Continence Society (ICS) 
diagnostic criteria for bladder dysfunction (Abrams et al., 2010), which specifically 
categorises lower urinary tract symptoms (LUTS), diurnal frequency, urgency, nocturia, 
retention and incontinence.  
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4.4.3 Quantitative Data Collection 
The four tools selected for use in this research were: the PDQ-39 (Jenkinson, 
Fitzpatrick, Peto, Greenhall & Hyman, 1997a; Jenkinson, Fitzpatrick & Petro, 1998), 
the NMSS (Chaudhuri, Martinez-Martin, Brown et al., 2007), the H&Y (Hoehn & Yahr, 
1967), the S&E (Gillingham & Donaldson, 1969) and a grouping of Numerical Rating 
Scales (Hjermstad etal. 2011, Ferreira-Valente, Pais-Ribeiro & Jenson, 2011). All are 
regarded as offering a gold standard insight to research about PD. Permission to use the 
PDQ-39 and NMSS was sought and received. The NRS, H&Y and S&E are free of 
copyright restrictions. 
The PDQ-39 was to be completed by the majority of participants immediately 
prior to the scheduled interview. The reason for this is that the Brain & Mind Institute 
(B&MI) planned to include this study’s participation invitation in one of their own mail-
outs, which was going to include the PDQ-39. The B&MI entered the returned and 
completed PDQ-39 into their own database and where, once this research had obtained 
the participants’ consent, the current researcher was provided access to the data the 
B&MI regularly collect.  All other questionnaires, including the NRS, NMSS, the H&Y 
and the S&E, were completed during and coded following the interview by the 
researcher. 
4.5 Instrumentation 
The following survey instruments and interview questions were used to collect 
participant information on disability, QoL, symptom frequency and severity.  
They are grouped as: 
1. Disability, general health rating  
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2. QoL, burden and service satisfaction scales. 
3. Specific NMS data collection tools 
4. Semi-structured open-ended interview questions. 
4.5.1 Disability and general health rating 
 The S3- Disability, the S3- Health, the H&Y and the S&E scales were used to 
measure the disabling impact of PD for these people. The H&Y and S&E are used 
extensively throughout the literature and in clinical practice to assess and score 
participants on their reported functional status and to allow for standardised groupings 
of participants to be made (Derost et al., 2007; Eng et al., 2006; Esselink et al., 2006; 
Forsaa et al., 2008; Kim et al., 2007; Marras et al., 2008; Martinez-Martin, Serrano-
Dueñas et al., 2007; Muslimovic, Post, Speelman, Schmand & de Haan, 2008; Post et 
al., 2008; Weaver et al., 2009; Zhao et al., 2010).  
 
4.5.1.1 H&Y staging of PD 
The H&Y staging of PD (Hoehn & Yahr, 1967) is used to locate the progression 
of the disease according to the presentation of symptoms along a five stage, increasing 
severity scale. Zhao et al. (2010), Goetz et al. (2004) and Fahn (2003) reported on the 
usefulness of the H&Y in compiling the stages of clinical progression of PD as well as 
aiding in the categorisation of individuals with this disease, especially in research. The 
H&Y is widely used and most commonly administered by the clinician at the time of a 
physical assessment or retrospectively from the patient’s medical records. The 
advantage of this staging tool lies is its ease of use by both specialised and non-
specialist clinicians, with a completion time of less than five minutes (Goetz et al., 
2004). This tool is acclaimed as the ‘gold standard’ for staging PD (D’Amelio et al., 
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2009; Diamond & Markham, 1983; Goetz et al., 2004; Li et al., 2010; Post et al., 2008; 
Weaver et al., 2009; Zhao et al., 2010).  
As a point of clarification, this study did not use the modified H&Y which 
includes three more stages with ‘0’ indicating no clinical signs of the disease, the 
second and third additions halved the score of the first and second stages, which read 
1.5 and a 2.5 (Fahn & Elton, 1987; Goetz et al., 2004). The original five stages were 
regarded as adequate for use in the current study to classify participants into research 
sub-groups. 
4.5.1.2  S&E ADL 
The S&E ADL scale was introduced at the Third Symposium of PD in 
Edinburgh, Scotland, in 1969 (Gillingham & Donaldson, 1969) and has since become 
one of the most widely used and recognised measures of ADL for people who have PD 
(Bhatia & Gupta, 2003; Brittle et al., 2008; Rejeski, Ip, Marsh, Miller & Farmer, 2008). 
This tool is used by both clinicians and consumers to assess functional abilities when 
compared with an independent person. The scale is a graduated percentage scale ending 
at zero with incremental rises of 10%. A total score of 100% indicates a completely 
independent person in all aspect of their ADLs, while a score of 0% indicates a person 
in a vegetative state (Gillingham & Donaldson, 1969; Martinez-Martin, Prieto & Forjaz, 
2006; Muslimovic et al., 2008; Schrag, Spottke, Quinn & Dodel, 2009). 
The S&E has been used extensively in many studies that assess disability and 
disablement in PD. This tool has not been the primary focus of studies undertaking the 
clinometric characteristic evaluation of PD disablement tools; however, it is used 
extensively as a moderator against which all other tools are rated (Carod-Artal et al., 
2007; Esselink et al., 2006; Marras et al., 2008; Martinez-Martin, Serrano-Dueñas et al., 
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2007; Martinez-Martin et al., 2005). The expert consensus of published research 
supports the continued use of the S&E, primarily as there is no similar tool; and it has 
been rated as being more sensitive to physical change than other health-related QoL 
measures tools. A longitudinal study conducted by Schrag et al. (2009, p. 816) found 
the S&E consistently rated ADL and total disability progression (change) accurately at 
one year post diagnosis [R=0.59; p 0.001; t (3.75) change 10.81 (17.5)] and again at 
four years [R=-1.01; p<0.0001; t (5.06) change -17.22 (22.9)]. Moreover the S&E is 
also reported as having good construct validity, inter-rater reliability and validity [R=-
0.83, P < 0.0001] (Glazener & Lapitan, 2002, 185; Ramaker, Marinus, Stiggelbout & 
van Hilten, 2002). 
This study chose the S&E to use as a subjective indicator of functional disability 
as reported by the participants and to classify their statements into homogeneous 
groups. 
4.5.2 QoL, burden and service satisfaction scales 
4.5.2.1 PDQ-39 
The PDQ-39 (Fitzpatrick et al., 2004; Jenkinson, Peto, Fitzpatrick, Greenhall & 
Hyman, 1995) is a Parkinson disease specific health related quality of life (HRQoL) 
tool that was developed by the Oxford University Health Services Research Unit. As 
with other HRQoL tools, the specificity of this tool to PD makes it one of the most 
widely used HRQoL tools. It can be self-administered and is time efficient, taking only 
15 minutes to complete. The PDQ-39 may be scored as a total summary index score 
(PDSI) of the eight PD-specific HRQoL domains, on a scale of 0=very good HRQoL 
through to 100=very poor HRQoL. Alternatively, each of the eight subscales can be 
scored separately and reported in a profile format. These scores enable information to be 
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classified as dependant variables, with lower scores indicative of better self-reported 
health status. 
The psychometric properties are reported as having good internal consistency, 
being dependable in testing and retesting and having good face and construct validity 
(Franchignoni et al., 2008; Hagell & Nilsson, 2009; Peter Hagell, Whalley, McKenna & 
Lindvall, 2003; Leung & Schnelle, 2008; Li et al., 2010; Martinez-Martin, Serrano-
Dueñas et al., 2007; Martinez-Martin et al., 2005; Pearl-Kraus, 2007; Serrano-Dueñas & 
Serrano, 2008). The PDQ was assessed by Luo et al. (2010) in a study for reliability 
using both Cronbach’s α [0.84–0.88] and intra-class correlation coefficient (ICC) [0.56–
0.82]. Franchignoni et al. (2008) and Hagell and Nygren (2007) also reported a 
Cronbach’s alpha respectively at [0.72 and 0.72–0.95]. Luo also examined the PDQ-39 
for convergent validity alongside the commonly used short-form functional health status 
questionnaire or SF-36 at [r= (−0.46)– (−0.69)] and the unified PD rating scale 
(UPDRS) [r=0.44–0.68] and was found to produce consistent agreement. More 
importantly, the PDQ-39 was found to significantly discriminate between people at 
different H&Y stages (Franchignoni et al., 2008; Hagell & Nygren, 2007; Santos & 
Santos, 2011). 
The items on the PDQ-39 measure the following eight HRQoL domains:  
 mobility 
 social support 
 ADL 
 cognition 
 emotional wellbeing 
 communication 
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 stigma 
 bodily discomfort (Peto, Jenkinson & Fitzpatrick, 2001). 
As demonstrated in the Luo et al. (2010) study, the PDQ-39 psychometric 
properties remain valid and reliable even when altered to accommodate different 
cultures and languages (Fontenla & Gould, 2003; Gaudet, 2002; Krikmann, Taba, Lai & 
Asser, 2008; Li et al., 2010; Martinez-Martin et al., 2005; Peto et al., 2001; Serrano-
Dueñas et al., 2004; Serrano-Dueñas et al., 2008). Concerns have been raised regarding 
the PDSI’s capacity to represent more than just a sum of scores. Hagell et al. (2003), 
Hagell and Nilsson (2009) and Nilsson, Westergren, Gunilla and Hagell (2010) have 
addressed this issue in terms of uni-dimensionality, claiming that the PDSI was not able 
to represent the essential characteristics of all eight domains by simply summing their 
sub-scores.  
This current study does not rely on the PDQ-39 PDSI scores, nor on the single 
domain scores as standalone traditional scores, with zero being a positive score and 100 
being a negative HRQoL score. Instead the study asked participants to provide a deeper 
context from which interpretation of their HRQoL disturbance can be made. In this way 
the research is able to relate people's bowel and bladder dysfunctions to how these 
symptoms affect their interpretations of a positive or negative HRQoL. Additionally, it 
also enables them to indicate their ability to adapt to physical and environmental 
challenges together with their attempts at remaining socially included by demonstrating 
this effect in their PDQ-39 scores. This approach is seen as potentially extending the 
usefulness of the PDQ-39 as a valid and reliable tool that is responsive to change and 
able to distinguish important HRQoL differences. 
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4.5.2.2 The symptom burden score (SBS)  
This tool differs from the other S3 group in that the symptom burden score 
(SBS) uses a 10 point scale, lineally scored - No symptom burden (0) to extreme 
symptom burden (10).  
The SBS 10 point response ratings, quantifies the impact of a person’s reported 
symptom(s) presence and severity and is the most common of all psychometric NRS 
tools used in healthcare environments and research. In this study, it was used to elicit a 
numerical ranking of the participant’s symptom severity and impact (burden). It was 
also used to categorise the participant qualitative statements about the symptom(s) they 
experience and call burdensome. However, due to the subjective nature of burden each 
participant’s scores could only be rudimentary compared with the experiences of other 
participants within the group. 
4.5.3 Specific non-motor symptom data collection tools 
4.5.3.1 NMSS  
The NMSS (see Table 4.2) was developed in 2007 by the PD Non-Motor Group, 
an international, multidisciplinary group of health practitioners and academics with an 
interest in the NMS that effect people with PD. The NMSS is the first clinical tool that 
comprehensively assists in identifying NMS as they relate to PD. The NMSS was 
assessed by Martinez-Martin, Serrano-Dueñas et al. (2007) for reliability using both 
Cronbach’s α [0.44 to 0.85] and ICC, which was [0.90] for the total score and ranged 
from [0.67 to 0.91] for each of the eight domains. The NMSS was also reported to have 
a satisfactory reproducibility, evidenced by a Lin’s concordance coefficient [0.88], and 
was free of floor or ceiling effects (Slieker-ten Hove, et al., 2010, p. 1588). Martinez-
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Martin, Serrano-Dueñas et al. (2007) also examined the NMSS for convergent validity 
alongside the PDQ-39 [rs=(0.57–0.70)] and it was found to produce a strong consistent 
agreement. Higher NMSS scores were found in women, those who had PD for longer 
periods of time and those categorised at a higher H&Y stage, all of which is in accord 
with current expert knowledge and expectation of PD. 
This tool has gained widespread attention as it addresses a range of NMS 
commonly reported by people with PD that have not previously been adequately 
addressed. The greatest advantage reported by many researchers is how the NMSS 
highlights and prioritises NMS, allowing the practitioner opportunities to correctly 
identify areas of expressed need without fear of missing bothersome symptoms because 
of time pressured consultations (Brittain et al., 2006; Buchanan, Wang, Huang, Simpson 
& Manyam, 2002; Caremel et al., 2012; Chaudhuri, Martinez-Martin et al., 2007; Evatt 
et al., 2009; Gallagher et al., 2010; Leroi, 2011; Li et al., 2010; Lim & Lang, 2010; 
O’Sullivan et al., 2008; Sakakibara et al., 2012; Slieker-ten Hove et al., 2010; Taylor et 
al., 2009; Zesiewicz et al., 2010). 
The NMSS uses a 30-item scale across nine domains to investigate the presence 
of NMS. The NMSS was suitable for this study as it is the only tool that incorporates 
gastrointestinal or urinary NMS frequency or severity in PD. The simplicity of the 
NMSS scoring and question composition also makes it an excellent tool to use during 
the telephone interviews. 
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Table 4.3 
The nine NMSS domains  
Domain 1: Cardiovascular Domain 6: gastrointestinal  
Domain 2: Sleep/fatigue Domain 7: Urinary 
Domain 3: Mood/cognition Domain 8: Sexual function 
Domain 4: Perceptual problems Domain 9: Miscellaneous 
Domain 5: Attention/memory  
(Chaudhuri, et al., 2007; Chaudhuri & Odin, 2010; Martinez-Martin et al., 2009) 
NB: A detailed analyisis of these domains are presented in chapter 5. 
 
 
4.6 Analysis 
The analysis of these QUANT ⇆ QUAL data sets incorporated standard qualitative 
content analysis, and quantitative descriptive statistical analysis before transforming the 
qualitative data into quantitative data sets to enable further interferential statistical 
testing to be done (see figure 4.2).  
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Figure 4.2. Analysis flowchart. 
4.6.1 Qualitative data analysis 
The qualitative data collections were categorised and themed according to 
content in a process is known as Content Analysis.  Content Analysis provides an 
objective method to explore the meanings, intent, consequence and context of, in this 
case, the spoken word of the participant. Seminal researchers, Cavanagh 1997, Downe-
Wamboldt 1992 and Lederman 1991 (cited in Elo & Kyngäs, 2008) suggest that 
Concept Analysis was a sound way to consider the meaning and critical processes of the 
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spoken word being explored. The participants’ statements (direct participant experience) 
alongside the reflective notes (diagnostic categories) were explored for collective 
threads of experience and understandings. The participants' shared experiences and 
understandings together with the generated diagnostic categories, are known as basic 
data categorises that are used to generate the larger group of shared sub-themes which 
then create the overarching core themes.  
4.6.2 Transformation and convergence of qualitative data 
The participants' verbal examples (basic data categories) were aligned to each of 
the participant’s NRS scores, to generate a numerical score that is supported by an 
explanatory statement providing context and meaning. In this process the study enabled 
statistical comparisons and to contrast findings from the standard PD questionnaires, in 
particular the NMSS and PDQ-39, with specificity to any bowel and bladder 
dysfunction reported by participants. This form of confirmatory and explanatory 
qualitative data organisation has been used by Arnon and Reichel (2009) in their study 
which explored the attributes of a good teacher according to parents of school children. 
Like Arnon and Reichel, content analysis was used in the current research to 
contextualise qualitative data prior to its numerical transformation and inclusion in the 
statistical analysis. 
 The complexity of the transformation and convergence process used in this 
study to interrogate the research questions is addressed in the following chapters. 
Chapters Five identifies and explored the bio-psycho-social burdens of bowel and/or 
bladder dysfunction for a person with PD. Specifically this chapter investigates the 
disabling effect of PD by using the H&Y and S&E scales alongside the NRS data, S3. 
This was then elaborated, by contrasting how the standard PD non-motor symptoms 
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instrument, the NMSS represents bowel and bladder dysfunction in for this group of 
people with PD. The SBS was used to contrast the participant generated scores given in 
the NMSS in relation to specific continence related interview questions captured by the 
SBS. Chapter Six addresses the HRQoL factors, as measured by the PDQ-39. As this 
questionnaire does not directly address bowel or bladder dysfunction it was augmented 
with the themed and categorised participant qualitative data in order to expand on the 
resulting PDQ-39 scores. This was done by specifically looking for elements where 
bowel and bladder dysfunction may have contributed to participant reported experiences 
of disturbed HRQoL. Chapter Seven differs from the previous results chapters, in that 
both the transformed and themed qualitative data inform an under-researched area, 
through specific analysis of bowel and bladder dysfunction as experienced by people 
with PD. This chapter provides a contemporary insight into the perceptions of 
participants in relation to the therapeutic satisfaction gained by them in managing their 
PD and bowel and bladder dysfunction.   
4.7 Conclusion 
The combined use of existing and innovative assessment tools in this study 
substantially adds to the current breadth and depth of knowledge about the personal 
experience of bowel or bladder dysfunctions associated with PD. Bowel or bladder 
symptoms in people with PD have, up until now, been largely ignored beyond knowing 
how many people with PD report these dysfunctions. This study takes the first step in 
exploring this new research area. The importance of gathering meaningful data to 
extend the current understanding of these two embarrassing and taboo subjects is 
acutely felt by those with PD. It is also important to overcome the current cultural 
attitude toward human excretory functions as a source of significant embarrassment and 
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discomfort, making the topic of bowel or bladder dysfunction difficult for people to talk 
about. This study recognises that there is a need to extend beyond a numerical 
accounting of these dysfunctions and brings a mixture of data and methods to reveal 
details of their nature; and the extent of the challenges faced by people with PD who 
experience bowel and bladder difficulties. 
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Chapter 5: The Bio-psycho-social burdens of bowel and bladder dysfunction 
experienced by a person with Parkinson’s Disease 
This chapter presents the results related to the research question: What are the 
bio-psycho-social burdens of bowel and bladder dysfunction experienced by a person 
with Parkinson’s disease?  It comprises of two sections; the first begins by introducing 
the participants at the centre of this research by focusing specifically on their generic 
PD symptoms, their ability to move freely and to perform everyday tasks. The 
participants were asked to describe and rate their health in terms of wellbeing and how 
disabled they believed themselves to be. The results generated from these discussions 
have been used to categorise participants in terms of disease staging and their level of 
dependence on others. The second section builds on this general overview, by more 
explicitly exploring the biological (physical), the psychological and social impacts 
directly associated with the participants’ bowel and bladder dysfunction, both of which 
are known to accompany this disease profile.  
The following instruments were used to compile the data presented in both 
sections one and two:  
 The NRS Group: 
a. S3-Disability used to quantify the impact of a person’s reported PD 
symptom(s) 
b. S3-QoL used to quantify how much the person with PD’s reported 
bowel and bladder symptom(s) affects their life 
c. S3-Health used to quantify the participants current level of physical 
wellness 
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d. SBS employed to elicit a subjective numerical ranking of the 
participant’s symptom severity and impact (burden).  
 The Schwab and England (S&E) ADL Scale used to measure the 
participant’s ability to perform every day activities or ADL’s (Gillingham & 
Donaldson, 1969) 
  The Hoehn and Yahr (H&Y) used to stage PD according to medical 
convention (Hoehn & Yahr, 1967).   
 The Non-Motor Symptom Scale (NMSS), recognised by clinicians as the 
‘gold standard’ in collecting PD specific NMS frequency and severity. 
 Open and closed ended interview questions used to explore the descriptive 
details of the participant’s reported autonomic bowel or bladder symptom(s). 
 Reflective notes, used to create diagnostic categories. To ensure researcher 
objectivity, the Rome III criteria for GIT dysfunction and the International 
Continence Society (ICS) criteria for urinary dysfunction were used to 
define and categorise these data according to convention.  
5.1  Section One - Generic PD symptom presentation 
5.1.1 Participant Profiles 
Participants reported a range of between 2 and 19 years as the intervening period 
since they were given a medical diagnosis of PD, giving a mean of seven years since 
their diagnosis was made. The study’s cohort was equally divided among men (n=34; 
50.7%) and women (n=33; 49.3%), with a mean age of 68.7 years, the oldest participant 
being 89 and the youngest 48 years of age. As discussed earlier, people who were 
younger than 65, an age that generally defines ageing were not excluded, as the research 
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focus was PD and the presence of bowel or bladder dysfunction, rather than 
chronological age.  
Just over half of the participants (n=38; 56.7%) resided within the NSW 
postcode areas that make up the Eastern Australian metropolitan centres of Sydney, 
Wollongong and Newcastle. The remaining 29 (43.5%) participants resided in small 
townships within postcode areas near these metropolitan centres. No participant lived in 
a remote environment or in regional centres. The majority of this group (77.6%) 
reported they were no longer employed, although a small number (22.4%) reported that 
they continued to hold either part time or full time employment (see Table 5.1). Male 
participants reported higher levels of employment (13.4%) than did female participants 
(8.9%). Participants with a higher staging of PD according to the H&Y were less likely 
to be employed (n=3: 4.4%) than those at H&Y stages 1 (n=5: 33.3%) and 2 (n=7: 
46.6%).  
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Table 5.1 
Participant profile 
Variables Results 
Age in years 68.6  7.5 (48–89 years a)  
Gender 
 Male 
 Female 
 
34 (50.7)
b 
33 (49.3) 
Residential geographic location by post code areas: 
Metropolitan: 
Sydney, 2000–2234 Wollongong, 2500–2534 
Newcastle, 2265–2333 
 
 
38 (56.7) 
 
Regional:  
2235–2999 
 
29 (43.3) 
In Paid Employment  
Male   
Female  
15 (22.4)  
  9 (13.4) 
  6 (8.9) 
Breakdown of employment status according H&Y 
staging 
Stage 1  
Stage 2  
Stage 3  
Stages 4 & 5 
 
5 (7.4) 
7 (10.4) 
3 (4.4) 
0 
Not-employed 52 (77.6) 
Time since diagnosis (years) 7   (2–17 a: 97% CI) 
 
Note. N=67 unless otherwise specified.  Mean  Standard Deviation (range) or (%) 
 
5.1.2 Health, disease and disability 
5.1.2.1 NRS: S3 - Health & S3 - Disability 
The S3 - health and disability were used to rate participants’ current disease 
status and to rate participants’ general wellness. The categories used to express the 
scores were grammatically altered to correspond with the question asked, very good (1) 
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to very poor (4) for the health related question and mild (1) to severe (4) for the 
disability related question.  
The results for general health were positively skewed with 35 participants 
(52.2%) rating their health as good, 23 (34.3%) rated their health as fair, and the final 9 
(13.4%) rating their general health as poor or very poor. When asked to rate the severity 
of their PD, disability as opposed to their general health, 25 participants (37.3%) scored 
their PD as mild, 33 (49.3%) rated their PD severity as moderate, 2 people (2.9%) rated 
their PD presentation as very mild and the remaining 7 (10.4%) rated their PD as severe, 
producing a negative skew.  
Variation in the distribution of scores between the S3-Health and S3-Disability 
was interpreted as an ability to discern between general health concerns and the 
disabling features of PD (see Figure 5.1). 
 
 
Figure 5.1   
Distinction between self-perceived health and self-perceived PD severity as measured 
by the S3-Health and the S3-PD Disability. 
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5.1.2.2 Schwab and England (S&E) ADL Scale 
The S&E assesses the effect PD has on a person’s independence. A score of 100 
indicates a person is ‘totally independent’, while a score of zero indicates a person is 
totally dependence on others for all their needs. The majority of participants (62.6%; 
n=42) reported an S&E ranking between 90% to 70%, indicating they were partially 
independent in performing their own basic personal care. However, they now required 
between two and four times longer to complete ADLs, as opposed to their pre-diagnosic 
ability to complete these same tasks (see Table 5.2).  
Table 5.2 
S&E ADL as reported by participants. N=67 
Rating Anchor Description N % 
100% 
Completely independent. Able to do all ADLs without slowness, 
difficulty, or impairment. 
3 4.5 
90% 
Completely independent. Able to do all ADLs with some slowness, 
difficulty, or impairment. May take twice as long.  
9 13.4 
80% 
Independent in most ADLs. Takes twice as long. Conscious of 
difficulty and slowing. 
24 35.8 
70% 
Not completely independent. More difficulty with ADLs. Up to 
three to four times longer. Some ADLs may take up a large part of 
day. 
9 13.4 
60% 
Some dependency. Can do most ADLs, but very slowly and with 
much effort they made many errors and some ADLs had become 
impossible to do. 
8 11.9 
50% 
More dependant needing assistance with half of ADLs. Difficulty 
doing everything. 
9 13.4 
40% 
Very dependant. Can assist with all ADLs but does only a few 
alone 
3 4.5 
30% 
With effort, now and then does a few ADLs alone. Much help 
needed 
1 1.5 
20% Can do nothing alone. Severe disability. 1 1.5 
10% Totally dependent. 0 0 
0% 
Vegetative functions present, i.e., swallowing with no voluntary 
functioning of bladder and bowel. Bedridden. 
0 0 
 67 100 
 
 93 
 
5.1.2.3 Hoehn and Yahr (H&Y)  
The H&Y staging of PD defines and contextualises PD in relation to the three 
prime motor symptoms: tremor, rigidity and bradykinesia, which together provide a 
definitive diagnosis of PD. In particular, the H&Y focuses on postural stability as its 
main index of disease staging. The H&Y disease stages of progression are: 
 Stage 1: When presenting symptoms affect one side of the body only.  
 Stage 2: When symptoms affect both sides of the body with noticeable 
changes to the person’s gait but not to their balance.  
 Stage 3: When symptoms begin to affect the person’s ability to walk or 
remain upright and steady.  
 Stage 4: When the disease affects balance and walking significantly, 
requiring confinement to a wheelchair.  
 Stage 5: When the person with PD is immobile and relying completely on 
others for any aspect of mobility (Goetz et al., 2004). 
Figure 5.2 demonstrates that the majority of participants (n=52: 77.6%) fell 
within stages two and three. This staging of disease is consistent with a moderate degree 
of disablement in comparison to stage four (n=4: 5.9%) and five (n=0), which are both 
viewed as representing a severe level of PD disablement. All four participants who fell 
within stage four stated they needed to use a wheelchair and accessed more formal care 
services than did other participants at stages two and three of the disease. No participant 
met the criteria for stage five. Overall, 76% of participants were bilaterally affected by 
the disease, which indicates an impaired gait, instability and postural changes.  
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Figure 5.2. Participants according to their stated H&Y stage 
Correlations between the variables, ‘time since diagnosis’ and 'H&Y staging' 
were statistically significant [N=67, r (.258), p .035] confirming that the length of time 
since diagnosis provides a good indicator of overall disease progression (see Table 5.3).  
Table 5.3  
H&Y staging of participants by time since diagnosis 
H&Y stages Time since diagnosis 
Participant 
N (%) 
 1–3 yrs 4–6 yrs 7–9 yrs 10–12 yrs 13–15 yrs 16+ yrs  
Stage 1 3 7 0 1 0 0 11 (16.4) 
Stage 2 6 10 5 4 3 3 31 (46.2) 
Stage 3 5 2 6 3 1 4 21 (31.3) 
Stage 4 0 1 1 0 1 1 4 (5.9) 
Stage 5 0 0 0 0 0 0 0 
Total  
N (%) 
14 (20.8) 20 (29.8) 12 (17.9) 8 (11.9) 5 (5.9) 8 (11.9) 67 (100) 
 
Around one in three participants (32.7%) had been diagnosed with PD at the 
time of data collection for at least 10 years this meant that 16.4% were diagnosed with 
PD in their forties (see Table 5.4).  
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Table 5.4  
Age at diagnosis by current H&Y disease staging 
 
Current H&Y disease staging Participant  
N (%) 
 
stage 1 stage 2 stage 3 stage 4 
Age at 
diagnosis 
< 49 0 4 6 1
a 
11 (16.4%) 
50 - 59 4 13 5 1
 
23 (34.3%) 
60 - 69 6 9 8 0 23 (34.3%) 
70+ 1 5 2 2 10 (14.9%) 
Totals 11 31 21 4 67 (100%) 
a 19 years since diagnosis 
 
The rate of PD progression and age has been discussed by both Zhao et al. 
(2010) and de la Fuente-Fernandez et al. (2011), with both suggesting that diagnosis at 
younger age is strongly associated with an overall slower disease progression and a 
longer duration at H&Y stages two (2) and three (3), regardless of disease management. 
The findings of the current study are consistent with those of Zhao et al. (2010) and de 
la Fuente-Fernandez et al. (2011).  
The combined results of the S&E, H&Y and the S3- Disability highlighted 
differences between the clinical presentation of PD and how people interpret and 
accommodate disablement into their life. The statistical correlation between these three 
assessment tools was strong (p ≤0.01) and was viewed as validating the psychometric 
scores of the S3- Disability (see Table 5.5). 
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Table 5.5 Correlation between H&Y, S3 and S&E 
 
S3- Disabilty H&Y S&E 
S3- Disability 
Pearson Correlation 1 .396
**
 .443
**
 
Sig. (2-tailed) 
 
.001 .000 
N 67 67 67 
H&Y 
Pearson Correlation .396
**
 1 .518
**
 
Sig. (2-tailed) .001 
 
.000 
N 67 67 67 
S&E 
Pearson Correlation .443
**
 .518
**
 1 
Sig. (2-tailed) .000 .000 
 
N 67 67 67 
** Correlation is significant at the 0.01 level (2-tailed). 
This is further evidenced by the increases in participants S3-Disability scores 
alongside the H&Y and S&E scores presented in Table 5.6. The importance of the S3-
Disability was that it enabled participants to incorporate a personalised representation of 
their everyday burdens into the analysis beyond that of a specific ADL task or the 
presence of specific PD symptoms, in that it represented an increase in personal 
difficulties encountered when in making lifestyle adjustments in response to their 
disease progression.   
Table 5.6 
Comparison of mean scores between H&Y, S&E and S3- PD severity 
 Frequency N=67  
 Very mild 
 
Mild Moderate Severe Mean (SD) 
S&E 
(100–0) 
11 25 29 2 3.8  (1.7) 
H&Y Staging  
(1–5) 
16 31 18 3 2.2  (0.8) 
S3- Disability 
(1–4) 
2 26 33 7 2.6 (0.7) 
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5.2 Section Two: Bowel and bladder bio-psycho-social aspects 
 Due to the complexity of generating, transforming and converging the multiple 
datasets, the subsequent analysis and presentation of results have been organised in the 
following way.  The presentations of descriptive quantitative results generated from the 
NMSS, SBS instruments are presented first, followed by a description of the 
contextually analysed themes, generated by the combined quantitative and qualitative 
data. The qualitative collections (participants interview data & reflective notes), were 
themed and quantitized to facilitate the resulting converged analysis of all data sets, as 
described in chapter four above (Driscoll, Appiah-Yeboah, Salib, & Rupert, 2007). 
Convergence entailed combining all the data to find points of agreement and 
disagreement and to ensure symptom specificity and clarity. 
The converged findings are presented in three discrete sub-sections each 
representing a specific symptom group: a): Bowel; b): Bladder & c) Combined Bowel 
and Bladder dysfunction (Double Incontinence).  The combined presentation of data 
under each specific grouping highlights the unique approach undertaken by this 
convergent, parallel designed study. The outcome of which unifies each approach used 
and provides a holistic view of the participants’ personal burden, not only in terms of 
the biological presentation of symptoms, but also of the participants’ psychological and 
social experiences in response to these presiding biological symptom(s). The separation 
into symptom presentations also ensures that the commonalities and uniqueness of each 
symptom group are defined and maintained. The bowel and bladder dysfunction 
(Double Incontinence) sub-section is smaller than the two preceding single symptom 
sub-sections as it does not repeat previously reported data.  It instead  provides a 
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contextual comparison against which findings specific to this combined symptom group 
can be fully understood.  
This presentation format is in keeping with other convergent research designed 
studies, which present results as both numerically and textually complete 
representations of the data (Arnon & Reichel, 2009). In regard to this study, the 
participants’ bio-psycho-social burdens as they relate to their bowel and bladder 
dysfunction  are presented.  
5.2.1 NMSS 
The NMSS (Chaudhuri, Martinez-Martin et al., 2007) incorporates 30 
questions grouped into nine domains. Each NMSS question consists of a severity 
score (0–3), which is multiplied by the symptoms’ frequency score (1–4) giving a 
possible total score of 12 for each question. The composite of question scores within 
each domain can then be summed to give a total domain score. Each domain score 
can then be further summed, giving an overall NMSS score out of 360. These 
domains with their respective scores are outlined in Table 5.7. 
 None of the participants reported difficulties in answering the 30 questions, 
nor did they question the relevance of the questions. The participants rated the 
following four domains highly: Domain 2, sleep and fatigue (10.8) and Domain 3, 
mood and cognition (11.1) along with the Domains 6, related to the Gastrointestinal 
Tract (GIT) (8.3) and Domain 7, Urinary (11.4) problems. Disruption to sleep 
(Chaudhuri, 2003) and mood (Heidrich & Wells, 2004; Watson, Currie, Curran, & 
Jarvis, 2000) are associated with the incidence and severity of urinary incontinence 
and as such will be included in the urinary specific symptom group sub-section. 
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However, as Domains 6 and 7 constitute the focus of this research the subsequent 
discussions will focus on the GIT and Urinary domains.  
Table 5.7 
NMSS Domains  
Domain Domain description 
Domain score. 
N=67 Mean (SD) 
1 Cardiovascular: 2 questions, which address postural changes 
inducing falls.   
2.7 (3.5) 
2 Sleep and fatigue: 4 questions.  10.8 (9.9) 
3 Mood and cognition: 6 questions  11.1 (13.8) 
4 Perceptual problems and hallucinations: 3 questions  2.3 (4.8) 
5 Attention and memory has three questions  
7.3 (9.5) 
6 Gastrointestinal Tract: 3 questions related to the ENS.   
1. Excessive drooling  
2. Swallowing difficulties 
3. Constipation 
8.3 (7.3) 
 
2.2 (3.3) a 
1.6 (2.4) a 
4.4 (4.5) a 
7 Urinary: 3 specific questions explore the three LUTS of 
1. Urgency  
2. Frequency  
3. Nocturia 
11.4 (11.6) 
3.8 (4.2)a 
3.5 (4.2) a 
3.8 (4.6) a 
8 Sexual function: 2 questions that address sexual interest and 
function 
3.7 (6.8)   
9 Miscellaneous, items that make up this domain are related to 
pain, sensory, changes in weight and excessive sweating 7.7 (9.2) 
Total  NMSS 
score 
The summative score of the combined domains 
62.0 (46.4) 
The individual question score a 
 
5.2.1.1 Domain 6 NMSS - Gastrointestinal tract (GIT) 
The NMSS domain 6 includes three questions that cover disorders of the upper 
and lower GIT. Two upper GIT questions investigated excessive drooling (Q19) and 
swallowing difficulties (Q20), and one lower GIT question investigates constipation 
(Q21). As expected, participants’ results demonstrated a strong correlation between 
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constipation and the total domain score [r=0.818, ≤ p0.01].  No relationship was found 
between constipation (Q21) and the swallowing difficulties (Q20). A relationship [r=. 
048, ≤ 0.05] was found between the excessive drooling (Q19) and the constipation 
(Q21). This association was interpreted as having more to do with the participants’ level 
of disability (H&Y) rather than having any direct relationship with constipation. This is 
supported by the reviewed research, which suggests that drooling is more related to 
muscle rigidity and bradykinesia in the jaw and face which impede the person’s ability 
to swallow (Kalf, Bloem, & Munneke, 2012; Leibner et al., 2010; Nobrega et al., 2008).   
Table 5.8 presents the participants’ mean scores for each of the 3 NMSS GIT 
questions. These scores reveal that the constipation question elicits a higher frequency 
and severity score as compared to the two upper GIT questions.  
Table 5.8 
NMSS GIT Domain 6 mean scores by each question (N=67) 
NMSS GIT 
NMSS drooling 
(Q19) 
NMSS swallowing 
(Q 20) 
NMSS constipation 
(Q 21) 
N=67 Mean (SD) 2.2 (3.3) 1.6 (2.4) 4.4 (4.5) 
 
5.2.1.2 NMSS domain 7—Urinary 
NMSS domain 7 consists of three lower urinary tract symptoms (LUTS) 
questions. These questions specifically addressed the presence and severity of urgency, 
frequency and nocturia. The NMSS provides a basic explanation to each stem question. 
The NMSS questions were: Q23: “Does the patient have difficulty holding urine?” 
(Urgency); Q23: “Does the patient have to void within two hours of last voiding?” 
(Frequency); and Q24: “Does the patient have to get up regularly at night to pass 
urine?” (Nocturia). The mean scores for these NMSS Domain questions revealed that 
the all three questions elicited similar frequency and severity scores (see Table 5.9).  
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Table 5.9 
NMSS Urinary Domain 7 mean scores by each question (N=67) 
NMSS Urinary 
NMSS Urgency 
(Q22) 
NMSS 
Frequency 
(Q23) 
NMSS Nocturia 
(Q24 ) 
Total Domain 7   
N=67 Mean (SD) 3.8 (4.2) 3.5 (4.2) 3.8 (4.6) 8.3 (7.2) 
 
5.2.2 The SBS 
Each participant was asked to rate on the SBS their bowel or bladder symptom 
burden, ‘no burden (0), mild burden (1- 2), moderate burden (3-5), severe burden (6-8) 
and extreme burden (9-10) (see Table 5.10).  The benefit of asking the participants to 
score their symptom(s) experience was twofold; first the researcher was not forced to 
categorise or interpret the participant’s personal burden and secondly, participants were 
able to present their symptom(s) without the need to justify the burden they imposed. 
The results outlined in Table 5.10 differentiate the burden scores of the 56 participants 
who reported the occurrence of a bowel dysfunction from the 62 participants who 
reported bladder dysfunction. This table also itemises a subset of participants who 
reported the occurrence of both bowel and bladder dysfunction. The burden scores were 
further analysed via a comparison of means (M) using a paired samples t-test. This 
analysis indicated that bowel dysfunction (n=56, M=7.4, SD=2.5) was significantly 
more burdensome [t (52) 338, p=0.023] for participants than was their bladder 
dysfunction (n=62, M=6.8, SD= 2.5).  
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Table 5.10 
 Symptom Burden Scores (SBS) according to each symptom reported (N=67) 
 Symptoms reported 
Burden Category 
Bowel Burden Bladder Burden 
Bowel and 
Bladder Burden 
Mild burden (1- 2) 0 2 0 
Moderate burden (3-5) 8 10 10 
Severe burden (6-8) 25 31 29 
Extreme burden (9-10) 23 19 12 
Mean Burden Score  
 n=: Mean (SD) n=56: 7.3 (2.5) n=62: 6.8 (2.5) n=51: 6.9 (2.4) 
 
The severity and significance of the participants’ bowel or bladder dysfunction 
burden became even more evident when these same burden scores were contrasted 
against the combined burden rating of the four PD primary motor symptoms, 
bradykinesia, resting tremor, rigidity, and postural instability and were found to be more 
burdensome than any of these primary motor symptoms. To express this statistically, a 
paired sample t-test was conducted comparing the participants’ ratings of their motor 
symptom burden (IV1) with bladder (IV2) and bowel dysfunction (IV3). A significant 
difference in the scores for IV1 (M=4.6, SD=3.4), IV2 (M=7.2, SD=2) and IV3 (M=7.6, 
SD=1.9) conditions was demonstrated for bladder dysfunction [t (57) =4.93, p=.0001]. 
These findings were also seen in the t-test conducted for bowel dysfunction [t (55) 
=5.93, p=.0001], where participants again reported significantly higher rates of burden 
than they recorded for the primary motor dysfunctions they experienced.  
5.2.3  Interview questions and reflective notes 
All participants were asked about their bowel and bladder symptom(s) and how 
they managed them on a daily basis. Their verbal descriptions and examples were used 
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to construct the core, sub-themes and the basic categories. The researcher’s reflective 
notes were used to categorise the participant symptom statements into clinically 
appropriate bowel and bladder diagnostic categories. The following questions informed 
and guided the discussion between the participant and researcher: 
 Q1: How much do you think your bladder/bowel problem affects your life? 
 Q2: How would you describe your bladder/bowel difficulties?  
Table 5.11 and Table 5.12 illustrate how these interview questions were 
contextually themed. 
Table 5.11 
Contextually themed qualitative data. Interview question one (N=67) 
How much do you think your bladder/bowel problem affects your life?  
Category - Personal Burden 
Core theme Sub-theme         Basic Categories with examples of (verbal 
citations) 
Independence 
and freedom 
Impact of Symptom on 
lifestyle, work and 
recreation 
1. Confidence (I don’t go out on bowel 
days. I don’t trust the medicines 
[laxatives] they are so unpredictable.) 
2. Experience (I cannot get too far without 
needing the bathroom.) 
Core theme Sub-theme         Basic Categories with examples of (verbal 
citations) 
Social 
participation 
Relationships: 
 Intimate 
Relationships 
 Relationships with 
friends and family 
 Professional support 
relationships 
1. Burden on others (I have had to move 
out of our bedroom.) 
2. Social isolation (I do not like people 
coming to visit me I often feel I am very 
smelly, my house smells and now 
homecare is refusing to clean) 
3. Hiding and secreting (I do not like 
talking to people about this as it is very 
embarrassing.) 
4. Information gathering and sharing (So 
little information is given by the Drs 
they make assumptions that you already 
know)  
5. PD support groups (He attended PD 
support group sessions on bladder 
problems and found it “enlightening 
and helpful”) 
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Table 5.12 
Contextually themed qualitative data. Interview question two (N=67) 
How would you describe your bladder/bowel difficulties?  Category - Clinical Categories 
Core theme Sub-theme         Basic Categories with examples of (verbal 
citations) 
Bowel 
dysfunction 
 
Constipation:  
According to the Rome III 
criteria - at least 2 of the 
following symptoms (Basic 
Categories) over the 
preceding 3 months. 
 
This category includes 
diarrhoea attributable to 
excessive laxative usage and 
not ‘Functional Diarrhoea’  
 
 
1. < 3 bowel movements per week: (I go to 
the toilet to open my bowels every 5 days, 
if I’m lucky.) 
2. Straining at Stool. (I strain and push for 
long periods of time.) 
3. Lumpy or hard stools. (The motion 
(stool) is so hard that it tears my bottom) 
4. Sensation of anorectal obstruction. (I 
cannot pass any stool and I am left 
pushing and straining) 
5. Sensation of incomplete defecation. (I do 
not feel as though I’m emptying my bowel 
out properly) 
6. Manual manoeuvring required to 
defecate. (I have to put on rubber gloves 
and edge the stool out with my hand)  
7. Loose stools are rarely present without 
the use of laxatives. (I am taking Movicol 
Sachet’s to help but if I take one it does 
nothing if I take two or three sachets I 
cannot leave the house.) 
 Functional Diarrhoea:  
According to the Rome III 
criteria – symptom present 
over the preceding 3 months 
with symptom onset of at 
least 6months 
1. Loose (mushy) or watery stools without 
pain occurring in at least 75% of stools. (I 
wear Tena lady pads to catch the 
constant faecal staining) 
 
Bladder 
Dysfunction 
Lower Urinary Tract 
Symptoms (LUTS) 
According to the ICS LUTS 
criteria and definitional terms 
(Basic Categories). 
 
1. Urge (I have to go straight away or I will 
not make it.) 
2. Diurnal Frequency (I have to go to the 
toilet every 1 -2 hours.) 
3. Nocturia (I wake up every 1.5 - 2 hours I 
have difficulty getting back to sleep.)  
4. Retention (It feels like my bladder has 
not fully emptied when I do go the toilet.) 
 Incontinence and Accidents  
 
1. Incontinence. (I generally have to change 
my underwear and my trousers, shoes 
and socks 3-4 times per day.) 
2. Accidents. (I had very bad Urge and 
frequency with lots of accidents.) 
Combined 
bowel and 
urinary 
concerns  
Double Incontinence 1. Constipation and frequency. (I try not to 
drink too much but I worry, if I don't 
drink my bowels will play up.) 
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The results of this content analysis enabled the basic categories to be 
numerically transformed. This was achieved by aligning each participants’ 
contextualised basic qualitative categories with their SBS score, as described in chapter 
four  above. This numerical pairing of basic category statements with the participants’ 
SBS scores created a data base of statements that indicated - no burden (0), mild burden 
(1- 2), moderate burden (3-5), severe burden (6-8) and extreme burden (9-10).   
The clinical data generated from the second interview question, how would you 
describe your bladder/bowel difficulties? were diagnostically categorised into the three 
symptom groupings. The researcher’s reflective notes and expertise, directed by the 
ICS, for urinary dysfunction and the Rome III criteria for bowel dysfunction (see 
Appendix J) facilitated the organisation of participant symptom statements into 
diagnostically accurate categories. The diagnostic categories presented in Table 5.13, 
indicated that 56 people (83.5%) reported constipation, with a subgroup of nine 
identified within this same constipation grouping as also experiencing frequent bouts of 
diarrhoea. Their basic category statements highlight that diarrhoea was primarily due to 
the combinations and excessive doses of laxatives they used to relieve their 
constipation, more so than as a result of a large bowel blockage. These findings are 
developed and explored later in this chapter.  
The clinical categorisation of urinary dysfunction were analysed in a similar 
fashion to the bowel dysfunctions described above; this time using the ICS lower 
urinary tract symptoms (LUTS) criteria. The clinical generation of diagnostic categories 
for urinary dysfunction or LUTS are also presented in Table 5.13.  The most commonly 
reported lower LUTS in the PD literature are diurnal and nocturnal frequency, both of 
which are accompanied by a very strong desire to pass urine—urgency (Iacovelli et al., 
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2010).  The participants’ basic category statements identified 62 participants stating 
they experienced diurnal frequency (n=44: 63.8%), nocturia (n=36: 52.2%) and urgency 
symptoms (n=46: 66.7%). These results are consistent with Iacovelli et al. findings 
described above. The participants also detailed the occurrence of two other urinary 
symptoms not frequently mentioned in the PD literature. The first of these symptoms 
was urinary retention, with 6 participants (8.9%) stating they were often unable to fully 
empty their bladder, with five of these male. The second symptom reported by a 
different group of six participants (8.9%), was urinary incontinence (UI) the involuntary 
loss or leakage of urine, with all being female. UI and retention are not identified in the 
scientific literature as being associated with PD.  
 
Table 5.13 
Participant-reported bowel and bladder symptoms as reported in interview (N=67) 
Bowel symptoms No symptoms- 11 
(16.4%) 
Constipation- 56 
(83.5%) 
Diarrhoea- 9 
(13.4%) 
Number of 
bowel 
symptoms 
reported 
None - 11 (16.4%) 
One - 47 (70.1%) 
Two - 9 (13.4%) 
Bladder symptoms 
  
  
  
No symptoms - 5 
(7.4%) 
Urge - 46 (69%) 
Frequency - 44 
(66%) 
Nocturia - 36 (54%) 
UI - 6 (8.9%) 
Retention – 6 
(8.9%) 
Number of 
bladder 
symptoms 
reported 
None - 5 (7.4%) 
One - 13 (19.4%) 
Two - 26 (39%) 
Three - 20 (30%) 
Four - 3 (4.4%) 
Reporting both bowel and bladder 
symptoms 
Yes - 51 (76%) 
No - 16 (24%) 
Note: Participant numbers for each symptom category may not equal total sample due 
to counting of participants against two or more criterion. 
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Retention is primarily associated with prostate enlargement in males and UI is 
primarily a negative outcome of an underlying specific LUTS (Greer, Arya, & Smith, 
2013). However, both of these symptoms are addressed in this study as the participants 
noted them both as producing significant levels of personal burden.  
 
5.3  Sub-Section A: Converged analysis of all bowel dysfunction data sets  
A synthesis of NMSS and data generated from the interviews (Basic Categories) 
revealed inconsistencies in the numbers of participants reporting constipation. This 
result was due to the definition for constipation used by the NMSS to guide people in 
answering NMSS-Q21. The criterion for constipation used by the NMSS is ‘A bowel 
action that occurred less than three times each week’ restricted the participants’ 
answers by over simplifying this complex condition.  As a consequence, the NMSS 
excluded 14 (25%) people who, on further investigation, reported significant concerns 
about their constipation. The following results highlight this phenomenon in more 
depth. 
Participants were asked during their interview to describe their bowel symptoms 
without any prompts or guidance from the interviewer, with all participants describing 
constipation in line with the Rome III criteria (R3). In that regard they defined their 
constipation more broadly than counting weekly bowel actions with 14 participants 
reporting that their stool frequency was equal to or greater than three times in one week. 
The following are some excerpts of the participants’ descriptions, which have been 
categorised according the R3 criteria for constipation. The excerpts have been labelled 
by participant code, gender and age. 
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P1(F:66): It feels to me like my bowel muscles are not strong enough to pass the 
stool down the back passage … but once it starts to move to the outside, I have 
to put on rubber gloves and edge the stool out with my hand. [R3: straining at 
stool and digital evacuation] 
P3(F:68): The feeling that I urgently need to go to move my bowels. However, 
when I go to the toilet, I cannot pass any stool and I am left pushing and 
straining. I am able to pass stool on an average of every second day. They are 
very dry and hard pebbles. [R3: straining at stool and dry, hard to pass stools] 
P5(M:66): I do go every day but it is only a little amount and it takes me a lot of 
effort for little result. I often bleed and push a lot. It recently has become a lot 
worse … I feel very full in the rectum … I try and go twice a day with a lot of 
difficulty. [R3: Straining at stool; incomplete bowel emptying and sensation of 
anal obstruction] 
P15(F:73): Constipation, I am passing stones. I have great difficulties passing 
stools. I bleed almost every time I go to the toilet. I do have to help them out of 
my bottom manually. [R3: dry, hard to pass stools, straining at stool and digital 
evacuation] 
P30(M:67): I go a lot but with much straining and very little result. Sometimes I 
go four or five times in one day I get a very big urge or need to go but then I sit 
there for 15 minutes straining with nothing happening. Passing such hard poo 
often makes me tear and bleed. [R3: straining at stool and dry, hard to pass 
stools] 
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P32(F:53): It takes me up to 45 minutes to pass stool … small hard stools that I 
pass with lots of effort a couple of times per week. [R3: straining at stool and 
dry, hard to pass stools] 
P67(M:73): I like to go to the toilet in the morning but it takes me a long time, 
about one and half hours … There is a lot of straining it takes me ‘sooo’ … [sic] 
much effort. I do get stomach pains but I have never bled. My poo is quite soft. I 
think this is why I have a lot of trouble pushing it out. I have had this difficulty 
for many years, at least five. [R3: straining at stool and anal obstruction or 
blockage] 
P37(M:69): Straining often [but] I don’t open my bowels for seven days. [R3: 
straining at stool and less than three stools per week] 
P44(M:64): I have chronic constipation, I take medications … My bowels don’t 
open for nine to 11 days … I always feel uncomfortable and it is distressing. 
[R3: straining at stool, dry, hard to pass stools, anal obstruction or blockage 
and less than three stools per week] 
A deeper investigation was conducted into the differences in mean scores 
between symptom severity or burden (SBS) and the NMSS constipation question 
(NMSS-Q21). A paired-samples t-test was used to compare the SBS and NMSS burden 
scores for constipation. A statistically significant difference [t (66)=-3.283, p.002] was 
found between the NMSS-Q21 (M=4.4, SD=4.5) and the participant reported 
constipation SBS score (M=6.4, SD=3.4). This result suggests that the NMSS-Q21 was 
not as sensitive for this group of participants as their reports of constipation burden 
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reported in the SBS. The extent to which this occurs is revealed in Figure 5.3, which 
shows the NMSS had inferior symptom identification alongside lower score amplitudes 
in the extreme burden and the moderate burden categories. 
 
Figure 5.3 Burden Comparison NMSS vs. SBS 
The participants who reported in the interviews, obstructive rather than just 
slower transit constipation were more inclined to be incorrectly categorised and 
subsequently had lower severity scores on the NMSS as they did not meet the strict 
criteria of a ‘Bowel action less than three times weekly’. Obstructive constipation 
primarily presents as straining at stool was reported by 39 (69.6%) participants 
reporting constipation in this study. These participants reported numerous symptoms, all 
associated with paradoxical contraction of the puborectalis muscle or obstructive 
defecation, such as extreme lower abdominal and rectal pain, difficult expulsion, 
excessive straining and the need to manually remove faeces.  
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As previously noted, nine participants (13.4%) described the occurrence of 
cyclical patterns of constipation followed by bouts of diarrhoea (see Table 5.13). 
Patterns of alternating lower GIT symptoms in neurological disease are either indicative 
of an obstructed bowel or an inappropriate usage of laxatives (Chatoor & Emmnauel, 
2009; Coggrave et al., 2006; Harari, Norton, Lockwood & Swift, 2004; Kaye et al., 
2006).  However, the participants did not perceive a relationship between their reported 
diarrhoea and constipation and therefore did not report their occurrences to their 
medical practitioner.  
P6(F;65): I have asked the doctor about the constipation but not about the 
diarrhoea. 
The nine participants who reported the combined presence of constipation and 
diarrhoea also reported high burden scores. The relationship between this symptom 
combination and burdensomeness was verified as statistically stronger than constipation 
alone [r=.357, n=56, p=0.006]. The participants reported that they had not completed 
the NMSS or any other similar tool that identified any of their NMS prior to this study, 
and that their doctors rarely initiated a conversation about constipation or other bowel 
problems. The later statement is discussed more completely in Chapter Seven. 
5.4 Sub-Section B: Converged analysis of all bladder dysfunction data sets  
Similar to the NMSS Bowel, noteworthy differences were noted between the 
numbers of LUTS identified in the NMSS urinary domain questions and the interview 
collections. These differences presented earlier in Figure 5.4, were consistent across all 
three LUTS symptoms. The NMSS Q22 (Urgency) did not identify two people (4.8%) 
who on interview, were distressed about their urinary urgency. The NMSS Q23 
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(Frequency) missed five people (11.9%) who, during the interview, reported 
bothersome urinary frequency. Finally, the NMSS Q24 (Nocturia) identified an 
additional three people (7.14%) who on interview were found to have night-time urinary 
frequency, not nocturia.  
 
Figure 5.4 LUTS identification—NMSS vs. interview 
The numerical anomalies seen between the NMSS and the interview data 
collections were again a result of using a different LUTS definition from those 
recommended by the ICS. In the case of nocturia, the ICS defines this symptom as a 
“...complaint that the individual has to wake at night one or more times to void each 
void is preceded and followed by sleep” (van Kerrebroeck, Abrams, Chaikin et al., cited 
in Weiss et al., 2011, p. 700). Whilst the NMSS defines nocturia more simply, without 
the inclusion of any need to recommence sleep. The NMSS does not make a distinction 
between nocturia and nocturnal frequency, an equivalent to diurnal (daytime) urinary 
frequency. The following participant’s statement, that she chose not to go back to sleep 
even though this constituted a very early start to their day, is an example of nocturnal 
frequency. 
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P40(F:75): The night-time bothers me as I have trouble getting back to sleep.  I 
just give up around 4 o’clock. 
A Pearson product-moment correlation coefficient was conducted to assess the 
strength of relationship between burden scores of the SBS and the Domain 7 (NMSS). 
A statistically significant correlation [r=0.331, N=67, p = 0.006] between these 
variables was found (see Table 5.14) confirming that urinary dysfunction was a great 
concern among this group of people and that both instruments were able to identify this 
burden similarly.  
Table 5.14 
The identification of burden – Correlation of the SBS and the NMSS Domain 7 scores  
Identification of Burden - Correlation of the SBS and the NMSS 
Domain 7 (N=67) 
 Domain 7 SBS  
NMSS domain 7 
 total score 
Pearson r. 1 .331** 
Sig.  .006 
N 67 67 
SBS –  
urinary Burden 
Pearson r. .331** 1 
Sig.  .006  
N 67 67 
** Correlation is significant at the 0.01 level (2-tailed). 
 
Gender and the numbers of LUTS reported were also explored, the rationale 
being that in the scientific literature, gender differences and LUTS presentation in non-
PD populations are well reported. This is not the case for people with PD where little 
has been reported. Figure 5.5 shows that in this group of 62 people, 32 male participants 
reported the presence of more individual LUTS symptoms than did the 30 female 
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participants and that both men and women found each additional LUTS increased their 
levels of burden. 
 
Figure 5.5 Presence of burden according to the number of LUTS reported 
Of further interest were the questions, did the increase in burden scores 
influence the participant in seeking of help from the doctors and was there a gender bias 
in this help-seeking behaviour? The data about seeking assistance had been collected as 
part to the interview. A paired sample test t-test was used to explore these extrapolated 
burden mean score differences. The first paired test was between the occurrence of 
burden (SBS) and seeking help from a doctor [t(59) -21.932 n=60 p= 0.01]. The second 
pair looked at the differences between men or women when choosing to reported their 
LUTS to the GP, which was not significant; and a final pairing looked at burden (SBS) 
expression between the men and women participants [t(59) -22.29 n=60 p=0.01]. These 
results have been interpreted as the burden of LUTS was not contributing to the 
likelihood that a person would seek advice and support from their doctors. That while 
advice seeking was not gender biased, gender did seem to play a part in the expression 
of burden with women expressing their LUTS as more burdensome than did the men in 
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this study. This difference in LUTS burden expression may indicate that a more 
complex relationship exists between burden (SBS) and symptom occurrences 
experienced by men (See Fig 5.5).  
This study’s findings indicate that men may either be more resilient to or more 
accepting of the presentation of LUTS than are women. The following participant 
statement is used to support this premise. This gentleman’s reports of nocturia, together 
with his day time urgency and frequency, which he reported as occurring almost every 
hour was reported as not concerning him too much, although he said it (LUTS) drove 
his wife mad. He was happy with his wife sourcing information, products and services. 
His use of the word we in his statement seem to present his LUTS as a shared problem. 
P62 (M:59) It drives my wife mad, she has spoken with a Nurse Continence 
Advisor who suggested uridomes but we haven't tried them yet, for no particular 
reason. I'm happy with the pads (which his wife purchases) and have a bottle 
next to the bed which is very helpful. 
In studies by Iacovelli et al. (2010) and Araki and Kuno (2000), LUTS was 
correlated with PD motor dysfunction severity, creating a functional incontinence. That 
is, incontinence due to an inability to get to the toilet in time or to have the dexterity to 
timely remove clothing enabling voiding without wetting clothes.  To establish if the 
participants’ LUTS presentation and burden scores corresponded with their PD severity 
the participants’ LUTS and SBS were explored via the H&Y disease staging (Table 
5.15).  
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Table 5.15 
Burden (SBS) and Numbers of LUTS reported according to H&Y Disease Staging 
(N=67) 
 H&Y Stage Frequency Mean SBS SD 
SBS - bladder according to H&Y  
 
 
 
 
 
 
Total 
1 11 5.3 3.9 
2 31 6.0 2.9 
3 21 6.8 2.8 
4 4 7.5 3.6 
 67 6.2 3.1 
Number of  LUTS according to 
H&Y  
1 11 1.7 1.1 
 
 
 
 
Total 
2 31 2.3 .94 
3 21 1.8 .91 
4 4 1.7 .95 
 
67 2.0 .99 
 
An analysis of variance (ANOVA) was used to complete this examination, 
however no statistically significant increases were noted between H&Y staging and 
LUTS burden, nor between the numbers of LUTS experienced. This was a little 
surprising as it was felt that the severity of these people’s disability would have had 
some effect on their LUTS presentation and burdensomeness.  
To ensure the research had not missed any aspect of a potential relationship 
between LUTS and H&Y, an analysis of the length of time a person had been aware of 
their burdensome urinary symptom(s) was explored. This information was collected 
during the interview when participants were requested to describe their LUTS and when 
they first became aware of them (M=4yrs, SD=5.2yrs). A significant correlation 
[p=.003] for this group indicated that the presentation of multiple LUTS occurred at or 
near the time their PD was diagnosed (see Table 5.16). However, the burdensomeness 
of LUTS did not correlate with these symptoms’ start time. 
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Table 5.16 
LUTS presentation according to date of PD diagnosis 
  Bladder 
symptoms 
reported 
Bladder 
burden 
score (SBS) 
Symptom 
start date 
bladder 
Number of 
bladder 
symptoms 
reported 
Pearson 
correlation 
1 .103 .357** 
Sig. (2-tailed) 
 
.440 .003 
N 67 58 67 
Bladder 
burden score 
(SBS) 
Pearson 
correlation 
.103 1 .085 
Sig. (2-tailed) .440 
 
.525 
N 58 58 58 
Symptom start 
date bladder 
Pearson 
correlation 
.357** .085 1 
Sig. (2-tailed) .003 .525 
 
N 67 58 67 
** Correlation is significant at the 0.01 level (2-tailed). 
 
A possible explanation to why these participants did not report an increase in 
LUTS burden according to their disease severity or the length of time these symptoms 
were present, was that they had already made significant life changes,  which had 
incorporated their toileting needs through clothing modification, as well as changes 
made to their, environment and social expectations. The following participant 
statements support this position: 
P14(F,63): I have adjusted what I wear to give me extra access and ease in 
getting undressed. 
P19(M,75): I am better when I am in the house. I do not travel anywhere of a 
long distance. So I only do things around the local area. 
P27 (M,75)I use a non-spill bottle that I now keep between my legs at night.  
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P30 (M,67): I am conscious of what I'm doing, where I am going and what I 
wear. I don’t wear lots of clothing with buttons or zippers now, they are just too 
hard to get off in time. 
 
5.4.1 Specific LUTS—Urgency 
Urgency is defined by the ICS as ‘a sudden need to empty the bladder which is 
very hard to ignore or put off till later’ (Haylen et al., 2009). Urgency has also been 
reported as occasionally being accompanied by urinary leakage. Urgency is rarely 
reported as a single symptom and, according to Irwin, Abrams, Milsom, Kopp and 
Reilly (2008), has not been shown to contribute in a major way to increasing levels of 
personal burden or decreases in QoL. Scores from the NMSS-Q22 (urgency) (n=44) 
recorded slightly lower rates than that established in the interviews (n=46), indicating 
that the NMSS missed 3% of qualified participants (see Fig 6.3). In the interviews, 
urgency was spoken about in terms of an ability to defer voiding or ‘hanging on’, 46 
people or 67% of this population stated that the call to void was so strong that they were 
unable to defer without fear or risk of having an accidental urinary leakage. Participants 
were questioned about their ability to defer going to the toilet and asked how long they 
would remain dry if they did defer going to the toilet. They were also asked if they 
regularly experienced urinary leakage with this reported urge to void, as they made their 
way to the toilet or as they were removing their clothing to use the toilet. Participants 
reported that they were able to hold off going to the toilet on average for 10 minutes 
from the time they first noted the urge to void, up until they wet themselves. The 
majority (95%) of those reporting urgency stated the need to empty their bladder very 
frequently. 
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P1(F,66): When I get an urge I need to go. I have to go straight away or I will 
not make it. Most of the time I do go immediately and still don’t get there on 
time. I have to use incontinence pads. I generally have to change underwear and 
long trousers shoes and socks three to four times per day. It is so humiliating if I 
have an accident. I rarely go out at all to social events or even have a night out 
with friends and family. 
P4(F,65): I have an urgent call to pass urine and I leak as I am going to the 
toilet. 
P23(F,56): As far as the urgency goes the feeling of urgency take precedence 
over everything. 
P28(M,65): When I get the urge … I can put off for a little time but tends not to 
be too long—10 minutes at the most. 
P55(F,69): I can’t ‘hang on’ for more than five minutes. I am always looking for 
toilets when out just in case. 
Table 5.17 shows the men on interview reported 15% more incidents of urgency 
than did women participants as compared to the NMSS, which recorded men as 
reporting 3% less urgency than did the women participants.  
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Table 5.17 
Reports of urinary urgency by gender (N=67) 
Reported diurnal 
urinary Urgency 
Interview n (%) NMSS n (%) 
Male Female Total Male Female Total 
 No 6 (9) 15 (22) 23 13 (19) 10 (15) 28 
Yes 28 (42) 18 (27) 44 21 (31) 23 (34) 39 
Total  34 33 67 34 33 67 
 
An independent-samples t-test was conducted comparing the NMSS Q23 burden 
scores for urgency according to gender. A significant difference [t (65) =1.977, 
p=0.052] was found in the scores for men (M=2.88, SD=3.51) as compared to women 
(M=4.90, SD=4.79). The results are interpreted that the male participants  reported 
urinary urgency as providing for them a higher burden than did the female participants. 
5.4.2 Specific LUTS—Frequency 
The ICS definition asks for a subjective response based on the participant’s 
belief that they urinate too often during the day. The NMSS refers to a numerical count 
of ‘120 minutes since their last void’. Forty-four (66%) people reported at interview 
burdensome levels of daytime frequency (see Table 5.18). The men were found to be 
25% more likely to report frequency than the women, with 26 men stating they 
experienced burdensome daytime frequency. 
Table 5.18 
Reports of diurnal urinary frequency by gender (N=67) 
Reported diurnal 
urinary frequency 
Interview n (%) NMSS n (%) 
Male Female Total Male Female 
Tota
l 
 No 8 (12) 15 (31) 23 16 (24) 12 (18) 28 
Yes 26 (39) 18 (27) 44 18 (27) 21 (31) 39 
Total  34 33 67 34 33 67 
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Of the 44 people, 97% stated that they voided more frequently than every two 
hours with, a range between 30 minutes and two hours.  
P2(F;66): I could keep the toilet busy between 6 am and 10 pm on average once 
an hour. 
P3(F;68): It is not uncommon for me to void three times in two hours. 
P57(F;68): My frequency symptoms vary. I can void every half hour at times. 
5.4.3 Specific LUTS—Nocturia 
The ICS definition requires a person to report more than one awakening 
overnight before nocturia is diagnosed. It additionally differentiates between nocturia 
and nocturnal frequency in that sleep must be pre- and post-micturition (Irwin et al., 
2008; Kraus et al., 2010; Wagg, Cardozo et al., 2008). The NMSS does not specify a 
number for nocturnal voids. However, grammatically its statement refers to multiple 
nocturnal awakenings rather than one, and sleep disturbance is not specifically 
mentioned. Consequently, the question was interpreted by participants as asking about 
nocturnal frequency rather than nocturia. When interviewed, the participants were able 
to differentiate between daytime frequency and night-time sleep disturbances with 58 
participants identifying nocturnal sleep disturbances differently from diurnal 
disturbances. However, they found it more difficult to differentiate between night-time 
frequency and nocturia. The interviews identified three individuals who were actually 
referring to nocturnal frequency rather than nocturia. 
According to interview data, true nocturia was reported by 36 (54%) participants 
(see Table 5.19) who stated they needed to wake more than once from their sleep to 
 122 
 
void. The results presented in Table 5.19 show men reporting nocturia 50% more than 
the women did. 
Table 5.19 
Reports of nocturia by gender (N=67) 
Reported 
Nocturia 
Interview n (%) NMSS n (%) 
Male Female Total Male Female Total 
 No 10 (15) 21 (31) 31 14 (21) 14 (21) 28 
Yes 24 (36) 12 (18) 36 20  (30) 19 (28) 39 
Total  
34 33 67 34 33 67 
 
Burden was however harder for them to discern, with many stating that they had 
no trouble falling back to sleep following the nocturnal void. Those who did report 
difficulties getting back to sleep, stated that they persisted and mostly achieved some 
somnolence following the void. Many of the participants saw nocturnal wakening to 
void as normal or expected and had incorporated this into their lives. It was the people 
who were no longer sleeping with their partners, because their wakefulness disturbed 
them or those who found falling back to sleep more difficult, who made the disparaging 
comments about nocturia. This phenomenon was also noted by Weiss et al. (2011) and 
Yoshimura (2012), who recognised that nocturia did not seem to influence a negative 
QoL response. 
P1(F,66): Because I was up and down all night I disturbed [husband]. He was 
being woken up so much we bought two king single beds. 
P7(M,67): [I wake up] every one and a half to two hours I have difficulty getting 
back to sleep. I occasionally take half a Mogadon to help me sleep … I have had 
to move out of our [bed]room. 
 123 
 
P29(M,61): Overnight I wake up to empty my bladder three times. I go to bed at 
10.30, sleep through to 2 am, then wake up at 4 am and then again at 5 am when 
I get up. 
P40(F,75): I have to go every two hours even at night. The night-time bothers 
me as I have trouble getting back to sleep. It makes it difficult to go away from 
home. I don’t drink after 5 pm. I wear a pad at night. 
P66(M,67): I sometimes have difficulties falling back to sleep, especially around 
4 am. So then I get up make lunch for the boys. 
P68(F,75): In the early morning I just give up and do not go back to sleep, so 
from 4 am after I empty my bladder I stay awake. 
P69(F,82): It wakes me up at least three times per night and I have to go to the 
toilet My main problem is that I am having real difficulty falling back to sleep. I 
wake up at 9 pm, and 2.30 am, then at 4am I give up and get up for the day, 
which make me very tired during the day and I am back in bed by 8.30pm. 
Similar to the Weiss (2011) and Yoshimura (2012) studies of nocturia, this study 
found that participants reported a high degree of overall acceptance and adaptation to 
these sleep disturbances. 
P2(F,75): At night I only get up twice over night. 
P9(M,64): I did not consider going to the toilet four times each night as 
excessive. I haven’t considered it a great problem. 
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The correlation between daytime frequency and night-time frequency, in 
neurological LUTS, has not been well reported (Lukacz, Whitcomb, Lawrence, Nager 
& Luber, 2009).  A Pearson product-moment correlation coefficient was used to explore 
the relationship between daytime NMSS Q23, frequency and night-time frequencyQ24, 
nocturia (see Table 5.20) and, as expected, a strong relationship between these two 
variables existed [r=0.663, N=67, p=0.01]. This finding is used to support that the 
presence of diurnal frequency continues overnight; a currently held clinical position that 
a urinary storage deficit experienced during daylight hours would continue overnight 
(Swithinbank, Vestey & Abrams, 2004).  
Table 5.20  
The relationship between diurnal and nocturnal frequency N=67 
  NMSS 
Q24 
nocturia 
NMSS Q23 
frequency 
NMSS Q24 
nocturia 
Pearson 
correlation 
1 .663** 
 Sig. (2-tailed)  .000 
    
NMSS Q23 
frequency 
Pearson 
correlation 
.663** 1 
 Sig. (2-tailed) .000  
 
5.4.4 Participant reports of UI and urinary retention 
Many of the participants stated they had frequent urinary ‘accidents’ for which 
they wore some form of disposable continence or menstrual pads to catch leakage 
events. Only six (9%) from a total group number of 67 participants interpreted these 
leakage events as UI; the majority of participants preferred instead to use the symptom 
(Frequency, Urge or Nocturia) rather than the negative outcome (UI) to describe their 
urinary dysfunction as incontinence.  
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P18(F,61): [I have] very bad urge and frequency with lots of accidents and 
leakage… P54(M,64): I get terrible urgency. I have lots of accidents. It is 
mainly due to me being so slow, you know, the PD. 
Of the six people reporting UI five managed their intractable incontinence by 
wearing disposable incontinence pad(s), the remaining participant using an indwelling 
supra-pubic urinary catheter (SPC). 
P1(F,66): I have no control over my bladder. I have to use incontinence pads 
[all of the time] and I [still] generally have to change underwear and long 
trousers shoes and socks three to four times per day.  
P3(F,68): Before the SPC insertion, I had terrible urinary frequency and 
incontinence. 
P16(F,67): I leak on movement. On standing, it pours down my legs. 
P57(F,68): I revolve my life around bladder issues. Once I step out of bed, urine 
just flows out. 
Retention was reported by six participants including management of the cluster 
of urgency, diurnal frequency and nocturia symptoms, which they also reported were 
often accompanied by frequent accidents (see Table 5.21).  
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Table 5.21 
Urinary rtention by gender 
 
Male Female Total 
No retention 29 32 61 
Retention 5 1 6 
Total 34 33 67 
 
Two men in this group had been diagnosed with a slow growing prostate cancer 
and had made the decision to ‘watch and wait’. The woman reporting retention had a 
long-standing history of recurrent urinary tract infections, for which she was being 
treated with prophylactic antibiotics. They most often described urinary retention as a 
feeling of wanting to go back to the toilet not long after their last void, a diagnosis 
confirmed by their urologist. Therefore, their stories of retention should not be regarded 
as being directly caused by their PD.  The following participant statements confirm the 
presence of urinary retention and its significance for them.  
P30(M,67): I feel that my bladder is not emptying fully and if I go back 15 
minutes later to re-empty, very little is there but it feels that there should be 
more. 
P53(F,68): At times I need to go back and do another shortly after my last pee 
… I had trouble with dysuria [pain on urination]. I have been on prophylactic 
Triprim for one year now. 
P58(M,84): This has been checked by my urologist who said I didn’t empty 
properly … I have prostate cancer, I am doing the watchful waiting for a ‘slow 
growing cancer’. 
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5.4.5 Presence of OAB in this study population 
Urinary urgency, diurnal and nocturnal frequency are the most common LUTS 
reported in general clinical practice (Iacovelli et al., 2010; Mostwin, 2002; Sakakibara 
et al., 2001). When these three LUTS are reported in combination, they are known as a 
‘symptom syndrome’, and if urinary urgency is the central feature of this symptom 
syndrome, they are defined, according to the ICS, as OAB (Abrams, 2003, 2005; 
Temml et al., 2005). Based on participant information obtained from the interviews, 42 
(63%) of this study’s population met the ICS criteria for OAB. 
While the NMSS was not designed to identify OAB, the combined presence of 
all three LUTS, frequency, urgency and nocturia symptoms reported by 50% of the 62 
participants reporting bladder dysfunction, supports the dominance of this symptom-
group for these participants as compared to OAB prevalence in non-PD populations of 
between 7% and 31% (Irwin, et al., 2011; Shaw & Burrows, 2011). The participants’ 
NMSS total domain 7 score was strongly associated [r=.821, n=67, p=< 0.01] with each 
of the three participants who reported LUTS; a result, that the presence and frequency 
of urgency, frequency and nocturia symptoms individually created high levels of 
distress for the participants. In response to these findings an additional clinical category 
of OAB was created and populated by the participant data who, by way of the NMSS 
(n=43:64%) and on interview (n= 42:62.7%), had a combination of all three LUTS. 
A series of cross-tabulations were used to examine if age and gender parallels in 
this group could be found (see Table 5.22).  
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Table 5.22  
Presence of OAB Interview data: Age vs Gender (N=67) 
 
Male Female 
Total OAB 
n(%) 
OAB Age into 3 
groups 
45–64 6 5 11 (16) 
65–74 11 9 20 (30) 
+75 8 3 11 (16) 
Total 25 17 42 (63) 
 
Using the newly created OAB data, obtained from interview transcripts, two 
hypotheses were formulated to investigate its presence according to the participants’ age 
and gender. 
1. That older participants would report higher incidence of OAB than younger 
participants. 
2. That female participants would report higher levels of OAB incidence than 
male participants. 
Hypothesis 1. The expectation that older aged participants would report higher 
levels of OAB than younger aged participants was not supported. This sample of people 
showed no increase in OAB symptom presentation alongside an increase in age (see 
Table 5.22). Neither older nor younger age groups demonstrated a relationship [ns] with 
the presence of OAB.  
A one-way ANOVA between subject examination was conducted to explore the 
effect of age on the incidence of any of the LUTS identified by data obtained from the 
NMSS domain 7. For a second time, age was not found to be an influencing factor in 
any of the three LUTS questions that make up domain 7; Q22 on urgency [f 
(28)=16.727, p=ns]; Q23 on frequency [f (28)=19.525, p=ns]; Q24 on nocturia [f 
(28)=19.879, p=ns] or the total domain 7 score [f (28)=135.797, p=ns]. These findings 
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strongly suggest that OAB reported by this sample is more likely to be associated with 
the participants’ underlying neurological condition rather than with their age.  
Hypothesis 2. The expectation that women participants would report higher 
levels of OAB than male participants was not supported. Much of what is known about 
gender and OAB indicates that women without PD are more affected by OAB 
symptoms than men. In contrast, this study found that men (n=25) reported higher rates 
of OAB symptoms than women (n=17). An odds ratio (OR) of 10:7 was calculated, 
however this finding did not reach statistical significance [n=42: OR, 0.7006: CI, 95%: 
Z score, 0.894: p=0.37]. 
5.4.6 Sub-Section 3—Double Incontinence 
A high rate of combined bowel and bladder symptoms, termed in the literature 
as double incontinence (DI) was experienced by 48 (72%) of the participants (see Table 
5.23). The high incidence of DI highlights the full effect this degenerative neurological 
disorder has on the participants’ lives. Only eight (12%) people in this study reported 
they experienced an isolated bowel difficulty and eleven (16.4%) reported an isolated 
bladder problem. This occurrence of DI is considerably higher than rates reported in any 
other prevalence studies of neurologically intact, institutionalised and non-
institutionalised elders. 
Table 5.23 
Frequency of double incontinence (N=67) 
 
Frequency % 
Yes 48 72 
No 19 28 
Total 67 100.0 
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Prevalence studies of non-institutionalised elders suffering from the combination 
of faecal and urinary symptoms are not plentiful, however, work conducted by 
Teunissen, van den Bosch, van den Hoogen and Lagro-Janssen (2004), Santos and 
Santos (2011), Slieker-ten Hove et al. (2010) and Stenzelius, Mattiasson, Hallberg and 
Westergren (2004) suggested a range of between 3% and 15%. All of these studies 
associate DI with older age and frailty.  When this study looked for a relationship, using 
a Pearson’s test between the participants’ age, their gender or the level of disability, it 
found no statistically significant association (table 5.24).  These results are viewed as 
supporting the basic premise of this thesis, that it is the neurological aspects of the PD 
which has a larger role in these people’s experiences of DI than any other factors.  
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Table 5.24  
The Incidence of DI according to Age, Gender, H&Y and S&E (N=67) 
 Gender Age H&Y 
(disease 
progression) 
S&E (level of 
disability) 
DI  
Gender Pearson 
correlation 
1 -.066 .042 .025 .043 
Sig. (2-tailed)  .594 .735 .840 .733 
N 67 67 67 67 67 
Age Pearson 
correlation 
-.066 1 -.011 .112 -.040 
Sig. (2-tailed) .594  .931 .367 .749 
N 67 67 67 67 67 
H&Y Pearson 
correlation 
.042 -.011 1 .518** .119 
Sig. (2-tailed) .735 .931  .000 .336 
N 67 67 67 67 67 
S&E Pearson 
correlation 
.025 .112 .518** 1 .154 
Sig. (2-tailed) .840 .367 .000  .214 
N 67 67 67 67 67 
DI Pearson 
correlation 
.043 -.040 .119 .154 1 
Sig. (2-tailed) .733 .749 .336 .214  
N 67 67 67 67 67 
** Correlation is significant at the 0.01 level (2-tailed). 
 
Moreover, the ADL profile of the participants’ according to the S&E, provides 
further evidence that their reports of DI are not likely to be related to any inability to 
manage or maintain aspects of self-care. This finding is at odds with the cited 
prevalence studies above, which declare DI to be more often associated with those who 
are more disabled, frail and aged. 
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5.5 Summary of results 
5.5.1 Section One 
The analysis of results presented in is chapter addresses the first research 
question, What are the bio-psycho-social burdens of bowel and bladder dysfunction. 
The first section of this chapter presented the participants’ generic symptoms of PD, 
along with details of their everyday lives in terms of wellbeing and how disabled they 
believed themselves to be. The results were used to calculate the staging of the 
participants’ primary disease and how these people’s PD had impacted on their ability 
to perform everyday tasks. In terms of life quality and independence participants were 
able to differentiate between their health concerns and the disabling effects of PD. 
Most of the 67 subjects lived in metropolitan areas of coastal New South Wales 
and had received their diagnosis of PD, on average, seven years before. The largest 
group were in the H&Y second stage with the next major group in the third stage. Braak 
and Del Tredici (2008) would describe these people’s disease as at stages four or five, 
where the basal ganglia are heavily depleted of dopamine-producing cells. The 
participants’ disease staging as opposed to the length of time since diagnosis was found 
to be more predictive of involvement in the workforce. 
Sixty-three percent of participants reported a moderate level of disability and 
independence when performing personal care. They highlighted on the S&E that they 
now required assistance from others and took much longer to perform ADL activities 
than they did prior to being diagnosed with PD.   
The clinical picture generated from these data is that on average participants 
have noticeable balance and gait deficits; difficulties with fine motor functions; and 
their movements were no longer smooth and well-coordinated. This impacts on their 
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ability to carry out their usual household and personal care activities which now takes 
them two or three times longer than they did previously. Despite these challenges 
participants' perceptions of their own independence and social or work engagement was 
more positive than the H&Y and S&E assessments appeared to portray them. 
5.5.2 Section Two  
The second section of this chapter presented the biological occurrence 
experienced by 56 participants of two bowel dysfunctions, constipation and diarrhoea. 
Diarrhoea was outlined by a subgroup of nine participants as regularly occurring 
alongside their reported constipation and may be related to their choice of constipation 
management. Inappropriate or excessive use of laxatives are a known causative factor of 
loose, watery stool in people with chronic constipation (Chatoor & Emmnauel, 2009; 
Coggrave et al., 2006; Harari, Norton, Lockwood & Swift, 2004; Kaye et al., 2006). 
Sixty-two participants identified the presence of three specific LUTS; urgency (n=28), 
frequency (n=26) and nocturia (n=24) with a subgroup of n=42 people stating that they 
experienced all three LUTS, a combination known as OAB. This symptom group was 
reported as occurring in this study at 63%, a much higher rate than the estimated 
occurrence of 7% to 31% in age and gender matched individuals without PD (Araki & 
Kuno, 2000; Iacovelli et al., 2010; Sammour et al., 2009). 
Two additional urinary symptoms of UI (n=6) and retention (n=6) were 
highlighted by 12 participants. These symptoms are not commonly identified as PD 
specific, in the case of retention each one of the six participants had been clinically 
diagnosed by a urologist as not being able to fully empty their bladder. There was, 
however, no firm evidence presented that could be used to rule out or confirm PD as the 
primary cause of these participants’ reported retention. The second symptom discussed 
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by the other six participants was UI. This symptom was seen as a negative consequence 
of the three LUTS rather than as a discrete symptom itself. Many of the participants 
stated they experienced frequent accidents or episodes of UI, but they refrained from 
using the term UI unless  their incontinence was regarded by them as amounting to an 
uncontrollable, constant and large leakage of urine. The collected data were used to 
confirm the presence of and relationship between the participants’ bowel and LUTS in 
the presence of a neurological disease, PD as distinct from that of an older person with 
non-pathological bowel and bladder changes. 
The convergence of all bowel and bladder quantitative and qualitative data 
collections made it possible to unravel how bowel and bladder symptoms were 
psychologically and socially interpreted and valued by each participant. The analysis 
revealed that each person’s perception of what constitutes a valid PD problem was 
influenced their ability to generate insights of symptom validity and legitimacy. This 
was viewed as a critically important factor for this group of people, most of whom were 
unsure of the links between their PD and their presenting bladder and bowel symptoms. 
Without this understanding, it becomes impossible for people to confidently raise these 
confronting symptoms in conversation with others, family and friends. Consequently, 
many participants spoke of adapting their lifestyle and restricting their social activities 
in preference to securing treatment plans and advice even when they rated their burden 
highly. The burden of bowel and bladder dysfunction was well addressed in this chapter 
with the participants rating  their bowel dysfunction as more burdensome than their 
bladder dysfunction, and the presence of either bowel or bladder dysfunction as more 
burdensome than their primary motor PD symptoms.  
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Chapter 6: The effects of bowel and bladder dysfunction on quality of life  
The overriding objective of this chapter is to analyse the contribution of bowel 
and bladder dysfunction on the participants’ Quality of Life (QoL).  Research published 
on PD has frequently indicated that QoL is negatively affected by the NMS of bowel 
and bladder dysfunction and that these negative effects increase with the duration of the 
disease. The following results and discussions explore the findings of the PDQ-39, a 
QoL measure specifically designed for use with people with PD, by a group of 
neurologists attached to Oxford University’s Public Health Unit. 
The following instruments were employed to collect the data: 
1. The PDQ-39, a QoL measure specifically designed for use with people with 
PD. As discussed in Chapter Four, the PDQ-39 is routinely used by the Brain 
and Mind Research Institute (B&MRI) for all their PD clients. They agreed 
to share their database of PDQ-39 coded results, obtained from each person 
who also consented to speak to this research project. In this current study, 
participants were asked to complete the PDQ-39 prior to undertaking the 
interview. Only five participants completed the PDQ-39 during the telephone 
interview, with all others completing the questionnaire and returning it to the 
PD clinic, along with other documentation unrelated to this research. All 
returned PDQ-39 questionnaires were collated and calculated using the 
coding instructions outlined in the PDQ-39 user manual (Jenkinson et al., 
1998), with the scores from each dimension … computed into a scale 
ranging from 0 (best, i.e., no problem at all) to 100 (worst, i.e., maximum 
level of problem) (Peto et al., 1998, p. S11). 
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2.  The H&Y, the PD staging tool. 
3. The S3-QoL, a psychomotor scale that requires each participant to place 
themselves along a numerical continuum, from 0, representing no disability, 
up to 4, representing a severe disability. This four-point NRS rating scale 
was  described in Chapter Four as part of the NRS group. This NRS was 
used to collect data during the structured interview, specifically addressing 
the quality of life question: How much do you think your Bladder/Bowel 
problem affects your life? 
6.1 Descriptive findings 
Measures of central tendency and dispersion were calculated to summarise the 
PDQ-39 variable data. These results, shown in Table 6.1, support the interpretation and 
analysis that gives meaning to this group’s PDQ-39 domain and SI scores. 
Table 6.1 
PDQ-39 domain scores (N=67) 
Domain Mean (SD) 
1:  Mobility total score 48.1 (28.8) 
2:  ADL total score 47.5 (26.0) 
3:  Emotional wellbeing total score 40.8 (26.1) 
4:  Stigma total score 30.3 (25.3) 
5:  Social support total score 30.3 (25.1) 
6:  Cognition total score 47.1 (25.2) 
7:  Communication total score 40.4 (26.8) 
8:  Bodily discomfort total score 56.3 (24.5) 
Total PDQ-39 QoL score 70.7 (35.4) 
PDQ-39SI score 37.4 (17.2) 
Note. The number of persons surveyed remains constant at N=67. 
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The participants’ mean scores shown in Table 6.1 fall within a mid-range from 
30 to 56. On a scale between 0 and 100 this indicates low to moderate levels of QoL 
disruption. As well, the SD ranges between 17 and 29, indicating that these participants’ 
scores vary widely in each domain question. On closer examination, none of the 
participant raw scores showed significant outliers that could skew the results. Instead, 
the large SDs indicate the presence of unidentified factors that make meaningful yet 
important differences to participants’ individual scores. 
6.1.1 Effect of PD on the lives of these people at this point in time 
The PDQ-39 scores from this study were compared to the originally published 
validation results conducted by Jenkinson, Fitzpatrick, Petro, Greenhall and Hyman in 
1997. Participant scores in the current study fell within a similar range of central 
tendency and dispersion to that published by Jenkinson et al. in 1997 (see Table 6.2).  
 
 138 
 
Table 6.2 
Comparison of PDQ-39 Scores Jenkinson vs. current study 
PDQ-39 
Domain 
Jenkinson et al. (1997, p. 355) Current study 
Postal 
 
N=201 M (SD) 
Clinic 
 
N=137 M 
(SD) 
Combined 
postal and 
telephone 
N=67 M (SD) 
Mobility 66.5 (28.2) 41.7 (31.6) 48.1 (28.8) 
ADL 55.8 (28.2) 40.4 (28) 47.5 (26) 
Emotions 43.2 (23.8) 31.9 (22.1) 40.8 (26.1) 
Stigma 34.6 (29) 30.8 (26.2) 30.3 (25.3) 
Social 24.2 (24) 13.6 (20) 30.3 (25.1) 
Cognitions 47.4 (23) 33.3 (22.9) 47.1 (25.2) 
Communica
tion 
37.0 (24.3) 25.6 (22.9) 40.4 (26.8) 
Bodily 
discomfort 
52.1 (24) 40.7 (28.1) 56.3 (24.5) 
PDQ-39 SI 44.6 (17.6) 31.6 (19) 37.4 (17.2) 
 
It was concluded that the current study’s participant group did not appreciably 
differ in their QoL scores from that of Jenkinson et al. (1997), who used moderately 
sized sample groups. To provide insight and depth of meaning as to what these scores 
actually represented, an exploration between disease-staging, self-perceived severity 
and PDQ-39 scored QoL was generated and the qualitative data, gathered from 
participant interviews, were contrasted against the more noteworthy PDQ-39 domains. 
This gave an opportunity to examine the relationship between QoL, the severity of PD 
and continence-specific symptoms. 
The two measures used in this study to categorise the participants’ degrees of 
disablement were the H&Y staging of PD and the S3-QoL, Measures of central 
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tendency and dispersion shown in Table 6.3 demonstrate both tools were equal and 
reliable measures of disease staging or severity. 
Table 6.3 
Measures of central tendency and dispersion (N=67) 
 M SD 
S3-QoL 2.67 .70 
H&Y disease staging 2.27 .81 
 
A Pearson product-moment correlation coefficient calculation was used to assess 
the association between participants’ disease severity and their QoL (see Appendix J). 
The findings demonstrated that for this group of people, a strong correlation existed 
between the severity of PD and their reports of a more negative QoL. A strong, positive 
association was noted between the H&Y and the S3-QoL [r=396, p=0.001 N=67]. 
However, the S3-QoL was demonstrably more sensitive across more of the domains 
and, in particular, the domains of mobility [r=0.439, p=0.000, N=67], ADLs [r=0. 413, 
p=0.001, N=67], cognition [r=0.439, p=0.000, N=67] and body discomfort [r=0.439, 
p=0.000, N=67], than was the H&Y. In light of these findings and as suggested by Ward 
(2000), who drew attention to a weak association between disability and QoL ratings, 
the S3-QoL was chosen as the tool to explore in more depth the QoL changes identified 
in the PDQ-39. 
The converged qualitative and quantitative data were used to explore 
participants’ reports of bowel and bladder dysfunction across each of the PDQ-39 
domains that scored a mean of 44 (see Table 6.1). The score of 44 was chosen as it 
reflects for this group, a score in the upper 50th percentile and is more indicative of a 
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negative QoL. The following four domains met the inclusion criteria for this 
exploration.  
1) Domain 1: Disturbances in mobility (M=48.1) 
2) Domain 2: Interruption to ADL (M=47.5)  
3) Domain 6: Changes to cognition (M=47.1)  
4) Domain 7: The experiences of bodily discomfort (M=56.3) 
6.1.2 Disturbances in mobility 
PD is classified by the IDC-10 under ‘extrapyramidal’ and ‘movement disorder’ 
and, as such, disturbances in movement are viewed as diagnostically fundamental to 
deficits in mobility, balance and movement used to stage PD severity. It was, therefore, 
expected in a study exploring PD that both mobility and ADL domains would produce 
high mean scores. The stem question used in the PDQ-39 was: Due to having PD, how 
often during the last month have you … 
 Q1: had difficulty doing the leisure activities which you would like to do? 
(M=2.3;SD=1.3) 
 Q2: had difficulty looking after your home, e.g., do-it-yourself, housework, 
cooking? (M=2.1:SD=1.3) 
 Q3: you had difficulty carrying bags of shopping? (M=2.1:SD=1.4) 
 Q4: had problems walking half a mile? (M=2:SD=1.4) 
 Q5: had problems walking 100 yards? (M=1.6:SD=1.3) 
 Q6: had problems getting around the house as easily as you would like?  
(M=1.6:SD=1.3) 
 Q7: had difficulty getting around in public? (M=1.8:SD=1.4) 
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 Q8: needed someone else to accompany you when you went out? 
(M=1.7:SD=1.5) 
 Q9: felt frightened or worried about falling over in public? (M=1.8:SD=1.4) 
 Q10: been confined to the house more than you would like?(M=1.6:SD=1.4) 
While the PDQ-39 separates mobility and ADL domains, most of the questions 
asked in the mobility domain primarily focused on ADL disturbances. A rationale for 
this could be that the self-administered questionnaire needs to be easily understood by 
the respondent, especially when there is no one available to interpret questions and, 
ideally, the respondent should be able to relate the questions to back to their personal 
situation. To achieve this, the majority of questions focused on the respondent’s ability 
to participate in activities rather than asking them about the action of the movement 
itself.  
When asked, all participants believed that the combination of their physical 
deficits and their bowel or bladder dysfunction created their toileting difficulties, 
including getting to a toilet in a timely manner. The participants’ comments seemed to 
fit more appropriately under this first domain, mainly due to their references to gross 
motor movement. Almost half of this group (46%) stated that their bowel and bladder 
dysfunction actually accentuated their experiences of movement disruption.  
P31(M;48): Having a full bladder definitely affects my gait. The urgency is often 
accompanied with very great gait disturbances. 
P28(M;65): Your physical limitations really affect your ability to manage things 
like toileting. The act of being able to undo your shorts to get your machinery 
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out adds into the challenge. I have urgent urination on top of the PD, and the 
lack of muscle control and the muscle relaxants I take makes urination an issue. 
P03: Having a SPC [catheter] has made it much easier for me. It has also made 
my mobility problems disappear. 
Additionally, the participant group highlighted abdominal pain, emotional stress 
and anxiety, which they saw as directly caused by their bowel and bladder dysfunction 
and which had a direct influence on their ability to move freely. 
P65(M;81): The [abdominal] pain has now made me resort to using a walking 
frame as it affects my standing and I’m leaning right over when I walk. 
P57(F;68): If I’m under stress, I have frequency and lack of control. My bladder 
is definitely worse when the dyskinesia is bad and dyskinesia can be worse if my 
bladder is bad. I find that stress affects both the dyskinesia and the bladder, 
which both affect each other. 
P51(M;79): I am able to discharge urine easier when I am relaxed. I can get 
into trouble when I am worried about getting [wetting] the seat, the toilet, the 
floor … getting undressed and prepared causes me much aggravation. 
The highest trending question within the mobility domain was Q1, which had an 
aggregated mean score of 2.3 (SD,1.3; n=67). As illustrated in Table 6.4, only 8 (12%) 
of this study’s participants stated that their disease had no effect on their leisure 
activities. 
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Table 6.4 
PDQ-39 Domain: Mobility  
Q1: During the Last Month, Have You Had Difficulty 
Doing Leisure Activities That You Would Like To Do? 
PDQ-39  
Domain1: Mobility 
Frequency % 
Never 8 11.9 
Occasionally 12 17.9 
Sometimes 11 16.4 
Often 19 28.4 
Always 17 25.4 
Total 67 100.0 
 
Gender differences also were also noted, with 32% of men stating that they often 
or always had difficulties doing leisure activities as compared to 29% of women (see 
Figure 6.1). 
 
Figure 6.1. Gender differences in PDQ-39 Q1. 
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Q1 implied that participation in leisure activities plays an important role in 
maintaining a positive QoL, and 88% of this participant group believed that their 
participation in leisure activities was compromised. The majority of participants were 
aged over 65 years and 78% of this group had been noted to be no longer engaged in 
paid employment (see Chapter 5, Table 5.1). In this context, Q1 was seen as important 
by the participants who reported difficulties in keeping up, physically, emotionally and 
financially with their spouses or friends who were unaffected by similar limitations. 
P01(F66): I rarely go out at all to social events or even have a night out with 
friends and family. 
P03(F;68): It [catheter care] does cost me quite a bit as I am not eligible to get 
a pension … I purchase a PCA [Personal Care Attendant] for 12 hours per week 
and catheter products at $250 per month … I have very little left over for 
anything else. 
P17(M;70): My son has complained that I go a lot. I cannot hold onto it. 
P26: I use the toilet frequently … yes, over and above my peers and friends … I 
am sure they notice it. 
Some participants spoke of their disease management as almost a full time job, 
which robbed them of the type of retirement that they had planned. In particular, visits 
to doctors, exercise clinics and medical specialists were all seen as reducing 
opportunities to enjoy their life in terms of recreation and socialising. 
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P06(F;76): I do not need to go to another specialist. I see too many already, it 
leaves no time for anything else. 
P11(M;61): If I let it, I would be going to this doctor or that doctor and I cannot 
do too much else each day, so I have had to choose. 
P20(M;65): If I did not put my foot down, I would be at another doctor every 
other day, It is just too much. 
In addition to the time spent medically managing their disease, the participants 
spoke of an overarching fear of leaving the house, in particular the fear of having an 
accident. The term accident was used by this group of participants to mean the 
experience of a leakage event or UI or FI. These accidents were spoken of as a main 
obstacle to enjoying an active social life. The participants’ stories provided deeper 
insights into this burden and, above all, how these bowel and bladder difficulties forced 
them to alter their social activities to compensate. While the participants spoke of 
making lifestyle changes, alterations or adaptations, they rarely blamed one aspect or 
symptom. Instead, they pointed to the single diagnostic term, PD. This was interesting, 
as most participants were still more likely to blame their bowel and bladder dysfunction 
on getting older than on the disease itself. 
P01(F;66): My lifestyle has altered so much because [a great silent pause] I used 
to go out all the time before I was diagnosed with PD. I was very involved in 
volunteer work, arts and craft, but I had to give that up because I have to stay 
close to the toilet. 
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P17(M;70): I have a lot of anxiety, this makes it worse … we went out to dinner 
and during the dinner I had to go three times. It can be very annoying, 
especially if I am waiting in a queue, say at the football match. I even had a 
traffic accident as I was trying to find somewhere to stop and pass urine. [At 
this point, his voice changed from light and breezy to one of exhaustion and 
embarrassment] … I have been that bad, that I had a small leak. 
P25(F;69): I restrict my movements, stay close to home and I reduce my fluid 
intake, especially if I am going out. 
P40(F;75): I hardly ever go out anymore to social events or even have a night 
out with friends and family. 
P57(F;68): I revolve my life around bladder issues. 
P65(M;81): I have put off going out because I do not think I will last the 
distance before it sneaks up on you … I can get to the shop but may not get back. 
The following participant’s statement was about faecal urgency accompanied by 
significant defecatory difficulties. He spoke at length about not going on holidays, 
because of his bowel difficulties. 
P49(M;77): I plan my day’s activities around using or not using my bowels … it 
makes it so hard [sic: difficult]. I do not go on holidays because of it. 
Incontinence or the fear of incontinence, especially in an older population 
whether they have or do not have PD, is widely recognised as creating leisure activity 
disturbances as well as socially isolating people (Cornwell, Laumann & Schumm, 2008; 
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Farage, Miller, Berardesca & Maibach, 2008; Landefeld et al., 2007; Levasseur et al., 
2004; St. John et al., 2010). In a similar way to the first PDQ-39 mobility question, Q10 
also addressed the issue of the participant being confined to their home because of 
mobility problems. This question focused on physically leaving the home environment, 
but was unlike Q1, which asked a more generalised question of leisure participation, 
which may or not have involved leaving the house. Despite the similarity, Q10 (N=67: 
M=1.6 SD=1.4) did not produce as high a mean score as did Q1.  
This result may indicate that either the participants’ problems did not inhibit 
movement beyond their home, or that this group of people had modified their 
expectations about leaving their house. The latter is the most logical interpretation when 
considered alongside respondents’ comments about leaving the house and how they had 
curtailed their leisure activities. The score for this question did not seem to adequately 
reflect the burden reported by 49 (73.1%) participants who stated, they frequently 
experienced high degrees of social restrictions, more so than isolation (see Table 6.5).  
Table 6.5 
PDQ-39 Domain: Mobility 
Q10: During the Last Month, Have You Been 
Confined to the House More Than You Would Like? 
PDQ-39 10 
mobility Frequency Valid per cent 
Never 18 26.9 
Occasionally 21 31.3 
Sometimes 8 11.9 
Often 9 13.4 
Always 11 16.4 
Total 67 100.0 
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Female participants also answered this question more negatively than did the 
males. As a result, the men’s scores had a more normal distribution than the women’s 
scores (see Figure 6.2). It is possible that women participants placed a greater 
importance on getting out of the home than the men in this group. These gendered 
observations were not further explored in this research, but may warrant follow-up 
studies to highlight gender differences in PD and QoL expression. 
 
Figure 6.2. PDQ-39, Q10 gender response 
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During the interviews, each participant indicated that any excursions away from 
home needed to be either well planned and geographically confined to their immediate 
neighbourhood, or confined to places well known to them. Personal experience was 
regarded by all participants as a precursor to any travel plan and any suggestion or 
information on new routes or places to try was seen as untrustworthy and entailing too 
much risk. Without reliable information or prior experience, no participant said they 
would leave their house for fear of bowel or bladder leakage accidents. 
P19(M;75): I am better when I am in the house. I do not travel anywhere of a 
long distance. So I only do things around the local [area].  
P26(M;64): I make sure I always know where the toilets are, especially before I 
leave on any journey. 
P40(F;75): It makes it very difficult to go away from home. 
P57(F;68): I revolve my life around my bladder issues. 
P51(M;79): My bladder causes me a bit of anxiety and I have to plan trips 
around my bladder at times. 
Participants reported that they mostly managed their bladder dysfunction by 
frequently using a toilet. The consequence of using the toilet often during the day was 
not considered a problem by any participant until they felt their use of the toilet was 
noticeably different from other people or it had an effect on their ability to perform 
daytime activities: 
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P26(M;64): I use the toilet frequently … yes, over and above my peers and 
friends … I am sure they notice it. 
P30(M;67): I used to be able to do so much more in the day. Now, I tend to plan 
my day around the toilet breaks. 
Participants also perceived bladder dysfunction as a problem if it disturbed their 
sleep. The effect of toileting habits on daytime activities is addressed within the 
discussion on the mobility domain, while nocturnal sleep disturbances are addressed 
within the cognitive domain discussion of this chapter. 
A particular concern raised by participants related to their need to identify where 
toilets were so they could quickly access them. The issue of access extended beyond 
getting to the bathroom in time and included the manual dexterity needed to efficiently 
remove clothing. Without exception, the participants spoke about their mobility deficits 
as one of the most significant factors inhibiting their access to a toilet. 
P01(F;66): Most of the time I don’t get there on time. 
P05((M;66): I make sure I know where the toilet is and get there before I need 
to use it. … as I get close to the toilet, it comes on very quickly … at the moment, 
I can undress quickly, but I have had a couple of misses, you know, accidents. 
P15(F;73): I’m much slower so I go to the toilet at every opportunity and 
approximately every two hours, but sometimes I do go just in case. 
P28(M;65): The front door syndrome [the feeling of great urgency on opening 
the front door of the house] is a real problem. I am currently managing [this] by 
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discharging my bladder in the garden and always using the toilet when you see 
one. I always use the toilet before I leave home or a social event. 
P55(F;69): Urgency, I can’t hang on for more than five minutes. I am always 
looking for toilets when out in case I need to go and now with Parkinson’s, well 
… you know. 
P56(F;66): I’m always looking for a toilet when I’m out. 
P58(M;84): I tend to look for a toilet all the time. I get an urgent call to go, but 
only pass small amounts. I can void every 15 minutes on a bad day. 
P61(F;89): At night it’s difficult to get out of bed due to stiffness and poor 
mobility so it’s difficult to get to a toilet. I have had to call my daughter to help 
me at times. 
P68(F;75): During the day I go to the toilet every hour. I cannot ignore the urge 
and it is terrible if I turn on taps or hear water running. It is definitely much 
worse as I get nearer the toilet. I have frequently leaked, especially now I have 
difficulty undressing.  
The mean scores for Q1 and Q10, when contrasted against participants’ S3-QoL 
scores, revealed a link between the degree of PD disability and its effect on the 
respondents’ ability to remain socially connected. The results, presented in Table 6.6, 
illustrated a coexistence of mobility disruption and isolation. Bowel and bladder 
dysfunction was clearly a more important factor contributing to social disruption for 
these people than the single aspect of mobility.  
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Table 6.6 
Comparison of measures: S3-QoL vs. PDQ-39 (N=67) 
S3-QoL 
 
PDQ-39 Q1 
mobility 
PDQ-39 Q10 
mobility 
1 = Very mild Mean .50 0 
n 2 2 
SD .7 0 
2 = Mild Mean 2 1.3 
 n 25 25 
 SD 1.4 1.1 
3 = Moderate Mean 2.4 1.7 
 n 33 33 
 SD 1.2 1.5 
4 = Severe Mean 3.4 2.5 
 n 7 7 
 SD .7 1.5 
 Total Mean 2.3 1.6 
 N 67 67 
 SD 1.3 1.4 
 
6.1.3 Interruption to ADL 
The PDQ-39 ADL domain presented six questions that highlighted proficiency 
across the ADLs of washing, dressing, writing, cutting up food and holding a drink 
without spilling the contents.  
Due to having PD, how often during the last month have you … 
 Q11: had difficulty washing yourself? (M=1.4:SD=1.4) 
 Q12: had difficulty dressing yourself? (M=2:SD=1.4) 
 Q13: had problems doing up your shoe laces? (M=1.8:SD=1.5) 
 Q14: had problems writing clearly? (M=3:SD=1.5) 
 Q15: had difficulty cutting up your food? (M=1.8:SD=1.4) 
 Q16: had difficulty holding a drink without spilling it? (M=1.6:SD=1.8) 
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The mean scores from each question were again recorded according to the 
participants’ S3-QoL rating. This was seen as an important way to understand how the 
participants’ degree of disability had influenced their ADL performance. 
The mean scores outlined in Table 6.7 also demonstrated a concurrence with this 
position in all but two questions, Q15 and Q16 which demonstrated a mean score 
decrease indicating that the participants ADL’s were not as severely affected.  
Table 6.7 
Comparison of mean scores: S3-QoL vs ADL (N=67) 
S3-QoL 
 
Q11 
ADL 
Q12 
ADL 
Q13 
ADL 
Q14 
ADL 
Q15 
ADL 
Q16 
ADL 
ADL 
domain 
total 
1 = Very mild Mean 0 0 0 1 0 0 4 
n 2 2 2 2 2 2 2 
SD 0 0 0 0 0 0 0 
2 = Mild Mean .9 1.4 1.3 2.4 1.4 1.6 36.6 
n 25 25 25 25 25 24 25 
SD .9 1.2 1.4 1.5 1.1 1.6 23.7 
3 = Moderate Mean 1.7 2.3 2.2 3.3 2.4 2 56.8 
n 33 33 33 33 33 33 33 
SD 1.5 1.3 1.5 1.5 1.4 1.9 24.2 
4   = Severe Mean 2.4 2.8 2.4 3.5 1.2 .5 55 
n 7 7 7 7 7 7 7 
SD 1.3 15 1.5 .7 .9 .5 19.5 
Total Mean 1.4 2 1.8 3 1.8 1.6 47.5 
N 67 67 67 67 67 67 67 
SD 1.4 1.4 1.5 1.5 1.4 1.8 26 
 
The score for Q15, the use of eating utensils to cut up solid food, and the score 
for Q16, drinking from a cup without spilling its contents, could indicate that the level 
of ADL difficulty had somehow been overcome and, as a consequence, allowed the 
participants to regain independence in performing these specific skills. This finding may 
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indicate that overcoming ADL deficits through the use of appropriate equipment or 
lifestyle modification has the propensity for increasing a person’s feelings of wellbeing 
and overall QoL.  
The participants who scored their S3-QoL at 4 equivalent to, severely affected 
by their bowel and bladder symptoms scored both PDQ-39 questions in a lower range, 
Q15 (M 1.2:SD 0.9) and Q16 (M 0.5:SD 0.5); whist the moderately symptom disturbed 
group scored these same questions as providing the highest bother (Q15: M 2.4: SD 1.4; 
& Q16: M 2: SD 1.9). The S3-QoL mildly disturbed group demonstrated smaller yet 
noteworthy differences occurring in Q15 (M 1.4: SD 1.1) and Q16 (M 1.6, SD 1.6). 
These results were interpreted as suggesting that forms of effective adaptation or 
modification had been made using specialised equipment to overcome these disruptions. 
No evidence was sought in the interviews to support this claim, however a logical 
assumption was made that participants with a more severe disability would be obtaining 
higher levels of assistance from carers; for example, eating foods in a way that required 
little cutting or using cups and bottles with lids or with drinking spouts so as not to spill 
their drink. This was also highlighted in the other ADL questions, not showing 
improvement in scores with disease severity, as they addressed skills not so easily 
rectified by the use of adaptive mechanical aids. The resulting interpretation is that Q11 
through Q14 were in accord with the assumption that as disease severity increased, 
people would find it more difficult to undertake ADL’s, while Q15 and Q16 did not 
demonstrate this relationship. 
Spector, Katz, Murphy and Fulton (1987), Holroyd-Leduc, Mehta and Covinsky 
(2004) and Roehrig, Hoeffken, Pientka and Wedding (2007) explained that ADLs can 
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be categorised into two major groupings. The first, known as basic ADLs (BADLs), 
measure a person’s ability to independently: 
 feed or dress oneself 
 maintain a good standard of personal hygiene 
 urinate and defecate in the toilet 
 transfer and ambulate. 
The second group of ADLs, known as instrumental ADLs (IADLs), are more 
advanced or higher order ADLs that extend beyond BADLs into areas that are more 
complex. IADLs are daily activities that people do in order to live independently in the 
community. They focus on a person’s ability to perform: 
 basic home cleaning and maintenance 
 shopping using telephones and computers 
 management of personal health and financial maintenance activities. 
The PDQ-39 has used IADLs within its mobility domain and BADLs within its 
ADL domain. The ability to voluntarily defecate and urinate in a socially appropriate 
manner is regarded as an integral component of any sound BADL measure and their 
omission is a major deficit of the PDQ-39 (Aditya et al., 2003; Bradway, 2003; 
Chiarelli, Brown & McElduff, 2000; Holroyd-Leduc et al., 2004; Rahman et al., 2008; 
Roehrig et al., 2007). However, the exclusion of toileting problems from this QoL 
measure may be related more to bowel and bladder dysfunction being seen as a 
symptom of PD than an outcome of the disabling effects of PD. Even though bowel and 
bladder dysfunction is widely recognised as an important factor that disrupts QoL in 
people with PD, it is a complex subject and, therefore, difficult to incorporate into a 
comprehensive QoL measure such as the PDQ-39 (Chaudhuri, Martinez-Martin et al., 
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2007; Coggrave et al., 2009; Evatt et al., 2009; Li et al., 2010; Sakakibara et al., 2008; 
Terai et al., 2004). 
The following four ADL questions drew the highest mean scores from the six 
questions: 
 Q12: Due to having PD, how often during the last month have you had 
difficulty dressing yourself? (M=2: SD=1.4) 
 Q13: Due to having PD, how often during the last month have you had 
problems doing up your shoe laces? (M=1.8: SD=1.55) 
 Q14: Due to having PD, how often during the last month have you had 
problems writing clearly? (M=3: SD=1.54) 
 Q15: Due to having PD, how often during the last month have you had 
difficulty cutting up your food? (M=1.8: SD=1.4) 
Being able to dress and undress independently is as significant a factor as a 
person’s ability to remain continent. A person who has frequent accidents or leakage 
due to an inability to remove clothing is considered to have a functional incontinence 
(Frick et al., 2009; Griebling, 2008; Hurlow, 2007; Kraus et al., 2010; Marshall & 
Baliey, 2008). For this participant group, their functional incontinence was made worse 
by urinary or faecal urgency and frequency. Kraus, Bavendam, Brake and Griebling 
(2010), Lord et al. (2003), Bradway (2003) and Frick et al. (2009) reported that older 
people with urinary symptoms such as frequency and urgency also had a higher risk of 
falls due in part to their haste to get to a toilet and to remove clothing. This combination 
was reported by the majority of participants as causing considerable concern.  
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P20(M;65): Occasionally I have to be pretty quick to miss my clothes as I get 
undressed at the toilet or urinal. 
P28(M;65): The act of being able to undo your shorts to get your machinery out 
adds into the challenge. I have urgent urination on top of the PD, this makes 
urination an issue. 
The removal of clothing was reported by this participant group to be of major 
importance and a source of increased stress that greatly affected excursions beyond their 
home. 
P62(M:59) I sometimes can’t get my pants down in time. 
P67(M;73): I am finding it harder when I am in the toilet to undress. 
6.1.4 Changes to cognition. 
The PQD-39 cognition domain, made up of four questions, was considered by 
many participants to be a major area of concern.  
Due to having PD, how often during the last month have you … 
 Q30: unexpectedly fallen asleep during the day? (M=1.9, SD=1.5) 
 Q31: had problems with your concentration, e.g., when reading or watching TV? 
(M=2.2, SD=1.5)] 
 Q32: felt your memory was bad? (M=2, SD=1.3) 
 Q33: had distressing dreams or hallucinations? (M=1.4, SD=1.3) 
The total mean score (M=47.1, SD=25.2) for this domain was recorded in the 
upper 50th percentile, indicating that the participants’ QoL was negatively affected by 
issues of memory, sleep, concentration and bad dream states. The contribution of bowel 
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and bladder dysfunction in this domain was explored by discussing sleep patterns, 
daytime concentration and tiredness. 
The mean score from the cognition domain offered very different insights into 
the symptomatic presentation of this disease compared to other more physical domains 
such as the ADL and mobility domains. In particular, participants reported the presence 
of disturbing cognitive changes well before they reported problematic physical 
disturbances. Consequently, this was the only domain where participants regarded a 
very mild disability as causing QoL disturbances. Using the mean and SD scores from 
each domain, a one-way ANOVA was used to identify if these participant reports were 
statistically significant. The question used to guide this examination was: Did 
disturbances in cognition become more severe alongside the participants’ reported S3-
Qol. No statistically significant effect was noted between the participants’ reports of 
cognitive disturbance and their degree of S3-QoL severity [f (3,63)=1.329, p=0.273]. 
The results showed that while cognition appeared early in their disease profile, these 
cognitive disturbances did not reduce the participants’ QoL.  As demonstrated in Table 
6.8 this participant group reported their S3-QoL severity was more profound in the mild 
stage (M=48.9: SD=32) and less so in the moderate (M=47.8, SD=20) and more 
severely staging (M=47.4, SD=32).   
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Table 6.8 
Comparision of measures: S3-QoL vs PDQ-39 Cognition Domain (N=67) 
S3-QoL Score Q30 Q31 Q32 Q33 Cognition 
total score 
1= Very mild Mean 0 1 1 0 12.5 
n 2 2 2 2 2 
SD 0 1.4 0 0 9.1 
2= Mild Mean 1.8 2.1 2.1 1.7 48.9 
n 25 25 25 25 25 
SD 1.5 1.5 1.3 1.5 32.1 
3= Moderate Mean 2 2 2 1.4 47.8 
n 33 33 33 33 33 
SD 1.4 1.3 1.2 1.1 20.1 
4= Severe Mean 2.2 2.4 1.7 1.1 47.4 
n 7 7 7 7 7 
SD .9 1.1 .7 1 16.3 
Total Mean 1.9 2.1 2 1.4 47.1 
N 67 67 67 67 67 
SD 1.4 1.3 1.2 1.3 25.2 
 
Individuals who rated themselves as being severely burdened (M=47.4: 
SD=16.3) reported cognitive-related QoL disruption at an intensity equal to those rating 
their PD disability as mild (M=48.9:SD=32.1) (see Table 6.8). This finding is 
diametrically opposite to those in the ADL and mobility domains, where PD 
progression was statistically correlated with disease severity. 
The noticeably large numerical difference between the mild (M=48.9: SD=32) 
and very mild grouping scores (M=12.5: SD=9.1) was statistically significant at p=0.05 
in t-tests. This finding revealed a point where participants recognised their cognitive 
changes as disease-specific symptoms rather than a cognitive change, commonly 
regarded by them as an occurrence of mental fatigue or age-related cognitive decline. 
The interpretation of this result is that there is a demonstrable peak time where 
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participants’ deficits in cognition may be more noticeable than their physical changes, 
as compared to later stages of this disease where the participants’ physical deficits 
become more evident and take on a central focus. 
These findings are consistent with the Braak theory of PD progression, which 
promotes cognitive disturbances as occurring early in stage two (Chaudhuri & Odin, 
2010; Del Tredici & Braak, 2012; Hawkes et al., 2010). That stage, where dopamine-
producing neurons remain adequate in number so as not to disturb a person’s gait, is 
known to have a greater effect on cognition, as well as on the performance of 
gastrointestinal and urinary systems. 
Many participants lamented the loss of abilities and how the PD had robbed 
them of being able to use their higher order or executive thinking skills (Schneider, 
2007). A participant (P9,M;64) was unable to tell his story easily, often leaving bits out 
and losing focus during conversation, expressed grief about not being more alert, as he 
stated ‘I’m just not with it any longer’. The participant’s incorporation of bowel and 
bladder dysfunction into this domain took the form of how much mental energy was 
used to manage their continence problems. The consensus among participants was that 
their toileting difficulties dominated their thoughts and was the main source of mental 
anguish and distress. While the PDQ-39 did not specifically address any aspect of 
bowel and bladder dysfunction, the participants’ interpretations of the cognition 
questions as they related to their current situation allowed them to incorporate their 
bowel and bladder symptoms, which they believed had stopped them thinking clearly or 
concentrating on tasks. 
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P51(M;79): I am anxious about many things. They play over in my head and 
leave room for nothing else … like my bladder—it just takes over everything 
else. 
Chaudhuri (2003) and Chaudhuri, Healy et al. (2006) have detailed the common 
occurrence of sleep deprivation in all people with PD as an important factor affecting a 
person’s cognition.  Many of the participants in this study reported that they 
experienced very disturbed sleeping patterns, which they blamed on their nocturnal 
urinary frequency. Furthermore, they proposed their poor sleep pattern affected their 
ability to think clearly during the day, yet on examination, the number of times a 
participant was woken through the night was not found to be significantly associated 
with any of the cognitive domain questions. What follows is a deeper exploration of 
these relationships, warranted by the participants’ comments regarding the significance 
of these issues to them. 
Disturbances to sleep were reported as being disturbed by the need to void more 
than twice each night by 36 participants (see Table 6.9). 
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Table 6.9 
Frequency of Nocturia by PDQ-39 Domain Score (N=67) 
Nocturia PDQ-39 cognition total score 
No Mean 45 
Median 44 
95% CI for mean 44.1 – 62.2 
n 31 
SD 26.6 
Yes 
 
Mean 48.9 
Median 50 
95% CI for mean 50.8 – 67.3 
n 36 
SD 24.1 
  
It was expected that these participants would report daytime tiredness and the 
need to catch up on lost sleep. Unexpected daytime sleeps were reported by 52 (77.6%) 
which equates to 50% of those participants answering Q30 in the affirmative, stating 
they often or always unexpectedly slept during the day. 
While not specifically asked during interviews whether they were tired or 
whether they needed to sleep during the day many participants’ volunteered statements 
that included rising very early in the morning and, therefore, needed to sleep early in the 
evening.  
P32(F;53): I have tried to go to sleep later but I am usually in bed by 6 or 7. 
The sleep disorder clinic, they told me I did not sleep well …I try to go to bed 
later. Tried not to do anything active before sleep. It makes no difference. I just 
gave up. 
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Never n=15 
Never n=9 
Never n=5 
Never n=15 
Occasionally n=14 
Occasionally n=16 
Occasionally n=22 
Occasionally n=31 
Sometimes n=12 
Sometimes n=15 
Sometimes n=16 
Sometimes n=6 
Often n=13 
Often n=12 
Often n=13 
Often n=7 
Always  n=13 
Always  n=15 
Always  n=11 
Always  n=8 
0 5 10 15 20 25 30 35
Q30 - Sleep
Q31 - concentration
Q32- memory
Q33 - Hallucination
PDQ-39 Cognition Domain Six 
A diagrammatic view of how participants addressed each of the four cognition 
questions within this domain is shown in Figure 6.3 and Table 6.10 below.  
Figure 6.3: PDQ-39 Domain Six Questions on Cognition 
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Table 6.10 
PDQ-39 Cognition Domain Results 
Q30 (Sleep) Frequency % 
Never 15 22.4 
Occasionally 14 20.9 
Sometimes 12 17.9 
Often 13 19.4 
Always (or cannot do at all, if applicable) 13 19.4 
Total 67 100 
Q31 (concentration) Frequency Valid per cent 
Never 9 13.4 
Occasionally 16 23.9 
Sometimes 15 22.4 
Often 12 17.9 
Always (or cannot do at all, if applicable) 15 22.4 
Total 67 100.0 
Q32  (memory) Frequency Valid per cent 
Never 5 7.5 
Occasionally 22 32.8 
Sometimes 16 23.8 
Often 13 19.5 
Always (or cannot do at all, if applicable) 11 16.4 
Total 67 100.0 
Q33 (Dreams & Hallucination’s) Frequency Valid per cent 
Never 15 22.4 
Occasionally 31 46.3 
Sometimes 6 9.0 
Often 7 10.4 
Always (or cannot do at all, if applicable) 8 11.9 
Total 67 100.0 
 
Q30 and Q31 are more relevant to sleep deprivation than issues related to 
memory, vivid dreams and hallucinations (Marschall-Kehrel, 2004; Norlinah et al., 
2009). They produced a more symmetrical score distribution compared with the other 
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two questions, Q33 and Q34, which were moderately and more positively skewed. 
These findings suggested for this group of participants that Q30 and Q31 were more 
indicative of a similar causal factor; in this instance possibly stemming from the 
participants’ reported nocturnal urinary frequency, which caused multiple sleep 
disturbances. Q32 ‘memory’ and Q33 ‘hallucinations’ represented different aspects of 
cognition and followed a trajectory that did not have diurnal tiredness or the ability to 
concentrate as a central feature. Both are viewed as co-dependent factors in nocturnal 
wakefulness. 
Chaudhuri, Healy et al. (2006), Marschall-Kehrel (2004), Norlinah et al. (2009), 
Pal et al. (2004) and Perez-Lloret et al. (2009) asserted that sleep disturbances, while 
common in PD and older adulthood, seemed to have little effect on reported QoL. The 
cognitive domain findings together with participants’ reports were consistent with this 
point of view. The main references by the participants suggested that sleep disturbances 
were not related to the number of times the person woke up, but rather whether they had 
difficulty getting back to sleep. Those who stated they had little difficulty getting back 
to sleep also said they were untroubled by the excessive number of awakenings needed 
to void. 
P07(M;67): Yes, I do have nocturnal frequency every two hours or so. No, only 
occasionally do I have difficulty getting back to sleep. Then I take half a 
Mogadon [sleeping tablet] to help me sleep. 
P09(M;64): I did not consider going to the toilet four times each night as 
excessive. I haven’t considered it a great problem. 
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P30(M;67): I wake up three to four times overnight on average: 10 pm, 12 
midnight, 2 am and 6.30 am. There is no difference in the amount I pee at night 
or the amount I pee during the day. Generally I have no trouble falling asleep. 
Conversely, those who had more difficulty getting back to sleep were more 
inclined to complain that waking up to void had a negative effect on their QoL. 
P25(F;69): I now wake up overnight once to empty my bladder. I do not like this 
at all as I have problems falling back to sleep. It makes everything else during 
the day so hard. 
P40(F;75): The night-time bothers me as I have trouble getting back to sleep. 
P41(F;73): I have difficulty going back to sleep. I hate it, it makes me so tired 
and irritable and I cannot think straight 
Only one participant thought of discussing these disturbances with a doctor. 
Interestingly, the participant chose to report the sleep disturbance rather than the need to 
empty their bladder, the main reason they woke. 
P32(F;53): I spoke with the neurologist about the sleep disturbances, not 
specifically the urine problems of waking up. 
This complaint resulted in a referral to a sleep disorder clinic from which she 
gained no helpful information or assistance, adding to her frustrations. 
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P32(F;53): They told me I did not sleep well. They made no other suggestions or 
recommendations or anything. I am not really happy with the limited help 
offered, I am not satisfied. 
6.1.5 Experience of bodily discomfort 
Bodily discomfort was seen by this group of people as having a profoundly 
negative effect on their QoL. This domain produced the strongest participant response, 
as indicated by its high score compared to all other domain scores for this group of 
people (N=67, M=56.3: SD=24.5). The domain, bodily discomfort, encompassed three 
questions:  
Due to having PD, how often during the last month have you … 
 Q37: had painful muscle cramps or spasms? (M=2.1: SD=1.1) 
 Q38: had aches and pains in your joints or body? (M=2.5: SD=1.2) 
 Q39: felt unpleasantly hot or cold? (M=2.0: SD=1.4) 
These domain questions drew a strong response from the participants who 
reported that their S3-QoL was directly related to increases in body discomforts (see 
Table 6.11).  
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Table 6.11 
Comparison of domain bodily discomfort mean scores:  S3-QoL vs PDQ-39  
S3-QoL 
Q37 Q38 Q39 
PDQ-39 
bodily 
discomfort 
total score 
1 = Very mild Mean 0 2 1.5 29 
n 2 2 2 2 
SD 0 1.4 0.7 5.7 
2 = Mild Mean 2 2.2 1.8 49.2 
n 25 25 25 25 
SD 1.1 1.4 1.7 24.9 
3 = Moderate Mean 2.3 2.8 2.3 61.9 
n 33 33 33 33 
SD 1.1 1.0 1.4 21.1 
4 = Severe Mean 2.6 2.7 2.3 63.3 
n 7 7 7 7 
SD 1.4 1.6 1.3 32.6 
Total Mean 2.1 2.6 2.1 56.4 
N 67 67 67 67 
SD 1.2 1.2 1.5 24.5 
 
Many participants referred to their bodily discomfort as pervasive and disturbing 
numerous aspects of their life, especially their sleep, and reducing their ability to move 
around freely. Participants reported irregularly taking over-the-counter (OTC) pain 
relieving medicines such as Panadol-Osteo, which is a sustained release paracetamol. 
Anti-inflammatory agents, or medicines prescribed by their specialist neurologists such 
as Amitriptyline (Endep), an antidepressant, were also used to relieve the effects of 
chronic neurological pain. Minerals and vitamin supplements, such as magnesium or 
Coenzyme Q10, were also reported to be used to relieve the spasms and cramps 
experienced by the participants. 
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P3(F;68): The pain in my bowel for the past five years—it gets better if I use an 
anti-inflammatory. 
P14(F;63): I have recently tried using Q10 and it seems to have helped. 
P29(M;61): The Neurologist recommended Endep as the pain is significant. I 
really do not know whether it helps. 
The participants raised issues of physical pain and bodily discomfort during the 
interviews, mostly within the context of continence and as a direct consequence of their 
constipation. However, pain was not confined to straining at stool. Participants also 
spoke of generalised abdominal pain, describing it in terms of spasms and cramping. 
These episodes were more often reported to occur prior to defecation and were 
interpreted by participants as the call to stool. Q37 specifically asked about spasms and 
cramps, though it did not specify where in the body these discomforts occurred. The 
participants’ answers to this question were interpreted as being in line with the bowel 
pain they experienced, especially as their pains, cramps and spasms were so prominent 
in their stories. There was no research or literature available on this topic of 
constipation-related pain or how this pain and cramping differs from, or is similar to, 
that experienced by others with and without PD. 
P01(F;66): I constantly have stomach pain and cramps and I feel like I’m in 
labour. That pain has now made me resort to using a walking frame as it affects 
my standing and I’m leaning right over when I walk. 
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P03(F;68): Pain in my bowel for the past five years. There is an increased pain 
and discomfort that gives me the feeling that I urgently need to go to move my 
bowels. 
P06(F:76): I get a pain in my tummy, which is very bad, usually in the left lower 
side. If I get this pain, I take Movicol (a laxative). 
P15(F:73): I have to wait a long time on the toilet, up to 30 minutes. It can make 
you very late for appointments and it is particularly painful and debilitating. 
P17(M;70): It is so bad [abdominal pain] that I perspire, it is so painful. 
P20(M;65):. I do need to ease the pain and stop the bleeding, that would make 
things better. Even my wife is not sure what to do about it.  
P25(F;69): It takes so much effort, it is like having a baby again, without the 
end benefit. 
P28(M;65): It can be a very painful experience and I can raise quite a sweat. I 
have found that when I am constipated it definitely affects my ability to urinate. 
Bodily discomforts as reported by Abeare, Cohen et al. (2010), Kurita and de 
Mattos Pimenta (2009) and Rutledge, Mouttapa and Wood (2008) were also reported by 
each participant in terms of it being a physically and mentally exhausting experience. 
The participants also spoke of medicines used to minimise their pain and how these 
drugs affected the quality and speed of their thinking. This finding is consistent with 
research published by Kurita and de Mattos Pimenta (2009), who found that the use of 
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pain medications had considerable and detrimental effects on participants’ ability to 
think clearly. 
The body aches and pains spoken about by this group were directly related to 
their bowel dysfunction and, in particular, to the peristaltic propulsion of stool from the 
large bowel into the rectum just prior to defecation. This phenomenon, reported by these 
people as affecting their movement and creating significant pain, has not been 
documented in the literature. This lack of knowledge about the relationship between 
abdominal pain, PD and bowel movements has undermined the ability of these 
participants to find a suitable resolution to their problem. Many participants reported 
that they used strong pain relieving products to manage their pain while realising that it 
also created the potential for further constipation as well as cognitive decline. This is an 
important finding, with the potential to influence clinical practice in this field. 
6.1.6 Domains of emotional wellbeing, stigma and social support 
As mentioned in the introduction of this chapter, the four domains covering 
emotional wellbeing (M=40.8), stigma (M=30.3), social support (M=30.3) and 
communication M=40.4) all scored below the 50th percentile (M=44), a result taken to 
mean that participants did not view these domains as contributing appreciably to their 
reported negative QoL (see Table 6.12).  
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Table 6.12  
Domains scoring below the 50th percentile (N=67) 
Emotional wellbeing (M=40.4, SD=26.1)  
Due to having PD, how often during the last month have you - 
Q17: felt depressed? (M=1.6, SD=1.3) 
Q18: felt isolated and lonely? (M=1.4, SD=1.2) 
Q19: felt weepy or tearful? (M=1.5, SD=1.3) 
Q20: felt angry or bitter? (M=1.2, SD=1.1) 
Q21: felt anxious? (M=1.9, SD=1.2) 
Q22: felt worried about your future? (M=1.8, SD=1.3) 
Stigma (M=30.3, SD=25.3)      
Due to having PD, how often during the last month have you -  
Q23: felt you had to conceal your Parkinson’s from people? (M=1.2, SD=1.4) 
Q24: avoided situations that involve eating or drinking in public? (M=1.4, SD=1.5) 
Q25: felt embarrassed in public due to having PD? (M=1.5, SD=2.2) 
Q26: felt worried by other people’s reaction to you? (M=1.2, SD=1.7) 
Social support (M=30.3, SD=25.1)   
Due to having PD, how often during the last month have you - 
Q27:  had problems with your close personal relationships? (M=1.3, SD=1.3) 
Q28:  lacked support in the ways you need from your spouse or partner?  (M=1.2, SD=1.2) 
Q29:  lacked support in the ways you need from your family or close friends?  (M=1.1, 
SD=1.3) 
 
Yet, with the exception of communication, the areas of emotional wellbeing, 
stigma and social support were all raised by the participants in their interview 
conversations as areas of great concern. These areas are also highlighted in continence 
literature as providing the most stress for people with incontinence (Bradway, 2003; 
Fitzgerald et al., 2000; Frick et al., 2009; Khan et al., 2009; Lachowsky, 2000; Smoger 
et al., 2000; Weber et al., 2000). In light of this, an overview encompassing the 
emotional wellbeing, stigma, social support domains has been compiled. 
Communication (see Table 6.13) as a topic was not raised by the participants in their 
interviews and has, therefore, been excluded from this overview.  
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Table 6.13 
Communication Domain (N=67) 
Due to having PD, how often during the last month have you … 
Q34:  had difficulty with your speech? (M=2, SD=1.3) 
Q35:  felt unable to communicate with people properly? (M=1.7, SD=1.2) 
Q36:  felt ignored by people? (M=1, SD=1) 
Total  Communication Domain Scores  (M=40.4, SD=26.8)     
 
6.1.6.1 Emotional wellbeing 
Fifty-two (85.4%) participants highlighted that they were emotionally 
distressed and anxious about their bowel and bladder dysfunction. Many of these 
participants referred to their overall disease management as being like a full time job, 
with no support to assist them or information to guide them. Their anxiety was reported 
as mainly stemming from a fear of potential or actual leakage events or accidents and 
the unpredictability of their bowel and bladder dysfunction was always foremost in their 
minds. 
P49(M;77): Won’t go on holidays due to bowel issues. 
P19(M;75): I sometimes don’t go out at times due to bowel concerns. 
P32(F;53): This is a serious concern for me, I have to know where the next toilet 
is. 
P57(F;68): I am afraid to go away at times. 
P4(F;65): I seem to have lost any predictable bowel actions.  
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P17: I even had a traffic accident as I was trying to find somewhere to stop and 
pass urine. [At this point, his voice changed from light and breezy to one of 
exhaustion and embarrassment] … I have been that bad, that I had a small leak. 
The entire participant group spoke of making lifestyle changes, alterations or 
adaptations in relation to their bowel and bladder dysfunction. They also spoke of 
having to source information and products for themselves and, when asked, all reported 
they just did not know where to begin this search. Some participants reported using 
friends and spousal advice, while others listened quietly to other people’s conversations 
and followed their lead. 
P21(M;86): I listen to my friends at the club speak and then I use what they use. 
I also get a lot out of the PD support group. 
The participants firmly believed that no one would be interested enough to help 
them and they stated that they were too embarrassed to ask for any help. 
P6(F;76): No, I have not asked for any help. I suppose if I thought the doctor 
could do anything I might. 
P5(M;66): I would not speak of this to any other person, especially my friends 
and family, it is a little personal 
Other participants felt particularly frustrated at the lack of scientific progress in 
the search to cure PD, as well as a lack of scientific interest in what they saw as the 
important issues, such as being able to go to the toilet. Participants expressed the view 
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that because toilet issues were not “sexy”, these symptoms were unappreciated and 
possibly the reason why so little research time or effort had been invested. 
P10(F;67): Everyone assumes that everyone is able to do it (urinate or defecate) 
and if they cannot then it is their responsibility to find a fix. 
P08(M;71): Off the record, none of the people I spoke to seemed too 
particularly interested. If not for my interest, none would have asked me about 
it. Fifty per cent of the PD support group I attend tell me that they have 
problems with constipation as well and they feel the same, just helpless and 
frustrated. 
P14(F;63): I am very embarrassed and do not think I can speak frankly to the 
doctor to ask for help. 
6.1.6.2 Social support 
Most participants relied very heavily on their spouse or friends to gain insight 
into their bowel and bladder dysfunction, with most stating they were more inclined to 
keep a quiet brave exterior than to bother others with this ‘embarrassing and stupidly 
insignificant concern’ (P21,M;86). Very few participants were aware of any social 
resources available to them in the form of financial assistance or specialist continence 
nurses working from local health services. Of the 67 participants in this study, only one 
had seen a continence nurse specialist and another had been signed up to the Continence 
Aids Payment Scheme (CAPS) by a local social worker. These two participants were 
the only ones who had any financial assistance or support in selecting the most 
appropriate continence aids. The CAPS is an Australian Commonwealth financial 
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payment made to all people over the age of five years who have permanent and severe 
incontinence due to a neurological condition. A payment of approximately $500 is 
indexed each year and paid directly to the eligible person’s bank account where it can 
be directed to a continence supplier of their choice. 
P3(F;68): The continence nurses come and change my catheter and order my 
supplies. It still costs me quite a bit [in addition to CAPS]. As I am not eligible 
to get a pension, the[Personal Care Attendant-(PCA)] service costs me. I 
purchase a PCA for 12 hours per week as well as the catheter products at $250 
per month. 
P19(M;75): I know about government support to buy pads. That is why I am 
able to try lots of different ones, I buy them from the local chemist at $6 per 
packet. 
The other participants using disposable continence products did so at their own 
cost, which they estimated to be between $50 and $100 each month. 
P25: I wear Poise pads, which I buy from Coles or the local chemist. This costs 
me approximately $20 per week. [This participant had never heard of the CAPS 
scheme.] 
6.1.6.3 Stigma 
Stigma was deeply entrenched in the conversations. Not one participant spoke 
about being labelled or discriminated against based on either their PD or their 
incontinence, yet they had all created a protective barrier shielding them from any 
potential distain others may have shown towards their disease. This protection took the 
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form of attributing many obvious PD-related symptoms to more socially acceptable 
ageing frameworks. Statements like ‘well at my age I would not expect less’ were 
commonplace. 
P26(M;64): I have a weaker than average stream. Yes, I use the toilet 
frequently. Yes, over and above my peers and friends, but isn’t that a normal 
part of ageing? 
It seemed likely from the tone of the participants’ voices that they concealed 
such information and did in fact experience embarrassment and stigma. Much of what 
they said was in hushed tones that included many sighs and pauses, all of which 
indicated the degree of difficulty they had talking to anyone, even an unmet researcher 
over the phone in a situation where they knew they would never be recognised. 
P3(F;68): I do not like talking to people about this as it is very embarrassing. 
Even the doctors do not feel comfortable about talking about these problems. 
Each participant came into this study knowing that the research was focused on 
bowel and bladder dysfunction and that to be part of this study they needed to have a 
bowel and or bladder problem. Every interview started with the same question: ‘Tell me 
about your bowel/bladder problem’. It was a continual surprise that many participants 
would say: ‘I do not have a bowel or bladder problem’. As an experienced clinician, the 
researcher would then ask more specific questions that usually guaranteed a much more 
detailed report of their presenting problems. For example, one participant (P10:F;67) 
started with ‘I do not have any bowel or bladder problems’. When specifically asked 
about frequency—‘How often do you go to the toilet?’—the researcher was told ‘every 
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hour’. The participant then continued the conversation, discussing how she thought she 
was not able to empty her bladder fully and that she always felt full and dribbled urine 
constantly and this was why she was going to the toilet so much and needed to wear a 
pad for protection. 
This pervasive and interesting feature dominated the participants’ stories and 
seemed to be used effortlessly by them to side-step toileting topics. Humiliation was 
omnipresent in the participants’ stories. 
 P1(F:66): It is so humiliating if I have an accident. 
The dominant rationale used was to blame their incontinence on getting older, 
rarely conceding that it was their PD that caused their bowel and bladder symptoms. 
P57(F;68): As I’ve gotten older [a great pause and sigh, then whispered] or my 
PD is worse, I have noticed that if I get stressed, bowel urgency and accidents 
will happen, which is very distressing and horrible. 
It is quite possible that they believed problems with bowel and bladder 
dysfunction were more acceptable if due to ageing. As such the participants seemed to 
place a higher level of stigma on having PD than they did on getting older. 
6.2 QoL concerns and participant confusion about bowel and blader aetiology. 
The study found the participants were unclear as to whether bowel and bladder 
dysfunction was caused by PD or whether it was more related to what they perceived as 
normal age-related changes. In doing so, the participants showed a great ability to 
compartmentalise symptoms that they did not attribute to or believed were unrelated to 
their PD. For the most part, participants thought of their PD as a disorder of movement, 
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because this was how the diagnosis had been explained to them by their doctors. The 
participants also stated this caused them considerable aggravation as they were not sure 
whom to ask for help, or how to ask the questions about their bowel and bladder 
dysfunction.  
P1(F;66): I am open to any suggestions that might help fix the problem. 
P6(F;76): No, I have not asked for any help. I suppose if I thought the doctor 
could do anything I might. 
P7(M;67): Bladder— Before I got PD, I did not wake up as often. I think it is a 
problem of getting older, you know, problems with your waterworks. Bowels 
well, everyone I spoke to were very unhelpful. I had to find out what the problem 
was and the cause. 
P8(M;71): I just feel helpless and frustrated. 
P24(M;62): My prostrate is of a normal size and the urologist was not relating 
any of my complaints to the PD. I am just going to put up with it and straighten 
my urethra. The doctors did not make any other recommendations. 
P32(F;53): I just gave up, I am not really happy with the limited help offered. I 
am not satisfied. 
6.3 Summary 
This chapter presented data which highlighted bowel and bladder symptoms as 
contributing significantly to these participants’ expression of a negative QoL. Despite 
the fact that the PDQ-39 does not specifically identify bowel and bladder symptoms, the 
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participants’ interpretations and expressions of QoL concern weredirectly linked to the 
answers they gave, especially across the four most disturbed PDQ-39 QoL Domains of; 
Bodily Discomfort, Mobility, ADL and Cognition.  
This was especially evident when the participants spoke of the pain directly 
associated with the constipation they experienced. Domain Eight, bodily discomfort 
with a mean score of 56.3 addressed aches, pains, spasms and changes in body 
temperature. The participants spoke of severe abdominal griping pain and discomfort 
associated with their constipation, as well as not being able to clear the contents of the 
rectum without physically damaging themselves. They also related bladder fullness and 
the discomfort it caused as having a direct influence on their ability to mobilise. The 
participant group, without exception, related strongly to this domain, detailing the very 
significant and disturbing bowel and bladder related aches, pains and spasms. Pain so 
severe that they stated it affected their ability to mobilise to be able to dress and undress 
themselves, and to be able to construct sensible thoughts and understandings, which in 
turn decreased their feelings of wellbeing.  
The second most disrupted domain of the PDQ-39 was Domain One, Mobility 
with a mean score of 48.1. This domain was identified by the participants as either, 
being affected by their bowel and bladder dysfunction or having an effect on their 
ability to get to a toilet safely to empty their bowel or bladder. The participants 
themselves raised the issue of mobility in their interviews, stating that their ability to 
move freely was severely compromised when they had a full bowel or a full bladder. 
This allowed further opportunities for aligning and interpreting bowel and bladder 
dysfunction alongside this domain as both addressed social restriction. This imposed 
social restriction also resulted in lower levels of lifestyle satisfaction.  
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The third most disrupted domain was ADL, with a mean score of 47.5. The 
participants’ stories and accounts of bowel and bladder dysfunction highlighted a 
difference between this and all other domains. The difference stemmed from the 
participants’ inability to independently perform ADL’s which in-turn created difficulties 
for these people in managing their bowel and bladder dysfunctions. These ADL 
performance difficulties accentuated the rate of functional incontinence experienced by 
participants, which in turn decreased their confidence and contributed to their social 
restrictions both of which intensified their reports of a poor QoL. 
The final domain with a high mean score of 47.1, was Domain Six, Cognition. 
This domain was less physically orientated than the three previously discussed PDQ-39 
domains. Unlike the previous three domains it was more difficult to ascertain if bowel 
and bladder dysfunction in this group of people had contributed to their cognitive 
domain scores. The primary symptoms viewed as potentially contributing to these 
people’s cognitive deficits were; nocturia and the pain associated with constipation. 
Nocturia was reported as disturbing many of this study’s participants; however many of 
these people stated they were not overly bothered by these nocturnal awakenings even 
when they also reported significant daytime somnolence and poor ability to concentrate. 
The experience of being in pain as well as the drugs used by this participant group to 
relive their pain are both known to effect a person’s ability to concentrate and may 
account for this domain being so highly scored.  However, like the effects of nocturia on 
both concentration and sleep pattern disturbance the experience of chronic and episodic 
bowel and bladder pain in PD remains poorly understood in terms of their impact on a 
person’s QoL and warrant further investigation. 
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These findings have highlighted how of bowel and bladder dysfunction has 
affected these people’s interpretation of what makes a good QoL. The bowel and 
bladder attributes identified and addressed in this chapter begin to shed light on their 
impact and on the context these participants’ report quality of life satisfaction. Of great 
importance is that these findings, presented throughout this chapter, have highlighted 
the interpretive possibilities of what QoL means to people with PD. 
  
 183 
 
Chapter 7: The therapeutic experiences of people with Parkinson’s Disease in the 
context of their bowel and bladder dysfunction 
The relationship between the participant and their doctor was identified in 
Chapter Six, as an essential element in maintaining a positive QoL for people with PD. 
In particular, participants who believed that they had control over their disease 
presented as having a more positive outlook about their future than those participants 
who felt overwhelmed by their PD. A major source of discontent identified in the 
participants’ interview statements stemmed from the lack of information or a perceived 
lack of support received in their attempts to manage their bowel or bladder dysfunction. 
This chapter examines more closely the relationship between the participant and their 
primary health practitioners; for this group, their GP and the medical specialists they 
were referred to, such as neurologists, gastroenterologists, urologists or 
urogynaecologists. Chapter Seven differs from the previous results chapters in that the 
voice of the participant is centralised with the quantitative data used to provide 
interpretive direction and confirmation.  
7.1 Instrumentation used to collect data 
7.1.1 Qualitative instruments  
During the interview participants were asked to discuss their therapeutic 
experiences through the following open-ended questions: 
1. Have you spoken to anyone to ask for help or assistance for this problem? 
2. What treatments/products have you tried to solve your difficulties? Were they 
successful? 
The interviewer took opportunities to elicit further clinical and general 
information by using inquiry stems such as ‘tell me more about …’ When asking for 
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clarification, participants were asked ‘What did you mean when you said …’ and to 
verify their statements, ‘Is this what you meant when you said …’.  
7.1.2 Quantitative instruments 
The NRS SBS was used by the participants to rate the burden they experienced 
and the NRS S3-Satisfaction was used by participants to rate their level of satisfaction 
regarding the help or assistance they received in this chapter.  
7.2 Results for interview Question One:  
The interview question one asked, “Have you spoken to anyone to ask for help 
or assistance for your bowel or bladder problem?”  From the total group of 67 
participants, 56 reported they experienced a bowel dysfunction and 62 reported bladder 
dysfunction. From within these two subgroups, 36 participants (54%) with bladder 
dysfunction and 45 participants (67%) with bowel dysfunction reported that they had at 
least once, expressed concerns about their bowel or their bladder to their medical 
practitioner (see Figure 7.1).  
 
Figure 7.1 Reports of bowel or bladder dysfunction to a GP 
Participants were asked to describe their experiences in seeking this help. They 
were additionally asked to rate the usefulness of the help they received on the S3-
YES 67% 
YES 54% 
NO 33% 
NO 46% 
Bowel (n=56) Bladder (n=62)
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Satisfaction NRS (see fig. 7.2 & 7.3). The participants identified their local general 
medical practitioners (LGP) as the main source for all their medical advice.  
 
Figure 7.2  
GP satisfaction rating—Bladder. 
 
Figure 7.3  
GP satisfaction rating—Bowel 
A neutral response was recorded by nine (15%) participants reporting bladder 
problems and 14 (25%) reporting bowel problems, meaning that they were neither 
satisfied nor dissatisfied with the help they received. These participants indicated they 
had expected very little help from their doctors and when they received very little help, 
it did not bother them too much, as one participant clearly affirms: 
P27 (M;75): I do not expect any help in that department  
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The 11 (16%) participants with bowel complaints and 26 (39%) participants 
with a bladder complaint had not discussed these symptoms with their doctor. They all 
gave reasons that either related to their own, or their doctors’ prioritisation of health 
problems or because they perceived it would embarrass either themselves or their 
doctor. Statements from 22 participants (33%) reporting bowel concerns, indicated that 
they were so dissatisfied with their doctor’s response that they would not to raise the 
subject of toileting difficulties with their doctor or anyone else ever again.  
P5(M;66): I will not ask the GP again and I would not speak of this to any other 
person, especially my friends and family. 
P15(F;73): I am sure doctors do not realise what you go through. I have 
given up. 
P8(M;71): The neurologist just fobbed me off. I get the impression that they 
[doctors] lack interest [in constipation]. 50% of the PD support group I attend 
tell me they feel the same, just helpless and frustrated. 
Participants with bladder symptoms were found to be less likely (n=36, 53.7%) 
than those with a bowel dysfunction (n=45, 67.2%) to raise concerns about their 
symptoms with their doctor. The participants’ gender, age or length of diagnostic time 
did not contribute or influence help-seeking behaviours. The major reasons given by 
participants in defence of not raising their bowel or bladder concerns with their doctors 
ranged from not seeing their bowel or bladder symptoms as a legitimate health concern 
or that they made an assumption that bowel or bladder symptoms were beneath their 
doctor’s level of interest or expertise.  
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P14(F;63): I did not know this was important, I know it is embarrassing, the 
doctor has never asked me about my bowels... he has not raised it with me as an 
issue. 
P18(F;61): None of the Dr.’s seemed particularly interested, they never raise 
the issue about bowels at any time. 
The participants indicated that if they had tried to broach the subject of bowel or 
bladder dysfunction and had felt dismissed, they concluded their doctors  were 
disinterested.  
P9(M;64): I told my doctor I was having difficulties... But he was not really very 
interested. 
P32 (F;53): Just gave up, I am not really happy with the limited help offered, I 
am not satisfied. 
The participants were also critical of the management options offered to them, 
reporting that their doctors had offered such basic information, usually in the form of 
‘eat more vegetables and drink more water’, that they were left believing that there was 
nothing more that could be learnt or achieved from further discussions. Moreover, the 
participants also viewed their doctor’s level of understanding as quite low. 
P6 (F;76): No I have not asked for any more help, I suppose if I thought the 
doctor could do anything I might. But I am not confident that he would know 
what to do.  
P7 (M;67): I had to find out what the problem was and the cause. I do not blame 
the doctor they cannot know everything. They are not God’s in everything  
P8 (M;71): I sent the GP a book so she would learn about PD. 
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P9 (M;64): I told my doctor I was having difficulties, he told me to keep 
drinking and eating your veg’s. But he was not really very interested. 
[Reflective notes: This participant added, that his diet was good and that he did 
eat and drink well] 
P29(M;61): I do! I try to eat a good amount of fibre, fruit Grains and pulses and 
5 cups of fluid per day; 2 x water 2 x coffee and 1 x fruit juice. 
The participants also stated that medical practitioners would wait for the 
participant to raise the issue of toileting dysfunction and that they were rarely proactive 
in asking the participant if they had any concerns in this area.  
P14 (F;63): The LGP has never asked me about my bowels. 
For the participants, this confirmed that bowel or bladder dysfunction was not 
important to doctors. The rationale used by the participants to reach this a conclusion 
was, if these symptoms were important or related to PD, the doctor would have asked 
about them, just as they always did for other important ailments like high blood 
pressure. By LGP not actively following up on the bowel or bladder dysfunctions 
reported, the participants formed the view that bowel or bladder dysfunction was not 
important.   
P16(F;67): He is more concerned about my angina and cardiac problems. 
Participants also anticipated that conversations about bowel or bladder 
dysfunction would increase their already high levels of anxiety and distress. 
P57 (M;84): If I'm under stress I have frequency and lack of control. I revolve 
my life around bladder issues.  
P18 (F;61): I tried to speak to my Dr about having troubles (passing stool) but I 
did not push it as I felt embarrassed and stressed by it all. 
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P30(M;67): I have not spoken to my LGP, it has not come up even though it is 
not an insignificant thing in my life. 
P9(M;64):My Dr. took blood tests and urine tests and told me nothing was 
wrong. I don’t think he considers it a great problem.[Reflective notes: This 
participant could not get through the 45 minute interview without having to go 
to the toilet, once before we started talking and again halfway through the 
interview]. 
P4(F;65): I spoke with my gynaecologist, he was not too interested. I have not 
spoken to my LGP. I am not too sure what is meant by normal any more. 
Another participant used the following example to highlight an interaction with 
her doctor about her complaint of constipation and excessive straining at stool. 
P8(M;71): The neurologist just fobbed me off, saying there was plenty on the 
market, I may find something that suits me, if not, then come back and see me 
[him]. 
Some doctors were reported as attempting to open up channels of 
communication by enquiring very generally about their patient’s  health. However, most 
of these enquires were regarded by their patients as closing statements, instead of their 
using this as an opportunity to express unaddressed concerns. The participants  reported 
they usually decided not to engage in further questions or comments. 
P16 (F;67): My LGP occasionally asks how I'm going. 
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P61(F;89): When my GP asks how I’m going. I tell him I’m fine, I do not want 
to whinge as he is just so busy and he’s really not too interested. 
Both men and women participants reported that the relationship between 
themselves and their doctors was at times difficult to negotiate, further inhibiting their 
attempts to raise a discussion about bowel and bladder symptoms. 
P6(F;76): I think I smell, I often feel I am very smelly. I do not talk to my LGP 
about this; he is so busy taking BP and eye drops and sorting out your other 
things... I know he can smell me! 
P10(F;67): I get the impression that LGPs do not like PD as they tend not to get 
involved, they lack interest. They just refer you on and never ask again.  
P25(F;69): I have very slow delivery [urine] with lots of leakage, but [I’ve been 
told] my prostrate is a normal size. The doctor did not make any other 
recommendations. He never does. 
Three sub-themes became evident within the participants’ conversations about 
their bowel and bladder symptoms: disgust, embarrassment and insignificance. They 
used these themes as a lens through which they defined and interpreted their doctor’s 
responses and advice. This may account for the overabundance of doctors’ initial 
responses being interpreted by participants as stemming from disgust, embarrassment or 
disinterest; the participants’ used these interpretations to justify and forgo further 
enquiry making or assistance seeking.  
P3 (F;68): Even the doctors do not feel comfortable talking about these 
problems.  
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P36(M;63): Even though I had mentioned it previously, I think they are also 
embarrassed, they have lots of things on their minds. 
Prioritisation of symptoms and their management were most evident in 
participants’ comments about bowel dysfunction, which appeared to generate a higher 
degree of discomfort for the participants than did their bladder symptoms. 
P14(F;63): When I am with my Dr. there are so many other things that are more 
important to discuss. 
The participants accepted their bladder and bowel symptoms as being related 
primarily to ageing and not to their chronic disease, PD. Participants therefore found it 
difficult to choose whom to speak to about their problem. They spoke of their friends, 
without PD who were also having difficulties maintaining a continent state. This 
seemed to confound participants who found it difficult to differentiate their problem 
from their friends’ problem.  
P26(M;64): I have a weaker than average stream but isn't that a normal part of 
ageing. Yes I use the toilet frequently yes over and above my peers/friends. 
Participants seemed to be confused about the pathological changes that had 
created their bowel or bladder incontinence. Some thought it might be due to their age, 
their limited ability to exercise, the drugs they were taking or changes to their food and 
fluid intake. It is quite possible that these pre-conceptions contributed to the disparate 
reporting patterns demonstrated in Figure 7.1, between bowel (67%) and bladder (54%) 
dysfunctions.  
P5(M;66): [Bladder] I think it is age-related. 
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P26(M;64): [Bladder] I have a weaker than average stream, but isn’t that a 
normal part of ageing? 
P7(M;67): [Bladder] I think it is a problem of getting older, you know, problems 
with your waterworks. [Bowel] I have had these problems for 6 years it started 
with the PD symptoms, I believe that it is the weak PD muscles which affect all 
of the body. 
P8(M;71): [Bowel] It started very slowly getting worse then it really kicks in 
just like PD slow & gradual. I had not seen anyone before as I had not related 
the constipation to PD. 
P14(F;63): [Bowel] I was not sure whether it had anything to do with PD. 
P57(F;68): [Bowel] As I’ve gotten older I have noticed that if I get stressed, 
bowel urgency and accidents will happen, which is very distressing and 
horrible. 
P59(F;60): [Bowel] I think bowel issues are related to my medications I take? 
The GPs were reported as adopting an integrative approach when the topic of 
bowel or bladder dysfunction was raised; this approach being seen by the participants to 
have an ageing or gendered focus. Not once did any participant talk about a 
neurological bowel or bladder dysfunction or a neurological investigation.  Rather, 
participants’ stories of bowel or bladder investigations focused around gerontological 
prostate enlargement or pelvic floor damage caused by multiparity.  As these age and 
gendered associated causes were eliminated, through a process of differential diagnosis, 
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other investigations or treatments, which would have focused on the neurological 
dysfunction prevalent in PD were not initiated. Primarily, the participants viewed these 
initial normal results, as final diagnostic outcomes for which nothing more could be 
done and as such did not return to their doctor for follow-up.  GPs were reported to 
readily make referrals to other medical specialist such as gastroenterologists and 
urogynaecologists, yet no participant reported a referral to other multidisciplinary 
services, such as a continence nurse specialist or a dietician. When the participants were 
asked in interview if they had seen a continence nurse advisor, they stated that they did 
not know of or had not been directed to this service. 
P06(F;76): No, I have not asked for any help … he usually sends me off to a 
specialist for women’s problems and I do not need to go to another specialist. I 
see too many already. No, I am not aware of any continence service. 
Of those referred to medical specialists, five participants complaining of 
constipation with excessive straining at stool were referred to a gastroenterologist. 
These people underwent a colonoscopy, which entailed a complete bowel wash-out and 
all were told that their now clean bowel looked very normal. None was given any advice 
or management options to assist them with their constipation and excessive straining at 
stool. 
P19(M;75): I went to a gastroenterologist. He did a colonoscopy but he was not 
interested in the constipation. 
P23(F;56): The doctor did a colonoscopy and said that the colon looked more 
normal than he expected. 
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P52(M;78): I had colonoscopy and was told to eat prunes, bran and increase 
water to help move things through. 
A participant who described their bowel dysfunction as intractable FI was 
offered and chose to have a colostomy performed. 
P48(F;67): I had such severe FI, it was awful, I had no control. The doctor said 
it would help and it is much easier to handle. I only have problems if the bag 
leaks. But I am much happier with the colostomy as I have more control. 
Many of the participants raised issues around the value of service and advice 
from their doctors, with some claiming that speaking with their doctor was not useful. 
They described the information given as not educative or informative and nor did it take 
into account their existing knowledge level. 
P4(F;65): So little information given by the doctors … they make assumptions 
that you know what they are looking for. 
P18(F;61): The doctor did not tell me the deep brain stimulation (DBS) will 
improve my urinary frequency. He only spoke about dyskinesia and ability to 
walk. Since the DBS, I still have some urgency and I still do not trust my bladder 
but I have noticed that it is a lot better. 
P27(M;75): I saw [a continence nurse] four months ago at Para Quad. I found 
her on the internet and referred myself to her. I have not spoken to my LGP. I do 
not expect any help in that department. 
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P8(M;71): In Feb, I went to a PD group seminar, then to my local chemist, then 
I spoke to my GP. I had not seen anyone before that … 50% of the PD support 
group I attend told me they have problems with constipation. 
P18(F61): I was told to increase my use of prunes, dietary fibre and fluid… 
none of these things have ever worked for me. 
Participants did not understand the network of medical co-referrals and became 
frustrated with what they perceived as doctors not understanding their PD and not 
knowing what was causing their bowel or bladder dysfunction. Participants identified 
activities associated with their medical management, such as travelling, waiting and 
numerous consultations as interfering with their life, and being particularly burdensome. 
In the following example participant 22 (M;68) alleged his doctors seemed to be 
confused by his symptoms he referred to his urinary frequency and urgency as being 
like ‘a hot coal that no one wanted to catch’. 
P22(M;68): I am very disappointed. The neurologist told me everyone blames 
PD. The urologist looked at my prostate he told me that my problem was related 
to my PD. Not much else was offered by the GP, who leaves it all up to the 
specialists. 
Other participants assumed that their symptoms must be related to normal 
ageing and nothing else, as they had been to a specialist who could not resolve their 
problems. 
P5(M;66): I have had my prostate checked by the GP. He said that there was 
nothing wrong. 
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P4(F;65): My specialist (gynaecologist) checked me out for a prolapse, I 
suppose I didn’t have one because he did not refer me for any other treatments. 
P12(M;66): I did have a PSA test and everything was ok. 
Participants also informed the researcher that there were some things that they 
just did not tell their doctor, family and friends. These unmentionable or taboo subjects 
were broached carefully and contextually because they believed that if they told anyone, 
they would risk not being seen as an independent individual. They believed they would 
risk losing the respect of others, or lose control over their own lives. In some 
conversations, remaining in control was emphasised, as in participant 21’s story, where 
he protected his secret by listening and not informing others. 
P21(M;86): I have not asked my doctor. I listen to my friends at the club speak 
and then I use what they use. 
P7(M;61): I protect them [Doctor, family and friends]. I do not tell them 
everything. I had to find out what the problem was and the cause.. 
P12(M;66): I do worry a bit about it but I have to work through it. 
P31(M:48): I found things out myself, no help from any of the doctors or my 
family. 
P51(M;79): I do not like the way doctors take control and will not let me 
manage my own impairments. I only need them to provide me with the 
information to help me manage myself. They are not in charge. 
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P32(F;53): It takes me up to 45 minutes to pass stool and I bleed, but I have 
never spoken to my doctor about it. I just won’t. 
The rationale given most often by participants in defence of not talking to their 
doctors about bowel or bladder dysfunction was embarrassment. Some participants 
reported that knowing their doctor did not reduce the degree of embarrassment they 
experienced. 
P3(F;68): I do not like talking to anyone about this as it is very embarrassing.  
P14(F;63): I am very embarrassed and do not think I can speak frankly to the 
doctor to ask for help.  
P55(F;69): I know it is embarrassing for both of us [the Dr. and I]. I do think 
about doing something but do not know where to start. 
P30(M;67): I have not spoken to my GP. It is just too hard, too hard. 
As the interviews concluded, many participants stated that this was the first time 
they had ever spoken to anyone about their bowel or bladder dysfunction in such detail 
and they were now a lot more encouraged to talk to their LGP. The participants 
indicated that bowel or bladder dysfunction was a difficult topic for them to raise and 
discuss with their doctors.  
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7.3  Results for Question Two  
Question two asked the particiapnts, “What products or treatments have you 
tried in an effort to solve your bowel or bladder dysfunction - Were they successful?” 
7.3.1 Management of bladder dysfunction—containment devices 
A considerable number of participants mentioned they used disposable sanitary 
pads to help them contain any accidents and maintain social dignity. The exact numbers 
of participants using pads, or how many pads these people used during a 24-hour 
period, was not able to be determined from the data, as the question was not posed to all 
participants. Only those who raised the subject of using disposable continence pads in 
the interview were asked about pad usage and financial costs. 
Australian residents are able to access financial support to purchase continence 
supplies through the federally funded and non-means-tested CAPS and, in NSW, the 
Program of Appliances for Disabled People (PADP) known as ENABLE NSW (CFA, 
2010). ENABLE is a means-tested continence supply scheme and as such is more 
difficult to obtain, and has long wait lists. Three participants mentioned accessing 
CAPS in their interviews, with one of these people additionally accessing PADP 
funding. Many other participants mentioned during the interviews the financial 
difficulties they encountered, because they had to purchase sanitary pads for their 
incontinence.  
The three participants who had accessed government continence-funding 
initiatives had all been seen by a continence nurse specialist located at their local 
hospitals at the suggestion of friends or family or following hospitalisation for the 
emergency treatment of urinary retention. 
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P16(F;67): The community nurses called in a continence nurse who put me onto 
PADP. 
P19(M;75): I did know about government support to buy pads. That is why I am 
able to try lots of different ones. I buy from the local chemist … at $6 per packet.  
P47(F;73): [reflective notes] The nurse continence advisor signed this lady up 
to CAPS.  
For those who had no knowledge of available financial assistance, conversations 
were dominated by the financial stressors of purchasing disposable continence aids. 
P6(F;76): I wear a pad, you know, the ones you get at Franklins with the wings, 
the same ones women wear for menstruation. They are very expensive. I do not 
get any financial assistance. 
P23(F;56): I wear pads all the time. Either I use a panty liner or Libra light or 
regular Poise. I purchase these pads from the local chemist and that is an 
expensive exercise, approximately $200 to $300 each month. 
P27(M;75): I stopped using the Uridomes [condom drainage devices] and pads 
because they were very expensive. I did not know I was entitled to any help 
[CAPS]. My GP did not tell me about this. 
P25(F;69): I wear Poise pads that I buy from Coles or the local chemist. This 
costs me approximately $40 per month 
P32(F;53): I wear pads, Ultra panty liners. I usually change them twice a day. 
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The most commonly used continence product identified was the continence pad. 
There are numerous styles, shapes and absorbencies available for purchase and these 
pads are widely available in supermarkets and pharmacies. With so many pads available 
and no professional advice, many participants took the position that they should use the 
smallest and cheapest ones available. Consequently, many of the participants reported 
problems and inadequacies with the product chosen. 
P1(F;66): I still cannot find the right pad yet. If I get the right shape, the 
absorbency isn’t right, and to get the right absorbency they are massive in size. I 
will have to try some other brands. 
P6(F;76): I wear a pad, you know, the ones you get at Franklins, the same ones 
women wear for menstruation. They are very expensive. I do not get any 
financial assistance. They are very expensive. Once or twice a week I have a 
leakage over the pad, and if I need to go to the toilet urgently, I often leak on the 
way there. 
P16(F;67): Generally, the pads catch it but often they are not effective. 
P18(F;61): I wear a sanitary pad but I often leak through it. I use over three 
each day. 
The major problem raised by participants was that the pad did not provide them 
with enough protection for them to feel confident enough to participate actively in all 
aspects of their life—in other words, being socially continent. Choosing the most 
efficacious product is of utmost importance, yet many participants spoke of using 
menstrual pads, which have very little capacity to absorb the large quantities of thin, 
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fast moving urine as compared to the slow, thicker menstrual blood flow they were 
designed to entrap. Consequently, participants were forced to change these pads 
frequently, thereby substantially increasing their continence management costs. The 
following participant stories highlight the importance of correct pad choice and the cost 
implication of poor product knowledge. 
P23(F;56): I wear pads all the time. Either I use a panty liner or Libra light or 
regular Poise. I purchase these pads from the local chemist and that is an 
expensive exercise, approximately $200 to $300 each month. 
P25(F;69): I wear Poise pads that I buy from Coles or the local chemist. This 
costs me approximately $40 per month 
Participant 23 wore a combination of continence products. The absorbent 
capacities of these products ranged from a panty liner that held less than 30mls through 
to the regular Poise pad, which has a capacity of up to 250mls. This participant spent 
$200 to $300 dollars per month, while participant 25 reportedly spent $40 dollars per 
month. Both participants predominantly used the Poise pads, purchased from their local 
shop. These pads retail for about $6 per pack of 18. This calculates as participant 25 
using two packs of 18 pads each week, compared to Participant 23, who used between 
eight and 10 packs of pads each week.  
The excessive use of pads was found to be a common problem across this 
participant group, especially when using a pad that had inadequate absorbent capacity. 
In this case, the participant overcame the pad’s deficiencies by using multiple pads 
together, one pad on top of the other. Participant 23 reported that she used up to four 
pads at one time, changing them all at least five times each day. What she failed to 
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consider was that each pad has a protective plastic under-layer that ensures urine does 
not flow through the bottom of the pad into the person’s clothing. When these pads are 
used in this layered manner, each pad remains independent and as the first pad’s 
capacity is reached, the urine spills over the top soaking the sides of each subsequent 
pad, making them equally unusable, although not utilising their full capacity. This 
participant would be financially and socially much better off buying larger capacity 
pads, which may be more expensive but she would need to only use three of them in a 
24-hour period instead of using four pads that were changed five times each day.  
Independent and reliable information about choosing appropriate continence 
pads is not easily accessible. Community dwelling adults rely on their LGP to advise 
them of other services and they are particularly disadvantaged if they not made aware of 
continence-specific health professionals, such as specialist continence nurses. 
7.3.2  Management of bladder dysfunction—medications 
The use of medications to treat neurological OAB in this participant group was 
not extensive. Only seven people stated that they had taken a drug to assist them in 
controlling their neurological OAB symptoms (see Table 7.1). 
Table 7.1 
Use of Drugs to Treat OAB  
Bladder drugs used Frequency % 
 No  60 89.5 
Yes 7 10.4 
Total 67 100 
 
These seven participants stated they tried to take Ditropan, Oxybutynin HCl, a 
drug commonly prescribed for OAB. They had all stopped taking it, because it produced 
a severely dry mouth, an unpleasant side effect. While other side effects are noted in the 
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literature such as constipation, urinary retention, increases in confusion and anxiety, as 
well as reports of impotence, no participant reported these occurrences of side effects. 
Most participants commenced on a low dose but this starting dose  was unable to be 
graduated upwards to reduce their OAB symptoms because their dry mouth was so 
uncomfortable. None of the participants was offered an alternative drug or a transdermal 
patch of Oxybutynin HCl, which is known to have a lower dry mouth profile 
(Oxybutynin HCl, 2012), because none of the participants returned to their doctors to 
report their discomforts. 
P11(M;61): [Ditropan—anticholinergic] The urologist gave me a medicine and 
said I could make another appointment if I needed to but I did not go back. The 
medicine was worse than the complaint. 
P7(M;67): [Ditropan—anticholinergic] My doctor gave me some Ditropan but 
that did not work so I stopped taking it. 
Participant 4 (F;65) was prescribed a topical hormonal cream, Ovestin, for her 
urinary dysfunction. She also stopped using the cream as she did not think she needed to 
use it long term. 
P4(F;65): The gynaecologist, gave me a cream called Ovestin. I used the cream 
but he gave me no instructions. I wasn’t sure why he had given me the cream. I 
just thought that it was for an infection and did not need to use it after. When I 
finished using it I did not ask for another. 
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This woman rated her neurological OAB symptoms on the SBS as six out of 10, 
a moderate burden. She had never been reviewed or treated by her neurologist for 
neurological OAB. 
7.3.3 Management of bowel dysfunction—containment devices 
Compared to bladder complaints, very few participants (n=3) stated they used 
disposable continence pads to assist them solely with bowel accidents. A number of 
participants spoke about using disposable pads for their combined bowel and bladder 
dysfunction. This made it difficult to obtain accurate numbers of people using 
disposable continence products just for their bowels. 
P3(F;68): I wear Tena lady pads to catch the constant faecal staining. 
P40(F;75): Once activated, it purges. It is very distressing. I pass wind and then 
the bowels open. I have to wear pads all the time. 
P56(F;66): I wear a pad just in case. 
For those participants who did not mention pad usage, but talked extensively 
about bowel accidents, it was assumed that pads would need to be used; however, no 
proof of pad usage was evident. 
P57(F;68): Bowel urgency and accidents will happen, which is very distressing 
and horrible. The stool is thick, custard like. I don’t go out at times due to bowel 
concerns. It is a serious concern for me. 
P23(F;56): I often have accidents at least a couple of times per day due to the 
uncontrolled diarrhoea. I do not seem to have any nervous control and cannot 
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tighten my anus. I believe it to be very relaxed and overactive. I cannot seem to 
tell the difference between gas and solid or liquid. I pass hot fluid with no 
control. 
7.3.4 Management of bowel dysfunction—medications 
In this population group, 40 people (59.7%) reported the need to use a 
pharmaceutical agent to assist them with defecation and 50 people (74.6%) used two or 
more drugs in combination to assist them in passing stool (see Table 7.2). Twenty 
Seven (40%) of people were opposed to the use of any drugs to assist with defecation. 
These people relied on food rich in fibre, plenty of fluids and exercise. However, they 
were the participants to more likely to complain in the interviews of very irregular 
bowel movements.  
Table 7.2 
Number of laxatives taken per participant (n=67) 
Number of Bowel 
preparations used Frequency % 
0 27 40.3 
1 15 22.4 
2 14 20.9 
3 5 7.5 
4 4 6.0 
5 2 3.0 
Total 67 100.0 
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Medications used for constipation are known as laxatives. There are four classes 
of laxatives commercially available, none require a medical prescription: 
1. bulking agents 
2. stimulant or irritative agents 
3. osmotic agents 
4. stool softening agents. 
Suppositories and enemas are not a separate class of laxative;  they differ only in 
the way they are administered, via the rectum and not orally. Suppositories and enemas 
more often sit within the stimulant or irritative laxative class. They are separated in 
Figure 7.4 itemising their use. 
 
Figure 7.4 Types of laxatives used by participants 
Bulking agents. The types of bulking agent used by 19.4% this participant group 
were Normacol
TM
 and Metamucil
TM
. These two products increase the volume of 
insoluble fibre in the person’s alimentary system. Osmotic laxatives. Macrogol, Epsom 
salts and Lactulose were the three osmotic laxatives reported as being used by 40.2% of 
n= 13 n= 17 n= 27 n= 14 n= 3 
0
5
10
15
20
25
30
Bulking agent Stimulant Osmotic Stool Softener Suppository or
enama
P
ar
ti
ci
p
an
t n
u
m
b
er
 N
=6
7
 
Laxative Type 
Laxative types used 
 207 
 
the cohort. These laxatives are made of inorganic salts or sugars. Stool softeners. 
Coloxyl
TM
 was reported as being used by 20.5% of this cohort. This medicine works by 
drawing water and fats towards the faeces increasing the softness of the stool. Stimulant 
laxatives. Stimulants were used by 25.3% of participants. This class of drug stimulates 
the motility and secretions primarily in the large bowel. Stimulants are recommended 
for people who have chronically infrequent bowel actions. The preparations most often 
cited by the participants were Nu-lax, a mix of dried fruit with Senna, Durolax, a trade 
name used for Bisacodyl, or Senna and Coloxyl, a combination of stimulant and stool 
softener.  
The osmotic laxative Macrogol was the most widely used laxative, with 27 
participants using this drug. All participants taking this drug reported that they had to be 
very careful when using it as it created very loose stools, which they found difficult to 
control and caused them a great deal of anxiety. They additionally reported that their 
doctors and pharmacists were unable to advise them on how to administer Macrogol 
effectively. In response the participants reported that they took this laxative 
predominantly on a ‘when needed’ basis. This drug was reported to be very effective, 
but participants stated they had to plan social engagements around its use. 
The expulsion of stool from the rectum in the form of excessive straining was 
raised by this participant group as being an issue that gave them considerable concern. 
Physiologically, these difficulties indicate the presence of a series of complex 
innervation problems that prohibit the expulsion of stool. In clinical practice, the need to 
override these innervation impediments has seen Macrogol being used to over-soften 
faecal matter to bypass the need to strain at stool. As a consequence, the majority of 
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participants reported higher incidences of faecal accidents or incontinent episodes, 
which restricted their movement beyond their home. 
Laxatives used in combinations. 
Many of the participants indicated that they often had to use more than one 
laxative type at any one time to initiate a single bowel movement. The numbers of 
laxative types, independent of dosage taken, i.e., two tablets of Triphenylmethane 5mg, 
are itemised in Table 7.4 and show 25 (25.9%) participants used more than one laxative 
type in combination. 
It was not possible to present a clear statistical combination of each participant’s 
dosing regimen, due mainly to the high variance in the doses used per participant and 
their inability to clearly articulate how they decided to take their medication. They often 
made statements along the lines of ‘I just know when I need to’ or ‘I sometimes take x-
many tablets and sometimes I do not’ or ‘It just depends on …’.  However, a 
relationship could be demonstrated between the use of stimulant laxatives, osmotic 
laxatives and suppositories via a Pearson product-moment correlation coefficient. The 
finding was that the participants choosing to use two or more laxative types more often 
used a combination of stimulant and osmotic laxatives [r=0.250, N=67, p=0.04] and the 
three participants who used a suppository did so in combination with an oral stimulant 
laxative [r=0.245, N=67, p=0.04]. These were not the only combinations used; however, 
these combinations were the only ones that had produced a statistically significant 
relationship. 
As previously stated, the vast majority of participants reported they had chosen 
the types of laxatives they used based on their friends’ or families’ recommendations. 
The osmotic agent, Macrogol was the only laxative recommended by the participants 
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LGP and the participants used this drug at a dose high enough to overwhelm their 
sphincter dyssynergia. With the exception of three participants using suppositories, no 
participant reported that they had been advised on the benefits of using a combination of 
rectal laxatives or digital stimulation; a common method of relaxing the anal sphincter 
and allowing a more comfortable and complete lower bowel clearance without the need 
to excessively strain at stool. 
The participants’ reliance on the combined use of osmotic and stimulant agents 
made them more susceptible to frequent, uncontrolled bowel accidents, which they 
reported as being extremely distressing. 
P40(F;75): It’s very distressing. Once activated, it purges. It’s very distressing. 
I pass wind and then the bowel opens. 
P44((M;64): I feel uncomfortable and it is distressing  
P57(F;68): bowel urgency and accidents do happen it is very distressing and 
horrible. 
The combined effect of taking a combination of stimulant and osmotic laxatives 
was described by a woman participant who places her incontinence at the centre of their 
social isolation and distress. She told a distressing account of living in a dreadful mess, 
soaked by both urine and faecal waste. She lamented that her home was now in such a 
state of great disrepair that no one, including her grandchildren, came to visit her any 
longer. Her carers were only employed to shower her three times per week and she had 
a cleaner who came in once each fortnight for two hours. She reported taking her 
medications from a pre-packaged Webster box that included her usual two Coloxyl and 
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Senna tablets, a stimulant and a stool softener, taken each morning and night. She also 
reported taking up to two sachets of Macrogol, an osmotic agent, each day as directed 
by her LGP. This woman reported constant faecal leakage and bouts of uncontrollable 
diarrhoea. However, when she stopped taking the medications, she became very 
constipated and bloated. 
P16(F;67): I often feel I am very smelly. I am only able to have a shower three 
times a week—Monday, Thursday and Friday. They are the only days the carers 
can come and help me. 
This participant reported a good relationship with her LGP, who regularly 
visited her in her home. From her accounts, it must have been obvious to the LGP who 
was visiting her that she was having difficulties with her ongoing self-care, even if she 
did not raise the subject of incontinence specifically with him. 
P16(F;67): I do not talk to my LGP about this [incontinence]. He is so busy 
sorting out your other things. He has not spoken about these things to me. 
Laxatives were purchased from local pharmacies and were used by the 
participants, as they needed them and not as a scheduled regular medicine. The vast 
majority took laxatives on an as needed basis, with only seven participants indicating 
that they took a regular laxative. More importantly, laxatives were taken irrespective of 
their pharmaceutical action and many of the participants stated that they chose a 
laxative based on a recommendation from a family member or someone they knew. No 
one gave an account of using a laxative according to a prescribed plan of care or based 
on rectifying the cause of their ineffectual bowel pattern. Consequently, conversations 
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were peppered by concerns of uncontrolled bowel actions, which stopped their  
performing daily activities and prohibited any forward planning that entailed leaving the 
house. 
P19(M;75): I sometimes don’t go out due to my bowel concerns. 
P32(F;53): This is a serious concern for me,  I have to know where the next 
toilet is. 
P49(M;77): Won’t go on holidays due to bowel issues. 
P57(F;68): I am afraid to go away at times. 
The participants also spoke of concerns about laxative dependency and stated 
that they did not want to take any more drugs than they needed to. 
P21(M;86): I have not asked my doctor because I do not want to take handfuls 
of pills. LGPs are chemical agents. 
P19(M;75): I’m already overloaded with medications and do not want to take 
any more. 
For the most part, the participants were very reluctant to try new bowel 
medications or to routinely take any laxative as they had lost confidence in any bowel 
medication offered primarily due to the unpredictability of the resulting bowel 
movements. 
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P1(F;66): I am taking Movicol sachets [osmotic] to help [with the constipation] 
but if I take one it does nothing, if I take two or three sachets I cannot leave the 
house. I was told that I could take up to four sachets a day if I would like. 
Anti-diarrhoeals, such as Loperamide Hydrochloride (Gastro-stop), were also 
used by participants to help them control the frequent bouts of loose bowel motions, 
primarily caused by the overuse of laxatives. The following is one example of the 
complexity of timings and drug combinations used by the participants to ensure a bowel 
movement. 
P3(F;68): I use Movicol, Senna with Coloxyl and Gastro-stop. If my stool 
becomes very explosive, then I do not take the Movicol. If I do not pass stool in 
three days then I use extra Senna with Coloxyl as it works quicker than the 
Movicol. 
On their doctors’ recommendation, 22 (32%) participants used the osmotic 
laxative Macrogol, traded in Australia as Movicol
TM
. However, not one of these 
participants reported being given dosing instructions by their doctors. In the main, they 
were told to take the Macrogol according to the instructions on the box. 
P17(M;70): The GP gave me a script for Movicol. He told me to take it 
according to the instructions. He did not advise me how best to take it and the 
instructions [on the box] really did not tell me very much … No, not very useful. 
P19(M;75): My GP told me to take the Movicol till I get diarrhoea and then 
back off. I did not know what he meant by back off. I really did not want to lose 
control of my bowels, you know, to be so runny, so I did not take it. 
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7.4 Bowel and bladder dysfunction as described by people with PD 
The bowel and bladder symptoms described by participants were clinically very 
complex and without a clinical examination that included urodynamic or anorectal 
studies, a primary cause and diagnosis is difficult to ascertain with any certainty. 
However, the clinical picture described by the participants aligns their bowel and 
bladder dysfunctions with neurological disease more clearly than with age, dietary 
decline or the side effects of pharmaceutical agents taken. 
Studies on neurological constipation by Abbott et al. (2001), Kaye et al. (2006) 
and Sakakibara et al. (2008) and on neurological OAB by Palleschi et al. (2006) and 
Iacovelli et al. (2010) have all stressed that neurological dysfunction of PD should be 
regarded by clinicians as having aetiological dominance over all toileting difficulties, 
especially regarding their management. However, the clinical interventions offered to 
participants in this study lacked a neurological focus. 
Very few participants sought assistance from allied health practitioners. The 
three participants who did speak to a dietician stated they too felt their PD was not taken 
into account; stating that this offer of health information was so basic that they felt very 
frustrated. Other participants referred to this information as not useful, as most of this 
advice had already been implemented and found to be unhelpful. 
P1(F;66): I spoke to the dietician, who told me to eat foods high in fibre, which I 
do every day. I’ve tried unprocessed bran, Weet-Bix, bread, nuts, fresh fruit and 
veg. I am desperate for an answer of what else I can do.  
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P67((M;73): I do! I eat lots of fruit, drink water, camomile tea, green tea and 
coffee [and still] there is a lot of straining, it takes me so much effort. My poo is 
quite soft. I think this is why I have a lot of trouble pushing it out. 
P9(M;64): He [LGP]told me to keep drinking and eating your vegies. It was my 
pharmacist who recommended Coloxyl. 
P15(F;73): I was told that I need to drink plenty, I d0! I drink up to 11 drinks 
per day … and I take prune juice! 
P17(M;70): The dietician at the hospital gave me a pamphlet on increasing my 
fibre, fruit and vegetables and fluid. She told me to drink more and use psyllium 
husk and digestive rusks as well as Sultana Bran. They actually thought I did not 
already know this. 
The management of bowel or bladder dysfunction in PD stands in stark contrast 
to other neurological diseases or injuries. The clinical profile of neurological 
dyssynergia presents as an obstructive problem, which requires the participant to exert 
excessively high pressures to override the contracted outlet sphincter. Of the 56 
participants reporting defecation difficulties, 91% stated their straining at stool was a 
considerable problem. Of the 62 participants reporting urinary dysfunction, 40% 
reported initiation difficulties, which required them to strain. 
Based on these reports, a clinical profile of neurological outlet dysfunction fits 
better with the evidence than the standard clinical approach which preferences age-
related, slow gut transition times, decreased bladder storage, or being a consequence of 
prescribed or OTC medications. 
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Iatrogenicly induced constipation was widely reported to have influenced the 
treatment and management options offered to this particular group. Participants reported 
being offered a very narrow range of advice and treatments related to increasing dietary 
fibre, to maintaining a good fluid intake and to undertaking a daily exercise regime. 
However, this basic advice was not expanded upon and, as a consequence, very little 
efficacious clinical support was obtained. 
7.5 Burden of bowel and bladder complaints 
Qualitative data collected in the interviews suggests that this participant group is 
resilient. Many participants demonstrated great adaptive skills used in response to the 
stresses imposed by their bowel and bladder symptoms. The entire group reported that 
bowel or bladder dysfunction was extremely harrowing to deal with and often required 
them to take stock, re-evaluate and redefine themselves. The participants often declared 
in interviews that they felt very alone, primarily as these symptoms were difficult topics 
to raise with other people. Several participants approached their symptoms as a 
challenge to be worked through in a logical way, with or without the aid of their 
doctors. Others described their symptoms as being so degrading and humiliating that 
they were unable to raise the subject at all and chose to retreat into the safety of their 
homes  
P20(M;65): I have not directly spoken to my doctor [about bowel or bladder 
dysfunction]. 
P15(F;73): I am sure doctors do not realise what you go through. I have now 
stopped taking everything, I have given up. 
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P14(F;63): I am very embarrassed and do not think I can speak frankly to the 
doctor to ask for help. 
It was noted that participants explored the constructs of adaptation, adjustment 
and resilience in either an explicitly cogitative way or from a more philosophical or 
spiritual basis. Some participants used faith to assist them in dealing with the emotional 
effort they needed in order to get up each morning. The resulting social isolation was 
also reported widely by the participants. 
P1(F;66): My lifestyle has altered so much. I used to go out all the time before I 
was diagnosed with PD. I was also very involved in volunteer work, arts and 
craft, but I have had to give that all up. 
P2(F;75): Much more changes since PD diagnosis. Within six months of 
diagnosis you notice significant changes. 
The participants also presented a strong argument about protecting others, 
shielding them from the harrowing effect their disease was creating. At other times it 
was not what was said, but rather the context and manner in which the dialogue took 
place, that prompted the researcher to draw conclusions about intent and meaning. 
P10(F;67): [reflective notes] She had accepted her lot in life. She made no 
changes and requested no assistance. 
P12(M;66): I predominantly deal with it myself. It is no good sharing it with 
everybody. 
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P65(M;81): I do not speak to friends [about my problems] as I do not want to be 
a bore or worry them. I protect them; I do not tell them everything. 
The participant group generated a picture of protecting others and secreting 
information, because they did not think anyone could help or that people would think 
less of them. Some participants even spoke about shielding the doctor from the 
existence of their bowel and bladder symptoms. The consensus was that bowel or 
bladder dysfunction was not something that their LGP needed to hear about, or that their 
bowel or bladder dysfunction was a minor issue and the doctor needed to concentrate on 
much more important things. 
7.6 Summary 
This chapter has investigated the two open ended questions posed to them 
during the interview. The first question asked if the participant had asked anyone for 
help or assistance in regard to their bowel or bladder dysfunction, and the second 
question asked the participants about the types of treatments or products they had used 
in an effort to ameliorate these presiding difficulties. The main findings of this chapter 
were that the participants’ satisfaction of either the medical services they received, and 
of the medications and continence products they used, did not provide them with the 
level of support and social confidence they wanted or expected to receive. 
The participants viewed their LGP as being their primary source of support and 
all had very high expectations of the type of service they required. Their stories 
highlighted difficulties each participant had both in initially raising the subject of bowel 
and bladder problems and then revisiting this same subject when the suggested 
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management or interventions undertaken did not resolve or reduce the burdensomeness 
of the symptoms.  
The participants’ stories emphasised a high degree of confusion stemming from 
these same symptoms origin. This aetiological confusion gave rise to participants’ 
questioning the medical legitimacy of their bowel and bladder dysfunction, and as a 
result many actively withheld information, which they saw as embarrassing or unworthy 
of their doctors’ attention. Bowel or bladder symptoms appeared to be a difficult topic 
for these participants to mention to their doctors, especially when they believe that their 
doctors would not regard these symptoms as important when compared to their other 
more legitimate health issues.  
Toileting difficulties and behaviours were viewed as a taboo subject that created 
conversational discomfort between the individual and their doctors, even when the 
participants stated they had an established good and trusting relationship with their 
LGP.  The participants used the word embarrassment to convey numerous and strong 
feelings about this taboo subject. The word embarrassment was used by the group to 
convey their feelings of burden, a weight they all said was made heavier by the constant 
and unpredictable threat of incontinence and their realisation that they were expected to 
bear it alone. It was also used to convey their feelings of helplessness and frustration in 
not being able to manage these symptoms in the same way they knew other people 
without PD did. 
Notably, the participants informed the study that their bowel symptoms were 
resistant to the basic management methods recommended to people with non-
neurological chronic constipation, such as increasing fluid, fibre and exercise. The 
group reported that this necessitated the use of a variety of laxatives and incontinence 
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pads both of which created further burdens. The laxatives, mostly sourced and 
administered independent of medical advice, created cyclical bouts of diarrhoea, which 
necessitated the implementation of socially restrictive practices.  The financial burden 
of purchasing disposable continence and menstrual pads was also spoken about by 
participants in this study as of major concern. A basic cost for a pack of 14 sanitary 
pads is currently around $6, the participants’ on averaged used between two and four 
pads each day. This equates to $50 each month, a substantial cost for any person on a 
fixed income such as a pension. The participants using pads had mentioned this to their 
LGP’s, yet only three people stated they were aware of the continence assistance 
program, a government initiative that financially supports people with neurological 
incontinence in making continence related purchases. The LGP’s were also noted as not 
referring any of their patients to continence-related allied health specialists  such as 
dieticians, continence nurse advisors or continence physiotherapists. These continence-
related allied health specialists would be more likely to have knowledge of financial 
schemes that assist people with the cost of purchasing products, as well as being able to 
offer the person with urinary incontinence and chronic constipation with a very specific 
range of treatment options. However, the participants stated that their PD already 
created a great burden on their lifestyle and that if they allowed it, their life would be 
consumed by attending numerous health appointments and that they would have little 
time left to pursue more enjoyable activities.  
 The unpredictability of the participants’ bowel and bladder dysfunctions and 
their poor access to the information and support they believed they needed was 
identified by this group of people as creating feelings of being overwhelmed, out of 
control and burdened. Participants indicated that they did not like to alert or worry other 
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people about their troubles and in doing so restricted their ability to obtain additional 
and useful information. They were hesitant to classify their bowel and bladder 
dysfunctions as incontinence and in not relating to the term incontinence could have led 
to them not accessing the continence information or services available on-line or 
through local health services. This reluctance to identify with incontinence or to talk 
with others about their toileting problems saw many participants retreat to their homes 
or well-known local venues where they felt safe and close to toilets.   
  
 221 
 
Chapter 8: Discussion 
This study extends current knowledge around two very common NMS, bowel 
and bladder dysfunction, affecting people who have the degenerative neurological 
disease PD. All 67 of the people who participated in this study reported that they had 
trouble managing their toileting needs. They identified constipation and emptying their 
bladder more frequently than they felt was reasonable as a particular problem to be 
endured and managed.  The research design centralised the voices of people with PD 
and in so doing, revealed their concerns about the effects that bowel and bladder 
dysfunction have on their quality of life, regardless of their age, and the burden 
associated with living with these challenges. Despite the involvement of health 
practitioners in advising and treating people with PD, these chronic and progressive 
symptoms of neurological dysfunction fit more appropriately within a construct of 
disability rather than being conceptualised as a treatable health concern or as a 
degenerative process commonly associated with ageing.  
The participants’ major concerns are used to guide the flow of discussion within 
this chapter and to continue the emphasis of this research on the primacy of their 
experiences since receiving their PD diagnosis. Through a synthesis of participants’ 
stories and the distillation of their experiences and perceptions, it has been possible to 
gain insights about factors that motivate or limit their approach to, and management of, 
their bowel and bladder dysfunction. These factors are used to illuminate the process 
participants used in deciding on how best to respond to the reality of their bowel and 
bladder symptoms. The three major concepts incorporating the factors are: 
1. The presence and legitimacy of the symptoms experienced by 
participants  
 222 
 
2. The participants’ use of and search for additional personal resources  
3. Burdens and quality of life disruptions created by symptoms and the 
search for help. 
Discussion of key research findings is structured around these concepts and 
focuses on explaining the meaning of participants’ collective wisdom and experiences. 
The study’s strengths, methodological effectiveness, methodological limitations and 
future research possibilities are also included here along with implications for practice, 
service provision and further study.  
8.1 Presence and legitimacy of symptoms experienced by participants  
8.1.1 Symptom presence 
The prevalence and pathophysiology of bowel and bladder dysfunctions in PD is 
commonly known among health practitioners, but until recently it has not been well 
researched nor described (Kaye et al., 2006; Mehndiratta et al., 2011; Sakakibara et al., 
2008; Sakakibara et al., 2012). Even so, attention has been focused by these researchers 
on the high incidence of these symptoms in populations of people with PD, citing 
estimates of between 45% to 90% for LUTS (Sakakibara et al., 2012), and reports of up 
to 80% for bowel dysfunction (Gao et al., 2011; Kishi et al., 2011; Pfeiffer, 2011). 
8.1.1.1 Bowel symptoms 
The bowel symptoms identified by 83% of the total participant group were 
diarrhoea (13%) and constipation (83%). Participants’ stories of diarrhoea suggest that 
this symptom exists in relation to their level of understanding of the processes involved 
in digestion of food and the origin of various symptoms. Many were not aware that the 
diarrhoea was being triggered by their use of irregular and very high doses of laxatives 
they used to overcome their frequently occurring constipation. All participants 
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identified excessive time spent straining at stool as a component of their constipation 
difficulties, indicating neurological dyssynergia as being the major clinical indicator 
rather than the length of time between bowel movements. Constipation clearly creates a 
significant burden for participants, with 73% rating its burden as being either high or 
extremely high.  
8.1.1.2 Bladder symptoms 
Combinations of four bladder symptoms were identified by 92.5% of the total 
participant group, 63% of this group had had their bladder dysfunction categorised as 
over active bladder (OAB) syndrome.  Researchers have associated the incidence of 
OAB strongly with older women (Lapitan & Chye, 2001; Milsom et al., 2001; Stewart 
et al. 2003; Temml et al., 2005; and Sims et al., 2011). In this participant group neither 
gender nor age were found to be significant contributors, possibly highlighting the 
neuropathophysiology of PD (Iacovelli et al., 2010; Sakakibara et al., 2008; and Walter 
et al., 2006) as the principal catalyst for their OAB occurrence. 
8.1.1.3 Combined bowel and bladder dysfunction 
The majority of participants (72%) reported a combined presentation of bowel 
and bladder dysfunction which is also referred to as double incontinence (DI). The 
occurrence of DI among participants is higher than results of between 3% and 15% 
found in reviewed community incontinence prevalence studies of people who were over 
80 years of age and who had high levels of frailty and an inability to self-care 
(Teunissen, van den Bosch, van den Hoogen & Lagro-Janssen, 2004; Santos & Santos, 
2011; Slieker-ten Hove et al., 2010 and Stenzelius, Mattiasson, Hallberg & Westergren, 
2004).  There was no evidence in the current study that functional self-care deficits or 
severe disability were occurring in the presence of DI among participants, a finding that 
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supports a conclusion that a neurological aetiology to bowel and bladder dysfunction is 
more likely than any other DI causal factor.  
Participants reported that these bowel and bladder symptoms resulted in frequent 
episodes of incontinence, which they referred to as ‘accidents’.  All reported that their 
toileting difficulties were burdensome and everyone had, in some way, altered their 
environment, clothing and social life to accommodate the unpredictability of their 
bowel and bladder events.  They further reported that efforts to obtain practical and 
helpful information were thwarted by the added pressures of having to make time to see 
different doctors, trialling new products and needing to take more medications, all of 
which were regarded by participants as adding to their existing burdens.  The frustration 
expressed by participants revolved around their belief that toilet problems, constipation 
and urinary urgency and frequency, should be an easy problem to fix, primarily because 
they regarded going to the toilet as a fundamental human need.  They were also 
cognisant these symptoms are experienced by many of their peers who do not have PD, 
yet unlike themselves their peers did not seem to be as restricted by these same 
symptoms as they are.  
8.2 Legitimacy of bowel and bladder concerns 
The reality of experiencing bowel and bladder dysfunction is ever present for 
people with PD; however legitimacy of the experience can depend on acknowledgement 
from others who observe the person with the dysfunction.  Pearson, Tucker, Bolt et al., 
(2002); and St. John et al., (2010) proposed that symptom legitimacy is an important 
factor in a person’s decision whether or not to raise discussion of its existence with a 
health professional. Symptom legitimacy can also be supported by accessing knowledge 
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about the symptom and its aetiology (Gallagher et al., 2010; Gallagher, Donoghue, 
Chenoweth & Stein-Parbury, 2008; and O’Sullivan et al., 2008). The participants in this 
study did not have access to such knowledge and attributed their bowel and bladder 
dysfunctions primarily to their age and gender, both of which are unchangeable key 
determinants of health. Some blamed their diet or prescribed PD medications as causal 
factors. Low levels of health literacy and understanding about PD was identified by the 
participants as a major reason for not raising or more actively pursuing their concerns 
about bowel and bladder dysfunctions with their doctors. Partly the reason for not doing 
so was their difficulty in finding the words to discuss this embarrassing topic, but also 
participants expressed concern over the ‘worthiness’ of their symptoms in relation to 
medical attention. This internalised debate between what constituted a ‘proper’ medical 
concern and what did not seems to reflect participant desires to test the importance of 
symptoms prior to raising the subject with their doctor. 
Participants reported in Chapter Five that they were reasonably healthy even though 
they experienced significant disability. The participants referred to their bowel and 
bladder dysfunctions as disabling factors which they perceived to be commonly 
associated with normal ageing. Unsurprisingly, people are unlikely to raise issues of 
disability with their doctors and instead, voluntarily restrict conversations within this 
vitally important interaction to legitimate health and disease related subjects (Duggan, 
Bradshaw, & Altman, 2010; Frosch, May, Rendle, Tietbohl, & Elwyn, 2012). Similar 
findings to this research were discussed by Paul, Ayis, and Ebrahim (2007) and 
Rothermund and Brandtstädter (2003) who found that people were more likely to draw 
on their own resources to make lifestyle adaptations to disabilities, and be more willing 
to alter their life goals rather than seek outside help. It was found that only when a 
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person’s concerns incrementally increased beyond their ability to cope did they seek 
assistance. In accord, participants in this study reported that it was only when bowel and 
bladder symptoms negatively influenced their ability to actively participate in social 
activities, and only when they had exhausted all-available resources to deal with the 
symptoms, did they seek advice.  All members of the participant group expressed 
ambivalence about their symptoms’ legitimacy as proper health concerns.  
8.3 Burdens and quality of life disruptions created by bowel and bladder 
dysfunctions and the search for help 
Throughout the study, participants reported that they had made what they believe to 
be significant changes to their lifestyle and personal goals. They expressed the extreme 
lengths to which they had gone to in making these adaptive changes, and the results in 
Chapters Six and Seven show that it was only when they had tried everything they could 
to resolve the distress caused by these symptoms, did they approach their doctors for 
assistance. This may explain participants’ negative satisfaction rating of medical 
services (see Chapter Seven for detailed results), as they believed that they had already 
found and tried most of the basic advice offered by their doctors or allied health services 
and were unwilling to pursue that line of enquiry again.  
Participants stated unequivocally that they were burdened by self-imposed 
restrictions made in response to these symptoms and this burden seemed heavier as they 
were no longer able to participate in activities that they understood to be part of normal 
life. Participants reported that these self-imposed restrictions originated from factors in 
their environmental and personal context; factors identified in the ICF framework as 
either a limiter or enhancer of a person’s ability to manage their bodily functions and to 
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participate in life activities (Rejeski, Ip, Marsh, Miller, & Farmer, 2008; WHO, 2001).  
Environmental factors, according to the ICF, are factors beyond the individual’s locus 
of control. Participants acknowledged that they had a knowledge deficit, particularly in 
relation to finding resources that could help them to manage their symptoms; this, 
together with their lack of confidence in the laxatives and containment products (pads) 
they used were all perceived as creating higher levels of burden. These external factors 
were compounded by the participants’ personal attitudes towards their bladder and 
bowel symptoms, which they regarded as being socially embarrassing and loathsome.  It 
is likely that these negative personal factors inhibited any effective problem solving 
discussions between the participants and their doctors, and reinforced participants’ 
evaluation of these symptoms as being unworthy of their doctor’s professional interest. 
Consequently, participants found they needed to draw upon their own personal 
resources, referred to by the ICF as personal contextual factors. Personal contextual 
factors are greatly influenced by the individual’s cultural and educational background 
and enable a person to be guided during times of adversity (Rejeski et al., 2008; WHO, 
2001). The excessive efforts towards self-reliance employed by participants when 
choosing containment devises and laxatives were described in detail throughout Chapter 
Seven.  
8.4 Difficulties encountered when asking for help  
Participants expressed very strong opinions during their interviews and these 
tended to frame their expectations of health professionals. The combined influences of 
not wanting to disturb or burden others with what the participants regarded as socially 
embarrassing problems, together with their attempts at self-management, led them to 
instigate poorly-informed treatments that often imposed further burden and social 
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restrictions.  Because of the taboos associated with discussing toileting difficulties and 
toileting behaviours participants admitted to avoiding subjects known to create 
conversational discomfort (Elenskaia et al., 2011) and in this study the discomfort 
associated with raising such topics significantly inhibited them from pursing discussions 
with their doctors about ongoing bowel or bladder problems. Much of this would have 
occurred without their doctors realising the difficulties their patients faced. 
Edwards and Jones (2001) in their UK study of older people residing in private 
homes also found high rates (54%) of people with faecal incontinence choosing not to 
discuss this problem with their doctors. This widespread reluctance to converse on 
bowel and bladder problems has been reported to affect the type and amount of 
bathroom-based research, along with a current lack of clinical attention being given to 
toileting dysfunction (Bradway, 2003; Landefeld et al., 2008; and Milsom, Abrams et 
al., 2001). Studies conducted by Ueda, Tamaki, Kageyama, Yoshimura and Yoshida 
(2000), Cochran (2000), Milsom, Abrams, Cardozo, Roberts, Thuroff and Wein (2001), 
Kaye et al. (2006) and Zesiewicz et al. (2010) on incontinence, also found high rates of 
medical non-involvement. However, these and subsequent studies have neglected to 
investigate why bowel or bladder dysfunctions remain largely unreported and under-
researched, even when the evidence establishes this line of enquiry as being important. 
To date, there has been limited research focused on why people do not report disturbing 
bowel or bladder symptoms to their doctors.  
 The current study found that many more participants stated that they had made 
an initial report of their bowel (67%) or bladder (54%) difficulties to their doctors when 
compared to the reviewed research which estimates that only 12- 35% of people with 
incontinence report its occurrence (Buckley & Lapitan, 2010; Fritel, Panjo, Varnoux, & 
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Ringa, 2013; Santos & Santos, 2011).  Evidence of reporting trends can be found in 
recent data compiled by the Australian Institute of Health and Welfare (AIHW, 2012) 
showing a rise of thirty thousand Medicare payments for medical specialist 
consultations specifying bladder incontinence between 2003 and for the year 2008-
2009. Interestingly, Medicare payments for local general medical practitioner (LGP) 
consultations, for specified bladder incontinence, rose by a mere two thousand visits 
across this same five-year period.  The report did not include data for bowel 
incontinence. The participants in the current study also talked about having been 
referred to multiple medical specialists for their bowel or bladder problems.  
Following their consultations with these medical specialists the participants became 
even more ambivalent about the legitimacy of their symptoms, especially as they did 
not receive the response or information they had expected. Many participants talked 
about sourcing information from others with PD via PD support groups, from local 
pharmacies and three male participants spoke of using their female partners to broker 
information and purchase continence products on their behalf.  
However, it was when these informal resources could no longer assist the participant 
that their level of anxiety and burden seemed to be more severe. In one participant’s 
report of bowel dysfunction, in which he reported his burden level as being 8 out of a 
possible 10, stated that he was left in a quandary as his main support person was also at 
a loss.  
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8.5 Key research findings  
8.5.1 Wisdom gleaned from participants’ experiences and collective insights 
From first-hand experience, the participants have pursued information and 
strategies and have gained considerable insights on what was happening to their bodies 
as a result of PD.  They were able to describe in biological terms, their bladder and 
bowel dysfunctions in terms that align with the known PD neuropathophysiology 
affecting the ENS and ANS pathways. They depicted their constipation and OAB 
symptoms as resulting from a paradoxical dyssyneria of the pelvic floor muscles and 
their external anal and bladder sphincters. Their vivid descriptions of excessive 
straining, regardless of stool formation and their detrusor hyperreflexia, unstable 
bladder storage and emptying were consistent with known pathophysiological 
mechanisms. Participants also deduced that their episodes of dyskinesia were directly 
linked to their bowel and bladder dysfunction, although they were not able to discern 
which one caused the other. They were convinced that the abdominal discomfort they 
experienced when they needed to go to the toilet to empty their bowel or bladder 
exacerbated their gait problems. Notably, participants acknowledged that these 
symptoms defied the basic management methods recommended to people with non-
neurological chronic constipation, such as increasing fluid, fibre and exercise, and 
persisted despite following this advice. Similarly, further burden was associated with 
managing and taking a variety of medications, laxatives or in using containment devices 
such as incontinence pads. All participants reported that the manifestation and 
management of these autonomic NMS significantly heightened their burden and 
distorted their quality of life. Participant insights on key biological changes and linkages 
between biological systems indicated that they understand what is happening and 
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continue to search for solutions that will relieve the burden of PD symptoms. Their 
contribution to understanding the specific clustering of autonomic NMS in otherwise 
well adults, addresses a gap in medical research where this phenomenon associated with 
PD is currently not well described nor acknowledged.  
Significant psychological disruption was reported by study participants who 
described their bladder and bowel dysfunctions as creating high levels of anxiety and 
accentuating their emotional distress. The participants considered their concerns and 
lifestyle options to be dominated by disempowering and highly emotional thoughts 
about their bowel and bladder disturbances. Living with these NMS was likened to 
having a full time job, one that required them to traverse unfamiliar medical terrain 
populated with people they held in high regard but who spoke a different language and 
whose actions seemed to be governed by processes beyond their understanding. It is not 
surprising that participants tended to withhold information they believed to be 
distasteful or not really a health issue. These cultural divides were not fully understood 
and therefore not resolved by the patients or their doctors and this could explain the 
high levels of dissatisfaction expressed by participants.  The consequences of not 
discussing symptoms with their doctor also impacted on their ability to obtain relevant 
resources. Australian government web sites and the Australian Continence Foundations 
helpline were not accessed by participants nor were continence services which are 
available at most local hospitals. The reason contributing to participants not accessing 
these resources was their refusal to accept themselves as being incontinent, preferring 
instead to put in place socially restrictive practices to avoid exposure.   
The uncertainty and unpredictability of leakage events caused most of the social 
disruptions reported by participants. Because only six of them stated they were 
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incontinent, it is possible that the remaining participants had not accessed continence 
specific resources, as they did not consider their leakage events as indications of 
incontinence. None spoke of accessing web based material such as the Bowel and 
Bladder Government website or the Australian Continence Foundations helpline and the 
apparent meagre use of continence services could have resulted in the participants 
reporting burdens associated with access to financial and social resources. All 
participants indicated that they felt excessively burdened by the possibility of being 
incontinent in public, an occurrence that they viewed as appalling and intolerable. Very 
few reported social isolation, rather they spoke of restricting their activities to familiar, 
local places close to their home. Again, the insights provided through this research on 
psychological and social effects of incontinence, contribute to medical research by 
conveying an understanding not previously described or acknowledged in any form 
about people with PD and experience of living with these two pervasive NMS.  
Throughout the interviews participants expressed their deep-seated frustration 
about how little they knew and how ineffectually they were managing their neurological 
constipation and OAB. They spoke of the difficulties in accessing appropriate 
information that they believed could assist them in managing their bowel and bladder 
dysfunctions. The information they were able to access provided them with basic 
dietary and fluid management information, but left them wanting more specific 
information on intervention options. The participants also believed that for their doctors 
to be able to advise and recommend management plans for them to follow, these doctors 
would need to be better informed as well. 
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8.5.2 Key findings 
The first key finding is that the signs and symptoms of constipation and OAB 
for these people are often mistaken as consequences and influences commonly 
associated with biological age rather than directly linked to their PD. The review of the 
literature presented in Chapter Two highlighted the extent to which misunderstandings 
about the processes of biological ageing frames current knowledge and management of 
both PD and incontinence constructs and in doing so limits the approach and attitudes 
taken by both the sufferer and their health care provider. In identifying this as a deficit, 
this study contextualised both PD and incontinence within a disability construct and in 
doing so was able to separate age bias from its analysis of these symptom presentations.  
As a result of this approach the second key finding was identified, that is, that 
the physical burdens of chronic constipation and incontinence as described by these 
people were of significantly greater concern than what would be considered usual in 
non-PD populations. The people in this study identified high rates of occurrence and 
degrees of severity in response to the presence of these symptoms as reported in 
Chapter Five. The exploration of how these symptoms disturbed the QoL for each 
participant became evident in terms of the impact of these symptoms across many more 
areas of the participants’ life than would normally have been expected if their causation 
was unrelated to their PD as reported in Chapter Six. Participants were then able to 
distinctly voice their concerns about the degree of physical burden these symptoms had 
in comparison to what they believed their peer group experienced.  
The third key finding identified was that symptom relief is rarely achieved via 
conventional management practices employed to treat the more common, age related 
chronic constipation and urinary incontinence.  Participants identified the treatments 
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they used as being similar to those used for any person with these same symptoms from 
any cause. The participants stated that the treatments they used did not provide them 
with any relief, instead they created additional burdens for them (see Chapter Seven). 
This finding highlights the impact of failing to identify the neurological aetiology of PD 
and its resulting bowel and bladder dysfunction. The outcome of not implementing a 
more intensively regulated neurologically focused treatment plan caused these people to 
be less able to adequately resolve the negative impact of symptoms. Interestingly GPs 
seemed to be unaware of the ineffectiveness of these management strategies, because 
the participants themselves admitted that they did not raise these treatment failures with 
them. This situation was further complicated by the participants’ doctors who were 
reported as not following-up on the efficacy of their given management suggestions. 
Participants then incorrectly interpreted this clinical deficit as an indication that these 
symptoms were not medically important.  
The physical presence of symptoms and lack of effective management strategies 
accessed by the participants is the fourth key finding: that the presence of constipation 
and OAB, as described by them, creates a substantial psychological burden. This 
psychological burden was expressed by the participants as causing high levels of 
anxiety and emotional distress, more than they experienced with any of their other PD 
NMS. This finding highlights the importance of disease knowledge and symptom 
legitimacy, both of which were raised in the review of literature and again in Chapter 
Seven. In particular, the importance of acknowledging the primacy of aetiological 
factors creating the pathophysiology is stressed, thereby legitimising the importance of 
the symptoms and the attention needed to manage them effectively.  
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The participants responded to symptom-related anxiety and emotional distress 
by restricting their movements beyond the home. This situation was viewed by them as 
the only method they could use to reduce their stressors and as such has been noted as 
the fifth key finding: that people with PD adopt self-imposed social restrictions in 
response to the unpredictable nature of their chronic constipation and OAB. They 
further stated that even though these self-imposed restrictions were effective, they had a 
dramatic effect on each person’s ability to fully participate in social and lifestyle actives 
and as a consequence negatively affected their quality of life.  
The final and sixth key finding relates to their ability to source information and 
assistance. Participants’ ability to source helpful resources was significantly impaired 
by their preconceived attitudes toward constipation and urinary incontinence and their 
evaluation of what constitutes a legitimate health concern. The participants did not 
regard their toileting problems as incontinence and therefore did not think to utilise 
specialist continence services or access Internet information and material. They were 
also concerned about becoming dominated by the medical activities related to managing 
their PD, which they saw as having the potential of taking over their life similar to a full 
time job. The participants were also cognisant of the needs of their spouse and families 
and were hesitant not to over-burden them or reduce their social movements. The 
combination of the above factors ensured that participants remained in a state of 
disequilibrium that was reinforced by the continued, unpredictable nature of their bowel 
and bladder dysfunction. 
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8.6 Limitations and strengths of the study 
8.6.1 Strengths 
The strength of this study begins with the importance of the topic explored, not 
just for the scientific and clinical communities, but for the participants themselves. 
Without exception, each participant stated on joining the research that the daily 
hardships they endured were insignificant compared with the trauma of not being able 
to use a toilet in the manner they wished. Their only request was that the findings of this 
study be used to raise the profile of these symptoms and to assist others like them to 
find more effective ways to resolve these toileting predicaments. A further strength is 
the mixed method converged design that allowed the research to focus on burden as the 
key issue, while ensuring the voices of participants were heard at all times through the 
research process. Other methodological approaches were considered, but none offered 
the comprehensiveness and flexibility needed to explore such new ground. 
The use of both quantitative and qualitative data collection methods provided 
significant opportunity to identify common issues associated with the physical presence 
of symptoms and the consequent burden they created for the individuals as they cope 
with various disturbed aspects of their QoL. It was only when these data sets were 
converged and contrasted through the conceptual framework of disability, rather than by 
referencing conventional health and treatment paradigms, did the true nature of 
participants' burden and QoL become apparent.  The benefit of looking at bowel and 
bladder dysfunction from a disability rather from a health construct enabled the study to 
identify the origin of burden and how participants made lifestyle adaptations to 
compensate.  The use of the ICF Framework enabled the study to explore participants’ 
bowel and bladder dysfunctions in terms of their physical presence, how these 
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dysfunctions affected their ability to complete self-care activities and finally, how their 
inability to complete self-care activities disrupted their community participation and life 
quality. Moreover, this conceptual framework supported the exploration of internal and 
external influential factors with equal importance; for instance, participants’ attitudes 
towards their body’s structural and functional deficits and the broader shared societal 
attitudes and approaches to health management, all of which shaped the participants 
perceptions of burden and interpretation of their QoL.  
By asking participants to score their perception of burden, and then using that 
score to incorporate their personal experience, the voices of participants remained 
central and influential in all stages of data collection, data analysis and data 
interpretation.  
8.6.2 Limitations 
The challenges of researching a poorly understood and relatively unpopular 
topic with a group of people at various stages of PD were known from the outset and 
efforts were made at each stage to ensure research rigour. The sample was drawn from a 
self-selected group of individuals interested in speaking to the researcher about their 
bowel and bladder dysfunction; however it is not known if more participants would 
have provided divergent or confirming insights. By talking with people with a deep 
personal experience of the research topic, the research outputs focused on the 
expressions and concerns of these participants whose views and issues may not be the 
same for others with PD (Collins et al., 2007). The issue of applicability of results to a 
wider group of people with PD does not arise in ethnography and this may be a 
limitation of the study that could be overcome with a multi-site, combined data analysis.  
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Even so, the results of this study highlight the issues of personal burden associated with 
PD and therefore contribute a foundation for further investigation.  
The study chose not to approach bowel and bladder dysfunction from a 
definitional basis of incontinence, and as such no specific incontinence outcome 
measurement tools were used. The rationale was that many participants refused to label 
their bladder and bowel dysfunction using this term and would have been 
disenfranchised from the study if incontinence details were more broadly addressed and 
data collection focused specifically on incontinence.  The study’s exploratory approach 
to this unexplored subject required a broader initial look and the decision to collect a 
more personalised description of these burdensome symptoms. Useful results from the 
study include the discovery of an association between constipation, pain and mobility 
which would not have been revealed if bowel dysfunction had been explored using a 
standardised incontinence assessment tool. 
The large amount of data collected was found to cover similar ground several 
times. It was felt that these aspects of similarity were important in understanding this 
previously under researched topic and proved valuable in confirming and validating the 
data collected from all possible sources.  
8.7 Recommendations for future research and clinical practice 
The participants raised some interesting and important issues that were outside 
the scope of this study’s research scope; however, they suggest opportunities for related 
research opportunities and the future development of clinical tools. 
The study adapted a commonly used pain severity rating scale to assist 
participants in numerically estimating the burden severity their bowel or bladder 
symptom created. The participants found this tool very useful and it is suggested that 
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this numerical rating scale be further investigated and validated beyond that of its 
current use as a pain scale.   
This study’s participants together with the wider medical literature have raised 
the need for futher clinical research and the provision of clinical management 
guidelines. The plethora of antecedent clinical management based on subjective 
professional experience and small poorly designed empirical studies dominate the 
medical literature and provide less than reliable bases from which neurological bowel 
and bladder guidelines can be constructed. According to the most recent Cochrane 
review of neurological bowel management (Coggrave, Wiesel, & Norton, 2009) and the 
American Academy of Neurology review of neurological OAB (Zesiewicz et al., 2010 
), it remains impossible to draw any conclusions on the best practice for managing 
neurologically induced constipation and OAB as research in this area is deficient in 
reducing problems in obtaining a comfortable and an effective bowel emptying.  Both 
of these reviews support results from the current study in that there is a need for sound 
multidisciplinary research to be conducted, as currently only non-empirical practice 
governs the approach to managing both of these significant autonomic non-motor 
symptoms. Research such as this may also provide important information useful to 
others with degenerative neurological diseases, such as multiple sclerosis. Without 
evidence-based practice guidelines, health professionals and their patients will continue 
to draw on their personal resources and experience to guide their approach to 
management without expert advice and guidance.  
In response to participants' concerns regarding symptom legitimacy, the 
development of self-care planning information tools, about neurological based 
constipation and OAB management for people PD are required. These tools would 
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ensure that these people remain independent and successful in self-care and have 
enough information to confidently begin conversations with their doctors about these 
common symptoms. Such information would need to include the types of 
pharmaceutical agents available, and how individuals can safely use them without 
risking unplanned and unpredictable episodes of incontinence. To reduce personal 
burdens these resources would also need to include how people with PD can access 
financial as well as specialist continence support.  
Participant insights on the relationship between their diurnal mental alertness 
and focus and their sleep disturbances as they related to multiple wakes overnight to 
void (nocturia) also offer potential research opportunities. This study found little 
statistical support that enabled any inferences to be drawn between these factors, 
especially for those who woke multiple times to void over-night and who reported 
concerns about their daytime mental alertness. This relationship warrants further 
investigation as it remains unexplored and poorly understood. 
No participant in this study raised concerns regarding intimacy within their 
relationships; most answered this question as part of the NMSS saying that they were no 
longer sexually active or that they had no problems in this area. However, in the 
interview their reports of moving from their marital bed as a consequence of their 
nocturnal wakefulness suggest that this topic was under approached by the study. While 
intimacy was not the focus of an examination in this study it remains a topic of interest. 
It is highlighted as a potential area of research interest as incontinence is known to 
change the way people perceive themselves sexually and therefore warrants further 
investigation. 
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8.8 Conclusions 
This study explored two personally burdensome autonomic NMS, constipation 
and OAB reported to affect 80% of all people who have PD, a degenerative 
neurological disease that affects 1% of the Australian population over the age of 60 
years. Through a mixed method design this research was able to explore previously 
under researched aspects of the life experience of people with PD.  The analysis 
converged interview and statistical data with participant estimations of personal burden 
levels to ensure that views of their experiences remained the central focus. The results 
reveal novel and informative insights on the level of information these people have 
about their changing biological responses; their strategies for coping unassisted with 
symptom management; and the adaptive choices they made in order to maintain their 
dignity and demeanour within their social contexts.  
The people participating in this study, prior to their PD diagnosis, led a diverse, 
disability free and satisfying adulthood from which they enjoyed a successful, 
community-based life full of family, social and vocational achievements. For the most 
part, the participants spoke of entering a time in their lives where they had to re-draw 
their life plans from that of transitioning comfortably into their ‘evening years’ made up 
of activities of their choosing without the financial pressures of raising young families. 
In contrast, they now viewed these ‘evening years’ as full of trepidation and concern.  
 
  
 242 
 
 
References 
Abbott, L. M., Naismith, S. L. & Lewis, S. J. G. (2011). Parkinson’s disease in general 
practice: Assessing knowledge, confidence and the potential role of education. 
Journal of Clinical Neuroscience, 18(8), 1044–1047. 
doi:10.1016/j.jocn.2010.12.041 
Abbott, R., Petrovitch, H., White, L., Masaki, K., Tanner, C., Curb, J. D., Grandinetti, 
A., Blanchette, P. L., Popper, J. S., Ross, G. (2001). Frequency of bowel 
movements and the future risk of Parkinson’s disease. Neurology, 57(3), 456–
462. 
Abdo, W. F., van de Warrenburg, B. P., Burn, D. J., Quinn, N. P. & Bloem, B. R. 
(2010). The clinical approach to movement disorders. Nature Reviews 
Neurology, 6(1), 29–37. 
Abeare, C. A., Cohen, J. L., Axelrod, B. N., Leisen, J. C., Mosley-Williams, A., & 
Lumley, M. A. (2010). Pain, executive functioning, and affect in patients with 
rheumatoid arthritis. Clinical Journal of Pain, 26(8), 683-689.  
Abrams, P. (2003). Describing bladder storage function: Overactive bladder syndrome 
and detrusor overactivity. Urology, 62(5, Suppl 2), 28–37. 
Abrams, P. (2005). Urgency: The key to defining the overactive bladder. British 
Journal of Urology International, 96(Suppl 1), 1–3. 
Abrams, P., Andersson, K. E., Birder, L., Brubaker, L., Cardozo, L., Chapple, C., 
Cottenden, A., Davila, W., de Ridder, D., Dmochowski, R., Drake, M., Dubeau, 
C., Fry, C., Hanno, P., Smith, J. H., … Members of Committees, Fourth 
International Consultation on Incontinence. (2010). Fourth international 
 243 
 
consultation on incontinence recommendations of the international scientific 
committee: Evaluation and treatment of urinary incontinence, pelvic organ 
prolapse, and fecal incontinence. Neurourology and Urodynamics, 29(1), 213–
240 
Abrams, P., Andersson, K., Brubaker, L., Cardozo, L., Cottenden, A., Denis, L. & 
Donovan, J. (2005). 3rd international consultation on incontinence: 
Recommendations of the International Scientific Committee. Plymouth, UK: 
Plymouth Distributors Ltd. 
Abrams, P., Artibani, W., Cardozo, L., Dmochowski, R., van Kerrebroeck, P. & Sand, 
P. K. (2006). Reviewing the ICS 2002 terminology report: The ongoing debate. 
Neurourology And Urodynamics, 25(3), 293–293. doi:10.1002/nau.20251 
Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., van 
Kerrebroeck, P., Victor, A., Wein, A. (2002). The standardisation of 
terminology of lower urinary tract function: Report from the standardisation 
sub-committee of the International Continence Society. Neurourology and 
Urodynamics, 21(2), 167–178. doi:10.1002/nau.10052 
Abrams, P., Cardozo, L., Khoury, S. & Wein, A. (2005). Incontinence. Paris, France: 
Health Publications. 
Abrams, P., Manson, J. & Kirby, M. G. (2012). Incidence and epidemiology of storage 
lower urinary tract symptoms. European Urological Review, 7(1), 50–54. 
ABS. (2009a). Basic confidentialised unit record file: Disability, ageing and carers ABS 
cat. no. 4430.0.00.001. Canberra: Australian Bureau of Statistics. 
ABS. (2009b). Disability, ageing and carers, Australia: User guide. ABS cat. no. 
4431.0.55.001. Canberra: Australian Bureau of Statistics. 
 244 
 
ABS. (2010). Themes: 3303.0 Causes of death, Australia: Underlying cause of death by 
selected ICD-10. Retrieved 29 March 2013, from Australian Bureau of Statistics 
www.abs.gov.au 
ABS. (2011). Themes: 3235.0 Population by age and sex, regions of Australia. 
Retrieved March 2013, from Australian Bureau of Statistics 
www.abs.gov.au/ausstats/abs@.nsf/Products/3235.0~2011~Main+Features~Mai
n+Features?OpenDocument#PARALINK0 
Access Economics. (2007). Living with Parkinson’s disease: Challenges and positive 
steps for the future. Retrieved from 
http://c.ymcdn.com/sites/www.worldpdcongress.org/resource/resmgr/docs/austr
alia_access_economic_re.pdf 
Aditya, B. S., Sharma, J. C., Allen, S. C. & Vassallo, M. (2003). Predictors of a nursing 
home placement from a non-acute geriatric hospital. Clinical Rehabilitation, 
17(1), 108–113. 
Ahan, M., Saderberg, S. & Lundman, B. (2003). Hovering between suffering and 
enduring: the meaning of living with serious chronic illness. Qualitative Health 
Research, 13(4), 528–542. 
AIHW. (2006a). Chronic diseases and associated risk factors in Australia PHE 81 (Vol. 
2008). Canberra. 
AIHW. (2006b). Australian incontinence data analysis and development cat. no. DIS 
44. Retrieved from http://www.aihw.gov.au/publications/index.cfm/title/10201. 
AIHW. (2012a). Incontinence in Australia: prevalence, experience and cost. AIHW 
bulletin no. 112. Cat. no. AUS 167. Canberra: AIHW. 
 245 
 
AIHW. (2012b). Risk factors contributing to chronic disease. Cat. no. PHE 157. 
Retrieved from http://www.aihw.gov.au/publication-detail/?id=10737421466 
AIHW. (2013). Incontinence in Australia. Cat. no. DIS 61. Canberra: AIHW. 
Akbarali, H. I., Grider, J. R., Gulick, M. A., Kuemmerle, J. F., Murthy, K. S., Qiao, L.-
Y., … Yu, S. J. (2012). Up-regulation of brain-derived neurotrophic factor in 
primary afferent pathway regulates colon-to-bladder cross-sensitization in rat. 
Journal of Neuroinflammation, 9, 30. 
Alma, M. A., Van der Mei, S. F., Groothoff, J. W. & Suurmeijer, T. P. B. M. (2012). 
Determinants of social participation of visually impaired older adults. Quality of 
Life Research, 21(1), 87–97. 
Araki, I. & Kuno, S. (2000). Assessment of voiding dysfunction in Parkinson’s disease 
by the international prostate symptom score. Journal of Neurology, 68(4), 429–
433. 
Arnon, S., & Reichel, N. (2009). Closed and Open-Ended Question Tools in a 
Telephone Survey About``The Good Teacher''An Example of a Mixed Method 
Study. Journal of Mixed Methods Research, 3(2), 172-196.  
Awad, R. A. (2011). Neurogenic bowel dysfunction in patients with spinal cord injury, 
myelomeningocele, multiple sclerosis and Parkinson’s disease. World Journal of 
Gastroenterology, 17(46), 5035–5048. 
Backer, J. H. (2000). Stressors, social support, coping, and health dysfunction in 
individuals with Parkinson’s disease. Journal of Gerontological Nursing, 
26(11), 6–16. 
Bambra, C., Fox, D. & Scott-Samuel, A. (2005). Towards a politics of health. Health 
Promotion International, 20(2), 187–193. 
 246 
 
Bannister, P. (2000). Parkinson’s disease in the elderly. Home Health Care Consultant, 
7(6), 20–24. 
Bennett, T. & Gaines, J. (2010). Believing what you hear: The impact of aging 
stereotypes upon the old. Educational Gerontology, 36(5), 435–445. 
doi:10.1080/03601270903212336 
Berg, D. (2008). Biomarkers for the early detection of Parkinson’s and Alzheimer’s 
disease. Neurodegenerative Diseases, 5(3–4), 133–136. 
Bhatia, S. & Gupta, A. (2003). Impairments in activities of daily living in Parkinson’s 
disease: Implications for management. NeuroRehabilitation, 18(3), 209–214. 
Bhutto, A. & Morley, J. E. (2008). The clinical significance of gastrointestinal changes 
with aging [Review]. Current Opinion in Clinical Nutrition and Metabolic Care, 
11(5), 651–660. 
Bichard, J. & Knight, G. (2010). Designing out environmental barriers to public toilet 
provision for an aging population. Gerontechnology, 9(2), 112–113. 
Blumenfeld, H. (2002). Neuroanatomy through clinical cases. Massachusetts: Sinauer 
Associates, Inc. 
Boddy, F., Rowan, E. N., Lett, D., O’Brien, J. T., McKeith, I. G. & Burn, D. J. (2007). 
Subjectively reported sleep quality and excessive daytime somnolence in 
Parkinson’s disease with and without dementia, dementia with Lewy bodies and 
Alzheimer’s disease. International Journal of Geriatric Psychiatry, 22(6), 529–
535. 
Bowling, A. (1995). What things are important in people’s lives? A survey of the 
public’s judgements to inform scales of health related quality of life. Social 
Science and Medicine, 41(10), 1447–1462. 
 247 
 
Bowling, A., Seetai, S., Morris, R. & Ebrahim, S. (2007). Quality of life among older 
people with poor functioning. The influence of perceived control over life. Age 
and Ageing, 36(3), 310–315. doi:10.1093/ageing/afm023 
Braak, H. & Del Tredici, K. (2008). Invited article: Nervous system pathology in 
sporadic Parkinson disease. Neurology, 70(20), 1916–1925. 
Bradway, C. (2003). Urinary incontinence among older women: Measurement of the 
effect on health-related quality of life. Journal of Gerontological Nursing, 29(7), 
13–19. 
Brannen, J. (2005). Mixing methods: The entry of qualitative and quantitative 
approaches into the research process. International Journal of Social Research 
Methodology, 8(3), 173–184. 
Brickman, P., Coates, D. & Janoff-Bulman, R. (1978). Lottery winners and accident 
victims: Is happiness relative? Journal of Personality and Social Psychology, 
36(8), 917–927. 
Brittain, K., Perry, S., Shaw, C., Matthews, R., Jagger, C. & Potter, J. (2006). Isolated 
urinary, fecal, and double incontinence: Prevalence and degree of soiling in 
stroke survivors. Journal of the American Geriatrics Society, 54(12), 1915–
1919. 
Brittle, N., Brown, M., Mant, J., McManus, R., Riddoch, J., Sackley, C., … Sackley, C. 
(2008). Short-term effects on mobility, activities of daily living and health-
related quality of life of a Conductive Education programme for adults with 
multiple sclerosis, Parkinson’s disease and stroke. Clinical Rehabilitation, 22(4), 
329–337. 
 248 
 
Brod, M., Mendelsohn, G. A. & Roberts, B. (1998). Patients’ experiences of 
Parkinson’s disease. Journal of Gerontology: Psychological Sciences, 53B, 213–
222. 
Buchanan, R. J., Wang, S., Huang, C., Simpson, P. & Manyam, B. V. (2002). Analyses 
of nursing home residents with Parkinson’s disease using the minimum data set. 
Parkinsonism and Related Disorders, 8(5), 369–380. 
Buckley, B. S. & Lapitan, M. C. M. (2010). Prevalence of urinary incontinence in men, 
women, and children—current evidence: Findings of the Fourth International 
Consultation on Incontinence, Epidemiology Committee. Urology, 76(2), 265–
270. 
Burton-Smith, R., McVilly, K., Yazbeck, M., Parmenter, T. & Tsutsui, T. (2009). 
Quality of life of Australian family carers: Implications for research, policy and 
practice. Journal of Policy and Practice in Intellectual Disabilities, 6(3), 189–
198. 
Cadeddu, F., Bentivoglio, A. R., Brandara, F., Marniga, G., Brisinda, G. & Maria, G. 
(2005). Outlet type constipation in Parkinson’s disease: Results of botulinum 
toxin treatment. Alimentary Pharmacology and Therapeutics, 22(10), 997–1003. 
Calne, D. B. (1995 ). Diagnosis and treatment of Parkinson’s disease. Hospital Practice, 
30(1), 83–86. 
Calne, S. M. & Kumar, A. (2003). Nursing care of patients with late-stage Parkinson’s 
disease. Journal of Neuroscience Nursing, 35(5), 242–251. 
Campbell, B. H., Marbella, A. & Layde, P. M. (2000). Candidate’s thesis: Quality of 
life and recurrence concern in survivors of head and neck cancer. Laryngoscope, 
110(6), 895–906. doi:10.1097/00005537–200006000–00003 
 249 
 
Cardol, M., de Jong, B. A., Gam, Beelen, A., de Groot, I. J. M. & de Haan, R. J. (2002). 
Beyond disability: Perceived participation in people with a chronic disabling 
condition. Clinical Rehabilitation, 16(1), 27–35. 
Caremel, R., Damon, H., Ruffion, A., Chartier-Kastler, E., Gourcerol, G., Michot, F., … 
Leroi, A. M. (2012). Can sacral neuromodulation improve minor incontinence 
symptoms in doubly incontinent patients successfully treated for major 
incontinence symptoms? Urology, 79(1), 80–85. 
Cardol, M., de Jong, B. A., Gam, Beelen, A., de Groot, I. J. M., & de Haan, R. J. 
(2002). Beyond disability: perceived participation in people with a chronic 
disabling condition. Clinical Rehabilitation, 16(1), 27-35.  
Carey, J. R. (2003). Life Span: A Conceptual Overview. In J. R. Carey & S. Tuljapurkar 
(Eds.), Life Span: Evolutionary, Ecological, and Demographic Perspectives, 
Supplement to Population and Development Review (Vol. 29, pp. 1-18). New 
York: Population Council. 
Carod-Artal, F. J., Vargas, A. P., Martinez-Martin, P., Carod-Artal, F. J., Vargas, A. P. 
& Martinez-Martin, P. (2007). Determinants of quality of life in Brazilian 
patients with Parkinson’s disease. Movement Disorders, 22(10), 1408–1415. 
Carter, M., Walker, C. & Furler, J. (2002). Developing a shared definition of chronic 
illness: The implications and benefits for general practice GPEP 843. 
Melbourne, VIC: Chronic Illness Alliance. 
Castles, F. G. & Uhr, J. (2007). The Australian welfare state: Has federalism made a 
difference? Australian Journal of Politics and History, 53(1), 96–117. 
 250 
 
CFA. (2010). The Continence Foundation of Australia: Bowel and bladder control 
problems can be prevented, treated, better managed and cured. Retrieved 
January 2010, from http://www.continence.org.au 
Chan, D., Cordato, D., Karr, M., Ong, B., Lei, H., Liu, J. & Hung, W. (2005). 
Prevalence of Parkinson’s disease in Sydney. Acta Neurologica Scandinavica, 
111(1), 7–11. 
Charlton, G. S. & Barrow, C. J. (2002). Coping and self-help group membership in 
Parkinson’s disease: an exploratory qualitative study. Health and Social Care in 
the Community, 10(6), 472–478. 
Chatoor, D. & Emmnauel, A. (2009). Constipation and evacuation disorders. Best 
Practice and Research Clinical Gastroenterology, 23(4), 517–530. 
doi:10.1016/j.bpg.2009.05.001 
Chaudhuri, K. & Odin, P. (2010). The challenge of non-motor symptoms in Parkinson’s 
disease. Progress in Brain Research, 184, 325–341. 
Chaudhuri, K. (2003). Nocturnal symptom complex in PD and its management. 
Neurology, 61(6, Suppl 3), 23. 
Chaudhuri, K., Healy, D. & Schapira, A. (2006). Non-motor symptoms of Parkinson’s 
disease: Diagnosis and management. National Institute for Clinical Excellence. 
Lancet Neurology, 5(3), 235–245. 
Chaudhuri, K., Martinez Martin, P., Schapira, A. H., Stocchi, F., Sethi, K., Odin, P., … 
MacPhee, G. (2006). International multicenter pilot study of the first 
comprehensive self completed nonmotor symptoms questionnaire for 
Parkinson’s disease: The NMSQuest study. Movement Disorders, 21(7), 916–
923. 
 251 
 
Chaudhuri, K., Martinez-Martin, P., Brown, R. G., Sethi, K., Stocchi, F., Odin, P., … 
Schapira, A. H. V. (2007). The metric properties of a novel non-motor 
symptoms scale for Parkinson’s disease: Results from an international pilot 
study. Movement Disorders, 22(13), 1901–1911. 
Chen, B., Covinsky, K., Cenzer, I., Adler, N. & Williams, B. (2012). Subjective social 
status and functional decline in older adults. Journal of General Internal 
Medicine, 27(6), 693–699. doi:10.1007/s11606–011–1963–7 
Chiarelli, P. (2010 ). The link between chronic conditions and urinary incontinence. 
Australian and New Zealand Continence Journal, 16(1), 7–14. 
Chiarelli, P., Bower, W., Wilson, A., Attia, J. & Sibbritt, D. (2005). Estimating the 
prevalence of urinary and faecal incontinence in Australia: Systematic review. 
Australasian Journal on Ageing, 24(1), 19–27. doi:10.1111/j.1741–
6612.2005.00063.x 
Chiarelli, P., Brown, W. & McElduff, P. (2000). Constipation in Australian women: 
Prevalence and associated factors. International Urogynecology Journal, 11(2), 
71–78. doi:10.1007/s001920050073 
Clarke, L. H. & Bennett, E. V. (2012). Constructing the moral body: Self-care among 
older adults with multiple chronic conditions. Health, 17(3), 211–228. 
doi:10.1177/1363459312451181 
Cochran, A. (2000). Don’t ask, don’t tell: The incontinence conspiracy. Managed Care 
Quarterly, 8(1), 44–52. 
Coggrave, M., Wiesel, P. & Norton, C. C. (2009). Management of faecal incontinence 
and constipation in adults with central neurological diseases [Systematic 
review]. Cochrane Database of Systematic Reviews, 1, 1. 
 252 
 
Coggrave, M., Wiesel, P. H., Norton, C. & Brazzelli, M. (2006a). Management of faecal 
incontinence and constipation in adults with central neurological diseases. 
Cochrane Database of Systematic Reviews(2), Art. No.: CD002115. 
doi:10.1002/14651858.CD002115 
Collins, K. M. T., Onwuegbuzie, A. J. & Jiao Qun, G. (2007). A mixed methods 
investigation of mixed methods sampling designs in social and health science 
research. Journal of Mixed Methods Research, 1(267), 267–294. 
doi:10.1177/1558689807299526 
Cornwell, B., Laumann, E. O. & Schumm, L. P. (2008). The social connectedness of 
older adults: A national profile. American Sociological Review, 73(2), 185–203.  
Corti, O., Lesage, S. & Brice, A. (2011). What genetics tells us about the causes and 
mechanisms of Parkinson’s disease. Physiological Reviews, 91(4), 1161–1218. 
Cote, L., Sprinzeles, L. L., Elliott, R. & Kutscher, A. H. (2000). Parkinson’s disease and 
quality of life. Loss and Care: A Journal of Professional Practice, 8(3–4). 
Cousineau, N., McDowell, I., Hotz, S. & Herbert, P. (2003). Measuring chronic 
patients’ feelings of being a burden to their caregivers: Development and 
preliminary validation of a scale. Medical Care, 41(1), 110–118. 
Cummins, R. (2005). Moving from the quality of life concept to a theory. Journal of 
Intellectual Disability Research, October 49 (part 10), 702–706. 
Curtin, M. & Lubkin, I. M. (1995). What is chronicity? In I. M. Lubkin (Ed.), Chronic 
illness: Impact and interventions (3rd ed., pp. 3–25). Boston: Jones & Bartlett. 
D’Amelio, M., Terruso, V., Palmeri, B., Di Benedetto, N., Famoso, G., Cottone, P., … 
Savettieri, G. (2009). Predictors of caregiver burden in partners of patients with 
Parkinson’s disease. Neurological Sciences, 30(2), 171–174. 
 253 
 
Davis, L. L., Gilliss, C. L., Deshefy-Longhi, T., Chestnutt, D. H. & Molloy, M. (2011). 
The nature and scope of stressful spousal caregiving relationships. Journal of 
Family Nursing, 17(2), 224–240. doi:10.1177/1074840711405666 
de Boer, A. G., Spruijt, R. J., Sprangers, M. A. & de Haes, J. C. (1998). Disease-
specific quality of life: Is it one construct? Quality of Life Research, 7(2), 135–
142. 
de Boer, A. G., Wijker, W., Speelman, J. D. & de Haes, J. C. (1996). Quality of life in 
patients with Parkinson’s disease: Development of a questionnaire. Journal of 
Neurological and Neurosurgical Psychiatry, 61, 70–74. 
de la Fuente‐Fernández, R., Schulzer, M., Kuramoto, L., Cragg, J., Ramachandiran, N., 
Au, W. L., . . . Sossi, V. (2011). Age‐specific progression of nigrostriatal 
dysfunction in Parkinson's disease. Annals of Neurology, 69(5), 803-810. 
Deloitte Access Economics. (2011). Living with Parkinson's Disease - update October 
2011: Parkinson's Australia. 
Del Tredici, K. & Braak, H. (2012). Lewy pathology and neurodegeneration in 
premotor Parkinson’s disease. Movement Disorders, 27(5), 597–607. 
doi:10.1002/mds.24921 
Dentzer, S. & Metz, D. E. (2009). Reorganizing chronic care delivery. Health Affairs, 
28(1), 63. doi:10.1377/hlthaff.28.1.63 
Denzin, N. (2009). The research act: A theoretical introduction to sociological 
methods. New York: Aldine De Gruyter. 
Department of Health and Ageing. (2011). Bladder and bowel. Canberra: Australian 
Government Department of Health and Ageing. Retrieved from 
http://www.bladderbowel.gov.au/ 
 254 
 
Depp, C. A. & Jeste, D. V. (2009). Definitions and predictors of successful aging: A 
comprehensive review of larger quantitative studies. Focus, 7 (1), 137–150. 
Derost, P. P., Ouchchane, L., Morand, D., Ulla, M., Llorca, P. M., Barget, M., … Durif, 
F. (2007). Is DBS-STN appropriate to treat severe Parkinson disease in an 
elderly population? Neurology, 68(17), 1345–1355. 
Diamond, S. G. & Markham, C. H. (1983). Evaluating the evaluations: Or how to weigh 
the scales of Parkinsonian disability. Neurology, 33(8), 1098. 
Dmochowski, R. R. & Gomelsky, A. (2011). Urinary incontinence in the aging female: 
Etiology, pathophysiology and treatment options. Aging Health, 7(1), 79. 
Dooley, Y., Kenton, K., Cao, G., Luke, A., Durazo-Arvizu, R., Kramer, H. & Brubaker, 
L. (2008). Urinary incontinence prevalence: Results from the national health and 
nutrition examination survey. Journal of Urology, 179(2), 656–661. 
Doughty, D. (2006). Urinary and fecal incontinence, current management concepts (3rd 
ed.). St. Louis, Missouri: Mosby Elsevier Health. 
Driscoll, D. L., Appiah-Yeboah, A., Salib, P., & Rupert, D. J. (2007). Merging 
Qualitative and Quantitative Data in Mixed Methods Research: How To and 
Why Not Ecological and Environmental Anthropology (University of Georgia), 
3(1). doi: http://digitalcommons.unl.edu/icwdmeea/18 
Duggan, A., Bradshaw, Y. S., & Altman, W. (2010). How do I ask about your 
disability? An examination of interpersonal communication processes between 
medical students and patients with disabilities. Journal of Health 
Communication, 15(3), 334-350.  
 255 
 
Dusek, P., Buskova, J., Ruzicka, E., Majerova, V., Srp, A., Jech, R., … Sonka, K. 
(2010). Effects of ropinirole prolonged-release on sleep disturbances and 
daytime sleepiness in Parkinson disease. Clinical Neuropharmacology, 33(4), 
186–190. 
Edwards, N. & Jones, D. (2001). The prevalence of faecal incontinence in older people 
living at home. Age and Ageing, 30(6), 503. 
Elenskaia, K., Haidvogel, K., Heidinger, C., Doerfler, D., Umek, W. & Hanzal, E. 
(2011). The greatest taboo: Urinary incontinence as a source of shame and 
embarrassment. Wiener Klinische Wochenschrift, 123(19–20), 607–610. 
Ellgring, H., Seiler, S., Perleth, B., Frings, W., Gasser, T. & Oertel, W. (1993). 
Psychosocial aspects of Parkinson’s disease. Neurology, 43(12, Suppl 6), S41. 
Ellis, T., de Goede, C. J., Feldman, R. G., Wolters, E. C., Kwakkel, G. & Wagenaar, R. 
C. (2005). Efficacy of a physical therapy program in patients with Parkinson’s 
disease: A randomized controlled trial. Archives of Physical Medicine and 
Rehabilitation, 86(4), 626–632. 
Elo, S., & Kyngäs, H. (2008). The qualitative content analysis process. Journal of 
Advanced Nursing, 62(1), 107-115. 
Eng, M. L., Lyons, K. E., Greene, M. S., Pahwa, R., Eng, M. L., Lyons, K. E., … 
Pahwa, R. (2006). Open-label trial regarding the use of acupuncture and yin tui 
na in Parkinson’s disease outpatients: A pilot study on efficacy, tolerability, and 
quality of life. Journal of Alternative and Complementary Medicine, 12(4), 395–
399. 
Engstrom, B. & Nordeson, A. (1995). What neurological patients regard as quality of 
life. Journal of Clinical Nursing, May, 4(3), 177–183. 
 256 
 
Esbensen, B. A., Thomé, B. & Thomsen, T. (2012). Dependency in elderly people 
newly diagnosed with cancer: A mixed-method study. European Journal of 
Oncology Nursing, 16(2), 137–144. 
Esselink, R. A., de Bie, R. M., de Haan, R. J., Steur, E. N., Beute, G. N., Portman, A. 
T., … Steur, E. N. H. J. (2006). Unilateral pallidotomy versus bilateral 
subthalamic nucleus stimulation in Parkinson’s disease: One year follow-up of a 
randomised observer-blind multi centre trial. Acta Neurochirurgica, 148(12), 
1247–1255. 
Evans, D. & Etienne, C. (2010). Health systems financing and the path to universal 
coverage. Bulletin of the World Health Organization [online], 88(6), 402–403. 
10.1590/S0042–96862010000600002 
Evatt, M. L., Chaudhuri, K. R., Chou, K. L., Cubo, E., Hinson, V., Kompoliti, K., … 
Goetz, C. G. (2009). Dysautonomia rating scales in Parkinson’s disease: 
Sialorrhea, dysphagia, and constipation—critique and recommendations by 
movement disorders task force on rating scales for Parkinson’s disease. 
Movement Disorders, 24(5), 635–646. 
Factor, S. A., Feustel, P. J., Friedman, J. H., Comella, C. L., Goetz, C. G., Kurlan, R., 
… Pfeiffer, R. (2003). Longitudinal outcome of Parkinson’s disease in patients 
with psychosis. Neurology, 60(11), 1756–1761. 
Fahn, S. & Elton, R. L. (1987). Members of the UPDRS Development Committee. The 
unified Parkinson’s disease rating scale. In S. Fahn, C. D. Marsden, D. B. Calne 
& M. Goldstein (Eds.), Recent Developments in Parkinson’s Disease (vol. 2, pp. 
153–163, 293–304). Florham Park, NJ: Macmillan Healthcare Information. 
 257 
 
Fahn, S. (2003). Description of Parkinson’s disease as a clinical syndrome. Annals of 
the New York Academy of Sciences, 991, 1–14. 
Farage, M., Miller, K., Berardesca, E. & Maibach, H. (2008). Psychosocial and societal 
burden of incontinence in the aged population: A review. Archives of 
Gynecology and Obstetrics, 277(4), 285–290. 
Fässberg, M. M., Orden, K. A. v., Duberstein, P., Erlangsen, A., Lapierre, S., Bodner, 
E., … Waern, M. (2012). A systematic review of social factors and suicidal 
behavior in older adulthood. International Journal of Environmental Research 
and Public Health, 9(3), 722–745. 
Federal Interagency Forum on Aging-Related Statistics. (2010). Older Americans: Key 
indicators of well-being. Washington, DC: U.S. Government Printing Office. 
Flynn, K. E., Smith, M. A., & Freese, J. (2006). When do older adults turn to the 
internet for health information? Findings from the Wisconsin Longitudinal 
Study. Journal of General Internal Medicine, 21(12), 1295-1301. 
Ferreira-Valente, M. A., Pais-Ribeiro, J. L., & Jensen, M. P. (2011). Validity of four 
pain intensity rating scales. Pain, 152(10), 2399-2404. 
Fitzgerald, S. T., Palmer, M. H., Berry, S. J. & Hart, K. (2000). Urinary incontinence. 
Impact on working women. American Association of Occupational Health 
Nurses Journal, 48(3), 112–118. 
Fitzpatrick, R., Norquist, J. M., Jenkinson, C., Fitzpatrick, R., Norquist, J. M. & 
Jenkinson, C. (2004). Distribution-based criteria for change in health-related 
quality of life in Parkinson’s disease. Journal of Clinical Epidemiology, 57(1), 
40–44. 
 258 
 
Fleming, A., Cook, K. F., Nelson, N. D. & Lai, E. C. (2005). Proxy reports in 
Parkinson’s disease: Caregiver and patient self-reports of quality of life and 
physical activity. Movement Disorders, 20(11), 1462–1468. 
Flick, U. (1992). Triangulation revisited: Strategy of validation or alternative? Journal 
for the Theory of Social Behaviour, 22(2), 175–197. 
Fontenla, M. & Gould, D. (2003). Young people with Parkinson’s disease: Report of a 
pilot study to identify the research issues and approaches to data collection... 
including commentary by Freshwater D. Northern Territory Research, 8(3), 
213–227. 
Forsaa, E. B., Larsen, J. P., Wentzel-Larsen, T., Herlofson, K., Alves, G., Forsaa, E. B., 
… Alves, G. (2008). Predictors and course of health-related quality of life in 
Parkinson’s disease. Movement Disorders, 23(10), 1420–1427. 
Forsaa, E., Larsen, J., Wentzel-Larsen, T. & Alves, G. (2010). What predicts mortality 
in Parkinson disease?: A prospective population-based long-term study. 
Neurology, 75(14), 1270–1276. doi:10.1212/WNL.0b013e3181f61311 
Fowler, C. J., Sakakibara, R., Frohman, E. M., Brady, C. M. & Stewart, J. D. (2007). 
Neurologic bladder, bowel and sexual dysfunction. World Federation of 
Neurology Seminars in Clinical Neurology. Retrieved 27 February 2012, from 
http://www.wfneurology.org 
Franchignoni, F., Giordano, A., Ferriero, G., Franchignoni, F., Giordano, A. & Ferriero, 
G. (2008). Rasch analysis of the short form 8-item Parkinson’s disease 
questionnaire (PDQ-8). Quality of Life Research, 17(4), 541–548. 
Francis, J., Johnston, M., Robertson, C., Glidewell, L., Entwistle, V., Eccles, M. P. & 
Grimshaw, J. M. (2010). What is an adequate sample size? Operationalising data 
 259 
 
saturation for theory-based interview studies. Psychology and Health, 25(10), 
1229–1245. doi:10.1080/08870440903194015 
Frick, A. C., Huang, A. J., Van den Eeden, S. K., Knight, S. K., Creasman, J. M., Yang, 
J., … Brown, J. S. (2009). Mixed urinary incontinence: Greater impact on 
quality of life. Journal of Urology, 182(2), 596–600. doi:S0022–
5347(09)00890–8 [pii] 10.1016/j.juro.2009.04.005 
Fritel, X., Panjo, H., Varnoux, N., & Ringa, V. (2013). The individual determinants of 
care-seeking among middle-aged women reporting urinary incontinence: 
Analysis of a 2273-woman cohort. Neurourology and Urodynamics, HAL 
(Hyper Articles en Ligne).  doi: 10.1002/nau.22461 
Frosch, D. L., May, S. G., Rendle, K. A. S., Tietbohl, C., & Elwyn, G. (2012). 
Authoritarian Physicians and Patients' Fear Of Being Labeled 'Difficult' Among 
Key Obstacles To Shared Decision Making. Health Affairs, 31(5), 1030-1038. 
Fuller, E., Welch, J., Backer, J. & Rawl, S. (2005). Symptom experience of chronically 
constipated women with pelvic floor disorders. Clinical Nurse Specialist, 19 
(January/February), 34–40. 
Gage, H., Hendricks, A., Zhang, S. & Kazis, L. (2003). The relative health related 
quality of life of veterans with Parkinson’s disease. Journal of Neurology,74(2), 
163–169. 
Gallagher, D., Lees, A. J. & Schrag, A. (2010). What are the most important nonmotor 
symptoms in patients with Parkinson’s disease and are we missing them? 
Movement Disorders, 25(15), 2493–2500. doi:10.1002/mds.23394 
 260 
 
Gallagher, R., Donoghue, J., Chenoweth, L. & Stein-Parbury, J. (2008). Self-
management in older patients with chronic illness. International Journal of 
Nursing Practice, 14(5), 373–382. 
Gao, X., Chen, H., Schwarzschild, M. A. & Ascherio, A. (2011). A prospective study of 
bowel movement frequency and risk of Parkinson’s disease. American Journal 
of Epidemiology, 174(5), 546–551. doi:10.1093/aje/kwr119 
Garber, C. E. & Friedman, J. H. (2003). Effects of fatigue on physical activity and 
function in patients with Parkinson’s disease. Neurology, 60(7), 1119–1124. 
Garin, O., Ayuso-Mateos, J. L., Almansa, J., Nieto, M., Chatterji, S., Vilagut, G., … 
Burger, H. (2010). Research validation of the ‘World Health Organization 
Disability Assessment Schedule, WHODAS-2’ in patients with chronic diseases. 
Health and Quality of Life Outcomes, 8, 51. doi:10.1186/1477-7525-8-51 
Gaudet, P. (2002). Measuring the impact of Parkinson’s disease: an occupational 
therapy perspective. Canadian Journal of Occupational Therapy, 69(2), 104–
113. 
Getliffe, K. & Dolman, M. (Eds.). (2007). Promoting continence: A clinical and 
research resource (3rd ed.). London: Churchill Livingstone Elsevier. 
Gillingham, F. J. & Donaldson, M. C. (Eds.). (1969). Schwab and England activities of 
daily living. In  Third Symposium of Parkinson’s Disease (pp. 152–157). 
Edinburgh, Scotland: E & S Livingstone. 
Giordano, J. A. (1988). Parents of the baby boomers: A new generation of young-old. 
Family Relations, 37(4), 411–414. doi:10.2307/584112 
 261 
 
Glazener, C. M. & Lapitan, M. C. (2002). Urodynamic investigations for management 
of urinary incontinence in adults [Review]. Cochrane Database of Systematic 
Reviews, 3. 
Glueckauf, R. L. & Ketterson, T. U. (2004). Telehealth interventions for individuals 
with chronic illness: Research review and implications for practice. Professional 
Psychology Research and Practice December, 35(6), 615–627. 
Goetz, C., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G., Counsell, C., … Seidl, L. 
(2004). Movement Disorder Society Task Force report on the Hoehn and Yahr 
staging scale: Status and recommendations. The Movement Disorder Society 
Task Force on rating scales for Parkinson’s disease. Movement Disorders, 19(9), 
1020–1028. 
Gómez -Esteban, J. C., Zarranz, J. J., Tijero, B., Velasco, F., Barcena, J., Rouco, I., … 
Ugarte, A. (2007). Restless legs syndrome in Parkinson’s disease. Movement 
Disorders, 22(13), 1912–1916. 
Gómez-Esteban, J., Zarranz, J., Lezcano, E., Tijero, B., Luna, A., F.Velasco, … 
Garamendi, I. (2007). Influence of motor symptoms upon the quality of life of 
patients with Parkinson’s disease. European Neurology, 57(3), 161–165. 
doi:10.1159/000098468 
Graycar, A. (Ed.). (1983). Retreat from the welfare state: Australian social policy in the 
1980s. North Sydney: George Allen & Unwin. 
Greer, J., Arya, L., & Smith, A. (2013). Urinary Incontinence: Diagnosis and Treatment 
in the Elderly. Current Translational Geriatrics and Experimental Gerontology 
Reports, 1-10. doi: 10.1007/s13670-013-0037-6 
 262 
 
Griebling, T. (2008). Predictors of urinary and fecal continence status after stroke. 
Master’s thesis, University of Kansas, United States. Retrieved from 
http://ezproxy.library.usyd.edu.au/login?url=http://proquest.umi.com/pqdweb?di
d=1605148201&Fmt=7&clientId=16331&RQT=309&VName=PQD 
Hagell, P. & Nilsson, M. H. (2009). The 39-item Parkinson’s disease questionnaire 
(PDQ-39): Is it a unidimensional construct? Therapeutic Advances in 
Neurological Disorders, 2(4), 205–214. doi:10.1177/1756285609103726 
Hagell, P. & Nygren, C. (2007). The 39 item Parkinson’s disease questionnaire (PDQ-
39) revisited: Implications for evidence based medicine. Journal of Neurology, 
Neurosurgery and Psychiatry, 78(11), 1191–1198. 
Hagell, P., Whalley, D., McKenna, S. & Lindvall, O. (2003). Health status measurement 
in Parkinson’s disease: Validity of the PDQ-39 and Nottingham Health Profile. 
Movement Disorders, 18(7), 773–783. 
Hannestad, Y., Rortveit, G., Sandvik, H. & Hunskaar, S. (2000). A community-based 
epidemiological survey of female urinary incontinence: The Norwegian 
EPINCONT study. Journal of Clinical Epidemiology, 53(11), 1150–1157. 
Harwood T.G. & Garry T. (2003) An overview of content analysis. The Marketing 
Review 3, 479–498. 
Harari, D., Norton, C., Lockwood, L. & Swift, C. (2004). Treatment of constipation and 
fecal incontinence in stroke patients: Randomized controlled trial. Stroke, 
35(11), 2549–2555. doi:10.1161/01.str.0000144684.46826.62 
Hassan, A., Wu, S. S., Schmidt, P., Malaty, I. A., Dai, Y. F., Miyasaki, J. M. & Okun, 
M. S. (2012). What are the issues facing Parkinson’s disease patients at ten years 
 263 
 
of disease and beyond?: Data from the NPF-QII study. Parkinsonism and 
Related Disorders, 18(Suppl 3), S10–14. 
Hatano, T., Kubo, S. I., Shimo, Y., Nishioka, K. & Hattori, N. (2009). Unmet needs of 
patients with Parkinson’s disease: Interview survey of patients and caregivers. 
Journal of International Medical Research, 37(3), 717–726. 
Hatfield, J. P., Hirsch, J. K. & Lyness, J. M. (2013). Functional impairment, illness 
burden, and depressive symptoms in older adults: Does type of social 
relationship matter? International Journal of Geriatric Psychiatry, 28(2), 190–
198. 
Hawkes, C. (2008). Parkinson’s disease and aging: Same or different process? 
Movement Disorders, 23(1), 47–53. 
Hawkes, C. H., Del Tredici, K. & Braak, H. (2010). A timeline for Parkinson’s disease. 
Parkinsonism and Related Disorders, 16(2), 79–84. 
Hawthorne, G. (2006). Measuring incontince in Australia: A project of the National 
Continence Management Strategy: An Australian Government initiative. 
Canberra, ACT: Commonwealth of Australia. 
Haynes, D. F. & Watt, P. J. (2008). The lived experience of healthy behaviors in people 
with debilitating illness. Holistic Nursing Practice, 22(1), 44–53. 
Heidrich, S. M. & Wells, T. J. (2004). Effects of urinary incontinence: Psychological 
well-being and distress in older community-dwelling women. Journal of 
Gerontological Nursing May, 30(5), 47–54. 
Hely, M. A., Morris, J. G. L., Traficante, R., Reid, W. G. J., O’Sullivan, D. J. & 
Williamson, P. M. (1999). The Sydney multicentre study of Parkinson’s disease: 
 264 
 
Progression and mortality at 10 years. Journal of Neurology, Neurosurgery and 
Psychiatry, 67(3), 300–307. doi:10.1136/jnnp.67.3.300 
Hernán, M. A., Chen, H., Schwarzschild, M. A. & Ascherio, A. (2003). Alcohol 
consumption and the incidence of Parkinson’s disease. Annals of Neurology, 
54(2), 170–175. 
Hernán, M., Takkouche, B., Caamaño-Isorna, F. & Gestal-Otero, J. (2002). A meta-
analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s 
disease. Annals of Neurology, 52(3), 276–284. 
Higa, R., Lopes, M. & D’Ancona, C. (2013). Male incontinence: A critical review of 
the literature. Texto and Contexto-Enfermagem, 22(1), 231–238. 
Higashi, R. T., Tillack, A. A., Steinman, M., Harper, M. & Johnston, C. B. (2012). 
Elder care as ‘frustrating’ and ‘boring’: Understanding the persistence of 
negative attitudes toward older patients among physicians-in-training. Journal of 
Aging Studies, 26(4), 476–483. 
Hildon, Z., Smith, G., Netuveli, G. & Blane, D. (2008). Understanding adversity and 
resilience at older ages. Sociology of Health and Illness, 30(5), 726–740. 
doi:10.1111/j.1467–9566.2008.01087.x 
Hillen, M. & Sage, J. (1996). Nonmotor fluctuations in patients with Parkinson’s 
disease. Neurology November, 47(5), 1180–1183. 
Hillermann, J. (2008). ABS approach to collecting disability data and relationship to the 
ICF: A joint paper by the ABS and the AIHW. Retrieved 2 September 2013, 
from http://www.cdc.gov/nvh/about/otheract/citygroup/products/hillermann.htm 
 265 
 
Hinnell, C., Hurt, C. S., Landau, S., Brown, R. G. & Samuel, M. (2012). Nonmotor 
versus motor symptoms: How much do they matter to health status in 
Parkinson’s disease? Movement Disorders, 27(2), 236–241. 
Hjermstad, M. J., Fayers, P. M., Haugen, D. F., Caraceni, A., Hanks, G. W., Loge, J. H., 
. . . Kaasa, S. (2011). Studies comparing Numerical Rating Scales, Verbal 
Rating Scales, and Visual Analogue Scales for assessment of pain intensity in 
adults: a systematic literature review. Journal of pain and symptom 
management, 41(6), 1073-1093.  
Hoehn, M. & Yahr, M. (1967). Parkinsonism: Onset, progression and mortality. 
Neurology, 17 (5), 427–442. 
Holroyd-Leduc, J. M., Mehta, K. M. & Covinsky, K. E. (2004). Urinary incontinence 
and its association with death, nursing home admission and functional decline. 
Journal of the American Geriatrics Society, 52(5), 712–718. 
Horrocks, S., Somerset, M., Stoddart, H., & Peters, T. J. (2004). What prevents older 
people from seeking treatment for urinary incontinence? A qualitative 
exploration of barriers to the use of community continence services. Family 
Practice, 21(6), 689-696. doi: 10.1093/fampra/cmh622 
Hoskins, C. N. & Mariano, C. (2004). Research in nursing and health: Understanding 
and using quantitative and qualitative methods (2nd ed.). New York: Springer 
Publishing Company. 
Hu, M., Cooper, J., Beamish, R., Jones, E., Butterworth, R., Catterall, L. & Ben-
Shlomo, Y. (2011). How well do we recognise non-motor symptoms in a British 
Parkinson’s disease population? Journal of Neurology, 258(8), 1513–1517. 
doi:10.1007/s00415–011–5972–6 
 266 
 
Huang, P. (2009). Social behavior, gender, and quality of life in Parkinson’s disease. 
Doctoral thesis, Boston University, United States. Retrieved from 
http://ezproxy.library.usyd.edu.au/login?url=http://proquest.umi.com/pqdweb?di
d=1792342071&Fmt=7&clientId=16331&RQT=309&VName=PQD 
Hurlow, J. (2007). ICD code for functional urinary incontinence. Journal of Wound 
Ostomy and Continence Nursing, 34(5), 473–474. 
doi:10.1097/01.WON.0000290721.78927.6400152192–200709000–00003 [pii] 
Hyde, M., Wiggins, R. D., Higgs, P. & Blane, D. B. (2003). A measure of quality of life 
in early old age: The theory, development and properties of a needs satisfaction 
model (CASP-19). Aging and Mental Health, 7(3), 186–194. 
Iacovelli, E., Gilio, F., Meco, G., Fattapposta, F., Vanacore, N., Brusa, L., … Inghilleri, 
M. (2010). Bladder symptoms assessed with overactive bladder questionnaire in 
Parkinson’s disease. Movement Disorders, 25(9), 1203–1209. 
doi:10.1002/mds.23093 
Ironside, P. M., Scheckel, M., Wessels, C., Bailey, M., Powers, S. & Seeley, D. (2003). 
Experiencing chronic illness: Co-creating new understandings. Qualitative 
Health Research, 13(2), 171–183. 
Irwin, D. E., Kopp, Z. S., Agatep, B., Milsom, I. & Abrams, P. (2011). Worldwide 
prevalence estimates of lower urinary tract symptoms, overactive bladder, 
urinary incontinence and bladder outlet obstruction. British Journal of Urology 
International, 108(7), 1132–1138. 
Irwin, D., Abrams, P., Milsom, I., Kopp, Z. & Reilly, K. (2008). Understanding the 
elements of overactive bladder: Questions raised by the EPIC study. British 
 267 
 
Journal of Urology International, 101, 1381–1387. doi:10.1111/j.1464–
410X.2008.07573.x 
Jellinger, K. A. (2009). Non-motor symptoms of Parkinson’s disease. European Journal 
of Neurology, 16(9), e168-e168. doi:10.1111/j.1468–1331.2009.02771.x 
Jenkinson, C., Fitzpatrick, R. & Petro, V. (1998). The Parkinson’s disease 
questionnaire: user manual for the PDQ-39, PDQ-8 and PDQ summary index. 
Oxford University: Health Services Research Unit–Department of Public Health. 
Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R. & Hyman, N. (1997a). The 
Parkinson’s disease questionnaire (PDQ-39): Development and validation of a 
Parkinson’s disease summary index score. Age and Ageing, 26, 353–357. 
Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R. & Hyman, N. (1997b). The PDQ-
8: Development and validation of a short-form Parkinson’s disease 
questionnaire. Psychological Health, 12, 805–814. 
Jenkinson, C., Peto, V., Fitzpatrick, R., Greenhall, R. & Hyman, N. (1995). Self-
reported functioning and well-being in patients with Parkinson’s disease: 
Comparison of the short-form health survey (SF-36) and the Parkinson’s disease 
questionnaire (PDQ-39). Age and Ageing, 24(6), 505. 
Jeste, D. V., Depp, C. A. & Vahia, I. V. (2010). Successful cognitive and emotional 
aging. World Psychiatry, 9(2), 78–84. 
Jiang, Y. & Hesser, J. E. (2012). Using disability-adjusted life years to assess the 
burden of disease and injury in Rhode Island. Public Health Reports, 127(3), 
293–303. 
Johnstone, P. L. (2004). Mixed methods, mixed methodology health services research in 
practice. Qualitative Health Research, 14(2), 259–271. 
 268 
 
Jones, R. N., Marcantonio, E. R. & Rabinowitz, T. (2003). Prevalence and correlates of 
recognized depression in US nursing homes. Journal of the American Geriatrics 
Society, 51(10), 1404–1409. 
Jorge, J., Marcio, N. & Wexner, S. (1993). Etiology and management of fecal 
incontinence. Diseases of the Colon and Rectum, 36(1), 77–97. 
doi:10.1007/bf02050307 
Kalf, J., Bloem, B., & Munneke, M. (2012). Diurnal and nocturnal drooling in 
Parkinson’s disease. Journal of Neurology, 259(1), 119-123.  
Kaye, J., Gage, H., Kimber, A., Storey, L. & Trend, P. (2006). Excess burden of 
constipation in Parkinson’s disease: A pilot study. Movement Disorders, 21(8), 
1270–1273. doi:10.1002/mds.20942 
Keegan, W. (2012). Just put a pad on: Where is the dignity in that? Nursing and 
Residential Care, 14(3), 128–133. 
Kepenekci, I., Keskinkilic, B., Akinsu, F., Cakir, P., Elhan, A. H., Erkek, A. B. & Kuzu, 
M. A. (2011). Prevalence of pelvic floor disorders in the female population and 
the impact of age, mode of delivery, and parity. Diseases of the Colon and 
Rectum, 54(1), 85–94. 
Khan, F., Pallant, J. F., Shea, T. L. & Whishaw, M. (2009). Multiple sclerosis: 
Prevalence and factors impacting bladder and bowel function in an Australian 
community cohort. Disability Rehabilitation, 31(19), 1567–1576. 
doi:10.1080/09638280802639566 [pii] 
Kidd, P. M. (2000). Parkinson’s disease as multifactorial oxidative neurodegeneration: 
Implications for integrative management. Alternative Medicine Review, 5(6), 
502–529. 
 269 
 
Kim, K. S., Kim, B. J., Kim, K. H., Choe, M.-A., Yi, M., Hah, Y.-S., … Kwon, S.-H. 
(2007). Subjective and objective caregiver burden in Parkinson’s disease. 
Daehan Ganho Haghoeji, 37(2), 242–248. 
King, G., Willoughby, C., Specht, J. A. & Brown, E. (2006). Social support processes 
and the adaptation of individuals with chronic disabilities. Qualitative Health 
Research, 16(7), 902–925. 
King, J., Yourman, L., Ahalt, C., Eng, C., Knight, S. J., Pérez-Stable, E. J. & Smith, A. 
K. (2012). Quality of life in late life disability: ‘I don’t feel bitter because I am 
in a wheelchair’. Journal of the American Geriatrics Society, 60(3), 569–576. 
Kishi, M., Ogawa, E., Sakakibara, R., Tateno, F., Uchiyama, T., Yamamoto, T. & 
Yamanishi, T. (2011). Bladder, bowel, and sexual dysfunction in Parkinson’s 
disease. Parkinson’s Disease. doi: 10.4061/2011/924605 
Koller, W. C. & Rueda, M. G. (1998). Mechanism of action of dopaminergic agents in 
Parkinson’s disease. Neurology June, 50(6), S11–S14. 
Kraus, S. R., Bavendam, T., Brake, T. & Griebling, T. L. (2010). Vulnerable elderly 
patients and overactive bladder syndrome. Drugs and Aging, 27(9), 697–713. 
doi:10.2165/11539020–000000000–00000 
Krikmann, U., Taba, P., Lai, T. & Asser, T. (2008). Validation of an Estonian version of 
the Parkinson’s disease questionnaire (PDQ-39). Health and Quality of Life 
Outcomes, 6, 23. 
Krippendorff K. (1980) Content Analysis: An Introduction to its Methodology. Sage 
Publications, Newbury Park. 
 270 
 
Krishnan, S., Sarma, G., Sarma, S. & Kishore, A. (2011). Do nonmotor symptoms in 
Parkinson’s disease differ from normal aging? Movement Disorders, 26(11), 
2110–2113. doi:10.1002/mds.23826 
Kristensson, K. (2006). Avian influenza and the brain: Comments on the occasion of 
resurrection of the Spanish flu virus. Brain Research Bulletin, 68(6), 406–413. 
Kumar, K. R., Lohmann, K. & Klein, C. (2012). Genetics of Parkinson disease and 
other movement disorders. Current Opinion in Neurology, 25(4), 466–474. 
Kurita, G. P., & de Mattos Pimenta, C. A. (2008). Cognitive impairment in cancer pain 
patients receiving opioids: a pilot study. Cancer Nursing, 31(1), 49-57. 
Lachowsky, M. (2000). Urinary problems around the menopause; emotional and 
psychological consequences; can we help our patients to cope with them? 
Maturitas, 34, S25–27. 
Lamontagne, M.-E., Poncet, F., Careau, E., Sirois, M.-J. & Boucher, N. (2013). Life 
habits performance of individuals with brain injury in different living 
environments. Brain Injury, 27(2), 135–144. 
Landefeld, C. S., Bowers, B. J., Feld, A. D., Hartmann, K. E., Hoffman, E., Ingber, M. 
J., … Trock, B. J. (2008). National Institutes of Health state-of-the-science 
conference statement: prevention of fecal and urinary incontinence in adults. 
Annals of Internal Medicine, 148(6), 449–458. 
Landefeld, S., Bowers, B. J., Feld, A. D., Hartmann, K. E., Hoffman, E., Ingber, M. J., 
… Trock, B. J. (2007). NIH state-of-the-science conference statement on 
prevention of fecal and urinary incontinence in adults. NIH Consensus and State 
of Science Statements, 24(1), 1–37. doi:2007–00030-STMT [pii] 
 271 
 
Lapitan, M. C. & Chye, P. L. (2001). The epidemiology of overactive bladder among 
females in Asia: A questionnaire survey. International Urogynecology Journal, 
12(4), 226–231. 
Lebouvier, T., Chaumette, T., Paillusson, S., Duyckaerts, C., Varannes, S., Neunlist, M. 
& Derkinderen, P. (2009 ). The second brain and Parkinson’s disease. European 
Journal of Neuroscience, 30, 735–741. doi:10.1111/j.1460–9568.2009.06873.x 
Lederman R.P. (1991) Content analysis of word texts. MCN. The American Journal of 
Maternal Child Nursing 16, 169. 
Leech, N. & Onwuegbuzie, A. (2007). An array of qualitative data analysis tools: A call 
for data analysis triangulation. School Psychology Quarterly, 22(4), 557. 
Lees, A. (2010). The bare essentials: Parkinson’s disease. Practical Neurology, 10(4), 
240–246. doi:10.1136/jnnp.2010.217836 
Lees, A. (2012). The relevance of the Lewy body to the pathogenesis of idiopathic 
Parkinson’s disease: Accuracy of clinical diagnosis of idiopathic Parkinson’s 
disease. Journal of Neurology, Neurosurgery and Psychiatry, 83(10), 954–955. 
doi:10.1136/jnnp-2012–302969 
Lees, A. J. (2007). Unresolved issues relating to the shaking palsy on the celebration of 
James Parkinson’s 250th birthday. Movement Disorders, 22(S17), S327–S334. 
Leibner, J., Ramjit, A., Sedig, L., Dai, Y., Wu, S. S., Jacobson IV, C., . . . Fernandez, H. 
H. (2010). The impact of and the factors associated with drooling in Parkinson's 
disease. Parkinsonism & Related Disorders, 16(7), 475-477. 
Leroi, A. M. (2011). The role of sacral neuromodulation in double incontinence 
[Review]. Colorectal Disease, 2, 15–18. doi:10.1111/j.1463–1318.2010.02520.x 
 272 
 
Leung, F. W. & Schnelle, J. F. (2008). Urinary and fecal incontinence in nursing home 
residents. Gastroenterology Clinics of North America, 37(3), 697–707. 
Levasseur, M., Desrosiers, J. & Noreau, L. (2004). Is social participation associated 
with quality of life of older adults with physical disabilities? Disability and 
Rehabilitation, 26(20), 1206–1213. 
Li, H., Zhang, M., Chen, L., Zhang, J., Pei, Z., Hu, A. & Wang, Q. (2010). Nonmotor 
symptoms are independently associated with impaired health-related quality of 
life in Chinese patients with Parkinson’s disease. Movement Disorders, 25(16), 
2740–2746. doi:10.1002/mds.23368 
Liang, J., Wang, C.-N., Xu, X., Hsu, H.-C., Lin, H.-S. & Lin, Y.-H. (2010). Trajectory 
of functional status among older Taiwanese: Gender and age variations. Social 
Science and Medicine, 71(6), 1208–1217. doi:10.1016/j.socscimed.2010.05.007 
Lim, S. Y. & Lang, A. E. (2010). The nonmotor symptoms of Parkinson’s disease—an 
overview [Review]. Movement Disorders, 25(1), S123–130. 
Lim, S.-Y., Fox, S. H. & Lang, A. E. (2009). Overview of the extranigral aspects of 
Parkinson disease. Archives of Neurology, 66(2), 167–172. 
doi:10.1001/archneurol.2008.561 
Linden, M. & Kurtz, G. (2010). A randomised controlled experimental study on the 
influence of patient age on medical decisions in respect to the diagnosis and 
treatment of depression in the elderly. Current Gerontology and Geriatrics 
Research, 2009. doi:10.1155/2009/475958 
Liu, R., Guo, X., Park, Y. C., Huang, X., Sinha, R., Freedman, N., … Chen, H. (2012). 
Caffeine intake, smoking, and risk of Parkinson disease in men and women. 
American Journal of Epidemiology, 175(11), 1200–1207. 
 273 
 
Lord, S. R., March, L. M., Cameron, I. D., Cumming, R. G., Schwarz, K., Zochling, J., 
… Sambrook, P. N. (2003). Differing risk factors for falls in nursing home and 
intermediate-care residents who can and cannot stand unaided. Journal of the 
American Geriatrics Society, 51(11), 1645–1650. 
Lukacz, E. S., Whitcomb, E. L., Lawrence, J. M., Nager, C. W. & Luber, K. M. (2009). 
Urinary frequency in community-dwelling women: What is normal? American 
Journal of Obstetrics and Gynecology, 200(5), 552–557. 
doi:10.1016/j.ajog.2008.11.006 
Lunney, J. R., Lynn, J., Foley, D. J., Lipson, S. & Guralnik, J. M. (2003). Patterns of 
functional decline at the end of life. Journal of the American Medical 
Association, 289(18), 2387–2392. doi:10.1001/jama.289.18.2387 
Luo, W., Gui, X.-h., Wang, B., Zhang, W.-y., Ouyang, Z.-y., Guo, Y., . . . Ding, M.-p. 
(2010). Validity and reliability testing of the Chinese (mainland) version of the 
39-item Parkinson’s Disease Questionnaire (PDQ-39). Journal of Zhejiang 
University SCIENCE B, 11(7), 531-538. 
McCall, B. (2003). Young-onset Parkinson's disease: a guide to care and support. 
Nursing Times, 99(30), 28-31.  
Macmillan, A. K., Merrie, A. E., Marshall, R. J. & Parry, B. R. (2004 ). The prevalence 
of fecal incontinence in community-dwelling adults: A systematic review of the 
literature. Diseases of the Colon and Rectum, 47(8), 1341–1349. 
Malhotra, R. (2008). Expanding the frontiers of justice: Reflections on the theory of 
capabilities, disability rights, and the politics of global inequality. Socialism and 
Democracy, 22, 83–100. 
 274 
 
Marek, K., Jennings, D., Tamagnan, G. & Seibyl, J. (2008). Biomarkers for Parkison’s 
disease: Tools to assess Parkinson’s disease onset and progression. Annals of 
Neurology, 64(Suppl 1), S111–S121. 
Marengoni, A., Von Strauss, E., Rizzuto, D., Winblad, B. & Fratiglioni, L. (2009). The 
impact of chronic multimorbidity and disability on functional decline and 
survival in elderly persons: A community based, longitudinal study. Journal of 
Internal Medicine, 265(2), 288–295. 
Marinus, J., Visser, M. & Stiggelbout, A. M. (2004). Quality of life and Parkinson’s 
disease: A systematic comparison of disease-specific instruments. Nederlands 
Tijdschrift Voor Fysiotherapie, 114(3), 67–71. 
Marinus, J., Visser, M., Martínez-Martín, P., van Hilten, J. J. & Stiggelbout, A. M. 
(2003). A short psychosocial questionnaire for patients with Parkinson’s disease: 
The SCOPA-PS. Journal of Clinical Epidemiology, 56(1), 61–67. 
Marjama-Lyons, J. M. & Koller, W. C. (2001 ). Parkinson’s disease: Update in 
diagnosis and symptom management. Geriatrics, 56(8), 24–25. 
Marras, C., McDermott, M. P., Rochon, P. A., Tanner, C. M., Naglie, G. & Lang, A. E. 
(2008). Predictors of deterioration in health-related quality of life in Parkinson’s 
disease: Results from the DATATOP trial. Movement Disorders, 23(5), 653–
659. 
Marschall-Kehrel, D. (2004). Update on nocturia: The best of rest is sleep. Urology, 
64(6 Suppl 1), 21–24. 
Marshall, L. L. & Baliey, W. (2008). Urinary incontinence management in geriatric 
patients. Consultant Pharmacists, 23(9), 681–694. 
 275 
 
Martinez-Martin, P., Arroyo, S., Rojo-Abuin, J. M., Rodriguez-Blazquez, C., Frades, 
B., de Pedro Cuesta, J., … de Pedro Cuesta, J. (2008). Burden, perceived health 
status, and mood among caregivers of Parkinson’s disease patients. Movement 
Disorders, 23(12), 1673–1680. 
Martinez-Martin, P., Chaudhuri, K., Rojo-Abuin, J. M., Rodriguez-Blazquez, C., 
Alvarez-Sanchez, M., Arakaki, T., … Gershanik, O. (2013). Assessing the non‐
motor symptoms of Parkinson’s disease: MDS‐UPDRS and NMS scale. 
European Journal of Neurology, 23(10), 1428–1434. 
Martinez-Martin, P., Forjaz, M. J., Frades-Payo, B., Rusinol, A. B., Fernandez-Garcia, 
J. M., Benito-Leon, J., … Catalan, M. J. (2007). Caregiver burden in 
Parkinson’s disease. Movement Disorders, 22(7), 924–931. 
Martinez-Martin, P., Jeukens-Visser, M., Lyons, K. E., Rodriguez-Blazquez, C., Selai, 
C., Siderowf, A., … Schrag, A. (2011). Health-related quality-of-life scales in 
Parkinson’s disease: Critique and recommendations. Movement Disorders, 
26(13), 2371–2380. doi:10.1002/mds.23834 
Martinez-Martin, P., Prieto, L. & Forjaz, M. (2006). Longitudinal metric properties of 
disability rating scales for Parkinson’s disease. Value in Health, 9(6), 386–393. 
Martinez-Martin, P., Rodriguez-Blazquez, C. & Forjaz, M. J. (2012). Quality of life and 
burden in caregivers for patients with Parkinson’s disease: Concepts, assessment 
and related factors. Expert Review of Pharmacoeconomics and Outcomes 
Research, 12(2), 221–230. doi:10.1586/erp.11.106 
Martinez-Martin, P., Rodriguez-Blazquez, C., K. Abe, K.B. Bhattacharyya, B.R. Bloem, 
F.J. Carod-Artal, … K.R. Chaudhuri. (2009). International study on the 
 276 
 
psychometric attributes of the non-motor symptoms scale in Parkinson disease. 
Neurology, 73, 1584–1591 
Martinez-Martin, P., Serrano-Dueñas, M. & Vaca-Baquero, V. (2005). Psychometric 
characteristics of the Parkinson’s disease questionnaire (PDQ-39)—Ecuadorian 
version. Parkinsonism and Related Disorders, 11(5), 297–304. 
Martinez-Martin, P., Serrano-Dueñas, M., Forjaz, M. & Serrano, M. (2007). Two 
questionnaires for Parkinson’s disease: Are the PDQ-39 and PDQL equivalent? 
Quality of Life Research, 16(7), 1221–1230. 
Martire, L. M., Lustig, A. P., Schulz, R., Miller, G. E. & Helgeson, V. S. (2004). Is it 
beneficial to involve a family member? A meta-analysis of psychosocial 
interventions for chronic illness. Health Psychology, 23(6), 599–611. 
Maserejian, N. N., Kupelian, V., McVary, K. T., Doshi, M., Link, C. & McKinlay, J. 
(2011). Prevalence of post-micturition symptoms in association with lower 
urinary tract symptoms and health-related quality of life in men and women. 
British Journal of Urology International, 108(9), 1452–1458. 
Mathison, S. (1988). Why triangulate? Educational researcher, 17(2), 13. 
McCall, B. (2003). Young-onset Parkinson's disease: a guide to care and support. 
Nursing Times, 99(30), 28-31.  
McCaffery, M., & Beebe, A. (1993). Pain: Clinical Manual for Nursing Practice. 
Baltimore: V.V. Mosby Company. 
McGuire, T., Wells, K. B., Bruce, M. L., Miranda, J., Scheffler, R., Durham, M., … 
Lewis, L. (2002). Burden of illness. Mental Health Services Research, 4(4), 
179–185. 
 277 
 
McKie, J., Shrimpton, B., Hurworth, R., Bell, C., & Richardson, J. (2008). Who should 
be involved in health care decision making? A qualitative study. Health Care 
Analysis, 16(2), 114-126. 
McLaughlin, D., Hasson, F., Kernohan, W. G., Waldron, M., McLaughlin, M., 
Cochrane, B. & Chambers, H. (2011). Living and coping with Parkinson’s 
disease: perceptions of informal carers. Palliative Medicine, 25(2), 177–182. 
doi:10.1177/0269216310385604 
McPherson, C. J., Wilson, K. G., Lobchuk, M. M., Brajtman, S. (2007). Self-perceived 
burden to others: patient and family caregiver correlates. Journal of Palliative 
Care, 23(3), 135–142. 
McPherson, C. J., Wilson, K. G., Murray, M. A., (2007). Feeling like a burden: 
Exploring the perspectives of patients at the end of life. Social Science and 
Medicine, 64(2), 417–427. 
McPherson, C., Wilson, K. & Murray, M. (2007). Feeling like a burden to others: A 
systematic review focusing on the end of life. Palliative Medicine, 21(2), 115–
128. 
McVilly, K. R., Stancliffe, R. J., Parmenter, T. R. & Burton‐Smith, R. M. (2008). 
Remaining open to quantitative, qualitative, and mixed‐method designs: An 
unscientific compromise, or good research practice? International Review of 
Research in Mental Retardation, 35, 151–203. 
McWilliam, C. L. (2009). Patients, persons or partners? Involving those with chronic 
disease in their care. Chronic Illness, 5(4), 277–292. 
doi:10.1177/1742395309349315 
 278 
 
Mehndiratta, M., Garg, R. K. & Pandey, S. (2011). Nonmotor symptom complex of 
parkinson’s disease–an under-recognized entity. Journal of the Association of 
Physicians of India, 59, 2. 
Mehta, P., Kifley, A., Wang, J. J., Rochtchina, E., Mitchell, P. & Sue, C. M. (2007). 
Population prevalence and incidence of Parkinson’s disease in an Australian 
community. Internal Medicine Journal, 37(12), 812–814. 
Mellick, G. D. (2013). Why we need better nationwide measures of Parkinson's disease 
incidence and prevalence in Australia. Australasian Epidemiologist, 20(1), May 
2013: 2020-2022. 
http://search.informit.com.au/documentSummary;dn=535681846716868;res=IE
LHEA 
Miller, M. & Daniels, L. (2000). Nutritional risk factors and dietary intake in older 
adults with Parkinson’s disease attending community-based therapy groups. 
Australian Journal of Nutrition and Dietetics, 57(3), 152–158. 
Milsom, I., Abrams, P., Cardozo, L., Roberts, R. G., Thuroff, J. & Wein, A. J. (2001). 
How widespread are the symptoms of an overactive bladder and how are they 
managed? A population-based prevalence study. British Journal of Urology 
International, 87(9), 760–766. 
Montbriand, M. J. (2004). Seniors’ life histories and perceptions of illness. Western 
Journal of Nursing Research, 26(2), 242–260. 
Morley, J. F. & Hurtig, H. I. (2010). Current understanding and management of 
Parkinson disease: Five new things. Neurology, 75(18, Suppl 1), S9–15. 
doi:10.1212/WNL.0b013e3181fb3628 
 279 
 
Mosley, R., Benner, E., Kadiu, I., Thomas, M., Boska, M., Hasan, K., … Gendelman, 
H. (2006). Neuroinflammation, oxidative stress, and the pathogenesis of 
Parkinson’s disease. Clinical Neuroscience Research, 6(5), 261–281. 
Mostwin, J. L. (2002). Pathophysiology: The varieties of bladder overactivity. Urology, 
60(5, Suppl 1), 22–26. 
Murray, C. J., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., … 
Abdalla, S. (2013). Disability-adjusted life years (DALYs) for 291 diseases and 
injuries in 21 regions, 1990–2010: A systematic analysis for the global burden of 
disease study 2010. Lancet, 380(9859), 2197–2223. 
Murray, S. A. & Sheikh, A. (2008). Care for all at the end of life. British Medical 
Journal, 336(7650), 958–959. doi:10.1136/bmj.39535.491238.94 
Murray, S. A., Kendall, M., Boyd, K. & Sheikh, A. (2005). Illness trajectories and 
palliative care. British Medical Journal, 330(7498), 1007–1011. 
doi:10.1136/bmj.330.7498.1007 
Murrow, E. J. & Oglesby, F. M. (1996). Acute and chronic illness: Similarities, 
differences and challenges [Review]. Orthopaedic Nursing, 15(5), 47–51. 
Muslimovic, D., Post, B., Speelman, J. D., Schmand, B. & de Haan, R. J. (2008). 
Determinants of disability and quality of life in mild to moderate Parkinson 
disease: Carpa study group. Neurology, 70(23), 2241–2247. 
Nay, R. & Garratt, S. (Eds.). (2009). Older people: Issues and innovations in care (3rd 
ed.). Australia: Elsevier. 
Newman, D. K. (1999). Entering the 21st century: Moving incontinence treatment 
options to the forefront. Ostomy Wound Management, 45(12), 5–6. 
 280 
 
Newman, D. K. (2002). Managing and treating urinary incontinence (2nd ed.). 
Baltimore: Health Professions Press. 
Newman, E. J., Breen, K., Patterson, J., Hadley, D. M., Grosset, K. A. & Grosset, D. G. 
(2009). Accuracy of Parkinson’s disease diagnosis in 610 general practice 
patients in the West of Scotland. Movement Disorders, 24(16), 2379–2385. 
Ng, Y., Lee, S., Cheung, T., Nicholls, J., Peiris, J. & Ip, N. (2010). Avian influenza 
H5N1 virus induces cytopathy and proinflammatory cytokine responses in 
human astrocytic and neuronal cell lines. Neuroscience, 168(3), 613–623. 
Nicholson, C., Jackson, C. L., Marley, J. E., & Wells, R. (2012). The Australian 
experiment: how primary health care organizations supported the evolution of a 
primary health care system. The Journal of the American Board of Family 
Medicine, 25(Suppl 1), S18-S26.  
Niglas, K. (2004). The combined use of qualitative and quantitative methods in 
educational research. Retrieved from 
http://www.tlulib.ee/files/arts/24/niglaf737ff0eb699f90626303a2ef1fa930f.pdf. 
Nilsson, M., Westergren, A., Gunilla, C. & Hagell, P. (2010). Uncovering indicators of 
the international classification of functioning, disability, and health from the 39-
item Parkinson’s disease questionnaire. Parkinson’s Disease. 
doi:10.4061/2010/984673 
Noble, C. (2000). Parkinson’s disease: The challenge. Nursing Standard, 15(12), 43–53. 
Norlinah, M. I., Afidah, K. N., Noradina, A. T., Shamsul, A. S., Hamidon, B. B., 
Sahathevan, R. & Raymond, A. A. (2009). Sleep disturbances in Malaysian 
patients with Parkinson’s disease using polysomnography and PDSS. 
Parkinsonism and Related Disorders, 15(9), 670–674. 
 281 
 
Noyce, A., Bestwick, J., Silveira-Moriyama, L., Hawkes, C., Giovannoni, G., Lees, A. 
& Schrag, A. (2012). Meta-analysis of early nonmotor features and risk factors 
for Parkinson disease. Annals of Neurology, 72(6), 893–901. 
O’Sullivan, S. S., Williams, D. R., Gallagher, D. A., Massey, L. A., Silveira-Moriyama, 
L. & Lees, A. J. (2008). Nonmotor symptoms as presenting complaints in 
Parkinson’s disease: A clinicopathological study. Movement Disorders, 23(1), 
101–106. doi:10.1002/mds.21813 
OECD. (2011). Health at a glance 2011: Indicators. OECD Publishing: 
10.1787/health_glance-2011-en. 
Olanow, C. & Tatton, W. (1999). Etiology and pathogenesis of Parkinson’s disease. 
Annual Review of Neuroscience, 22(1), 123–144. 
Olsen, K. M. & Dahl, S.-A. (2007). Health differences between European countries. 
Social Science and Medicine, 64, 1665–1678. 
Onwuegbuzie, A. J. & Leech, N. L. (2007). A call for qualitative power analyses. 
Quality and Quantity, 41(1), 105–121. 
Pahwa, R. & Lyons, K. E. (2010). Early diagnosis of Parkinson’s disease: 
Recommendations from diagnostic clinical guidelines. American Journal of 
Managed Care, 16(4), 94–99. 
Pal, P. K., Thennarasu, K., Fleming, J., Schulzer, M., Brown, T. & Calne, S. M. (2004). 
Nocturnal sleep disturbances and daytime dysfunction in patients with 
Parkinson’s disease and in their caregivers. Parkinsonism and Related 
Disorders, 10(3), 157–168. 
 282 
 
Palacios, N., Gao, X., McCullough, M. L., Schwarzschild, M. A., Shah, R., Gapstur, S. 
& Ascherio, A. (2012). Caffeine and risk of Parkinson’s disease in a large cohort 
of men and women. Movement Disorders, 27(10), 1276–1282. 
Palleschi, G., Pastore, A. L., Stocchi, F., Bova, G., Inghilleri, M., Sigala, S. & Carbone, 
A. (2006). Correlation between the Overactive Bladder questionnaire (OAB-q) 
and urodynamic data of Parkinson disease patients affected by neurogenic 
detrusor overactivity during antimuscarinic treatment. Clinical 
Neuropharmacology, 29(4), 220–229. 
Palmer, M. (2009). Urinary incontinence quality improvement in nursing homes: Where 
have we been? Where are we going? Urologic Nursing, 2(23) 439–444. 
Parkinson’s Australia. (2008). About Parkinson’s: Nursing care. Retrieved from 
http://www.parkinsons.org.au/about-ps/nursing.htm 
Parmenter, T. (1994). Quality of life as a concept and measurable entity. Social 
Indicators Research, 33, 9–46. 
Parmenter, T. (1996). The use of quality of life as a construct for social and health 
poilicy development. In R. Renwick, I. Brown & M. Nagler (Eds.), Quality of 
life in health promotion and rehabilitation. London: Sage Publications. 
Paul, C., Ayis, S. & Ebrahim, S. (2007). Disability and psychosocial outcomes in old 
age. Journal of Aging and Health, 19(5), 723–741. 
Pearl-Kraus, L. (2007). Effects of two Parkinson’s disease patient education models on 
disease self-management and quality of life. Doctoral thesis, Western Michigan 
University, United States. Retrieved from 
http://ezproxy.library.usyd.edu.au/login?url=http://proquest.umi.com/pqdweb?di
d=1362534821&Fmt=7&clientId=16331&RQT=309&VName=PQD 
 283 
 
Pearson, J., Tucker, I., Bolt, J., Kelly, S., Eastwood, S., Finucane, P. & Paterson, J. 
(2002). Incontinence: Why people do not seek help. A Report prepared for the 
Australian Government Department of Health and Ageing. Canberra: 
Department of Health and Ageing. 
Perez-Lloret, S., Rossi, M., Nouzeilles, M. I., Trenkwalder, C., Cardinali, D. P. & 
Merello, M. (2009). Parkinson’s disease sleep scale, sleep logs, and actigraphy 
in the evaluation of sleep in parkinsonian patients. Journal of Neurology, 256(9), 
1480–1484. 
Peto, V., Jenkinson, C. & Fitzpatrick, R. (1998). PDQ-39: A review of the development, 
validation and application of a Parkinson’s disease quality of life questionnaire 
and its associated measures. Journal of Neurology, 245(Suppl 1), S10–S14. 
Peto, V., Jenkinson, C. & Fitzpatrick, R. (2001). Determining minimally important 
differences for the PDQ-39 Parkinson’s disease questionnaire. Age and Ageing, 
30, 299–302. 
Pfeiffer, R. F. (2011). Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism 
and Related Disorders, 17(1), 10–15. 
Phelan, E. A., Anderson, L. A., Lacroix, A. Z. & Larson, E. B. (2004). Older adults’ 
views of ‘successful aging’: How do they compare with researchers’ 
definitions?. Journal of the American Geriatrics Society, 52 (2), 211–216. 
doi:10.1111/j.1532–5415.2004.52056 
Plewis, I. & Mason, P. (2005). What works and why: Combining quantitative and 
qualitative approaches in large-scale evaluations. International Journal of Social 
Research Methodology, 8(3), 185–194. 
 284 
 
Poewe, W. & Mahlknecht, P. (2009). The clinical progression of Parkinson’s disease. 
Parkinsonism and Related Disorders, 15 (Suppl 4), S28–S32. 
doi:10.1016/S1353–8020(09)70831–4 
Polinder, S., Haagsma, J. A., Stein, C. & Havelaar, A. H. (2012). Systematic review of 
general burden of disease studies using disability-adjusted life years. Population 
Health Metrics, 10(1), 1–15. 
Politis, M., Piccini, P., Pavese, N., Koh, S. & Brooks, D. (2008). Evidence of dopamine 
dysfunction in the hypothalamus of patients with Parkinson’s disease: An in 
vivo 11C-raclopride PET study. Experimental Neurology, 214(1), 112–116. 
Porter, M. E. (2010). What is value in health care? New England Journal of Medicine, 
363(26), 2477–2481. doi:10.1056/NEJMp1011024 
Post, B., van der Eijk, M., Munneke, M. & Bloem, B. R. (2011). Multidisciplinary care 
for Parkinson’s disease: Not if, but how! Postgraduate Medical Journal, 
87(1031), 575–578. doi:10.1136/pgmj.2011.241604rep 
Potter, J., Peel, P., Mian, S., Lowe, D., Irwin, P., Pearson, M. & Wagg, A. (2007). 
National audit of continence care for older people: Management of faecal 
incontinence. Age and Ageing, 36(3), 268–273. doi:10.1093/ageing/afm004 
Powers, K., Smith-Weller, T., Franklin, G. M., Longstreth, W., Swanson, P. & 
Checkoway, H. (2003). Parkinson’s disease risks associated with dietary iron, 
manganese, and other nutrient intakes. Neurology, 60(11), 1761–1766. 
Pradilla, G., Vesga, B. & Leon-Sarmiento, F. (2003). National neuroepidemiological 
study in Colombia. Pan American Journal of Public Health, 14(2), 104–111. 
 285 
 
Pretzer-Aboff, I., Galik, E. & Resnick, B. (2011). Feasibility and impact of a function 
focused care intervention for Parkinson’s disease in the community. Nursing 
Research, 60(4), 276–283. 
Pusey, M. (2003). The experience of middle Australia: The dark side of economic 
reform. Port Melbourne: Cambridge University Press. 
Rahman, S., Griffin, H. J., Quinn, N. P., Jahanshahi, M., Rahman, S., Griffin, H. J., … 
Jahanshahi, M. (2008). Quality of life in Parkinson’s disease: the relative 
importance of the symptoms. Movement Disorders, 23(10), 1428–1434. 
Ramaker, C., Marinus, J., Stiggelbout, A. M. & van Hilten, B. J. (2002). Systematic 
evaluation of rating scales for impairment and disability in Parkinson’s disease. 
Movement Disorders, 17(5), 867–876. 
Rao, S., Hofmann, L. & Shakil, A. (2006). Parkinson’s disease: Diagnosis and 
treatment. American Family Physician, 74(12), 2046–2054. 
Rayner, C. K. & Horowitz, M. (2013). Physiology of the ageing gut. Current Opinion in 
Clinical Nutrition and Metabolic Care, 16(1), 33–38. 
Razali, R., Ahmad, F., Rahman, F. N., Midin, M. & Sidi, H. (2011). Burden of care 
among caregivers of patients with Parkinson disease: A cross-sectional study. 
Clinical Neurology and Neurosurgery, 113(8), 639–643. 
doi:10.1016/j.clineuro.2011.05.008 
Redfern, S. & Ross, F. (Eds.). (2006). Nursing older people (4th ed.). London: Elsevier. 
Reimann, M., Schmidt, C., Herting, B., Prieur, S., Junghanns, S., Schweitzer, K., … 
Ziemssen, T. (2010). Comprehensive autonomic assessment does not 
differentiate between Parkinson’s disease, multiple system atrophy and 
 286 
 
progressive supranuclear palsy. Journal of Neural Transmission, 117(1), 69–76. 
doi:10.1007/s00702–009–0313-y 
Rejeski, W. J., Ip, E. H., Marsh, A. P., Miller, M. E. & Farmer, D. F. (2008). Measuring 
disability in older adults: the International Classification System of Functioning, 
Disability and Health (ICF) framework. Geriatrics and Gerontology 
International, 8, 48–54. 
Rhodes, R., Battin, M. & Silvers, A. (Eds.). (2012). Medicine and social justice: Essays 
on the distribution of health care. New York: Oxford University Press. 
Roehrig, B., Hoeffken, K., Pientka, L. & Wedding, U. (2007). How many and which 
items of activities of daily living (ADL) and instrumental activities of daily 
living (IADL) are necessary for screening. Critical Reviews in Oncology 
Hematology, 62(2), 164–171. 
Ross, G. W., Abbott, R. D., Petrovitch, H., Tanner, C. M. & White, L. R. (2012). Pre-
motor features of Parkinson’s disease: the Honolulu-Asia Aging Study 
experience. Parkinsonism and Related Disorders, 18, S199–S202. 
Rothermund, K., & Brandtstädter, J. (2003). Coping With Deficits and Losses in Later 
Life: From Compensatory Action to Accommodation. Psychology and Aging, 
18(4), 896-905. doi: 10.1037/0882-7974.18.4.896 
Rowe, J. W. & Kahn, R. L. (1987). Human aging: Usual and successful. Science and 
Medicine, 237, 143–149 
Rutledge, D. N., Mouttapa, M., & Wood, P. B. (2009). Symptom clusters in 
fibromyalgia: potential utility in patient assessment and treatment evaluation. 
Nursing Research, 58(5), 359-367.  
 287 
 
Sakakibara, R., Shinotoh, H., Uchiyama, T., Sakuma, M., Kashiwado, M., Yoshiyama, 
M. & Hattori, T. (2001). Questionnaire-based assessment of pelvic organ 
dysfunction in Parkinson’s disease. Autonomic Neuroscience, 92(1–2), 76–85. 
doi:10.1016/s1566–0702(01)00295–8 
Sakakibara, R., Tateno, F., Kishi, M., Tsuyuzaki, Y., Uchiyama, T. & Yamamoto, T. 
(2012). Pathophysiology of bladder dysfunction in Parkinson’s disease. 
Neurobiology of Disease, 46(3), 565–571. doi:10.1016/j.nbd.2011.10.002 
Sakakibara, Uchiyama, Yamanishi, Shirai & Hattori. (2008). Bladder and bowel 
dysfunction in Parkinson’s disease. Journal of Neural Transmission, 115(3), 
443–460. doi:10.1007/s00702–007–0855–9 
Sammour, Z. M., Gomes, C. M., Barbosa, E. R., Lopes, R. I., Sallem, F. S., Trigo 
Rocha, F. E., … Srougi, M. (2009). Voiding dysfunction in patients with 
Parkinson’s disease: impact of neurological impairment and clinical parameters. 
Neurourology and Urodynamics, 28(6), 510–515. 
Sansoni, J., Marosszeky, N., Sansoni, E. & Hawthorne, G. (2006). Refining continence 
measurement tools (final report). Centre for Health Service Development, 
University of Wollongong and the Department of Psychiatry, University of 
Melbourne. 
Santos, C. R. & Santos, V. L. (2011). Prevalence of self-reported double incontinence in 
the urban population of a Brazilian city. Neurourology and Urodynamics, 30(8), 
1473–1479. doi:10.1002/nau.21116 
Schalock. R. (2004). The concept of quality of life: what we know and do not know. 
Journal of Intellectual Disability Research, 48(3), 203–216. 
 288 
 
Schalock, R. L., & Alonso, M. A. V. (2013). The Impact of the Quality of Life Concept 
on the Field of Intellectual Disability. In M. L. Wehmeyer (Ed.), The Oxford 
Handbook of Positive Psychology and Disability (pp. 37). New York, USA: 
Oxford University Press. 
Schapira, A. (2008). Mitochondria in the aetiology and pathogenesis of Parkinson’s 
disease. Lancet Neurology, 7(1), 97–109. doi:10.1016/S1474–4422(07)70327–7 
Schmidt, J., Dogan, N., Langenbach, R. & Zirngibl, H. (2009). Fecal urge incontinence 
after stapled anopexia for prolapse and hemorrhoids: a prospective, 
observational study. World Journal of Surgery, 33(2), 355–364. 
doi:10.1007/s00268–008–9818-z 
Schneider, J. S. (2007). Behavioral persistence deficit in Parkinson’s disease patients. 
Journal of Neurology, 14, 300–304. 
Schoen, C., Osborn, R., How, S. K. H., Doty, M. M. & Peugh, J. (2009). In chronic 
condition: Experiences of patients with complex health care needs, in eight 
countries, 2008. Health Affairs, 28(1), w1–w16. 
Schrag, A., Jahanshahi, M. & Quinn, N. (2000). What contributes to quality of life in 
patients with Parkinson’s disease?. Journal of Neurology, Neurosurgery and 
Psychiatry, 69(3), 308–312. 
Schrag, A., Spottke, A., Quinn, N. & Dodel, R. (2009). Comparative responsiveness of 
Parkinson’s disease scales to change over time. Movement Disorders, 24(6), 
813–818. 
Schulz, J. B. (2008). Update on the pathogenesis of Parkinson’s disease. Journal of 
Neurology, 255(Suppl 5), 3–7. 
 289 
 
Sells, D., Sledge, W., Wieland, M., Walden, D., Flanagan, E., Miller, R. & Davidson, L. 
(2009). Cascading crises, resilience and social support within the onset and 
development of multiple chronic conditions. Chronic Illness, 5(2), 92. 
Serrano-Dueñas, M., Martinez-Martin, P. & Vaca-Baquero, V. (2004). Validation and 
cross-cultural adjustment of PDQL-questionnaire, Spanish version (Ecuador) 
(PDQL-EV). Parkinsonism and Related Disorders, 10(7), 433–437. 
Serrano-Dueñas, M. & Serrano, S. (2008). Psychometric characteristics of PIMS—
compared to PDQ-39 and PDQL—to evaluate quality of life in Parkinson’s 
disease patients: Validation in Spanish (Ecuadorian style). Parkinsonism and 
Related Disorders, 14(2), 126–132. 
Shamliyan, T., Wyman, J., Bliss, D. Z., Kane, R. L. & Wilt, T. J. (2007). Prevention of 
urinary and fecal incontinence in adults. Evidence Report/Technology 
Assessment, 161,1–379. 
Shaw, H. A. & Burrows, L. J. (2011). Etiology and treatment of overactive bladder in 
women [Review]. Southern Medical Journal, 104(1), 34–39. 
Shearer, J., Green, C., Counsell, C. & Zajicek, J. (2012). The impact of motor and non 
motor symptoms on health state values in newly diagnosed idiopathic 
Parkinson’s disease. Journal of Neurology, 259(3), 462–468. 
doi:10.1007/s00415–011–6202-y 
Shin, H., Lee, J. Y., Youn, J., Kim, J. S. & Cho, J. W. (2012). Factors contributing to 
spousal and offspring caregiver burden in Parkinson’s disease. European 
Neurology, 67(5), 292–296. doi:10.1159/000335577 
Siderowf, A. (2001). Parkinson’s disease: Clinical features, epidemiology, and genetics. 
Neurologic Clinics, 19(3), 565–578. 
 290 
 
Simmons, L. A. (2007). Self-perceived burden in cancer patients: Validation of the self-
perceived burden scale. Cancer Nursing, 30(5), 405–411. 
Sims, J., Browning, C., Lundgren-Lindquist, B. & Kendig, H. (2011). Urinary 
incontinence in a community sample of older adults: prevalence and impact on 
quality of life. Disability and Rehabilitation, 33(15–16), 1389–1398. 
Slieker-ten Hove, M. C., Pool-Goudzwaard, A. L., Eijkemans, M. J., Steegers-
Theunissen, R. P., Burger, C. W. & Vierhout, M. E. (2010). Prevalence of 
double incontinence, risks and influence on quality of life in a general female 
population. Neurourology and Urodynamics, 29(4), 545–550. 
Sloan, K. L., Sales, A. E., Liu, C.-F., Fishman, P., Nichol, P., Suzuki, N. T. & Sharp, N. 
D. (2003). Construction and characteristics of the RxRisk-V: A VA-adapted 
pharmacy-based case-mix instrument. Medical Care, 41(6), 761–774. 
Slowinski, J. L., Putzke, J. D., Uitti, R. J., Lucas, J. A., Turk, M. F., Kall, B. A., … 
Wharen, R. E. (2007). Unilateral deep brain stimulation of the subthalamic 
nucleus for Parkinson disease. Journal of Neurosurgery, 106(4), 626–632. 
Smoger, S. H., Felice, T. L. & Kloecker, G. H. (2000). Urinary incontinence among 
male veterans receiving care in primary care clinics. Annals of Internal 
Medicine, 132(7), 547–551. doi:200004040–00006 [pii] 
Soh, S., McGinley, J., Watts, J., Iansek, R. & Morris, M. (2012). Rural living and 
health-related quality of life in Australians with Parkinson’s disease. Rural and 
Remote Health, 12, 2158. 
Soh, S.-E., Morris, M. E. & McGinley, J. L. (2011). Determinants of health-related 
quality of life in Parkinson’s disease: A systematic review. Parkinsonism and 
Related Disorders, 17(1), 1–9. doi:10.1016/j.parkreldis.2010.08.012 
 291 
 
Spector, W., Katz, S., Murphy, J. & Fulton, J. (1987). The hierachical relationship 
between activities of dily living and instumental activities of daily living. 
Journal of Chronic Diseases, 40, 418–489. 
Špica, V., Pekmezović, T., Svetel, M., & Kostić, V. S. (2013). Prevalence of non-motor 
symptoms in young-onset versus late-onset Parkinson’s disease. Journal of 
Neurology, 260(1), 131-137.  
St. John, W., Wallis, M., Griffiths, S. & McKenzie, S. (2010). Daily-living management 
of urinary incontinence: A synthesis of the literature. Journal of Wound Ostomy 
and Continence Nursing, 37(1), 80–90 
10.1097/WON.1090b1013e3181c1068f1099d. 
Stenzelius, K., Mattiasson, A., Hallberg, I. R. & Westergren, A. (2004). Symptoms of 
urinary and faecal incontinence among men and women 75+ in relations to 
health complaints and quality of life. Neurourology and Urodynamics, 23(3), 
211–222. 
Stewart, T. L., Chipperfield, J. G., Perry, R. P. & Weiner, B. (2012). Attributing illness 
to ‘old age’: Consequences of a self-directed stereotype for health and mortality. 
Psychology and Health, 27(8), 881–897. 
Swithinbank, L. V., Vestey, S. & Abrams, P. (2004). Nocturnal polyuria in community-
dwelling women. British Journal of Urology International, 93(4), 523–527. 
Tapia, C. I., Khalaf, K., Berenson, K., Globe, D., Chancellor, M. & Carr, L. K. (2013). 
Health-related quality of life and economic impact of urinary incontinence due 
to detrusor overactivity associated with a neurologic condition: A systematic 
review. Health and Quality of Life Outcomes, 11(1), 13. 
 292 
 
Taylor, T. N., Caudle, W. M., Shepherd, K. R., Noorian, A., Jackson, C. R., Iuvone, P. 
M., … Miller, G. W. (2009). Nonmotor symptoms of Parkinson’s disease 
revealed in an animal model with reduced monoamine storage capacity. Journal 
of Neuroscience, 29(25), 8103–8113. doi:10.1523/jneurosci.1495–09.2009 
Temml, C., Heidler, S., Ponholzer, A. & Madersbacher, S. (2005). Prevalence of the 
overactive bladder syndrome by applying the international continence society 
definition. European Urology, 48(4), 622–627. 
doi:10.1016/j.eururo.2005.04.026 
Terai, A., Matsui, Y., Ichioka, K., Ohara, H., Terada, N. & Yoshimura, K. (2004). 
Comparative analysis of lower urinary tract symptoms and bother in both sexes. 
Urology, 63(3), 487–491. doi:10.1016/j.urology.2003.09.070 
Teunissen, T. A., van den Bosch, W. J., van den Hoogen, H. J. & Lagro-Janssen, A. L. 
(2004). Prevalence of urinary, fecal and double incontinence in the elderly living 
at home. International Urogynecology Journal, 15(1), 10–13. 
Teunissen, T., De Jonge, A., Van Weel, C. & Lagro-Janssen, A. (2004). Treating 
urinary incontinence in the elderly-conservative measures that work: A 
systematic review. Journal of Family Practice, 53(1), 25–32. 
Thomas, S., Nay, R., Moore, K., Fonda, D., Hawthorne, G., Marosszeky, N. & Sansoni, 
J. (2006). Continence outcomes measurement suite project (final report). 
Canberra: Australian Government Department of Health and Ageing. 
Tickle-Degnen, L. & Lyons, K. D. (2004). Practitioners’ impressions of patients with 
Parkinson’s disease: The social ecology of the expressive mask. Social Science 
and Medicine, 58(3), 603–614. 
 293 
 
Tolosa, E., Gaig, C., Santamaria, J. & Compta, Y. (2009). Diagnosis and the premotor 
phase of Parkinson disease. Neurology, 72(7 Supplement 2), S12. 
Tosato, M., Zamboni, V., Ferrini, A. & Cesari, M. (2007). The aging process and 
potential interventions to extend life expectancy. Clinical Interventions in Aging, 
2(3), 401. 
Tozun, M., Ayranci, U. & Unsal, A. (2009). Prevalence of urinary incontinence among 
women and its impact on quality of life in a semirural area of Western Turkey. 
Gynecologic and Obstetric Investigation, 67(4), 241–249. 
Ueda, T., Tamaki, M., Kageyama, S., Yoshimura, N. & Yoshida, O. (2000). Urinary 
incontinence among community-dwelling people aged 40 years or older in 
Japan: Prevalence, risk factors, knowledge and self-perception. International 
Journal of Urology, 7(3), 95–103. 
Uitti, R. J. (1998). Tremor: How to determine if the patient has Parkinson’s disease. 
Geriatrics, 53(5), 30–34. 
Vaismoradi, M., Turunen, H., & Bondas, T. (2013). Content analysis and thematic 
analysis: Implications for conducting a qualitative descriptive study. Nursing & 
Health Sciences, 15(3), 398-405. doi: 10.1111/nhs.12048 
Valderas, J. M., Starfield, B., Sibbald, B., Salisbury, C. & Roland, M. (2009). Defining 
comorbidity: Implications for understanding health and health services. Annals 
of Family Medicine, 7(4), 357–363. doi:10.1370/afm.983 
Vallès, M., Vidal, J., Clavé, P. & Mearin, F. (2006). Bowel dysfunction in patients with 
motor complete spinal cord injury: Clinical, neurological, and 
 294 
 
pathophysiological associations. American Journal of Gastroenterology, 
101(10), 2290–2299. 
van der Marck, M. A., Kalf, J. G., Sturkenboom, I. H., Nijkrake, M. J., Munneke, M. & 
Bloem, B. R. (2009). Multidisciplinary care for patients with Parkinson’s 
disease. Parkinsonism and Related Disorders, 15(3). doi:10.1016/S1353–
8020(09)70819–3 
Vaughan, C. P. (2012). What is the best approach for treating urinary incontinence in 
Parkinson’s disease?. Aging Health, 8(5), 525. 
Vaughan, C. P., Juncos, J. L., Burgio, K. L., Goode, P. S., Wolf, R. A. & Johnson, T. 
M., 2nd. (2011). Behavioral therapy to treat urinary incontinence in Parkinson 
disease. Neurology, 76(19), 1631–1634. 
Vaughan, J. & Hardie, R. J. (2002). The differential diagnosis of Parkinson’s disease. 
Reviews in Clinical Gerontology, 12(1), 40–51. 
Verbrugge, L. M. & Chan, A. (2007). Giving help in return: Family reciprocity by older 
Singaporeans. Ageing and Society, 28(01), 5–34. 
doi:10.1017/S0144686X07006447 
Vilariño-Güell, C., Ross, O. A., Wider, C., Jasinska-Myga, B., Cobb, S. A., Soto-
Ortolaza, A. I., … Melrose, H. L. (2010). LINGO1 rs9652490 is associated with 
essential tremor and Parkinson disease. Parkinsonism and Related Disorders, 
16(2), 109–111. 
Wacquant, L. “Scrutinizing the Street: Poverty, Morality, and the Pitfalls of Urban 
Ethnography.” American Journal of Sociology 107-6 (May 2002): 1468-1532 
Wagg, A., Cardozo, L., Chapple, C., Diaz, D. C., de Ridder, D., Espuna-Pons, M., … 
Kirby, M. (2008). Overactive bladder and continence guidelines: 
 295 
 
Implementation, inaction or frustration? International Journal of Clinical 
Practice, 62(10), 1588–1593. 
Wagg, A., Potter, J., Peel, P., Irwin, P., Lowe, D. & Pearson, M. (2007). National audit 
of continence care for older people: Management of urinary incontinence. Age 
and Ageing, 37(1), 39–44. doi:10.1093/ageing/afm163 
Waite, L. M., Broe, A., Creasey, H., Greyson, D., Cullen, J., O’Toole, B. & Edelbrock, 
D. (1997). Neurodegnerative and other chronic disorders among people aged 75 
years and older in the community. Medical Journal Australia, 167(8), 429. 
Walsh, K. & Bennett, G. (2001). Parkinson’s disease and anxiety. Postgraduate 
Medical Journal, 77(904), 89. 
Walter, U., Dressler, D., Wolters, A., Wittstock, M. & Benecke, R. (2006). Overactive 
bladder in Parkinson’s disease: Alteration of brainstem raphe detected by 
transcranial sonography. European Journal of Neurology, 13(12), 1291–1297. 
Watson, A. J., Currie, I., Curran, S. & Jarvis, G. J. (2000). A prospective study 
examining the association between the symptoms of anxiety and depression and 
severity of urinary incontinence. European Journal of Obstetrics and 
Gynecology and Reproductive Biology, 88(1), 7–9. doi:S0301211599001220 
[pii] 
Weaver, F. M., Follett, K., Stern, M., Hur, K., Harris, C., Marks, W. J., Jr., … Huang, 
G. D. (2009). Bilateral deep brain stimulation vs best medical therapy for 
patients with advanced Parkinson disease: A randomized controlled trial. 
Journal of the American Medical Association, 301(1), 63–73. 
 296 
 
Webb, E. J., Campbell, D. T., Schwartz, R. D., & Sechrest, L. (2000). Unobtrusive 
Measures: nonreactive research in the social sciences (revised ed.). Thousand 
Oaks: Sage Publications Inc. 
Weber, B. A., Roberts, B. L. & McDougall, G. J., Jr. (2000). Exploring the efficacy of 
support groups for men with prostrate cancer. Geriatric Nursing, 21(5), 250–
253. doi:S0197457200508179 [pii] 
Weintraub, D., Comella, C. & Horn, S. (2008). Parkinson’s disease—part 1: 
Pathophysiology, symptoms, burden, diagnosis, and assessment. American 
Journal of Managed Care, 14(2 Suppl), S40–S48. 
Weintraub, D., Moberg, P. J., Duda, J. E., Katz, I. R. & Stern, M. B. (2004). Effect of 
psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. 
Journal of the American Geriatrics Society, 52(5), 784–788. 
Weiss, J. P., Wein, A. J., van Kerrebroeck, P., Dmochowski, R., Fitzgerald, M., 
Tikkinen, K. A. & Abrams, P. (2011). Nocturia: New directions. Neurourology 
and Urodynamics, 30(5), 700–703. 
Welsh, M., McDermott, M., Holloway, R. & al., e. (1997). Development and testing of 
the Parkinson’s disease quality of life scale: The PDQUALIF. Movement 
Disorders, 12, 836. 
Welch, L. C., Taubenberger, S., & Tennstedt, S. L. (2011). Patients' experiences of 
seeking health care for lower urinary tract symptoms. Research in nursing & 
health, 34(6), 496-507.  
 
 297 
 
Whetten-Goldstein, K., Cutson, T., Zhu, C. & Schenkman, M. (2000). Financial burden 
of chronic neurological disorders to patients and their families: What providers 
need to know. Neurology Report, 24(4), 140–144. 
White, M. (2012). An overview of trends in baby boomer finances, employment, and 
retirement: Facts and challenges. Geriatric Care Management, 10. 
Whitehead, W. E., Borrud, L., Goode, P. S., Meikle, S., Mueller, E. R., Tuteja, A., … 
Ye, W. (2009). Fecal incontinence in US adults: Epidemiology and risk factors. 
Gastroenterology, 137(2), 512–517. 
WHO. (1980). International classification of impairments, disabilities and handicaps. 
Retrieved March 2009, from http://www.who.int/classifications/icf/en/ 
WHO. (2001). International Classification of Impairments, Disabilities and Handicaps  
Resolution WHA 54.21  World Health Organisation.,.   Retrieved April 2008, 
from http://www.who.int/classifications/icf/en/ 
WHO. (2008). The global burden of disease project: A response to the need for 
comprehensive, consistent and comparable information on diseases and injuries 
at global, regional and national levels. Retrieved 16 April 2008, from 
http://www.who.int/healthinfo/bodabout/en/index.html 
WHO. (2008). ICD-10: International statistical classification of diseases and related 
health problems (10th Rev. ed.). New York, NY: World Health Organization. 
WHOQoL Group. (1998). The World Health Organization quality of life assessment 
(WHOQoL): Development and general psychometric properties. Social Science 
and Medicine, 46, 1569–1585. 
Williams, D. & Lees, A. (2009). Progressive supranuclear palsy: Clinicopathological 
concepts and diagnostic challenges. Lancet Neurology, 8(3), 270–279. 
 298 
 
Winge, K., Skau, A.-M., Stimpel, H., Nielsen, K. K. & Werdelin, L. (2006). Prevalence 
of bladder dysfunction in Parkinsons disease. Neurourology and Urodynamics, 
25(2), 116–122. doi:10.1002/nau.20193 
Winney, J. (1998). Constipation. Nursing Standard, 13(11), 49–53, 55–56. 
Wright Willis, A., Evanoff, B. A., Lian, M., Criswell, S. R. & Racette, B. A. (2010). 
Geographic and ethnic variation in Parkinson disease: A population-based study 
of US Medicare beneficiaries. Neuroepidemiology, 34(3), 143–151. 
Yoshimura, K. (2012). Correlates for nocturia: A review of epidemiological studies. 
International Journal of Urology, 19(4), 317–329. doi:10.1111/j.1442–
2042.2011.02956.x 
Zesiewicz, T. A., Sullivan, K. L., Arnulf, I., Chaudhuri, K. R., Morgan, J. C., Gronseth, 
G. S., … Weiner, W. J. (2010 ). Practice parameter: Treatment of nonmotor 
symptoms of Parkinson disease: Report of the Quality Standards Subcommittee 
of the American Academy of Neurology. Neurology, 74, 924–931. 
Zhao, Y. J., Wee, H. L., Chan, Y. H., Seah, S. H., Au, W. L., Lau, P. N., … Tan, L. C. 
(2010). Progression of Parkinson’s disease as evaluated by Hoehn and Yahr 
stage transition times. Movement Disorders, 25(6), 702–708. 
  
 299 
 
 
Appendix A 
Burden Literature Tables 
 Group 1 The individual with PD’s experience of burden (n5) 
Author & year Title Journal methods:  Subjects  
Haahr A, Kirkevold M, 
Hall EO & Ostergaard K. 
(2011). 
Living with advanced Parkinson's 
disease: a constant struggle with 
unpredictability.  
Journal of Advanced Nursing, 67, 
408-17.  
(also located in CINAHL) 
research type Quant  
G1 Qual  
Subject people with PD  
N=11 Carers  
 
Spouse 
 
Other 
 
Hackney ME; Earhart 
GM; (2010) 
Effects of dance on balance and 
gait in severe Parkinson disease: a 
case study. 
Disability & Rehabilitation,; 32 (8): 
679-84 
research 
type Quant  
G1 Qual  
Subject people with PD  
N=1 Spouse Carers  
 
Other 
  
 
Luo N, Ng WY, Lau PN, 
Au WL & Tan LC. (2010). 
Responsiveness of the EQ-5D and 
8-item Parkinson's Disease 
Questionnaire (PDQ-8) in a 4-year 
follow-up study.  
Quality of Life Research, 19, 565-
9. 
 
research type Quant  
G1 Qual  
Subject people with PD  
N=31 Carers  
 
Spouse 
 
Other 
 
Martignoni E, Citterio A, 
Zangaglia R, Godi L, 
Pacchetti C, Fundaro C, 
et al. (2011). 
How parkinsonism influences life: 
the patients' point of view.  
Neurological Sciences, 32, 125-31.  
research type Quant  
G1 Qual  
Subject people with PD  
N=1256 Carers  
 
Spouse 
 
Other 
 
Martinez-Martin P, 
Hernandez B & Q10 
Study Group (2012). 
The Q10 questionnaire for 
detection of wearing-off 
phenomena in Parkinson's 
disease.  
Parkinsonism & Related 
Disorders, 18, 382-5. 
research 
type Quant  
G1 Qual  
Subject people with PD  
N=162  Spouse Carers  
 
Other 
  
 
  
 300 
 
 Group 2 The Burden experienced by the family as informal carers (25) 
Author & year 
Title Journal methods:  Subjects  
Carne W; Brown R; 
Pegg P; Ong J; 
Qutubuddin A; Baron 
MS (2006) 
Caregiver distress in 
parkinsonism. 
Journal of Rehabilitation 
Research & Development, Jul-
Aug; 43 (4): 499-507 
research 
type Quant  
G2 Qual  
Subject people with PD 
N=49 Carers  
 
Spouse  
 
Other 
 
Cifu DX, Carne W, 
Brown R, Pegg P, Ong 
J, Qutubuddin A, et al. 
(2006). 
Caregiver distress in 
parkinsonism.  
 
 Journal of Rehabilitation 
Research & Development, 43(4), 
499-508. 
research 
type Quant  
G2 Qual  
Subject people with PD  
N=49 Spouse Carers   
 
Other 
  
 
D'Amelio M, Terruso 
V, Palmeri B, Di 
Benedetto N, Famoso 
G, Cottone P, et al. 
(2009). 
Predictors of caregiver burden in 
partners of patients with 
Parkinson's disease.  
 Neurological Sciences, 30, 171-4. 
research 
type Quant  
G2 Qual  
Subject people with PD  
N=40 Spouse Carers   
 
Other 
  
 
Goldsworthy B & 
Knowles S. (2008). 
Caregiving for Parkinson's disease 
patients: an exploration of a 
stress-appraisal model for quality 
of life and burden.  
Journals of Gerontology Series B-
Psychological Sciences & Social 
Sciences, 63(6), P372-6.  
 
research type Quant   
G2 Qual  
Subject N=136 people with PD 
 
Carers  
 
Spouse  
 
Other  
 
Hounsgaard, L; 
Pedersen, E; Wagner, 
L. (2011) 
The daily living for informal 
caregivers with a partner with 
Parkinson's disease - an interview 
study of women's experiences of 
care decisions and self-
management. 
Journal of Nursing & Healthcare 
of Chronic Illnesses, Dec; 3 (4): 
504-12 
research 
type Quant  
G2 Qual   
Subject people with PD  
N=10  Spouse Carers  
 
Other 
  
 
Jones CA, Pohar SL & 
Patten SB. (2009). 
Major depression and health-
related quality of life in 
Parkinson's disease.  
General Hospital Psychiatry, 31, 
334-40 
research 
type Quant  
G2 Qual  
Subject people with PD  
N=40 Spouse Carers   
 301 
 
 
Other 
  
 
Kim KS, Kim BJ, Kim 
KH, Choe MA, Yi M, 
Hah YS, et al. (2007). 
Subjective and objective 
caregiver burden in Parkinson's 
disease.  
 
Journal of Korean Academy of 
Nursing Vol. 37, No. 2 242-8. 
research 
type Quant  
G2 Qual  
Subject people with PD  
N=76 Carers Carers  
 
Spouse  
 
Other 
 
Lau, Kam-Mei; Au, 
Alma (2011) 
Correlates of Informal Caregiver 
Distress in Parkinson's Disease: A 
Meta-Analysis. 
Clinical Gerontologist, Mar-Apr; 
34 (2): 117-31 
research 
type Quant  
G2 Qual  
Subject people with PD  
10 small 
studies Spouse Carers  
 
 Other 
  
 
Lokk J. (2008). Caregiver strain in Parkinson's 
disease and the impact of disease 
duration.  
European journal of physical & 
rehabilitation medicine., 44(1), 
39-45. 
research 
type Quant  
G2 Qual  
Subject people with PD  
N=451 Spouse Carers   
 
Other 
  
 
Martinez-Martin P, 
Benito-Leon J, Alonso 
F, Catalan MJ, Pondal 
M, Zamarbide I, et al. 
(2005) 
Quality of life of caregivers in 
Parkinson's disease.  
Quality of Life Research, 14(2), 
463-72. 
research 
type Quant  
G2 Qual  
Subject people with PD  
N=72 Carers  
 
Spouse  
 
Other 
 
Martinez-Martin P, 
Forjaz MJ, Frades-
Payo B, Rusinol AB, 
Fernandez-Garcia JM, 
Benito-Leon J, et al. 
(2007). 
Caregiver burden in Parkinson's 
disease.  
 
Movement Disorders, 22(7), 924-
31 
research 
type Quant  
G2 Qual  
Subject people with PD  
N=80  Carers  
 
Spouse  
 
Other 
 
Muller T & Woitalla D. 
(2010). 
Quality of life, caregiver burden 
and insurance in patients with 
Parkinson's disease in Germany.  
European Journal of Neurology, 
17, 1365-9. 
research 
type Quant  
G2 Qual  
Subject people with PD  
N=2603 Spouse Carers  
 
Other 
  
 
McLennon SM; 
Habermann B; Davis 
LL (2010) 
Deciding to institutionalize: why 
do family members cease 
caregiving at home? 
Journal of Neuroscience Nursing, 
Apr; 42 (2): 95-103 
research 
type Quant  
G2 Qual  
Subject people with PD  
N=11 Spouse Carers  
 302 
 
 
Other 
  
 
McLaughlin D, Hasson 
F, Kernohan WG, 
Waldron M, 
McLaughlin M, 
Cochrane B, et al. 
(2011). 
Living and coping with 
Parkinson's disease: perceptions 
of informal carers.  
Palliative Medicine, 25, 177-82. 
(also located in CINAHL) 
research type Quant  
G2 Qual  
Subject people with PD 
N=26 Carers  
 
Spouse  
 
Other 
 
Pretzer-Aboff IA; 
Galik, E., Resnick B. 
(2009) 
Parkinson’s Disease: Barriers and 
Facilitators to Optimizing 
Function  
Rehabilitation Nursing • Vol. 34, 
No. 2 • March/April 55-63 
research 
type Quant  
G2 Qual  
Subject people with PD  
N=10  Carers  
 
Spouse  
 
Other 
 
Roland KP, Jenkins ME 
& Johnson AM. (2010). 
An exploration of the burden 
experienced by spousal 
caregivers of individuals with 
Parkinson's disease.  
Movement Disorders, 25, 189-93. 
research 
type Quant  
G2 Qual  
Subject people with PD  
N=5 Spouse Carers  
 
Other 
  
 
Schrag A, Hovris A, 
Morley D, Quinn N & 
Jahanshahi M. (2006). 
Caregiver-burden in Parkinson's 
disease is closely associated with 
psychiatric symptoms, falls, and 
disability.  
Parkinsonism & Related 
Disorders, 12(1), 35-41. 
research 
type Quant  
G2 Qual  
Subject people with PD  
N=123  Spouse Carers  
 
Other 
  
 
Soulas T, Sultan S, 
Gurruchaga JM, Palfi S 
& Fenelon G. (2012). 
Changes in quality of life, burden 
and mood among spouses of 
Parkinson's disease patients 
receiving neurostimulation.  
Parkinsonism & Related 
Disorders, 18, 602-5 
research 
type Quant  
G2 Qual  
Subject people with PD 
N=26 Carers  
 
Spouse  
 
Other 
 
Secker DL & Brown 
RG. (2005). 
Cognitive behavioural therapy 
(CBT) for carers of patients with 
Parkinson's disease: a preliminary 
randomised controlled trial.  
Journal of Neurology, 
Neurosurgery & Psychiatry, 76(4), 
491-7. 
research type Quant  
G2 Qual  
Subject people with PD 
N=30 Carers   
 
Spouse  
 
Other 
 
Shim, Bomin; 
Landerman, Lawrence 
R.; Davis, Linda L.; 
(2011) 
Correlates of care relationship 
mutuality among carers of people 
with Alzheimer's and Parkinson's 
disease. 
Journal of Advanced Nursing, 
Aug; 67 (8): 1729-38 
research 
type Quant  
G2 Qual  
Subject people with PD  
N=91 Spouse Carers   
 
Other 
 303 
 
  
 
Stella F; Banzato CEM; 
Quagliato EMA; Viana 
MA; Christofoletti G; 
(2009) 
Psychopathological features in 
patients with Parkinson's disease 
and related caregivers' burden. 
International Journal of Geriatric 
Psychiatry, Oct; 24 (10): 1158-65 
research 
type Quant  
G2 Qual  
Subject people with PD  
N=50  Spouse Carers  
 
 Other 
  
 
Tanji H, Anderson KE, 
Gruber-Baldini AL, 
Fishman PS, Reich SG, 
Weiner WJ, et al. 
(2008). 
Mutuality of the marital 
relationship in Parkinson's 
disease.  
Movement Disorders, 23, 1843-9. 
research 
type Quant  
G2 Qual  
Subject people with PD   
N=96 pairs  Spouse Carers  
 
Other 
  
 
Tan SB, Williams AF & 
Morris ME. (2012). 
Experiences of caregivers of 
people with Parkinson's disease 
in Singapore: a qualitative 
analysis.  
Journal of Clinical Nursing, 21, 
2235-46.  
research type Quant  
G2 Qual  
Mixed  people with PD 
Subject Carers  
N=21 Spouse 
 
Other 
 
Tokunaga S; Washio 
M; Miyabayashi I; 
Fortin E; Shin Y; Arai Y; 
(2009) 
Burden among caregivers of 
Parkinson's disease patients. 
International Medical Journal, 
Jun; 16 (2): 83-6 
research 
type Quant  
G2 Qual  
Subject people with PD  
N=54 Spouse Carers   
 
Other 
  
 
Williams S; Keady J; 
(2008) 
'A stony road... a 19 year 
journey': 'bridging' through late-
stage Parkinson's disease. 
Journal of Research in Nursing, 13 
(5): 373-88  
 
research 
type Quant  
G2 Qual  
Subject 
N=13 people with PD  
 
Carers  
 
Spouse  
 
Other 
 
  
 304 
 
 Group 3 The Burden experienced by the Public, society based Burden (9) 
Author & year Title Journal methods:  Subjects  
Cosentino M, 
Martignoni E, 
Michielotto D, 
Calandrella D, 
Riboldazzi G, Pacchetti 
C, et al. (2005). 
Medical healthcare use in 
Parkinson's disease: survey in a 
cohort of ambulatory patients in 
Italy.  
 BMC Health Services Research, 
5(1), 26. 
Health service usage 
research 
type Quant   
G3 Qual  
Subject people with PD  
N=130 PD Carers  
 
Spouse  
 
Other 
 
Cubo E, Alvarez E, 
Morant C, de Pedro 
Cuesta J, Martinez 
Martin P, Genova R, et 
al. (2005). 
Burden of disease related to 
Parkinson's disease in Spain in the 
year 2000.  
Movement Disorders, 20(11), 
1481-7. 
research 
type Quant  
G3 Qual  
Subject people with PD  
Total 
Population 
study Carers  
 
Spouse  
 
Other 
 
Di Fazio I; Franzoni S; 
Frisoni GB; Gatti S; 
Cornali C; Stofler PM; 
Trabucchi M; (2006) 
 Predictive role of single diseases 
and their combination on recovery 
of balance and gait in disabled 
elderly patients. 
Journal of the American Medical 
Directors Association, May; 7 (4): 
208-11 
Not realy a good one to have PD 
used as a comobidity 
research 
type Quant  
G3 Qual  
Subject people with PD  
N=170 Carers  
 
Spouse 
 
Other 
 
Findley L J. (2007). The economic impact of 
Parkinson's disease.  
Parkinsonism & Related Disorders, 
13 Suppl, S8-S12. 
research 
type Quant  
G3 Qual  
Subject people with PD  
Total 
Population 
study Carers  
 Spouse  
 
Other 
 
Jones CA, Pohar SL & 
Patten SB. (2009). 
Major depression and health-
related quality of life in 
Parkinson's disease.  
 General Hospital Psychiatry, 31, 
334-40 
research 
type Quant  
G3 Qual  
Subject people with PD  
N=259 Spouse Carers  
 
Other 
  
 
Kim HJ, Park SY, Cho YJ, 
Hong KS, Cho JY, Seo 
SY, et al. (2009). 
Nonmotor symptoms in de novo 
Parkinson disease before and after 
dopaminergic treatment.  
research 
type Quant  
G3 Qual  
Subject people with PD  
 305 
 
Journal of the Neurological 
Sciences, 287, 200-4. 
N=23D Carers  
 
Spouse  
 
Other 
 
Takeda Y; Kuroiwa Y; 
Watabe S; Gokita K; 
Chuman T; Wang L; Li 
M; Toda H; Kamitani T; 
Omoto S; et al.; 
Relationships among impairment, 
disability, handicap, burden of 
care, economic expenses, event-
related potentials and regional 
cerebral blood flow in Parkinson's 
disease.  
Geriatrics & Gerontology 
International, 2005 Sep; 5 (3): 189-
201 
Predictive Economics 
research 
type Quant  
G3 Qual  
Subject people with PD  
N=14 
caregivers Spouse Carers  
N=24 
patients 
 
 
Other 
 
Wada-Isoe K, Ohta K, 
Imamura K, Kitayama 
M, Nomura T, Yasui K, 
et al. (2008). 
Assessment of hallucinations in 
Parkinson's disease using a novel 
scale.  
Acta Neurologica Scandinavica, 
117(1), 35-40. 
research 
type Quant  
G3 Qual  
Subject people with PD  
N=41  Spouse Carers  
 
Other 
  
 
Zesiewicz TA; Patel-
Larson A; Hauser RA; 
Sullivan KL (2007) 
Social Security Disability Insurance 
(SSDI) in Parkinson's disease. 
Disability & Rehabilitation, Dec 30; 
29 (24): 1934-6 
Economic - costs 
research 
type Quant  
G3 Qual  
Subject people with PD  
N=68 Carers  
 
Spouse 
 
Other 
 
 306 
 
Appendix B 
PDQ-39 Questionnaire 
 
 307 
 
 308 
 
 
 309 
 
Appendix C 
Non-motor System Assessment Scale for Parkinson’s Disease 
 310 
 
 
 
 311 
 
Appendix D 
H&Y Staging of PD 
 
  
 312 
 
Appendix E 
S&E ADL 
 
  
 313 
 
Appendix F 
Formal Interview Schedule 
 
 314 
 
 315 
 
 316 
 
 317 
 
 318 
 
 
  
 319 
 
Appendix G 
Participant Documents 
 
 320 
 
 321 
 
 
 322 
 
 323 
 
 324 
 
 
  
 325 
 
Appendix H 
Sydney University Human Ethics Committee approval 2007 
 
  
 326 
 
 
 
 327 
 
Appendix I –  
International Continence Society – LUTS definitions  
Rome III – criteria for GIT dysfuntions: Constipation & Diarrhea 
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Appendix J 
Relationship between PDQ-39 Domains and Disease Severity 
Domain total score Mobility ADL Emotional wellbeing Stigma Social support 
Mobility Pearson R 1 .746** .614** .535** .484** 
Sig. (2-tailed)   .000 .000 .000 .000 
N 67 67 67 67 67 
ADL  Pearson R .746** 1 .609** .530** .419** 
Sig. (2-tailed) .000   .000 .000 .000 
N 67 67 67 67 67 
Emotional 
wellbeing 
Pearson R .614** .609** 1 .648** .654** 
Sig. (2-tailed) .000 .000   .000 .000 
N 67 67 67 67 67 
Stigma  Pearson R .535** .530** .648** 1 .403** 
Sig. (2-tailed) .000 .000 .000   .001 
N 67 67 67 67 67 
Social 
support 
Pearson R .484** .419** .654** .403** 1 
Sig. (2-tailed) .000 .000 .000 .001   
N 67 67 67 67 67 
Cognition Pearson R .495** .651** .623** .477** .398** 
Sig. (2-tailed) .000 .000 .000 .000 .001 
N 67 67 67 67 67 
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Communi-
cation  
Pearson R .691** .637** .569** .428** .534** 
Sig. (2-tailed) .000 .000 .000 .000 .000 
N 67 67 67 67 67 
Bodily 
discomfort  
Pearson R .540** .508** .470** .230 .349** 
Sig. (2-tailed) .000 .000 .000 .061 .004 
N 67 67 67 67 67 
PDQ-39 SI 
score 
Pearson R .855** .848** .788** .678** .675** 
Sig. (2-tailed) .000 .000 .000 .000 .000 
N 67 67 67 67 67 
Subjective 
disease status 
Pearson R .439** .413** .128 .009 .101 
Sig. (2-tailed) .000 .001 .302 .943 .416 
N 67 67 67 67 67 
H&Y disease 
staging 
Pearson R .297* .163 .011 .019 .151 
Sig. (2-tailed) .015 .188 .931 .878 .224 
N 67 67 67 67 67 
Domain total score PDQ-39 cognition 
total score 
PDQ-39 
communication total 
score 
PDQ-39 bodily 
discomfort total score 
PDQ-39SI score Subjective disease 
status 
Mobility Pearson R .495** .691** .540** .855** .439** 
Sig. (2-tailed) .000 .000 .000 .000 .000 
N 67 67 67 67 67 
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ADL  Pearson R .651** .637** .508** .848** .413** 
Sig. (2-tailed) .000 .000 .000 .000 .001 
N 67 67 67 67 67 
Emotional 
wellbeing 
Pearson R .623** .569** .470** .788** .128 
Sig. (2-tailed) .000 .000 .000 .000 .302 
N 67 67 67 67 67 
Stigma  Pearson R .477** .428** .230 .678** .009 
Sig. (2-tailed) .000 .000 .061 .000 .943 
N 67 67 67 67 67 
Social 
support 
Pearson R .398** .534** .349** .675** .101 
Sig. (2-tailed) .001 .000 .004 .000 .416 
N 67 67 67 67 67 
Cognition Pearson R 1 .553** .483** .760** .082 
Sig. (2-tailed)   .000 .000 .000 .509 
N 67 67 67 67 67 
Communi-
cation  
Pearson R .553** 1 .447** .812** .453** 
Sig. (2-tailed) .000   .000 .000 .000 
N 67 67 67 67 67 
Bodily 
discomfort  
Pearson R .483** .447** 1 .668** .294* 
Sig. (2-tailed) .000 .000   .000 .016 
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N 67 67 67 67 67 
PDQ-39 SI 
score 
Pearson R .760** .812** .668** 1 .345** 
Sig. (2-tailed) .000 .000 .000   .004 
N 67 67 67 67 67 
Subjective 
disease status 
Pearson R .082 .453** .294* .345** 1 
Sig. (2-tailed) .509 .000 .016 .004   
N 67 67 67 67 67 
H&Y disease 
staging 
Pearson R -.027 .329** .259* .232 .396** 
Sig. (2-tailed) .827 .007 .035 .059 .001 
N 67 67 67 67 67 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
 
